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Abstract 
 
There is good evidence that high dietary calcium intake reduces the incidence 
of colorectal cancer.  The mechanism by which calcium acts is unknown.  It 
was hypothesised that parathyroid hormone (PTH) acts on colorectal 
epithelium and that calcium acts by suppressing serum PTH. Real-time PCR 
demonstrated expression of the PTH receptor PTHR1 in normal and 
neoplastic colon, indicating that the colon was sensitive to PTH.  Gene 
expression profiling using oligo-nucleotide micro-arrays was performed to 
identify genes;  
a) Differentially expressed in response to PTH in an in-vitro model of the 
colorectal epithelium. 
b) For which expression in normal rectal mucosa correlated with serum PTH 
level. 
c) Differentially expressed in normal rectal mucosa in response to modulating 
PTH by dietary calcium supplementation. 
A common finding of all three studies was regulation of the wnt signalling 
pathway by PTH.  In the in-vivo studies, expression of genetic markers of 
differentiation was negatively correlated with PTH.  Calcium supplementation 
resulted in increased expression of genetic markers of differentiation.  This 
suggests PTH inhibits differentiation and that calcium by suppressing PTH 
promotes differentiation.  There was also significant overlap between the 
genes changed by calcium, those negatively correlated with PTH and those 
changed by PTH in-vitro.  These findings provide support for the stated 
hypotheses. 
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“Diseases can rarely be eliminated through early diagnosis or 
good treatment, but prevention can eliminate disease.” 
Denis Burkitt 
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Chapter 1 
BACKGROUND 
 
1.1: Introduction 
 
The context of this thesis is the prevention of colorectal cancer with dietary 
agents.  In particular, to investigate the mechanism of action of dietary 
calcium: This has been shown to reduce the incidence of colorectal neoplasia.  
This background discussion will review: current understanding of the biology 
of colorectal cancer and its management.  The evidence relating to the 
protective effect of calcium will be presented.  A hypothesis for the preventive 
action of calcium will be given, along with the evidence supporting it.  Further 
discussion will focus on the normal colorectal epithelium: the signalling 
pathways that control it and the previously reported effects of calcium on it. 
 
1.2: Colorectal cancer 
1.2.1 Incidence 
Colorectal cancer is the third commonest cancer worldwide with over one 
million new cases per year.  This high incidence rate translates into a 
significant mortality rate, colorectal cancer being the fourth commonest cause 
of cancer death in the world, with over 600,000 deaths per annum (Karsa, 
Lignini et al. 2010).  There is geographical variation in incidence and the 
United Kingdom (UK) is a high incidence region.  In the UK the lifetime risk of 
developing colorectal cancer is 6%(Davies, Miller et al. 2005).  As well as 
being a major cause of morbidity and mortality, the management of colorectal 
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cancer is a significant burden on healthcare budgets and therefore represents 
a major public health issue. 
1.2.2 Age 
The incidence of colorectal cancer increases with age: with a mean age at 
onset of sixty three (Cunningham, Atkin et al. 2010).  Despite its incidence 
being highest in the older age group, it does occur in younger patients with 
around 8% of colorectal cancer occurs under the age of fifty (Edwards, Howe 
et al. 2002).  
1.2.3 Sex 
Overall the incidence of colorectal cancer is marginally higher in men than 
woman with an Odds ratio of 1.5.  There is also a minor difference in tumour 
location, with the ratio of rectal to colonic cancer higher in men than women 
(McCashland, Brand et al. 2001). 
1.2.4 Geography 
There is significant variation in the incidence of colorectal cancer around the 
world, with up to 25 fold variation in incidence between countries (Center, 
Jemal et al. 2009).  The areas of highest incidence are those nations 
considered to be „westernised‟, particularly those in: Europe, North America 
and Oceania (Australia and New Zealand).  In contrast, the lowest rates of 
colorectal cancer are found in Asia, Africa and South America (Center, Jemal 
et al. 2009). 
 
1.2.5 Predisposing factors 
The development of colorectal cancer has both genetic and environmental 
influences.  The majority of cases of colorectal cancer are sporadic, occurring 
in individuals with no personal risk factors other than increasing age.  The 
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following factors have been shown to increase the risk of developing 
colorectal cancer. 
1.2.5.1 Adenomatous polyps 
A past history of a colorectal adenoma increases the risk of developing 
colorectal cancer by 2-4 times (Lotfi, Spencer et al. 1986).  This increased risk 
varies depending on the nature of the adenoma.  Features that are associated 
with the greatest increased risk are: multiplicity of adenomas (>3) and the 
presence of an adenoma with advanced features (Winawer, Zauber et al. 
2006).  The features of an advanced adenoma are: size>1cm, tubulo-villous 
or villous histology or the presence of high grade dysplasia (Levine and 
Ahnen 2006).  
1.2.5.2 Genetic predisposition 
Genetic influences play a part in the development of up to a third of cases of 
colorectal cancer (Dove-Edwin, Sasieni et al. 2005).  The presence of genetic 
predisposition is identified by the presence of a family history of colorectal 
cancer.  The extent of family history is helpful in stratifying patients into 
different levels of risk.  In around 2-3% of patients with colorectal cancer there 
is a clear genetically inherited syndrome with high penetrance.  The two main 
genetic syndromes predisposing to colorectal cancer are hereditary non-
polyposis colorectal cancer (HNPCC) and familial adenomatous polyposis 
(FAP).  Both of these are inherited in an autosomal dominant fashion.  
Though relatively uncommon, these genetic syndromes provide 
understanding of the molecular biology of sporadic cancers.  
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1.2.5.2.1 Hereditary non-polyposis colorectal cancer (HNPCC) 
HNPCC is the commonest inherited condition and is caused by mutations in 
the DNA mismatch repair genes (MLH1, MSH2, MSH6 and PMS2).  Carriers 
of the mutation have a lifetime risk of colorectal cancer of 40-80% and 
increased risk of extra-colonic malignancies (Vasen, Taal et al. 1995; Dunlop, 
Farrington et al. 1997).  Cancers from patients with HNPCC invariably 
demonstrate micro-satellite instability (MSI) in tumour DNA.  This is the result 
of the development of deficient DNA mismatch repair and a „mutator 
phenotype‟ which is associated with a specific mutational spectrum in tumour 
DNA.   
1.2.5.2.2 Familial adenomatous polyposis (FAP) 
FAP is less common than HNPCC but has a distinctive phenotype with the 
development of hundreds of polyps throughout the colon and a 100% lifetime 
risk of colorectal cancer (Bulow 1989).  Mutations in the adenomatous 
polyposis coli (APC) gene are responsible for FAP and are identified in over 
60% of families (Wallis, Morton et al. 1999).  The Wnt signalling pathway is 
regulated by APC and de-regulation of the Wnt pathway is found in the polyps 
of FAP patients and also sporadic colorectal cancers (Kinzler and Vogelstein 
1996). 
1.2.5.2.3 Other genetic conditions  
There are also other rarer dominantly inherited genetic conditions which 
predispose to colorectal cancer including Peutz-Jehgers syndrome (PJS) and 
juvenile polyposis (JPS).  Mutations in STK11 have been identified in PJS and 
in SMAD4 and BMPR1A in JPS (Dunlop 2002).  More recently, (Mut-Y 
Homolog) MYH-associated polyposis which is inherited in an autosomal 
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recessive fashion was identified (Sampson, Dolwani et al. 2003).  More 
common are the patients with one or more relatives affected with colorectal 
cancer but without any of the syndromes described above.  These individuals 
constitute 10- 15% of patients with colorectal cancer and have an increased 
risk 2-5x that of the general population (Dunlop 2002).  
1.2.5.3 Inflammatory bowel disease 
Patients diagnosed with Ulcerative colitis or Crohn‟s colitis have an increase 
risk of developing colorectal cancer.  The risk of colorectal cancer increases 
with duration of colitis.  With colorectal cancer rates of 2%, 8% and 18% after 
10, 20 and 30 years respectively (Eaden, Abrams et al. 2001). 
1.2.5.4 Environmental factors 
A number of risk factors have been identified, these include: red meat, high-
fat diet, inadequate intake of fibre, obesity, sedentary lifestyle, diabetes 
mellitus, smoking, and high alcohol consumption (Cunningham, Atkin et al. 
2010).  
1.2.6 Pathology of colorectal cancer 
Colorectal cancers are most commonly of the adenocarcinoma type, arising 
from the epithelium of the large intestine.  There is a recognised pattern of 
tumour location around the colon with two thirds of cancers arising distal to 
the splenic flexure (Ponz de Leon, Marino et al. 2004). 
1.2.6.1 Adenoma-carcinoma sequence 
The widely accepted model by which colorectal cancer develops is the 
adenoma-carcinoma sequence.  In this model, the development of cancer 
progresses from normal colorectal mucosa via the intermediate stage of the 
adenoma to a cancer.  There is considerable evidence to support this model 
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of development of colorectal cancer.  That cancers arise from adenomas was 
first proposed in the 1920‟s (Lockhart-Mummery and Dukes 1928).  This was 
based on a number of observations; firstly the development of cancer in 
patients with previous polyps, the presence of polyps at the site where 
cancers develop and the presence of malignant change in adenomas and 
residual adenomatous elements in cancers (Lockhart-Mummery and Dukes 
1928).  These initial observations have been confirmed in subsequent studies.  
Adenomas have the same anatomical location as cancer, predominating distal 
to the splenic flexure (Clark, Collan et al. 1985) and their prevalence peaks 
five to ten years before that of cancer (Muto, Bussey et al. 1975).  Foci of 
cancer are found in up to 8% of polyps and adenomatous tissue is found in 
continuity with around 20% of cancers (Leslie, Carey et al. 2002). 
 That cancers arise from adenomas is widely accepted, but it is also 
clear that not all adenomas turn into cancer.  Around 40% of the population 
will have an adenoma by the age of sixty (Levine and Ahnen 2006), which 
compares with the lifetime risk of colorectal cancer of around 6%.  The risk of 
developing cancer is greater for larger adenomas particularly in those >1cm. 
One study has demonstrated that polyps >1cm or more progress to cancer at 
a rate of about 1% per year (Stryker, Wolff et al. 1987).  The risk is less for 
smaller adenomas, but even small adenomas can have foci of cancer.  Thus, 
removal of all adenomas detected endoscopically is recommended.  In 
addition to progression of adenomas to cancer, they may remain stable or 
regress (Loeve, Boer et al. 2004). 
Of patients who have an adenoma removed, 30-35% will have a recurrent 
adenoma within 3-4 years (Neugut, Johnsen et al. 1985).  Colonoscopic 
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surveillance of these patients is therefore essential; guidelines based on the 
features of the baseline adenoma have been developed (Atkin and Saunders 
2002).  Consequently, polyp surveillance results in a large number of the 
colonoscopies performed in the NHS.  The ability to identify those at greatest 
risk of developing further adenomas would be of clinical utility. 
1.2.7 Molecular pathology of colorectal cancer 
The molecular mechanisms underlying the development of colorectal cancer 
via the adenoma-carcinoma sequence were first proposed by Vogelstein and 
Fearon (Fearon and Vogelstein 1990).  In this model, colorectal cancer 
develops by a multi-step genetic process, with mutational inactivation of 
tumour suppressor genes and mutational activation of oncogenes. 
1.2.8 Genetic alterations occurring in colorectal cancer 
Screening of colorectal cancer for somatic mutations has identified up to 
ninety mutated genes, of these fourteen are considered to occur at high 
enough frequency to indicate functional importance.  Of these the three 
commonestly mutated genes are APC, K-ras and P53 (Sjoblom, Jones et al. 
2006). 
1.2.8.1 Adenomatous polyposis coli (APC) 
Inactivating mutations of the adenomatous polyposis coli (APC) gene are 
found in up to 80% of sporadic colorectal cancers (Powell, Zilz et al. 1992).     
Mutational inactivation of APC results in loss of its ability to bind β-catenin, 
this results in increased accumulation of β-catenin.  One important 
consequence of β-catenin accumulation is increased T-cell factor (TCF) 
mediated transcription.  Increased β-catenin/TCF mediated transcription and 
gene expression has been demonstrated in colorectal cancers (Kinzler and 
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Vogelstein 1996).  Inactivating mutations of β-catenin have been found in the 
majority of tumours with wild type APC (Morin, Sparks et al. 1997), 
highlighting the importance of this pathway in colorectal tumorigenesis. 
1.2.8.2  K-ras 
K-ras (Kirsten ras) is an oncogene, which undergoes activating mutations, 
which are found in over a third of colorectal cancers (Vogelstein, Fearon et al. 
1988).  K-ras is a (GTP) guanosine- triphosphate binding protein, mutations 
result in decreased GTPase activity and constitutive activation, influencing 
diverse signalling pathways (Bos 1989). 
1.2.8.2 P53 
P53 has been identified as “the guardian of the genome”, as it blocks cell 
proliferation in the presence of DNA damage and to result in apoptosis if the 
damage is irreparable (Lane 1992).  As well as being frequently mutationally 
inactivated in colorectal cancer, P53 is the most commonly mutated gene in 
all cancers (Caron de Fromentel and Soussi 1992). 
In addition to genetic mutation, other somatic changes have been recognised 
in cancers, these include: chromosomal losses and gains, aneuploidy and 
promoter methylation (Leslie, Carey et al. 2002). 
1.2.9 Staging 
The pathological staging of colorectal cancer is of clinical significance in 
predicting the outcome of treatment.  The first staging system for colorectal 
cancer was that devised by Dukes (Dukes 1932).  Tumours were classified 
into stage A, B, or C, where stage A tumours were confined to the rectal wall, 
stage B tumours breached extra-rectal tissues, and stage C tumours had 
metastasised to lymph nodes.  The significance of Dukes findings was his 
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demonstration of poorer outcomes with advancing stage of the disease.  Due 
to its clinical utility and ease of use the Dukes staging system remains in 
common usage.  And though not described by Dukes, stage D, representing 
the presence of distant metastases has been added to the staging bearing his 
name (Turnbull, Kyle et al. 1967).  The site of distant metastases for 
colorectal cancer is most commonly the liver, with pulmonary metastases also 
found. 
The other staging system commonly used for colorectal cancer, often in 
conjunction with Dukes staging, is the TNM system (Sobin and Wittikind 
2010).  This describes features of the primary tumour (T stage), the presence 
and features of nodal metastases (N stage) and the presence of distant 
metastases (M stage).  In the past, the only staging of colorectal cancer 
occurred following surgery with the pathological examination of the surgical 
specimen.  Pre-operative staging using various imaging modalities: Computed 
tomography (CT) and Magnetic resonance imaging (MRI), are now used to 
provide pre-operative staging.  These are used to guide the use of pre-
operative therapy.  The pathological staging however remains the final arbiter 
on prognosis following surgical treatment. 
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1.3: Diagnosis of colorectal cancer 
There are two main paradigms in which diagnosis of colorectal cancer occurs: 
symptomatic presentation and detection during screening of asymptomatic 
individuals 
1.3.1 Symptomatic presentation 
Patients presenting with symptoms, such as: rectal bleeding, change in bowel 
habit, or abdominal pain is the commonest mode of diagnosis and historically 
was the only method.  It is important to note, that of patients presenting with 
symptoms, half have advanced disease (Dukes stage C or D) including 20% 
with metastases (Hardcastle, Chamberlain et al. 1996).  As outcome following 
treatment for colorectal cancer is related to stage of the disease, the outcome 
for this group is poor.  Also, up to 30% of patients with colorectal cancer will 
present as an emergency (Scott, Jeacock et al. 1995).  These patients have 
bowel obstruction or perforation, requiring urgent treatment.  The outcome for 
these emergency patients is particularly poor (McArdle and Hole 2002). 
1.3.2 Screen detected 
The advanced stage of presentation at symptomatic presentation led to the 
development of tools for screening asymptomatic individuals.  The aim was to 
identify the disease at an earlier stage thus improving the outcome from 
treatment.  In the United Kingdom two approaches have been shown to be 
effective.  The use of faecal occult blood testing (FOBT) followed by 
colonoscopy for those who test positive has been shown in a randomised 
controlled trial to reduce colorectal cancer mortality by 15% after eight years 
follow up.  This is principally based on the diagnosis of a greater proportion of 
early stage tumours in the screened group (Hardcastle, Chamberlain et al. 
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1996).  This study, as well as similar findings from others around the world 
(Kronborg, Fenger et al. 1996; Mandel, Church et al. 1999), has led to the 
introduction of a national bowel cancer screening programme in the UK.  In 
this, individuals aged from 60 to 69 are invited for biennial FOBT.  Initial 
results indicate that the cancers detected by screening are of earlier stage 
compared to those presenting symptomatically (Steele 2004). 
 Direct endoscopic screening has also been studied.  A trial of 
screening for colorectal cancer using a one off flexible sigmoidoscopy 
between the ages of 55 and 64 has been carried out.  This also showed high 
rates of early stage cancer (Atkin, Edwards et al. 2010).  After eleven years 
follow up, there was a 31% reduction in colorectal cancer mortality in the 
intention to treat analysis and in those who actually underwent sigmoidoscopy 
(per protocol analysis) there was a 43% reduction (Atkin, Edwards et al. 
2010). 
1.3.2.1 Effect of screening on the incidence of colorectal cancer 
Another consequence of screening, by either of these two methods, is a 
reduction in the incidence of colorectal cancer in the screened compared to 
the control group.  In the flexible sigmoidoscopy study there was a 23% 
reduction in the incidence of colorectal cancer after a mean of eleven years 
follow up(Atkin, Edwards et al. 2010).  This decrease in incidence was 33% in 
those who actually underwent screening, with a 50% reduction in distal 
colorectal cancer.  A 20% reduction in incidence of colorectal cancer has also 
been shown in those undergoing annual FOBT screening after eighteen years 
of follow up (Mandel, Church et al. 2000).  The reduction in incidence of 
colorectal cancer in subjects who have undergone screening is due to the 
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detection and removal of polyps.  The effect of sigmoidoscopy is of greater 
magnitude and apparent earlier.  This is likely to be because of the greater 
rate of polyp detection with sigmoidoscopy, which is 12% (Atkin, Cook et al. 
2002) compared to 0.6% with FOBT (Steele 2004). 
 The effectiveness of screening in reducing colorectal cancer incidence 
and mortality has been demonstrated.  There are, however, a number of 
issues with screening that limit its potential effectiveness.  Uptake of 
screening is poor whichever method is employed, with only just over half of 
those invited taking up the offer of screening (Atkin, Cook et al. 2002; Steele 
2004).   FOBT testing has a sensitivity of around 50%, with subsequent 
interval cancer rate.  Similarly it has a positive predictive value of only 50%, 
such that around half of patients undergoing colonoscopy have no 
abnormality (Steele 2004).  There is also the question of managing the 
patients identified with polyps, who are at increased risk of developing 
colorectal cancer.  Currently the only option is to offer them continued 
colonoscopic surveillance, which is very demanding of resources. 
1.3.3 Treatment of colorectal cancer 
The curative treatment of colorectal cancer is predominantly by surgery.  The 
principles of surgery are: resection of the primary tumour and draining lymph 
nodes, dissection in anatomical planes and adequate resection margins.  
Additionally radiotherapy and chemotherapy have a role in reducing local 
recurrence and improving the survival from colorectal cancer in selected 
patients (Cunningham, Atkin et al. 2010). 
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1.3.4 Prognosis 
 
The main determinant of outcome of colorectal cancer is the tumour stage.  
Cancer registry data has shown that 5year survival rates for Dukes stage A is 
85%, 67% for stage B and 37% for stage C (Cunningham, Atkin et al. 2010).  
The long term survival of patients with metastases is very low.  Due to the 
stage distribution at presentation, overall survival for colorectal cancer is 
around fifty percent.  This confirms the principle that, stage of disease at 
presentation is a major determining factor in the outcome of colorectal cancer. 
1.4: Prevention of colorectal cancer 
Prevention of colorectal cancer would appear to be self evidently a good 
thing.  Additionally, the evidence above that current treatment strategies are 
not able to cure a significant proportion of patients makes this more desirable.  
There are three mechanisms by which the incidence of colorectal cancer can 
be reduced, these are: Surgery, colonoscopic polypectomy and 
chemoprevention. Surgery and polypectomy form part of current clinical 
practice.  Chemoprevention remains a research intervention and is not yet 
part of routine clinical practice.  
1.4.1 Surgery 
Surgical removal of the colon and rectum, removes all of the epithelium at risk 
of neoplastic transformation.  Prophylactic removal of the colon and rectum is 
the recommended treatment for patients with FAP, to prevent the inevitable 
development of colorectal cancer (Dunlop 2002).  It is also the treatment for 
patients with long standing colitis who develop dysplastic change in the 
colonic mucosa (Eaden, Abrams et al. 2001).  For the majority of patients who 
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are not at significantly increased risk of colorectal cancer, surgical prophylaxis 
is clearly not an acceptable approach to preventing colorectal cancer. 
1.4.2 Polypectomy 
The adenoma-carcinoma sequence model is now widely accepted as the 
mode by which colorectal cancer develops.  It is predicted from the adenoma-
carcinoma model that removal of adenomatous polyps would reduce 
colorectal cancer incidence.  There is substantial evidence that this is the 
case in a number of clinical scenarios.  Colonoscopic surveillance in patients 
with HNPCC has been shown to reduce mortality from colorectal cancer 
(Jarvinen, Aarnio et al. 2000).  This is attributed to earlier stage disease at 
diagnosis.  However, surveillance is also associated with a reduction in 
incidence of colorectal cancer which is secondary to the removal of polyps by 
polypectomy (Jarvinen, Aarnio et al. 2000).  Colonoscopic removal of polyps 
in patients with sporadic adenomas at standard population risk has been 
shown to reduce colorectal cancer incidence in two cohort studies by 70-90% 
(Winawer, Zauber et al. 1993; Citarda, Tomaselli et al. 2001).  Further 
evidence that removal of polyps reduces the incidence of colorectal cancer 
comes from screening studies.  As was described in section 1.5.2.1, both 
FOBT and endoscopic screening reduce the incidence of colorectal cancer. 
 The efficacy of endoscopic polypectomy in reducing colorectal cancer 
incidence is reasonably clear.  There are however, a number of difficulties in 
the clinical application of colonoscopy and polypectomy as a preventive 
strategy.  These include: identifying groups of individuals in whom the benefits 
of colonoscopy outweigh the risks, improving the uptake of population 
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screening, defining the role of endoscopy as a screening tool and manpower 
issues relating to increased number of colonoscopies performed.  
1.4.3 Chemoprevention 
Chemoprevention is the use of oral agents, nutrient or pharmacological, to 
prevent the development of colorectal cancer (Martinez, Marshall et al. 2008).  
That such an approach may be feasible is based on the observed wide 
variation in incidence and mortality between geographically distinct 
populations and the changes in incidence in migrant populations.  These 
differences have been attributed to variation in environmental and dietary 
factors.  Indeed, it has been suggested that around a third of cancer deaths 
might be due to dietary factors (Doll and Peto 1981).  The recognition that the 
development of symptomatic colorectal cancer from normal mucosa occurs 
over ten to fifteen years provides a window of opportunity to intervene. 
1.4.3.1 Chemo-preventive agents 
Epidemiological studies have provided evidence for an association between a 
number of dietary factors and the incidence of colorectal cancer.   These 
include: fibre, folate and calcium, as well as pharmacological agents: aspirin 
and other non-steroidal anti-inflammatory drugs (NSAID‟s).(Martinez, Marshall 
et al. 2008).  Subsequently, randomised controlled adenoma prevention trials 
of these agents have been carried out.  Adenoma prevention trials are 
secondary prevention trials in which the subjects have had a previous 
adenoma removed and are randomised to intervention or placebo and 
undergo follow up colonoscopy after 3-4 years, with adenoma recurrence as 
the primary endpoint.  Despite the epidemiological evidence for a preventive 
effect of fibre and folate, randomised controlled trials of both of these agents 
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have shown no effect on adenoma recurrence (Asano and McLeod 2002; 
Cole, Baron et al. 2007; Logan, Grainge et al. 2008).  However, there are 
agents with proven efficacy, the agent for which there is the greatest evidence 
is Aspirin. 
1.4.3.1.1 Aspirin 
There is evidence from both epidemiological and intervention studies that 
aspirin reduces the incidence of colorectal cancer.  Epidemiological studies 
have shown that those taking aspirin had a lower incidence of colorectal 
cancer after 10 years (Flossmann and Rothwell 2007).   There have also been 
four adenoma prevention trials of aspirin.  In a meta-analsyis of these four 
trials there was a statistically significant 17% relative reduction in the risk of 
any adenoma and a 28% relative risk reduction in the risk of an advanced 
neoplasm (Cole, Logan et al. 2009).  As polypectomy has been shown to 
reduce colorectal cancer incidence, it would be hypothesised that this 
reduction in adenoma incidence would result in a reduction of colorectal 
cancer incidence.  None of these trials yet have long enough follow up to 
demonstrate this.  Nor are they likely to as participants will be under 
colonoscopic surveillance which will substantially reduce the subsequent rate 
of colorectal cancer.  The question of whether a reduction in adenoma 
recurrence rate will translate into reduction in colorectal cancer incidence has 
been recently addressed.  A meta-analysis of other studies, using aspirin for 
thrombosis prevention, was carried out to look at the effect of aspirin on the 
risk of colorectal cancer over 20 years.  This demonstrated that aspirin 
reduced the incidence of colorectal cancer by 30%, with no effect seen until 
after ten years follow up (Flossmann and Rothwell 2007).  This latency of 
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effect of aspirin is consistent with our understanding of the development of 
colorectal cancer and suggests a mechanism of action in the early stages of 
colorectal tumorigenesis. 
These combined data, demonstrating that: aspirin prevents adenomas after 
three years and also reduces colorectal cancer incidence after ten years 
demonstrates the utility of adenoma prevention trials.  The mechanism by 
which aspirin acts is not fully known, though it is thought that this is via 
inhibition of cyclo-oxygenase-2 (COX2).  COX2 promotes proliferation and is 
commonly up-regulated in colorectal tumours (Eberhart, Coffey et al. 1994).  
Further support for this mechanism of action was provided by a large cohort 
study comparing COX2 expression in 636 incident cancers with self-reported 
intake of aspirin.  In this a reduction in the incidence of tumours with moderate 
or high expression of COX2 in those taking aspirin was demonstrated (Chan, 
Ogino et al. 2007). 
This finding provided a rationale for testing the effect of selective COX2 
inhibitors; these have an improved gastrointestinal side effect profile 
compared to Aspirin.  The Adenomatous Polyp Prevention on Vioxx 
(APPROVe) trial of the selective COX2 inhibitor Rofecoxib (Vioxx) 
demonstrated a significant 34% relative reduction in adenoma incidence 
compared to placebo after three years (Baron, Sandler et al. 2006).   This was 
however associated with a significantly increased risk of thrombotic 
cardiovascular events (Bresalier, Sandler et al. 2005), resulting in withdrawal 
of Rofecoxib.  The use of aspirin is also associated with a number of side 
effects particularly gastrointestinal bleeding.  In view of this, and despite 
evidence of efficacy, it is felt that more research is required before Aspirin can 
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be recommended for colorectal cancer chemoprevention (Cuzick, Otto et al. 
2009). 
The data relating to NSAID‟s and Aspirin in particular indicate that 
chemoprevention is possible and that adenoma prevention trials are capable 
of identifying appropriate agents.  However, in view of the uncertain risk-
benefit profile, alternative agents with acceptable safety and tolerability are of 
interest in the further study of colorectal cancer chemoprevention. 
1.5: Dietary calcium and colorectal cancer 
Calcium is the only other agent that has been shown to reduce adenoma 
formation in randomised placebo controlled trials.  The aim of this thesis is to 
investigate the mechanism of action of calcium.  The evidence relating to 
calcium and colorectal chemoprevention will be presented below. 
1.5.1 Epidemiology 
Evidence that diets high in calcium may reduce the incidence of colorectal 
cancer came initially from epidemiological studies.  A meta-analysis of ten 
studies of calcium intake, which included 534,536 individuals, was carried out.  
This demonstrated a reduced incidence of colorectal cancer in those with the 
highest compared to the lowest intake of calcium (Cho, Smith-Warner et al. 
2004).   
1.5.2 Animal studies 
There is also evidence from studies of rodents that calcium reduces dietary or 
experimentally induced colonic tumours either alone (Appleton, Davies et al. 
1987; Pence and Buddingh 1988) or in conjunction with vitamin D(Newmark, 
Yang et al. 2009). 
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1.5.3 Randomised controlled trials 
These epidemiological and animal data supported the testing of calcium in 
adenoma prevention trials.  Of which there have been two, one carried out in 
the USA (Baron, Beach et al. 1999) and one in Europe (Bonithon-Kopp, 
Kronborg et al. 2000).  These two trials were the subject of a meta-analysis 
(Weingarten, Zalmanovici et al. 2008).  In these two studies a total of 1346 
patients with a history of adenomas were enrolled and the recurrence of 
adenoma assessed by colonoscopy.  The two studies differed in the duration 
(4 vs 3 years) and daily dose of calcium (1.2g vs 2g).  The outcome of the 
meta-analysis was a moderate but statistically significant reduction in 
adenoma recurrence in those patients receiving calcium compared to 
placebo, with an Odds Ratio of 0.74 (95% confidence interval 0.58-0.95).  
Importantly, there was no increase in serious adverse events in the calcium 
treated patients. 
 Further analysis of the larger American study demonstrated a number 
of other important outcomes.  Firstly the effect of calcium was most 
pronounced on the recurrence of advanced neoplasms (Tubulovillous or 
villous adenomas or carcinoma-in-situ) with a RR of 0.65 (95%CI 0.46-0.93) 
compared to tubular adenoma RR 0.89 (0.77-1.03) (Wallace, Baron et al. 
2004).  Subsequently the protective effect of calcium was demonstrated to be 
prolonged after the end of randomised treatment.  There was a statistically 
significant reduction in the incidence of adenomas (RR 0.63 (0.46-0.87)) in 
the first five years after the end of treatment (Grau, Baron et al. 2007).  
Unfortunately, neither of these trials will be able to demonstrate a reduction of 
colorectal cancer incidence in the long term because the patients are under 
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colonoscopic surveillance, which in itself reduces the incidence of colorectal 
cancer. 
 The authors of the meta-analysis concluded that; there is evidence that 
calcium supplementation may reduce adenoma recurrence, but the evidence 
is not strong enough to recommend the use of calcium supplements in the 
primary or secondary prevention of adenomas.  They recommend that “further 
work is needed on the factors involved in individual susceptibility to colorectal 
cancer in order to identify any subgroups that might benefit from calcium 
supplementation” (Weingarten, Zalmanovici et al. 2008).  Understanding the 
mechanism by which calcium reduce the incidence of colorectal neoplasia will 
facilitate its rational use in strategies to reduce an individual‟s risk of 
developing colorectal cancer. 
1.5.4 Mechanism of action of calcium 
The mechanism by which calcium reduces the development of colorectal 
neoplasia has not been elucidated.  However, a number of mechanisms of 
action have been proposed.  Firstly, it has been hypothesised that calcium 
acts in the intestine binding bile acids and reduce their carcinogenic effect 
(Lupton, Steinbach et al. 1996).  Alternatively it has been hypothesised that 
calcium acts directly on the colonic mucosa via the calcium sensing receptor 
and changes in c-myc and e-cadherin expression have been demonstrated in-
vitro (Chakrabarty, Radjendirane et al. 2003).  An alternative hypothesis is 
proposed below along with the evidence supporting it; this hypothesis will be 
addressed in part by the experiments described in this thesis. 
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1.5.5 Hypothesis to explain mechanism of action of calcium in 
preventing colorectal neoplasia 
The hypothesis has three parts: 
1. Raised serum PTH increases the risk of developing colorectal 
neoplasia. 
2. Parathyroid hormone acts directly on colonic epithelial cells to alter cell 
signalling and gene expression.  The changes induced by PTH will be 
consistent with a pro-neoplastic effect. 
3. Dietary calcium acts to reduce colorectal neoplasia by reducing serum 
PTH levels and thus results in changes in colonic epithelial cells 
opposite to those seen in response to PTH. 
There is both direct and indirect evidence that raised serum PTH increases 
the risk of colorectal cancer.  This will be presented here in the introduction.  
The second and third parts of the hypothesis will be addressed by the 
experimental studies described in this thesis. 
1.5.6 Parathyroid hormone physiology 
The physiological role of Parathyroid hormone is of relevance to 
understanding how it relates to dietary calcium intake and therefore potentially 
to the incidence of colorectal cancer. 
 Parathyroid hormone (PTH) is a classical endocrine hormone produced 
by the parathyroid glands in the anterior region of the neck.  PTH is an 84 
amino acid polypeptide, derived from a 115 amino acid precursor molecule 
and is the product of a single gene on chromosome 11.  The major function of 
PTH is the maintenance of normal levels of calcium in extra-cellular fluid, 
including serum.  The physiological actions of PTH are mediated by activation 
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of the PTH receptor (PTHR1) on kidney and bone and also indirect actions on 
the intestine.  In response to a fall in ionised calcium levels in the extra-
cellular fluid, decreased stimulation of the Calcium sensing receptor (CaSR) 
on the parathyroid glands results in increased PTH secretion which acts to 
increase calcium levels in three ways: 
1. Acting on the kidney to increase tubular calcium re-absorption thus 
decreasing urinary calcium loss.   
2. Stimulation of osteoclast resorption on bone to mobilise skeletal 
calcium. 
3. Via action on the kidney PTH promotes the conversion of 25OH-
vitamin D to 1,25OH-vitamin D which increases calcium absorption 
from the gastrointestinal tract. 
These actions increase extra-cellular fluid calcium and via a classic endocrine 
feedback loop increased calcium acts via the CaSR to decrease PTH 
secretion (Wass and Shalett 2002).  It is therefore no surprise that dietary 
intake of calcium is a significant, but not the only determinant of serum PTH 
level (Saleh, Jorde et al. 2006). 
1.5.7 Causes of raised serum PTH (hyperparathyroidism) 
1.5.7.1 Primary hyperparathyroidism 
Primary hyperparathyroidism (pHPT) is due to excess secretion of parathyroid 
hormone by an autonomously acting parathyroid adenoma and affects around 
1% of the adult population.  Patients with primary hyperparathyroidism have 
high serum calcium secondary to elevated levels of serum PTH. 
1.5.7.2 Secondary hyperparathyroidism 
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Secondary hyperparathyroidism (SHPT) is a raised serum PTH which occurs 
as a compensatory response to a reduction in serum calcium.  It is 
characterised by a raised serum PTH and a normal or low/normal serum 
calcium level.  There are several factors which have been positively 
associated with SHPT, these include: increasing age (Jorde, Bonaa et al. 
1999), high body mass index (BMI) (Kamycheva, Sundsfjord et al. 2004), 
serum creatinine (Stein, Flicker et al. 2001), vitamin D deficiency (Saleh, 
Jorde et al. 2006), low dietary calcium intake (Saleh, Jorde et al. 2006) and 
dosage of loop diuretic (Stein, Flicker et al. 2001).  
1.6: Raised serum Parathyroid hormone as a risk factor for the 
development of colorectal neoplasia 
There is both direct and indirect evidence, that raised serum PTH is 
associated with an increased risk of developing colorectal cancer.   This 
evidence comes from several sources.  The principal purpose of this 
discussion is to understand the mechanism of action of calcium.  Therefore, 
the evidence relating calcium, PTH and colorectal neoplasia will be presented 
first.  
1.6.1 Calcium acts together with vitamin D on colorectal neoplasia 
There is evidence that calcium acts together with vitamin D to reduce the 
incidence of colorectal neoplasia.  Perhaps the most significant is from the 
American adenoma prevention trial (Baron, Beach et al. 1999).  In this study 
serum 25OH-vitamin D and 1, 25OH-vitamin D levels were measured at the 
start of the study.  The results of the study were analysed with the participants 
divided into two groups, those with serum levels of both vitamin D metabolites 
above and below the median level.  For participants with 25OH-vitamin D 
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levels below the median no effect of calcium was seen on adenoma 
recurrence.  For participants with serum 25OH-Vitamin D levels above the 
median there was a significant reduction in risk of adenoma recurrence (Grau, 
Baron et al. 2003).  There was no difference between the two groups when 
stratified by 1,25OH-Vitamin D measurements.  There was also no 
relationship between serum 25OH-Vitamin D levels and the risk of colorectal 
neoplasia in the placebo treated group but increasing serum 25OH-Vitamin D 
levels were associated with a reduction in risk in those taking calcium 
supplements (Grau, Baron et al. 2003).   These findings led the authors to 
conclude that; “Vitamin D and calcium appear to act jointly, not separately on 
colorectal carcinogenesis” and “Overall, the associations we describe provide 
a strong indication that vitamin D and calcium have a joint anti-neoplastic 
effect in the large bowel”  (Grau, Baron et al. 2003). 
 There is similar evidence from a case control study; this examined the 
relationship between serum levels of 25OH-Vitamin D, dietary calcium intake 
and colorectal adenoma occurrence (Peters, McGlynn et al. 2001).  In this 
study, there was an inverse association between serum 25OH-Vitamin D level 
and colorectal adenoma occurrence.  There was also evidence of an 
interaction between 25OH-Vitamin D and calcium intake, the inverse 
association between 25OH-Vitamin D and adenoma occurrence was stronger 
in those with higher dietary calcium intake (Peters, McGlynn et al. 2001).  A 
similar interaction between vitamin D and calcium and colorectal neoplasia 
has also been observed in two cohort studies (Zheng, Anderson et al. 1998; 
Wu, Willett et al. 2002).  A synergistic effect of calcium and vitamin D on 
colorectal carcinogenesis has also been observed in a rodent study, in this 
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the protective effect of calcium was absent in the presence of vitamin D 
deficiency (Sitrin, Halline et al. 1991).   
 Calcium and vitamin D are inter-related particularly in relation to 
skeletal physiology.  That calcium and vitamin D appear to act jointlym, is 
therefore perhaps not surprising and has implications for the mechanism of 
action of calcium.  It suggests that the effect is not mediated in the intestinal 
lumen as most vitamin D is synthesised in the skin and is not found in the 
intestinal lumen.  Indeed, it seems likely that the action is due to calcium 
absorption that is increased with higher levels of 25OH-Vitamin D (Heaney, 
Dowell et al. 2003; Heaney 2004).  Consistent with the stated hypothesis, 
serum PTH is lowest in individuals with the highest levels of both dietary 
calcium and serum  25OH-Vitamin D (Adami, Viapiana et al. 2008).   
 The evidence that calcium and vitamin D act together, has led to the 
running of adenoma prevention trials testing the combined effect of calcium 
and vitamin D on adenoma occurrence (www.clinicaltrials.gov ID number, 
NCT00153816).  There have also been randomised trials of the effect of 
calcium and vitamin D on the incidence of cancer.  In the women‟s health 
initiative study, the effect of calcium (1000mg) and vitamin D (400 IU) 
supplementation on colorectal cancer incidence showed no effect on 
colorectal cancer incidence after seven years follow up (Wactawski-Wende, 
Kotchen et al. 2006).  This study has been criticised for a number of reasons, 
including the high calcium intake of participants at baseline(Martinez, Marshall 
et al. 2008) and the low dose of vitamin D used (Schwartz and Blot 2006).  
Comparison with the studies of aspirin also suggests that the length of follow 
up was too short, as the effect of aspirin did not become apparent until after 
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ten years of treatment (Flossmann and Rothwell 2007).  In contrast, a 
different study of daily supplementation with 1500mg of calcium and 1100 IU 
of vitamin D resulted in a significant reduction in incidence of any cancer 
(including colorectal) after four years follow up (Lappe, Travers-Gustafson et 
al. 2007).  This study can also be criticised for its short follow up time and the 
use of any cancer as an end point. 
 
1.7: Vitamin D 
As calcium and vitamin D act by the same mechanism, to understand the 
mechanism of action of calcium, it is important to study the data relating 
vitamin D to colorectal cancer.  As well as an association with colorectal 
cancer, there is an increasingly large body of evidence demonstrating an 
inverse association between vitamin D and the risk of a number of other 
cancers (Grant 2010). 
1.7.1 Physiology of Vitamin D  
Vitamin D is a fat soluble vitamin with an essential role in calcium 
homeostasis.  By strict definitions, it is not a vitamin as all requirements can 
be met from the none-dietary source of ultraviolet radiation.  It is well 
recognised that here is a relationship between sunlight and UVB exposure 
and serum levels of 25OH vitamin D.  Lower levels of vitamin D are found at 
higher latitudes where exposure to UVB  radiation is lower (Mithal, Wahl et al. 
2009), even within the United Kingdom, serum 25OH-Vitamin D is lower at 
more northerly latitudes (Macdonald, Mavroeidi et al.).  Serum 25OH-Vitamin 
D also varies by season being higher in the summer and lower in the winter 
(Pasco, Henry et al. 2004; Mithal, Wahl et al. 2009), when exposure to UVB 
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radiation is low (Kimlin 2004).  Important to this discussion is the fact that: 
serum PTH level is negatively correlated with serum 25OH-vitamin D level 
(Lips 2001) and supplementation with vitamin D suppresses serum PTH level 
(Malabanan, Veronikis et al. 1998). 
 
1.7.2 Vitamin D and colorectal cancer 
The evidence linking vitamin D and colorectal cancer is predominantly 
observational.  The starting point for all of these studies is the hypothesis 
proposed by Garland and Garland linking sunlight, exposure to ultraviolet B 
(UVB) radiation and vitamin D to the risk of dying from colorectal cancer 
(Garland and Garland 1980). 
1.7.3 Sunlight exposure and colorectal cancer 
This hypothesis arose from the observation of increased death rates from 
colorectal cancer in areas of low sunlight exposure (Garland and Garland 
1980).  Ground level radiation values, from the United States weather service 
were used to create a map of solar radiation exposure for the whole of the 
United States.  Comparison of this, with published rates of colorectal cancer 
deaths, demonstrated an inverse association between solar radiation 
exposure and deaths from colorectal cancer.  It was also observed that urban 
areas had higher death rates from colorectal cancer compared to rural areas.  
In these urban areas the relationship between solar radiation exposure and 
death rates from colorectal cancer were even stronger.  This paper was not 
the first to report a relationship between higher latitude and death from 
cancer.  In 1941 a link between all cancer mortality and reduced exposure to 
solar radiation in the United States was demonstrated (Apperly 1941).  In this 
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study, the observed lower mortality from cancer was attributed to a relative 
immunity to cancer induced directly by exposure to sunlight. 
What was new in the 1980 paper (Garland and Garland 1980) was the 
linking of the relationship between reduced solar radiation and colorectal 
cancer death to vitamin D levels.  The authors drew a parallel with rickets, the 
childhood bone disease.  Rickets is associated with urban living and lack of 
exposure to solar radiation.  It was subsequently found that rickets was 
caused by low levels of vitamin D and could be treated with vitamin D 
supplements or sunlight exposure (Rajakumar 2003).  The authors proposed 
a similar explanation for the inverse association between solar radiation 
exposure and the risk of colorectal cancer death.  It was hypothesised that 
low levels of vitamin D were associated with an increased risk of death from 
colorectal cancer and that this effect is mediated by a direct effect of vitamin D 
on the colorectal epithelium. 
1.7.4 Serum vitamin D levels 
 
Following on from this ecological evidence, it was hypothesised that if the 
effect of sunlight was mediated by vitamin D that individuals with high levels of 
serum vitamin D would have a lower incidence of colorectal neoplasia 
compared to those with lower levels.  This has been studied in a number of 
observational studies of colorectal cancer and adenoma.   
1.7.4.1 Colorectal cancer incidence and serum 25OH-vitamin D 
The relationship between serum 25OH-vitamin D and a diagnosis of colorectal 
cancer was the subject of a meta-analysis (Gorham, Garland et al. 2007).  
Five studies were included with a total of 535 cases and 913 controls.  The 
five studies were all nested case control studies of healthy volunteers, with 
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pre-diagnostic blood samples who were followed up for 2-25 years after blood 
sample collection.  Four of these studies were carried out in the United States 
and one in Finland.  Individually, three of these studies showed statistically 
significant odds ratio in individuals with higher 25OH-vitamin D levels 
(Tangrea, Helzlsouer et al. 1997; Feskanich, Ma et al. 2004; Wactawski-
Wende, Kotchen et al. 2006) and two showed none significant trends in the 
same direction (Garland, Comstock et al. 1989; Braun, Helzlsouer et al. 
1995).  In the meta-analysis, the odds ratio of the highest versus lowest 
quintile was 0.49 (0.32-0.64), which was highly significant ( p<0.0001).  Two 
of these studies investigated the association between both serum 25OH-
vitamin D and 1,25OH-vitamin D, in both of these there was a significant 
association between colorectal cancer and 25OH-vitamin D but no association 
was seen for 1,25OH-vitamin D (Tangrea, Helzlsouer et al. 1997; Feskanich, 
Ma et al. 2004). 
The meta-analysis demonstrates with greater certainty than the five 
individual studies alone that there is an inverse relationship between serum 
25OH-vitamin D and colorectal cancer incidence.  Importantly, the relationship 
observed is between 25OH and not 1,25OH-Vitamin D.  25OH-Vitamin D is 
the storage form of vitamin D and represents the body‟s reserves; it also has 
an inverse relationship with PTH. 
1.7.4.2 Colorectal adenoma incidence and serum 25OH-vitamin D 
Colorectal adenomas are the precursor to the majority of colorectal cancers.  
As it seems likely that vitamin D acts early in colorectal tumorigenesis; 
studying the relationship between serum 25OH-vitamin D levels and the 
presence of adenomas may provide support for the hypothesis.  A number of 
 30 
studies measuring serum 25OH-vitamin D and determining the risk of 
colorectal adenoma have been carried out.  Recently, a meta-analysis of 
these has been performed (Wei, Garland et al. 2008).  Seven studies were 
identified for inclusion, all of which were carried out in the United States 
between 1989 and 2000.  There were: three case control studies (Levine, 
Harper et al. 2001; Peters, McGlynn et al. 2001; Peters, Hayes et al. 2004), 
one nested case control study (Platz, Hankinson et al. 2000), two cohort 
studies (Grau, Baron et al. 2003; Jacobs, Alberts et al. 2007) and one cross-
sectional study (Miller, Keku et al. 2007).  A total of 2628 cases and 3787 
controls were included.  In the meta-analysis, the odds ratio of colorectal 
adenoma occurrence was 0.7 (95% CI 0.56-0.87), for the highest versus the 
lowest levels of circulating 25OH-vitamin D.  The finding of a risk reduction 
was also observed in six of the studies alone, with the seventh showing no 
effect (Platz, Hankinson et al. 2000).   
1.7.5 Mechanism of action of vitamin D 
Having observed an apparent protective effect of 25OH-Vitamin D on 
colorectal cancer incidence, a direct effect of vitamin D on the colon was 
hypothesised.  In this 25OH-Vitamin D is converted to the active form: 
1,25OH-Vitamin D by 25OH-Vitamin D-1α-hydroxylase, which activates the 
vitamin D receptor (VDR).  Expression of both, 25OH-Vitamin D-1α-
hydroxylase and the VDR has been shown in benign and malignant colonic 
tissues (Matusiak, Murillo et al. 2005). 
1.7.6 Vitamin D and causation of colorectal neoplasia 
These data relating vitamin D to colorectal cancer provides evidence for it 
having a role in the development of cancer.  However, there is only limited 
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randomised controlled trial data.  Therefore, it could be argued that there is 
insufficient evidence that the relationship between vitamin D and reduced 
colorectal cancer incidence is directly causal.  This brings into question 
whether the proposed mechanism of action of vitamin D is direct as described 
above.  It has been argued, using the criteria of Hill (Hill 1965), that the most 
likely explanation for the vitamin D-colorectal cancer observations is causation 
(Grant 2009).  It will be argued here, using the same criteria that though there 
is significant evidence in support of a protective effect of vitamin D, that there 
are weaknesses.  And, that this suggests an alternative mechanism of action 
of vitamin D. 
 In his seminal lecture; „On the environment and disease: association or 
causation‟ (Hill 1965) Sir Austin Bradford Hill highlighted the difficulties of 
inferring causation from epidemiological evidence.  In acknowledging the 
difficulties of differentiating between association or causation, he observed 
that the vital question was whether the presence of a disease B (e.g. 
colorectal cancer) would be reduced by changing an environmental feature A 
(e.g. vitamin D levels).  To aid in the differentiation between causation and 
association, he proposed nine features that could be considered to make 
causation the most likely interpretation. It was clearly stated that none of 
these criteria can be used to confirm causation, only to aid in the decision.  
These nine criteria are listed below. 
1. Strength 
2. Consistency 
3. Specificity 
4. Temporality. 
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5. Biological gradient 
6. Plausibility  
7. Coherence 
8. Experiment 
9. Analogy 
As has been argued (Grant 2009), for most of the criteria the evidence for 
vitamin D being directly protective is reasonably compelling.  However it will 
be argued, that two of these criteria (specificity and biological gradient) are 
not met and that the data suggest an alternative explanation. 
1.7.6.1 Specificity 
As discussed above, there is a body of evidence indicating that calcium and 
vitamin D act to inhibit colorectal neoplasia together, rather than separately.  It 
is of note that, it is not just the effect of calcium that depends on the level of 
vitamin D, but that the effect of vitamin D depends on calcium intake (Peters, 
McGlynn et al. 2001; Grau, Baron et al. 2003).  This implies that both agents 
act jointly through the same mechanism, via a factor modulated by both of 
them.  This argues against Vitamin D having a directly protective effect 
against colorectal neoplasia.  
1.7.6.2 Biological gradient 
The presence of a linear biological gradient, or dose response curve, has not 
been demonstrated for vitamin D and colorectal neoplasia.  Indeed, there are 
studies demonstrating a none-linear relationship between serum levels of 
25OH-Vitamin D and colorectal neoplasia.  The most clear evidence of a non 
linear relationship between 25OH-Vitamin D and colorectal neoplasia is from 
an adenoma case-control study; in this an inverse association between 25OH-
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Vitamin D and colorectal adenoma was demonstrated (Peters, McGlynn et al. 
2001).  This inverse relationship was greatest in the deficiency range, which 
was defined by a node at 12.6ng/ml, identified using piecewise linear 
regression modelling.  Above 12.6ng/ml, the risk of adenoma decreased by 
only 2% for each 1ng/ml increase in 25OH-Vitamin D, in contrast below 
12.6ng/ml the risk of adenoma decreased by 45% for each 1ng/ml increase in 
25OH-Vitamin D.  In most studies of colorectal cancer, categorical 
comparisons have been performed.  These do not precisely show the nature 
of the relationship with 25OH-Vitamin D.  In a meta-analysis of these studies a 
non linear relationship was demonstrated between the risk of colorectal 
cancer and serum 25OH-Vitamin D (Grant 2010).  The risk of colorectal 
cancer was greatest in the vitamin D deficiency range with the benefit per unit 
of nano-mole per litre decreasing at higher serum 25(OH)-Vitamin D levels 
(Grant 2010).  The absence of a linear relationship between serum 25OH-
Vitamin D and colorectal neoplasia argues against a direct protective effect of 
vitamin D on colorectal neoplasia and suggests an alternative explanation. 
 There is a striking similarity between the relationship of 25OH-Vitamin 
D and the risk of colorectal neoplasia (Peters, McGlynn et al. 2001; Grant 
2010) and the relationship between serum 25OH-Vitamin D and PTH (Need, 
O'Loughlin et al. 2004). The relationship between 25OH-Vitamin D and PTH is 
similarly non linear, with little relationship between the two variables above a 
25OH-Vitamin D level of around 45nmol/l and a significant inverse relationship 
below this level.  These observations provide indirect evidence that the risk of 
colorectal neoplasia is greatest when serum PTH is highest and suggest an 
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indirect action of 25OH-Vitamin D in reducing the risk of colorectal neoplasia 
by modulating serum PTH levels.  
 
1.8: Serum PTH levels and colorectal neoplasia 
In addition to the indirect evidence described above there is direct evidence 
that raised serum PTH is associated with an increased risk of colorectal 
cancer.  This comes from two studies published ten years apart (Niv, Sperber 
et al. 1999; Charalampopoulos, Charalabopoulos et al. 2010).  In these two 
small case control studies, both vitamin D and PTH levels were measured and 
both showed the same results.  Higher levels of PTH and lower levels of 
vitamin D were found in cases with colorectal cancer compared to controls.  
Strikingly both studies demonstrated that PTH levels were higher in subjects 
with more advanced disease, suggesting a possible effect on the progression 
as well as the development of cancer.  In both of these studies the primary 
hypothesis of the study relate to the levels of vitamin D and only in the second 
study was a possible role for PTH in colorectal cancer development 
suggested (Charalampopoulos, Charalabopoulos et al. 2010).  These studies 
could be criticised as the serum levels were measured after diagnosis and 
may have been influenced by the disease process rather than causing it.  
However, a report (only published in abstract form) of a nested case-control 
study of 1248 cases from within the EPIC (European investigation into cancer 
and nutrition) cohort study examined the relationship between pre-diagnostic 
levels of serum PTH and the subsequent risk of colorectal neoplasia (Fedirko, 
Riboli et al. 2010).  This showed an increased risk of colorectal cancer in 
patients with serum PTH levels >65 compared to those below this with a 
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relative risk of 1.41 (1.03-1.93).  This increased risk was independent of 
25OH-Vitamin D levels. 
1.8.1 Hyperparathyroidism 
There are a number of clinical situations in which a raised serum PTH is 
found.  Epidemiological evidence that these conditions are associated with an 
increased risk of colorectal neoplasia is presented here and provides further 
indirect evidence that raised serum PTH is a risk factor for the development of 
colorectal cancer. 
1.8.1.1 Primary hyperparathyroidism 
An increased risk of developing colorectal cancer has been demonstrated in 
patients with primary hyperparathyroidism (Palmer, Adami et al. 1988; 
Nilsson, Zedenius et al. 2007), an effect that persists for up to 15 years after 
parathyroidectomy.   
1.8.1.2 Secondary hyperparathyroidism 
The risk factors for secondary hyperparathyroidism have been described in 
section 1.5.7.  It is predicted that these factors may also be associated with an 
increased risk of colorectal cancer.  The evidence that increasing age, low 
dietary calcium and vitamin D deficiency are risk factors for developing 
colorectal cancer have been presented above.   High Body Mass Index (Lin, 
Zhang et al. 2004; Samanic, Chow et al. 2006) and loop diuretic intake 
(Tenenbaum, Grossman et al. 2001) have also been associated with an 
increased risk of colorectal cancer.  The evidence for raised serum creatinine 
is less clear but patients with end stage renal failure have an increased risk of 
colorectal cancer (Iseki, Osawa et al. 1993).  These observations are 
intriguing and consistent with the hypothesis, but of only limited support for it. 
 36 
 
1.8.2 Raised serum PTH and the risk of other cancers 
There is also similar evidence for other cancers that serum PTH may be a risk 
factor for the development of cancer or involved in its progression.  
1.8.2.1 Breast cancer 
Vitamin D 
Similar to the findings with colorectal cancer, there is an inverse association 
between the risk of breast cancer and sunlight exposure (Grant 2002).  In a 
meta-analysis, low levels of serum vitamin D are also associated with an 
increased risk of breast cancer (Grant 2010).  As with colorectal cancer, there 
is evidence of a non linear relationship between 25OH-Vitamin D and breast 
cancer incidence. There is an individual study (Abbas, Linseisen et al. 2008), 
as well as a meta-analysis (Grant 2010) that show a non linear relationship.  
These show minimal variation in risk at higher 25OH-Vitamin D levels, with a 
marked inverse association in the vitamin D deficiency range, when PTH is 
highest.   
Serum PTH level 
There is also direct evidence that serum PTH levels are higher in patients with 
breast cancer compared to controls (Fierabracci, Pinchera et al. 2001).  
Serum PTH levels are also significantly higher in patients with advanced 
compared to early breast cancer (Palmieri, MacGregor et al. 2006). 
Primary hyperparathyroidism 
Patients with primary hyperparathyroidism also have an increased risk of 
breast cancer (Palmer, Adami et al. 1988; Michels, Xue et al. 2004; Nilsson, 
Zedenius et al. 2007).    
1.8.2.2 Prostate cancer 
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The evidence relating PTH to prostate cancer, relates more to advanced 
stage of disease and influence on prognosis.  Raised serum PTH is 
commonly found in patients with prostate cancer, particularly those with bony 
metastases (Murray, Grill et al. 2001).  In another study, higher levels of 
serum PTH were associated with poorer survival (Schwartz 2008).  These 
effects are hypothesised to be mediated in part via the action of PTH on bony 
metastases.  An effect on the early development of prostate cancer has not 
been reported.  However a recent study, demonstrated that in patients without 
prostate cancer serum prostate specific antigen (PSA) is positively correlated 
with serum PTH levels (Skinner and Schwartz 2009).  This is consistent with 
PTH having a growth promoting effect on normal prostate. 
The observation that raised serum PTH is found in three different tumour 
types suggests a similar pathological mechanism is in play for each of them.  
 
1.9: Normal colorectal mucosa 
Based on the findings above, raised serum PTH appears to be a potential risk 
factor for the development of colorectal neoplasia.  It is hypothesised that 
PTH acts directly on colorectal epithelium.  This is based on the evidence 
that, calcium works early in colorectal tumorigenesis to reduce the occurrence 
of adenomas.  There are several studies which have demonstrated an effect 
of dietary calcium supplementation on the normal epithelium and these will be 
reviewed below.  In this thesis, an alternative approach to that of others using 
oligonucleotide micro-arrays will be used to investigate the influence of 
calcium and PTH on gene expression in the normal colorectal mucosa.   The 
following section will briefly review: current understanding of colonic crypt 
organisation, the signalling pathways that regulate this, the effect of calcium 
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on the colonic crypt and normal epithelial markers of the risk of developing 
colorectal cancer. 
1.9.1 Organisation of the colonic crypt 
The colorectal epithelium is a rapidly renewing tissue in which cell 
homeostasis is a balance between proliferation, growth arrest, differentiation 
and apoptosis.  It is made up of a single sheet of columnar epithelial cells 
lying on top of the underlying connective tissue into which this sheet 
invaginates forming millions of crypts, which are the basic unit of the colon.  At 
the base of each crypt are stem cells, these form part of the stem cell niche 
along with the surrounding peri-cryptal myofibroblasts (Humphries and Wright 
2008).  These myofibroblasts secrete a number of factors involved in the 
regulation of stem cell behaviour (Fevr, Robine et al. 2007).  There are four 
types of differentiated epithelial cells in the colon: colonocytes or absorptive 
cells, mucous secreting goblet cells, peptide hormone secreting entero-
endocrine cells and paneth cells which are uncommon and usually only found 
in the ascending colon.  These different cell types all arise from the multi-
potent stem cells at the crypt base.  At a simplistic level, the proliferating cells 
are found at the crypt base and as cells migrate up the crypt they undergo 
growth arrest, differentiate and subsequently undergo apoptosis. 
 It is clear from this description that stem cells are important in 
maintaining the colonic crypt, as the rest of the cells within it will inevitably die.  
This fact has led to the hypothesis that stem cells are the cells of origin of 
colorectal cancer, as it is only in these long lived cells that mutations leading 
to colorectal cancer will have the time to develop.  Consistent with this 
hypothesis, is the finding that deletion of the APC gene in stem cells results in 
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progressive neoplasia, which does not occur if APC is deleted in transit 
amplifying cells (Barker, Ridgway et al. 2009).  Signalling pathways that 
regulate colonic stem cells are therefore of interest.  These stem cell 
regulating pathways along with those that regulate proliferation and 
differentiation in colonic crypts are discussed below. 
1.9.1.1 Wnt signalling pathway 
The Wnt signalling pathway has important functions in the normal colonic 
epithelium and deregulation of the Wnt signalling pathway is a defining feature 
of colorectal neoplasia.  The Wnt signalling pathway is named after the 
wingless Drosophila that was found to be due to mutations in the gene which 
became recongised as components of the Wnt signalling pathway. 
Subsequently the Wnt signalling pathway has been found to have an 
important role in human embryological development and the regulation of 
proliferation and differentiation in several adult tissues as well as the colon. 
Description of Wnt signalling pathway 
The components of the Wnt signalling pathway and their interactions are 
described below and are shown in Figure 1.1.  There are a number of 
components with overlapping functions and tissue specific expression of 
different components is recognised and has been described for the colon 
(Gregorieff, Pinto et al. 2005).  The focus of this introduction will be a general 
overview of the pathway and a specific focus on those components of 
functional relevance in the colon and those altered in colorectal neoplasia.  
There are classically two wnt signalling pathways activated by wnt ligands; the 
canonical and non-canonical pathways.  The canonical pathway acts via β-
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catenin mediated transcription and as this is the pathway deregulated in 
colorectal cancer it will be the focus of this introduction. 
To simplify the pathway, the components can be described in three cellular 
domains; extra-cellular signals and the plasma membrane receptors they 
interact with, the cytoplasmic machinery that controls β-catenin stability and 
the contents of the nucleus that control β-catenin mediated transcription. 
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Figure  1.1 The Wnt signalling pathway. 
http://www.stanford.edu/group/nusselab/cgi-bin/wnt/ 
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Extra-cellular/plasma membrane 
There are a number of (19) secreted Wnt proteins that bind to Frizzled 
receptors in the plasma membrane and their LRP5/6 (low density lipoprotein 
receptor-related protein) co-receptors.   The presence of Wnt ligand results in 
the activation of a signalling cascade that controls the stability of β-catenin.  
There are several inhibitors of Wnt signalling that act to prevent wnt-Frizzled 
interactions.  These include; the SFRP‟s (Secreted Frizzled-related proteins), 
the Dikkopf‟s (DKK‟s) and Wnt inhibitory factor 1 (WIF1).  The expression of 
these inhibitors adds another level of control of the signalling cascade in 
addition to the presence or absence of the wnt ligands.  
 
Cytoplasmic machinery 
 
In the absence of an extra-cellular wnt signal β–catenin in the cytoplasm is 
recruited to a destruction complex, this consists of APC (Adenomaous 
polyposis coli) and Axin.  In this complex β–catenin is phosphorylated by 
GSK3β (Glycogen syynthase kinase 3β) and CK1α (Casein kinase 1α).  This 
phosphorylation results in β–catenin being targeted for proteasome 
dependent degradation, involving interaction with β-TRC, a component of the 
ubiquitin ligase complex.  This process results in low levels of cytoplasmic β–
catenin. 
 In contrast, the presence of wnt ligand activates a signalling cascade 
that results in the stabilisation of cytoplasmic β-catenin.  The results of Wnt 
ligand signalling are phosporylation of LRP5/6 by GSK3β and CK1α.  
Recruitment of Dishevelled to the plasma membrane leads to polymerisation 
of multiple dishevelled moieties and interaction with Frizzled receptors.  These 
processes lead to the inactivation of the destruction complex via translocation 
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of axin to the plasma membrane.  Inactivation of the destruction complex 
leads to the cytoplasmic stablisation of β-catenin, where it is free to 
translocate into the nucleus. 
 
Nucleus 
Following translocation to the nucleus β-catenin forms a complex with the 
transcription factors LEF (Lymphoid enhancing factor) and TCF (T-cell factor). 
This results in the expression of downstream target genes, which have been 
widely studied.  These genes have been characterised (van de Wetering, 
Sancho et al. 2002) and include several genes with key roles in cell 
proliferation and colorectal tumorigenesis, particularly c-Myc (He, Sparks et al. 
1998). 
Deregulation of the Wnt signalling pathway in colorectal cancer 
The most relevant observation implicating deregulation of the Wnt signalling 
pathway in colorectal tumorigenesis is the finding of mutation of the APC gene 
in 85% of sporadic colorectal cancers(Kinzler and Vogelstein 1996).  Germline 
mutations in APC also underlie FAP(Bulow 1989).  Mutations in other 
components of the Wnt signalling pathway are found less frequently.  These 
include CTNNB1 (the gene for β-catenin) and Axin (Satoh, Daigo et al. 2000).  
These mutations lead to the accumulation of β-catenin in the cytoplasm and 
its translocation to the nucleus.  This results in the increased expression of 
Wnt (TCF/LEF) target genes.  Consistent with this is the finding that colorectal 
cancer cells show constitutive activation of β-catenin/TCF complex (Korinek, 
Barker et al. 1997) and high expression of downstream Wnt/β-catenin target 
genes are found in colorectal cancer (Yan, Wiesmann et al. 2001). 
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In additional to mutational activation of the Wnt signalling pathway, promoter 
methylation resulting in decreased expression of several wnt antagonists 
(sFRP1 and DKK1) has been found in colorectal cancers (Caldwell, Jones et 
al. 2004; Gonzalez-Sancho, Aguilera et al. 2005). 
Normal intestine 
The Wnt signalling pathway is the main regulator of the colonic crypt and is 
implicated in maintenance of intestinal stem cells (Crosnier, Stamataki et al. 
2006).  Over activation of the Wnt signalling pathway results in crypt hyper-
proliferation (Sansom, Reed et al. 2004) and blockage of the pathway results 
in loss of proliferating crypt cells (Korinek, Barker et al. 1998).  Similarly, loss 
of Wnt signalling results in differentiation of crypt cells (Mariadason, 
Bordonaro et al. 2001).  Consistent with these observation are the finding that 
Wnt/TCF target genes are strongly expressed in proliferating cells at the crypt 
base and conversely genes negatively regulated by Wnt/TCF are expressed 
in differentiated cells found at the top of the colonic crypt (Kosinski, Li et al. 
2007). 
 
PTH activation of the Wnt signalling pathway 
 
Of relevance to this study is the observation that PTH has been shown to 
activate the Wnt sginallng pathway in bone.  PTH treatment of osteosarcoma 
cell lines results in increased β-catenin expression and increased activity of a 
Wnt reporter gene (Kulkarni, Halladay et al. 2005) with a similar finding in 
mouse osteoblastic cells(Tobimatsu, Kaji et al. 2006).  More recently it has 
been shown that PTHR1 interacts directly with dishevelled and that PTH 
activates β-catenin independent of Wnt (Romero, Sneddon et al. 2010).  
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Whether PTH activates the Wnt signalling pathway in the colon is therefore of 
interest in this study. 
 
1.9.1.2  Hedgehog pathway 
The Indian hedgehog (IHH) signalling pathway has been shown to regulate 
the intestinal stem cell niche.   Knockout of IHH results in: increased 
proliferation, decreased differentiation, increase Wnt signalling and increased 
numbers of stem cells (Kosinski, Stange et al. 2010).  Increased activity of the 
IHH pathway showed the opposite effects (van Dop, Uhmann et al. 2009).  
There is evidence that some of the effects of hedgehog on the colonic crypt 
are mediated by BMP (Bone morphogenetic protein) signalling, with BMP 
signalling limiting the expansion of the proliferative crypts (Crosnier, 
Stamataki et al. 2006). 
 
1.9.2 Features that predict the development of colorectal cancer 
There are two features of normal colorectal epithelium that have been shown 
to predict the risk of developing colorectal cancer.  These are of relevance to 
studying the effect of chemo-preventive agents on normal colorectal mucosa. 
1.9.2.1 Apoptosis 
Reduced apoptosis has been shown to predict current (Anti, Armuzzi et al. 
2001) and future neoplasia (Keku, Amin et al. 2008). 
1.9.2.2 Proliferation and Differentiation 
The presence of proliferating cells in the upper part of the colonic crypt has 
been demonstrated to predict the risk of current (Ponz de Leon, Roncucci et 
al. 1988; Risio, Lipkin et al. 1991) or future neoplasia (Scalmati, Roncucci et 
al. 1990; Anti, Marra et al. 1993). 
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1.9.3 Effect of calcium on normal colorectal mucosa 
 
1.9.3.1 Proliferation and Differentiation 
Several studies have examined the effect of calcium on proliferation markers.  
Some studies have shown no effect of calcium (Gregoire, Stern et al. 1989) or 
only in some individuals (Rozen, Fireman et al. 1989).  In several studies 
calcium reduced the proliferation index, sometimes with a reduction in the 
total number of proliferating cells (Wargovich, Isbell et al. 1992).   The 
commonest finding was a reduction in the number of proliferating cells in the 
upper parts of the crypt, with a redistribution of the proliferation zone to the 
lower portion of the crypt (Nobre-Leitao, Chaves et al. 1995; Holt, Atillasoy et 
al. 1998; Holt, Wolper et al. 2001).  In the only randomised double blind 
placebo controlled trial, with 170 patients, no change in overall proliferative 
index was seen.  However,  again there was a decrease in the number of 
proliferating cells in the upper portion of the crypt, resulting in what the 
authors describe as a normalisation of the distribution of proliferating cells 
(Bostick, Fosdick et al. 1995).  A study of ninety two patients demonstrated 
that calcium increased the expression of p21 (CDKN1A), a cyclin-dependent 
kinase inhibitor only expressed in fully differentiated cells but had no effect on 
the expression of the proliferation marker MIB-1 (Fedirko, Bostick et al. 2009).  
These findings suggest that calcium induces the earlier differentiation of crypt 
cells as they migrate up the crypt, restricting proliferation to the crypt base. 
1.9.3.1 Apoptosis 
Other studies have investigated whether calcium results in increased 
apoptosis in colorectal epithelium, some of these have shown no effect on 
apoptosis (Holt, Wolper et al. 2001; Holt, Bresalier et al. 2006), while others 
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have suggested that calcium may enhance apoptosis (Miller, Keku et al. 2005; 
Fedirko, Bostick et al. 2009). 
1.9.4 Effect of PTH on normal colorectal mucosa 
There are no studies of the effect of PTH on the colorectal mucosa; this will 
be addressed in this study. 
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Chapter 2 
Methods 
 
2.1: Cell culture 
Caco-2 cells (passages 36) were maintained in culture at 37°C in a humidified 
atmosphere of 5% CO2 in Dulbecco‟s Modified Eagle Medium supplemented 
with 10% heat inactivated foetal calf serum.  The methods used to prepare 
Caco2 for the experiments are described in chapter three.  
 
2.2: RNA extraction 
Frozen colonic tissues were thawed on ice and homogenised in 1ml Trizol 
(Invitrogen) using a tissue homogeniser whilst being kept chilled.  The 
samples were incubated at room temperature for five minutes to enable 
complete dissociation of nucleoprotein complexes. To each sample 0.2ml of 
chloroform was added and the tube vortexed for 15 seconds, then incubated 
at room temperature for three minutes. Samples were then centrifuged at 
12,000g for fifteen minutes at 4°C and the upper aqueous phase harvested. 
The RNA was precipitated by addition of 0.5ml isopropanol and incubation for 
ten minutes at room temperature.  The RNA was spun to a pellet by 
centrifugation at 12,000g at 4°C for ten minutes and the supernatant removed.  
The pellet was washed with 75% ethanol, spun at 7,500g at 4°C for five 
minutes.  The supernatant was removed and the pellet allowed to air dry at 
room temperature for ten minutes, the RNA was then re-suspended in an 
appropriate volume of  nuclease free water (30-70μl). For cells-lines, 1x106 
cells were washed with PBS x2 and harvested in 1 ml of TRIzol Reagent 
(Invitrogen) and RNA extracted as described above. RNA was stored at  
-80°C. 
 49 
  
2.2.1 Quantification of RNA 
Total RNA was quantified by measuring the optical density at 260nm of 1μl of 
the RNA suspension using the NanoDrop spectrophotometer (Labtech 
International).  The quality of the RNA was measured using the 260/280nm 
ratio, with values >1.8 and <2.1 indicative of high nucleic acid content 
comparet to non-nucleic acid content. 
 
2.3: cDNA synthesis 
The Promega reverse transcription system A3500 was used. For each sample 
a mastermix of 18μl was made with the following reagents: 
1.0μl (500ng) random primers 
0.75μl (15 units) of Avian Myeloblastosis Virus (AMV) reverse transcriptase 
2.0μl (1/10 volume) of 10X reverse transcriptase buffer 
0.5μl (20 units) of RNase inhibitor 
4.0μl (5mM MgCl2) 
2.0μl (1mM) dNTPs 
7.75μl dH20 
2μl (approximately 200-300ng) of total RNA was added to this mastermix 
giving a final volume of 20μl. An equivalent volume of dH2O was added to an 
additional tube (instead of RNA) which acted as a negative control.  The 
mixture was then reverse transcribed at 42°C for 30 min, followed by 94°C for 
2 min to inactivate the reverse transcriptase. The cDNA was then stored at -
20°C for future use. 
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2.4: SYBR-Green semi-quantitative real-time polymerase chain reaction 
Semi-quantitative real-time polymerase chain reaction (SQRT-PCR) was 
carried out using SYBR-Green.  Analsyses were carried out in triplicate 25μl 
reactions.  Each of which contained 1x Sensimix (Quantace), 20-40ng cDNA, 
9pmoles each primer, 1x SYBRGreen solution (Quantace), 4mM MgCl2 and 
0.5 units UNG (Quantace).  SQRT-PCR was carried out in a 96 well optical 
plate sealed with a plastic cover.  This was carried out using an ABI Prism 
7000 (Applied Biosystems) following the manufacturer instructions. The PCR 
cycle included incubation at 37°C for 10 minutes followed by incubation at 
95°C for 10 minutes.  Then 40 cycles of 95°C for 15 seconds, 58°C for 30 
seconds and 72°C for 30 seconds were performed. 
 
2.4.1 SQRT-PCR data analysis 
SQRT-PCR data was first analysed using ABI Prism 7000 software (Applied 
Biosystems) following the manufacturer guidelines.  Cycle threshold (Ct) 
values were determined for both KRT8 internal control and gene of interest in 
each sample by placing a threshold line through the exponential phase of the 
PCR cycle profiles. This data was then exported to Microsoft Office Excel 
where the average Ct values were calculated from the triplicates. 
2.4.2 Primers for semi-quantative real time PCR 
 For each gene of interest, the cDNA sequence was downloaded from 
Ensembl and primers were designed using Primer3 
(http://frodo.wi.mit.edu/primer3).  The primer pairs used in the SQRT-PCR 
ananlyses amplified an amplicon which crosses an exon-exon boundary.  To 
confirm the presence of a single amplicon of the expected size and the 
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absence of amplified genomic DNA the PCR product was visualised on an 
agarose gel. 
2.4.3 Primer sequences 
PTHR1  Left: GACACACGGCAGCAGTACC 
  Right: GTGTGGCCATGAAGACAATG 
 
AREG  Left TGGTGCTGTCGCTCTTGATA 
  Right ACTGTGGTCCCCAGAAAATG 
 
CYP1A1 Left GACAGATCCCATCTGCCCTA 
  Right GGTTGATCTGCCACTGGTTT 
 
GSN  Left TGGGTTGGAAAGGATTCTCA 
  Right ACAAAGGAGGGAGGCTCAAA 
 
CTBP1 Left CATCGAGATGCGAGAGGAG 
  Right GGCTGTCAGATGGTCCTTGT 
 
STT3A Left GTGTGGACCGTGAAGGTTCT 
  Right CAATCTCAGCATTTCGGACA 
 
GJA1  Left CAATCACTTGGCGTGACTTC 
  Right CCTCCAGCAGTTGAGTAGGC 
 
PDCD4 Left GCTGGAGCGGTTTGTAGAAG 
  Right CCTCCATCTCCTTCGCTTAC 
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2.5: Micro-array expression analysis 
Micro-array expression analysis allows the simultaneous analysis of the 
expression levels of thousands of genes.  Affymetrix expression gene chips 
are single colour oligo-nucleotide micro-arrays.  Two different chips were used 
in the experiments described in this thesis.  The human genome focus array 
was used in chapter four and has around 8,700 probes representing 8,400 
genes.  The human genome U133A 2.0 array was used in chapters six and 
seven and has around 22,000 probes representing 14,500 genes; this 
includes all those on the focus array.  The oligo-nucleotide probes consist of 
25mers and the hybridisation of biotin labelled target sequences in the 
experimental sample to these probes is detected by staining with a 
streptavidin-phycoerythrin and measuring the light emitted at 570 nm. The 
signal produced is proportional to the target gene bound at each location on 
the array, which reflects the transcript levels present in the original target 
population. A number of control genes are used to normalise and scale 
between each array to enable differences in signal intensities to be compared.   
 
2.5.1 Sample preparation for micro-array analysis 
Sample RNA needs to undergo a number of processes prior to micro-array 
analysis. 
2.5.1.1 RNA clean up 
Firstly sample RNA was purified using the Qiagen® RNeasy mini kit as per 
the manufacturer‟s instructions.  Briefly, the RNA samples were adjusted to 
100 μl volume with RNAse free water.   To this 350 μl of buffer RLT is added 
and mixed, this inactivates RNAses.   To this mixture is added 250 μl of 100% 
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ethanol. The mixture is added to the silica-gel membrane within the column 
and centrifuged for 15 seconds at 8000 x g and the flow-through is discarded.  
Subsequently, 500 μl of RPE buffer is added to the column which is again 
centrifuged and the flow-through discarded. This is repeated with a prolonged 
period of centrifugation, to ensure the column is dry and to avoid carry over of 
ethanol.   Finally, 30 μl of RNAse free water is passed through the column to 
elute the RNA. 
2.5.1.2 First-strand cDNA synthesis 
10 μg RNA was reverse transcribed to first-strand cDNA by adding 100 pmol 
T7(dT)24 primer, 2 μl poly-A controls and made up to 11 μl with DEPC-treated 
water. This reaction was incubated at 70ºC for 10 minutes, then a master mix 
consisting of: 4 μl 5X First Strand buffer, 2 μl 0.1M DTT, and 1 μl 10 mM 
dNTPs was added. The samples were then incubated at 42ºC for 2 minutes.  
Then 2 μl Superscript II Reverse Transcriptase was added and the sample 
incubated at 42ºC for 1 hour followed by 2 minutes incubation on ice. 
2.5.1.3 Second-strand cDNA synthesis 
For the second-strand cDNA synthesis a master mix containing: 30 μl 5 X 
Second strand buffer, 3 μl 10 mM dNTPs, 1 μl 10U/μl E.Coli DNA ligase, 4 μl 
10U/μl E. Coli DNA Polymerase I, 1 μl 2U/μl E. Coli RNAse H and 91 μl DEPC 
treated water was made up.  The second-strand cDNA synthesis reaction was 
performed using 130 μl of the master mix added to each of the first strand 
reaction tubes and incubated at 16ºC for 2 hours.  Next 2 μl T4 DNA 
Polymerase was added and incubated at 16ºC for a further 2 minutes, this 
was followed by the addition of 10 μl 0.5M EDTA. 
2.5.1.4 Clean-up of double stranded cDNA 
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To clean up the cDNA, 600 μl of cDNA binding buffer was added to the cDNA 
sample. The sample was place on a cDNA cleanup spin column in a collection 
tube and centrifuged for 1 minute at full speed. The flow-through was 
discarded.   The column was washed with 750 μl wash buffer applied to the 
column and the sample was centrifuged again for 1 minute at full speed. The 
spin column was transferred to a new collection tube and centrifuged for 5 
minutes at maximum speed. The purified cDNA was eluted by adding 14 μl of 
elution buffer and spinning for 1 minute at 10,000 rpm. 
2.5.1.4 In vitro transcription reaction 
This converts the cDNA to cRNA and labels the molecules with biotinylated 
ribonucleotides.  In vitro transcription (IVT) was carried out in the presence of 
T7 RNA polymerase, a biotinylated nucleotide analog/ribonucleotide mix for 
complementary RNA (cRNA) amplification and biotin labelling.  To 6 μl of the 
cDNA sample was added 34 μl of a master mix comprising of: 4 μl 10 X IVT 
labelling buffer¸ 12 μl IVT labelling NTP mix, 4 μl IVT labelling enzyme mix 
and 14 μl DEPC treated water. The sample mixture was incubated over night 
at 37ºC. 
2.5.1.5 cRNA Clean-up 
To purify the cRNA 60 μl RNAse free water was added to the IVT reaction.   
Then 350 μl cRNA binding buffer was added and the mixture vortexed, next 
250 μl of 100% ethanol was mixed with this.  The sample was passé through 
a cRNA cleanup column, centrifuged at full speed for 15 seconds and he flow-
through was discarded.  The column was washed with 500 μl wash 
Buffer, centrifuged and the flow through discarded.  The column was washed 
again this time with 500 μl of 80% ethanol.  The sample was centrifuged for 
 55 
15 seconds at full speed and transferred to a new collection tube and 
centrifuged for a further 5 minutes.  The cRNA eluted from the column with 
RNase free water, this was incubated at room temperature for one minute and 
then centrifuged into an Eppendorf tube.  The RNA concentration and 
A260/A280 ratio was noted using the NanoDrop spectrophotometer (Labtech 
International). 
2.5.1.6 cRNA fragmentation 
The final step prior to hybridisation is fragmentation of the cRNA.  25 μg cRNA 
was fragmented in 10 μl 10X fragmentation buffer which was made up to 50 μl 
with DEPC treated water. The reaction was incubated at 94ºC for 35 minutes 
and then placed on ice. The fragmented cRNA was stored at -80ºC until 
required. 
2.5.1.7 Hybridization to gene chip and scanning 
Hybridization, washing and staining was performed according to the 
manufacturer‟s instructions. This was carried out by Sim Sahota, research 
technician in the department of cancer studies.   A hybridization cocktail was 
prepared containing control oligonucleotide B2 (3nM) 5 μl, 20 x eukaryotic 
hybridisation controls 15 μl, hybridisation mix 150 μl, 30 μl of DMSO and 
nuclease free water made up to 300 μl .  The sample of fragmented cRNA 
was added to this. This mixture was hybridized to the array for 16 hours. 
Following hybridization the array was processed through an automated 
washing and staining protocol on the fluidics station. The arrays were 
scanned using a gene-chip Scanner (Affymetrix GeneChip Scanner 3000; 
Affymetrix).  The cell intensity data for each probe was calculated from the 
scanned image using the GCOS software. 
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2.6: Identification of differentially expressed genes 
2.6.1 Rank product 
The Rank products method (Breitling, Armengaud et al. 2004) was used to 
identify differentially expressed genes (chapters 4 and 6), following RMA 
(Robust Multiarray Analysis) (Irizarry, Bolstad et al. 2003). Briefly, this method 
involves the ranking of genes based on fold change for each replicate 
experiment; and then calculation of the Rank Product.  This identifies those 
genes that appear near the top (or bottom) of the list in all of the replicate 
experiments.  The significance of the results is determined by permutation 
testing a number of random experiments and calculating the percentage of 
false positives (PFP) for each gene.   This allows the determination of the 
false positive rate, if all genes with a similar estimate of the percentage of 
false positives were considered differentially expressed; giving a conservative 
estimate of the chance that a gene is significantly regulated. 
2.6.2 GCOS Change Algorithm 
Differentially expressed genes in rectal mucosa before and after calcium 
treatment were identified using the GCOS change algorithm, which was 
applied with default settings.  For each subject paired comparison was made 
between the arrays before and after calcium supplementation.  The 
Wilcoxon‟s Signed Rank test for paired data was used in a comparison 
analysis; each probe set on the calcium treated array was compared to its 
counterpart on the untreated array.  A change p-value is calculated indicating 
an increase (I), decrease (D), or no change (NC) in gene expression.   
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The number of increase and decrease calls of each probe set was calculated 
using MS Excel and probe sets with the highest number of changes (either 
increased or decreased) among the six subjects were identified.  A threshold 
of a similar change in half the subjects (3/6) was used to identify the group of 
genes considered differentially expressed. 
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Chapter 3 
INVESTIGATION OF THE EXPRESSION OF PTHR1 IN NORMAL AND 
NEOPLASTIC COLON USING SEMI-QUANTITATIVE REAL TIME PCR 
AND IMMUNOHISTOCHEMISTRY 
 
3.1: Aims 
The primary aims of this study were to: 
1. Using semi-quantitative real-time PCR: investigate the relative expression 
of PTHR1 mRNA in colorectal cancer and adenoma cell lines to establish 
suitability for future experiments. 
2. Using semi-quantitative real-time PCR: investigate the relative expression 
of the PTHR1 mRNA transcript in colorectal cancer and adenomas compared 
to normal mucosa. 
3. Using Immuno-histochemistry: investigate the expression of PTHR1 protein 
in colorectal cancers. 
3.2: Introduction 
The hypothesis of this thesis is that PTH acts directly on colonic epithelial 
cells, whether normal or neoplastic.  It is therefore a requirement that colonic 
epithelium is sensitive to PTH.  The physiological action of PTH is mediated in 
an endocrine manner via activation of the PTH receptor (PTHR1), which is 
expressed on its two classical target organs kidney and bone (Gensure, 
Gardella et al. 2005).   PTHR1 is a class B G-protein coupled receptor, 
containing the characteristic seven trans-membrane domains (Juppner, Abou-
Samra et al. 1991).  It mediates the action of both parathyroid hormone (PTH) 
and parathyroid hormone related peptide (PTHrP) on bone (Lanske, Divieti et 
al. 1998).  The downstream signalling of PTHR1 is mediated by activation of 
adenylate cyclase and phospholipase C (Karaplis and Goltzman 2000). 
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The colorectal epithelium is not involved in calcium homeostasis and is 
not a classical PTH target organ, so may not be expected to express PTHR1.  
However, as well as being expressed in bone and kidney, PTHR1 has been 
demonstrated in a wide range of other normal rat tissues including: brain, 
lung, heart, breast, muscle, skin and various parts of the gastrointestinal tract 
(Urena, Kong et al. 1993).  Expression of PTHR1 has also been demonstrated 
in several different human cancers including: breast (Linforth, Anderson et al. 
2002), renal cell (Massfelder, Lang et al. 2004), prostate (Bryden, Hoyland et 
al. 2002), glioma (Evliyaoglu, Carroll et al. 2000) and osteosarcoma (Yang, 
Hoang et al. 2007). 
Expression of PTHR1 in colonic tissues has not been widely studied.  
In the only human study that has investigated colorectal cancers, 2/5 tumours 
demonstrated expression of PTHR1 when assessed by RT-PCR (reverse 
transcriptase polymerase chain reaction) (Carron, Fraser et al. 1997), but 
expression of PTHR1 was not investigated in normal colon or adenomatous 
polyps. 
 In this study the relative expression of PTHR1 mRNA in neoplastic 
compared to normal colon has been investigated.  This was done to 
determine whether PTHR1 is expressed in colorectal cell lines and normal 
and neoplastic colon and whether there is any association between relative 
PTHR1 expression and tumour characteristics.  Similarly expression of 
PTHR1 protein was investigated in a series of colorectal cancers. 
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3.3: Methods and Subjects  
3.3.1 Calculation of Fold changes in PTHR1 expression 
Semi-quantitative real time PCR for PTHR1 was carried out on ten cancers, 
six adenomas and nine samples of normal mucosa.  For each sample Ct 
values were measured for PTHR1 and KRT8.  Mean Ct values were 
calculated from the triplicate analyses.  KRT8 (Cytokeratin 8) is an epithelial 
specific marker and was used to normalise PTHR1 expression.  Fold change 
was calculated in the following standard manner.  For each tumour, polyp and 
normal mucosa sample Dct was calculated.  Fold change was calculated by 
comparison was made with matched normal mucosa as shown below as an 
example for Tumour 1. 
1. DCt for T1= Ct (T1 PTHR1) – Ct (T1 KRT8) 
2. DdCt = DCt (T1) – DCt (N1) 
3. Fold change= 2-DdCt 
Where matched normal mucosa was not available the mean DCt value for all 
the normal samples was used. Relative expression of PTHR1 in the cell lines 
was compared to the mean DCt value for all the normal mucosa samples. 
 
3.3.2 Patient characteristics, Cancers 
The characteristics of the patients and their tumour samples used in the real 
time PCR studies of PTHR1 expression in cancers are described below and 
shown in Table 3.1.  There were 5 males and 5 females.  Mean age was 69.8 
(range 43-83).  In six patients the cancer was proximal to the splenic flexure 
and in four it was distal.  Four of the samples were stage 2 (Dukes B) and six 
were stage 3 (Dukes C) cancers, the TNM stage is shown in Table 3.1.   
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Seven tumours showed moderate and three showed poor differentiation.  One 
tumour (T7) was from a patient with a mutation in MSH2 and showed 
evidence of micro-satellite instability, the other tumours were sporadic with no 
significant family history.  Three out of ten patients were alive and free of 
recurrence at three years; these three patients had stage 2 tumours.  All four 
patients with stage 3 tumours had recurrence.  
 
Table3.1 Patient and tumour characteristics of samples studied 
The patient and tumour features of the ten samples (T1-T10) studied in the 
real time PCR studies of PTHR1 expression are shown.  3YRFS= three year 
recurrence free survival. 
 Site of tumour TNM Differentiation Sex Age 3 YRFS 
T1 Rectum 300 Moderate M 74 No 
T2 Transverse 410 Poor F 76 No 
T3 Sigmoid 300 Moderate M 75 Yes 
T4 Sigmoid 410 Moderate M 66 No 
T5 Ascending 300 Moderate F 83 Yes 
T6 Caecum 400 Poor F 79 No 
T7 Caecum 410 Moderate M 45 No 
T8 Rectum 300 Moderate M 78 No 
T9 Ascending 310 Moderate F 43 No 
T10 Caecum 400 Poor F 79 Yes 
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3.3.3 Patient characteristics, Adenomas 
The characteristics of the six patient samples used in the real time PCR 
studies of PTHR1 expression in adenomas are described below and shown in 
Table 3.2.  One polyp P3 was from a patient with FAP, the remainder were 
from patients with sporadic polyps.  Three were tubulo-villous adenomas 
(TVA) and three were tubular adenomas.  They ranged in size from 7-10mm 
in diameter, four showed moderate and two mild dysplasia and all six 
adenomas were from distal to the splenic flexure.  Four of the patients were 
male and two female and the mean age was 54, (range 21-64). 
Table 3.2 Patient and pathological features of the six adenomas 
The patient and pathology features of the six polyps (P1-P6) studied in the 
real time PCR studies of PTHR1 expression.   
 Site of Adenoma 
Size 
(mm) Dysplasia Pathology Sex Age 
P1 Sigmoid 10 Moderate TVA M 64 
P2 Sigmoid 8 Moderate TVA F 59 
P3 Descending 7 Mild Tubular M 21 
P4 Rectum 8 Moderate Tubular M 57 
P5 Sigmoid 7 Mild Tubular F 63 
P6 Sigmoid 10 Moderate TVA M 62 
 
 
3.3.4 Normal colonic mucosa 
Nine samples of normal mucosa were analysed.  Eight of these were matched 
normal samples from the patients with cancer and one from a patient with a 
polyp, P3.  These samples are taken from macroscopically normal colon away 
from the tumour or polyp.  No matched normal samples were available from 
tumours T4 and T10 and the other patients with polyps.  Five of the normal 
mucosa samples were from proximal to the splenic flexure and four were 
distal. 
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3.3.5 Expression of PTHR1 protein using immuno-histochemistry 
Expression of PTHR1 was studied in fourty-four cancers.  Apart from two 
cases these were a different cohort of patients from those studied using PCR. 
Immunohistochemistry was performed using the streptavidin–biotin indirect 
immunoperoxidase method.  Slide mounted MCF7 breast cancer cells were 
used as a positive and negative control with the primary antibody omitted in 
the latter.  The primary antibody ab3271 (Abcam) is a mouse monoclonal 
antibody that  detects amino acids 146-169 of human PTHR1 (Ferguson, 
Seaner et al. 1998) and was used at a concentration of 1:1000.  
Slide mounted sections were de-waxed by immersion in xylene twice followed 
by 100% ethanol twice, each for five minutes, with a further wash in 70% 
ethanol for five minutes. The slides were then placed in a hydrogen 
peroxide/methanol (1:10) mixture for 5 minutes in order to remove 
endogenous peroxidase activity. Non-specific binding was blocked by 
incubation with 20% normal goat serum for 30 min.   Sections were then 
incubated for with the primary antibody diluted in 20% normal goat serum (see 
above) at 4°C overnight. Following two washes with PBS (phosphate buffered 
saline) sections were then incubated with 1: 500 dilution of biotinylated goat 
anti-mouse (Dako) for 30 min.  Serial PBS washes were undertaken and the 
slides then incubated with streptavidin-peroxidase conjugate (Dako) prior to 
visualisation of immunoreactivity by incubation with diaminobenzidine 
tetrahydrochloride (Sigma).  Sections were counterstained with haematoxylin. 
Sections were then washed in tap water, dehydrated by taking through 
ethanol (70% then 100%) for 10 minutes each, xylene for 10 minutes and then 
mounted in Depex.  Mounted sections were analysed by light microscopy.  
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The sections were scored as positive or negative, depending on whether 
immunoreactivity was seen in the sections with reference to the positive and 
negative control sections.  These were scored independently by me and Dr 
Philippe Taniere, Consultant Pathologist. 
3.3.6 Patient and tumour characteristics 
Of the fourty-four patients studied using immunohistochemistry, twenty-five 
were male and nineteen female.  The location of the tumour was proximal to 
the splenic flexure in fifteen (34%) and distal in twenty nine (66%).  The 
Dukes stage of the tumours was as follows: Dukes A; 5 (11%), Dukes B; 14 
(32%), Dukes C; 16 (36%) and Dukes D; 9 (21%).
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3.4: Results 
3.4.1 Expression of PTHR1 mRNA in normal and neoplastic colon 
Semi-quantitative real time PCR for PTHR1 was carried out on five cell lines, 
nine normal colonic samples, ten cancers and six adenomas.  Mean Ct values 
were calculated from the triplicate analyses and expression compared to 
normal mucosa.   Expression of PTHR1 was seen in all normal, adenoma and 
tumour samples.  Positive controls also demonstrated expression (Mean Ct 
for PTHR1 of 25.34 and 25.67) and the mean Ct values for the negative 
controls were >39.   
 
3.4.2 Expression of PTHR1 mRNA in Cell Lines 
The three colorectal cancer cell lines tested (CACO2, SW480, LOVO) 
expressed PTHR1, in contrast the two adenoma cell lines (RGC2, AAC1) did 
not express PTHR1 with Ct values similar to the negative controls.  Compared 
to the mean expression of PTHR1 in all of the nine normal mucosa samples 
all three cancer cell lines showed increased expression with fold changes of 
33.5 in CACO2, 45.4 in LOVO and 5.2 in SW480.   The relative expression of 
PTHR1 in RGC2 and AAC1 compared to normal mucosa was decreased by a 
magnitude greater than 10,000 fold and are therefore not shown in Figure 3.1. 
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Figure 3.1 Relative expression of PTHR1 mRNA in colorectal cancer cell 
lines compared to normal mucosa 
The Y-axis is fold change (log10 scale) 
1
10
100
Lovo Caco2 SW480
 
 
3.4.3 Relative expression of PTHR1 mRNA in Cancers 
For the ten cancers the mean (range) Ct value for PTHR1 was 31.8 (28.1-
34.3) and for KRT8 23.5 (20.7-25.5).  Comparison was made to matched 
normal mucosa for eight of the samples.  For the two tumours with no 
matched normal sample (T4 and T10) comparison was made to the mean 
PTHR1 expression for all of the normal samples.  Four out of ten tumours 
showed increased (>2 fold) expression of PTHR1, range +5 to +33.4 fold.   
Expression levels of PTHR1 similar to normal mucosa (<2 and >-2 fold 
change) were seen in 2/10 tumours (+1.03 and +1.69 fold difference).  The 
remaining four samples showed decreased expression of PTHR1 (<-2 fold 
change) compared to normal mucosa, range -4.6 to -7.6.    The fold changes 
in tumours showing increased expression were greater than those showing 
decreased expression.  Mean fold change for these ten cancers was +6.3 
fold.  These results are shown graphically in figure 3.2 and table 3.3. 
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Figure 3.2 Relative expression of PTHR1 mRNA in colorectal cancers 
compared to normal mucosa.     
The Y-axis is fold change (log10 scale) 
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Table 3.3 Relative expression of PTHR1 mRNA in the ten cancers 
compared to normal mucosa. 
Relative expression of PTHR1 in the ten cancers is shown along with the 
patient and tumour characteristics.   The samples have been put into three 
groups showing increased, similar or decreased expression compared to 
normal mucosa.  For those tumours showing decreased expression of PTHR1 
two figures are given to aid clarity.  The first is fold change and the second in 
brackets is fold reduction, calculated by -1/fold change. 
 
 
Site of 
tumour TNM Differentiation 3 YRFS 
Relative 
expression of 
PTHR1  
(T vs N) 
Tumours showing increased expression of 
PTHR1 compared to normal mucosa 
T2 Transverse 410 Poor No +33.4 
T5 Ascending 300 Moderate Yes +10.8 
T6 Caecum 400 Poor No +5.1 
T8 Rectum 300 Moderate No +16.7 
Tumours showing similar expression of 
PTHR1 compared to normal mucosa 
T3 Sigmoid 300 Moderate Yes +1.03 
T4 Sigmoid 410 Moderate No +1.69 
Tumours showing decreased expression of 
PTHR1 compared to normal mucosa 
T1 Rectum 300 Moderate No 0.14 (-7.25) 
T7 Caecum 410 Moderate No 0.13 (-7.6) 
T9 Ascending 310 Moderate No 0.22 (-4.56) 
T10 Caecum 400 Poor Yes 0.15 (-6.55) 
 
3.4.4 Comparison of PTHR1 mRNA expression with patient and tumour 
characteristics  
PTHR1 expression levels were compared to the tumour features shown in 
Table 3.3.  In this small group no clear trends or significant association of any 
of these features with PTHR1 expression was seen.  These results are 
described below and summarised in Table 3.4. 
Tumour site 
Of the six cancers proximal to the splenic flexure three showed increased and 
three showed decreased expression compared to normal.  Of the four distal 
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cancers one showed increased and one showed decreased expression and 
the other two showed expression levels similar to normal mucosa. 
Tumour stage 
Of the six stage 2 (Dukes B) cancers, three showed increased expression, 
two showed decreased relative expression and one showed expression 
similar to normal mucosa.  Of the four stage 3 (Dukes C) cancers, one 
showed increased expression, two showed decreased expression and one 
expression levels similar to normal mucosa. 
Differentiation 
Two out of three poorly differentiated tumours showed increased relative 
expression of PTHR1, the third showed decreased relative expression.  Of the 
seven moderately differentiated cancers, two showed increased and three 
decreased relative expression and two showed expression similar to normal 
mucosa. 
Recurrence free survival 
Three year recurrence free survival was not associated with either decreased 
or increased expression of PTHR1.  One out of four patients with increased 
expression was alive and free of recurrence after three years and similarly 
one out of four patients with decreased expression was alive and free of 
recurrence after three years.  One out of two patients with expression levels 
similar to normal mucosa was alive and recurrence free at three years. 
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Table3.4 Relationship between relative expression of PTHR1 mRNA and 
tumour features. 
Comparison is made between cancers showing increased, decreased or 
equivalent expression of PTHR1 and pathological and clinical features. 
Relative expression of 
PTHR1 (T vs N) Increased Equivalent Decreased 
Tumour Site  Proximal 3 0 3 
Distal 1 1 2 
Tumour stage Two 3 1 2 
Three 1 1 2 
Differentiation Poor 2 0 1 
Moderate 2 2 3 
3 Year RFS Yes 1 1 1 
No 3 1 3 
 
3.4.5 Relative expression of PTHR1 mRNA in adenomas 
For the six adenomas the mean (range) Ct values for PTHR1 was 32.8 (31.6-
33.8) and for KRT8, 23.7 (22.3-25.2).  Comparison to matched normal 
mucosa was made for P3, for the rest comparison was made to the mean 
PTHR1 expression for all of the normal samples.  Of the six adenomas two 
showed increased and four showed decreased relative expression of PTHR1 
compared to normal mucosa.  These results are shown in Table 3.5 and 
figure 3.3.  The magnitude of the expression changes ranged from +3.2 fold to 
-3.3 fold change and Mean fold change was +1.3.  The size of the change in 
expression was smaller than those seen in the cancers and the variability in 
relative expression was less compared to that seen in the cancers.  No 
association between relative PTHR1 expression and any pathological features 
were seen.   Increased expression of PTHR1 was seen in one out of three 
tubular adenomas and one out of three TVA‟s.  One out of two mildly 
dysplastic polyps and one of four moderately dysplastic polyps showed 
increased expression of PTHR1. 
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Figure 3.3 Relative expression of PTHR1 mRNA in colorectal adenomas 
compared to normal mucosa.   
The Y-axis is fold change (log10 scale) 
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Table 3.5 Relative expression of PTHR1 mRNA in adenomas compared 
to normal mucosa and adenoma characteristics.   
For those adenomas showing decreased expression of PTHR1 two figures 
are given to aid clarity. The first is fold change and the second in brackets is 
fold reduction, calculated by -1/fold change. 
 Site of Adenoma 
Size 
(mm) Dysplasia Pathology 
Relative expression 
of  PTHR1 
P1 Sigmoid 10 Moderate TVA 0.3 (-2.8) 
P2 Sigmoid 8 Moderate TVA +3.1 
P3 Descending 7 Mild Tubular 0.4 (-2.5) 
P4 Rectum 8 Moderate Tubular 0.6 (-1.8) 
P5 Sigmoid 7 Mild Tubular +3 
P6 Sigmoid 10 Moderate TVA 0.3 (-3.3) 
 
 
3.4.6 Immuno-histochemical expression of PTHR1 protein in colorectal 
cancers 
Of the forty-four cancers tested, forty (91%) were positive and four (9%) 
tumours were negative for PTHR1 expression.  Of the forty positive tumours 
the majority (36) showed homogenous expression, whilst four showed patchy 
positivity. The PTHR1 protein was localised in the epithelial tumour cells, with 
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no significant expression in the tumour stroma apart from the occasional 
neutrophil.  PTHR1 was expressed in the cytoplasm and plasma membrane of 
the epithelial cells with expression in the apical brush border, indicating 
expression at the cell membrane.  There was no nuclear staining.  Expression 
of PTHR1 by Dukes stage was; Dukes A 5/5 (100%), Dukes B 14/15 (93%), 
Dukes C 15/16 (94%) and Dukes D 7/9 (78%).  There was no relationship 
between Dukes stage or tumour localisation and PTHR1 expression.  
 
 
Figure 3.4.  Immuno-histocehmistry for PTHR1 in colorectal cancer 
samples. 
Slide mounted MCF7 cells were used as a positive control. Figure A shows 
MCF7 positive for PTHR1 and B is MCF7 with no primary antibody which 
shows no immunoreactivity for PTHR1 (both x400magnification).  
A B
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Figure 3.4 Continued.  Figs. C and D are of a moderately differentiated rectal 
cancer (C x100, D x400 magnification) shows expression of PTHR1 in the 
glandular epithelium with no nuclear expression or staining of stromal tissue.  
The mos positive staining is seen at the apical border of the tumour glands. 
C
 
 
 
D
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Figure 3.4 Continued.  Figure E (x200) shows a well differentiated caecal 
cancer, similarly showing staining of the glandular epithelium with staining 
seen throughout the cytoplasm but most marked at the apical membrane.  
Figure F (x400) is of a moderately differentiated sigmoid cancer showing no 
positivity for PTHR1. 
 
E
 
 
F
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3.5: Discussion 
This study has demonstrated that normal and neoplastic colon express 
PTHR1 mRNA and protein.  The colonic epithelium and neoplasms 
developing from it are therefore likely to be sensitive to the level of circulating 
serum PTH.  PTHR1 mRNA was more frequently expressed in cancers than 
in the study of Carron who showed expression of mRNA in only 2/5 (Carron, 
Fraser et al. 1997).  In contrast in this study 10/10 tumours demonstrated 
PTHR1 mRNA expression.  This may be explained by the use in this study of 
semi-quantitative real time PCR which is more sensitive than RT-PCR.  In 
other tumour types similar frequencies of PTHR1 expression have been 
reported: 99/107 breast tumours (Downey, Hoyland et al. 1997), 12/12 
prostate tumours (Bryden, Hoyland et al. 2002) and 55/55 osteosarcomas 
(Yang, Hoang et al. 2007) demonstrated PTHR1 expression.   
 This study has demonstrated expression of PTHR1 mRNA and protein.  
Expression of PTHR1 protein was also recently demonstrated in a study 
published since this work was carried out; using immuno-histochemistry, 
PTHR1 protein expression was shown in normal colorectal mucosa, with 
expression localised to the basolateral membrane of epithelial cells(Lupp, 
Klenk et al. 2010).  Interestingly, expression of PTHR1 was seen throughout 
the colonic crypt in most of the colon but in the ascending colon expression 
was limited to cells found at the base of the crypt, a pattern that was also 
seen in the small bowel(Lupp, Klenk et al. 2010).  However in the current 
study there was no relationship between relative expression level and tumour 
site.  No adenomas were studied but all eleven colorectal cancers showed 
expression of PTHR1 protein (Lupp, Klenk et al. 2010).  This contrasts with 
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this larger study in which expression was not universal but only found in 90% 
of tumours.  The reason for this is not clear, it may be that expression is 
heterogenous and is present in other parts of the tumour.  Alternatively the 
level of PTHR1 expression may be below the level of detection or not found in 
a small proportion of tumours. 
The presence of PTHR1 in normal colon as well as adenomas and cancers 
indicate that it is not an oncofoetal protein but has a function in normal as well 
as neoplastic colon. The presence of PTHR1 in the normal as well as 
neoplastic tissue is a also feature of a number of other tumours, including the 
breast (Linforth, Anderson et al. 2002), kidney (Massfelder, Lang et al. 2004), 
prostate (Bryden, Hoyland et al. 2002), brain (Evliyaoglu, Carroll et al. 2000) 
and bone (Yang, Hoang et al. 2007). 
 The samples for the mRNA study were selected to provide initial 
information on PTHR1 expression in colorectal cancers.  There were tumours 
from throughout the colon, with varying degrees of differentiation.  Dukes 
stage B and C cancers were studied to investigate whether there was any 
influence of PTHR1 expression on recurrence, because of this, no early 
(Dukes A) or tumours with metastases were studied.  In contrast in the 
immunohistochemistry study, all tumour stages were studied with no clear 
difference in expression.  One of the polyps P3 was from a patient with FAP 
and one tumour T7 from a patient with a mutation in MSH2.  Both T7 and P3 
showed decreased expression of PTHR1 compared to normal, but were not 
significantly different from the other samples.  The cell line Lovo also carries 
mutation in MSH2 (Umar, Boyer et al. 1994) as does T7 and Lovo showed 
high level expression of, suggesting that decreased expression of  PTHR1 
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need not be a feature of mismatch repair deficient tumours.  The three cancer 
cell lines strongly expressed PTHR1 indicating they would be suitable to study 
the effect of PTH in-vitro.  The reason for the absence of PTHR1 expression 
from the two adenoma cell lines is not clear as PTHR1 is expressed in 
adenomas in-vivo at a similar level to normal mucosa.  It demonstrates the 
differences between the in-vitro and in-vivo situation and means that these 
cell lines are not suitable for studying the effect of PTH in-vitro. 
 The high relative expression of PTHR1 in the colorectal cancer cell 
lines and its absence from the adenoma cell lines suggests that PTHR1 may 
be over-expressed in the cancer samples.   In fact, a similar number of 
tumours showed increased and decreased relative expression of PTHR1, 
suggesting the cell line data is slightly misleading.  For, though there were a 
similar number of tumours showing increased or decreased relative 
expression of PTHR1: the magnitude of the relative expression change was 
greater in the tumours, showing increased expression with a mean fold 
change for all ten tumours of +6.3.  Mean expression of PTHR1 increased 
marginally from normal mucosa to adenoma (+1.3 fold) and again to cancer 
(+6.3 fold).  This suggests a possible role in the progression of colorectal 
neoplasia.  Increasing expression of PTHR1has been shown with advancing 
stage of breast cancer.  Increased expression of PTHR1 compared to normal 
was reported in half of breast tumours (Downey, Hoyland et al. 1997)  and 
bony metastases showed expression levels greater than primary breast 
tumours (Hoey, Sanderson et al. 2003).  In this small study of colorectal 
cancers, no clear association with pathological features was demonstrated.  A 
larger study would be required to determine whether over-expression of 
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PTHR1 was of clinical significance in colorectal cancer.  This is a possibility, 
as a functional role for PTHR1 in tumorigenesis has been suggested in a 
number of other cancers.  Early breast cancers expressing PTHR1 had poor 
clinical outcomes, particularly disease free survival and overall survival 
(Linforth, Anderson et al. 2002).  Consistent with this clinical observation, 
over-expression of PTHR1 in the breast cancer cell line MCF-7 resulted in 
increased proliferation (Hoey, Sanderson et al. 2003).  Similarly, 
osteosarcomas which relapsed or had metastases had higher levels of 
PTHR1 mRNA than those without (Yang, Hoang et al. 2007).  Over-
expression of PTHR1 in HOS; an osteosarcoma cell line, resulted in: 
increased proliferation, motility, invasion and delayed differentiation (Yang, 
Hoang et al. 2007).     
Having demonstrated expression of PTHR1 in the colon, the question 
remains, what is its function?  It would seem likely as has been proposed by 
others that in non-classical PTH target organs, the „natural‟ ligand for PTHR1 
is PTHrP acting in a paracrine or autocrine fashion.  PTHrP was first 
recognised as the mediator of humoral hypercalcaemia of malignancy (Suva, 
Winslow et al. 1987) due to its over expression by tumours and entry into the 
circulation where it activates PTHR1 on bone and kidney raising serum 
calcium.   Over expression of PTHrP is a common finding in several cancers 
including colorectal.  PTHrP is not expressed in adenomas but is found in 
cancers with higher levels of expression associated with advanced stage of 
disease (Nishihara, Ito et al. 1999).  These findings of expression of both 
PTHrP (Nishihara, Ito et al. 1999) and PTHR1 (current study) (Lupp, Klenk et 
al. 2010) in colorectal cancers suggest a role for PTHrP signalling via PTHR1 
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in colorectal neoplasia.  Indeed, over-expression of PTHrP in a colorectal 
cancer cell line results in increased proliferation, invasion and migration 
(Shen, Mula et al. 2007). 
In addition to a pathological role in the development of cancer, PTHrP 
and PHTR1 interactions have a number of physiological functions in 
embryological development and normal tissue homeostasis.  The skeleton is 
the most obvious organ system in which PTHrP/PTHR1 interactions have a 
role in development (Lanske, Karaplis et al. 1996).  There is also evidence 
that PTHrP and PTHR1 are involved in the embryological development of a 
large number of other tissues including, heart, lung, breast, skin and blood 
vessels (Clemens, Cormier et al. 2001).   Based on highly regulated 
expression level of PTHR1, a role in intestinal development has also been 
suggested (Lepourcelet, Tou et al. 2005).   Regulation of normal adult tissues 
by PTHrP/PTHR1 signalling has been demonstrated for the skin, where 
PTHrP acting via PTHR1 has been shown to delay keratinocyte differentiation 
and apoptosis and promote proliferation (Foley, Longely et al. 1998).  Based 
on co-expression of PTHrP and PTHR1 in several normal adult tissues, 
similar roles are proposed in other tissues.  These include the rat intestine 
where PTHrP was expressed only in the upper part of the crypts and a role in 
controlling proliferation and differentiation proposed (Li, Seitz et al. 1995).  
Any such role in the intestine has not been defined, but it can be seen how 
circulating PTH would be able to interfere with any regulation of the colonic 
crypt mediated by PTHrP interacting with PTHR1. 
 80 
3.5.1 Conclusion 
This study has demonstrated expression of PTHR1, the receptor for 
parathyroid hormone, in normal and neoplastic colorectal tissue.  This 
indicates that they are likely to be sensitive to circulating PTH levels.  The 
mean relative expression of PTHR1 increased with the progression of 
neoplasia but with variability between samples.  In this small series there was 
no association of PTHR1 expression with any adverse pathological features. 
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Chapter 4A 
INVESTIGATION OF THE EFFECT OF PARATHYROID HORMONE ON 
GENE EXPRESSION IN AN IN-VITRO MODEL OF THE COLORECTAL 
EPITHELIUM 
 
4A.1: Aim 
 1. Identification of genes differentially expressed in response to 
 parathyroid hormone treatment of an in-vitro model of normal colonic 
 epithelium using oligo-nucleotide micro-arrays. 
  a. Identify genes regulated by PTH and also known to be altered 
  in colorectal tumorigenesis 
  b. Identify genes regulated by PTH in this study and known to be 
  regulated by PTH in other systems. 
 
4A.2: Introduction 
 
In the previous chapter, expression of PTHR1 was demonstrated in normal 
and neoplastic colon, indicating these tissues are likely to be sensitive to PTH.  
The hypothesis of this study is that PTH acts directly on colorectal epithelium 
resulting in changes in gene expression consistent with a pro-tumorigenic 
effect.  The aim of the work described in this chapter is to identify genes 
differentially expressed in response to parathyroid hormone treatment in an 
in-vitro model of normal colorectal epithelium; the cell line Caco2.  In the 
previous chapter, the colorectal cancer cell line Caco2 was shown to strongly 
express PTHR1.  Caco2 forms a polarised monolayer and differentiates with 
time in culture forming crypt like architecture.  Upon differentiation it has been 
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shown to have a gene expression profile similar to normal colonic epithelium 
(Saaf, Halbleib et al. 2007).  And this feature will enable closer comparison 
with experiments on normal colonic epithelium described in chapter three. 
Gene expression profiling using micro-arrays allows the investigation of 
the expression of multiple genes simultaneously.  The gene expression level 
can be compared in diseased versus normal tissue: or, in response to 
chemical or genetic manipulation. This technique has been used to identify 
genes differentially expressed in colonic adenomas and carcinomas 
compared to normal mucosa in several different studies (Cardoso, Boer et al. 
2007).  Gene expression profiling has also been used to identify PTH 
regulated genes in rat osteoblasts in-vitro(Qin, Qiu et al. 2003) and in 
particular to differentiate between the in-vivo effects of intermittent and 
continuous PTH on bone, which are known to have different effects (Li, Liu et 
al. 2007).  The functional effect of PTH on colonic epithelium is unknown, 
although a role in colorectal tumorigenesis is hypothesised.   Gene expression 
profiling is therefore well suited to use in this study in which there are no 
known targets of parathyroid hormone in colonic mucosa and only a general a 
priori hypothesis.     
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4A.3: Methods 
4A.3.1 Cell culture  
In this study, the Caco-2 human colorectal cancer cell line (Passage 36) was 
used.  For the micro-array studies, cells were plated in twelve T25 flasks.  The 
media was changed every 48 hours and the cells were grown until confluence 
was reached, assessed by light microscopy as >90% of cells in contact with 
surrounding cells.  The cells were grown for a further seven days (confluence 
+7), after this time point no further changes in gene expression have been 
shown to occur (Kosinski, Li et al. 2007).  At this point the cells were washed 
with warm PBS and were transferred from Dulbecco‟s Modified Eagle Medium 
(DMEM) + 10% foetal calf serum (FCS) to DMEM + 1% FCS and incubated 
overnight (Approximately 16 hours), as was carried out in another similar 
study (Yu, Seitz et al. 1992) .  The medium was then changed and replaced 
with DMEM + 1% FCS containing 10-7 Parathyroid hormone (Bachem) in the 
test or a similar volume of vehicle in the control samples. The cells were 
treated with N-terminal PTH 1-34, which has the same activity as full length 
PTH (1-84)(Habener, Rosenblatt et al. 1984).  The effect of PTH was studied 
at two time points (4 and 24 hours) to identify early and late targets of PTH. 
The samples were harvested at 4 hours (3 test and 3 controls) and 24 hours 
(2 test and 2 controls).  RNA extraction was carried out and the concentration 
and purity of the RNA was measured as described in the methods.  These 
values are shown in table 4A.1.  
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Table 4A.1 Concentration and purity of RNA extracted from cell lines 
used in the studies described in chapter four.  PTH=PTH treated sample; 
CONT=Control samples and 4 and 24 refer to the number of hours of 
treatment. 
Sample 
RNA  
concentrati
on (ng/µl) 
RNA purity 
(260/280nm ratio) 
PTH4A 1790 2.05 
PTH4B 1581 2.08 
PTH4C 1436 2.03 
CONT4A 1768 2.05 
CONT4B 1840 2.07 
CONT4C 1524 2.07 
PTH24A 1627 2.06 
PTH24B 1425 2.07 
CONT24A 1067 1.99 
CONT24B 2158 2.05 
 
 
4A.3.2 Identification of differentially expressed genes 
Affymetrix Focus micro-arrrays were used in this study; these are single 
colour, oligo-nucleotide arrays with over 8,000 probe sets representing over 
8000 individual genes.  The robust multi-array average (RMA) (Irizarry, 
Bolstad et al. 2003) approach was used to normalise the array data and 
calculate gene expression values.  
 Several methods have been used to identify differentially expressed 
genes in micro-array studies, in this study the Rank products method 
(Breitling, Armengaud et al. 2004) was used.  Briefly, this method involves the 
ranking of genes based on fold change for each replicate experiment; and 
then calculation of the Rank Product.  This identifies those genes that appear 
near the top (or bottom) of the list in all of the replicate experiments.  The 
significance of the results is determined by permutation testing a number of 
random experiments and calculating the percentage of false positives (PFP) 
for each gene.   This allows the determination of the false positive rate, if all 
genes with a similar estimate of the percentage of false positives were 
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considered differentially expressed; giving a conservative estimate of the 
chance that a gene is significantly regulated.  The Rank Products method has 
been shown to perform well compared to t-test based methods such as SAM 
(Significance analysis of micro-arrays) (Breitling, Armengaud et al. 2004) and 
performs well in the presence of a small number of replicates or noisy data 
(Jeffery, Higgins et al. 2006).  In this study genes were defined as 
differentially expressed using Rank Product based on a PFP (percentage 
false positive) cut off below 10%.  
4A.3.3 Fold change 
Fold change was calculated in the standard fashion.  The mean expression 
level of each gene for all post-treatment replicates was divided by the mean 
expression level of each gene for all pre-treatment replicates. 
 
4A.3.4 Analysis of the results from Micro-array experiments 
The first part of the analysis addresses specific hypotheses by identifying 
differentially expressed genes that are: 
1. Known targets of parathyroid hormone.  
2. Known to be differentially expressed in colorectal neoplasia. 
This was done by reviewing the literature using online search tools Pubmed 
and google scholar. 
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4A.4: Results 
4A.4.1 Differentially expressed genes in Caco2 following PTH treatment 
Differentially expressed Genes were identified in the PTH treated samples 
compared to control at 4 and 24 hours.  This was done using Rank Product 
with a PFP cut off of 10% as described in the methods. 
4A.4.1.1 Four hours 
After four hours treatment with PTH eighty two genes were differentially 
expressed.  Increased expression was seen in five genes and decreased 
expression in seventy seven genes.  The fold changes in expression in the 
five genes showing increased expression ranged from +1.4 to +3.2 fold. The 
fold changes in gene expression in the genes showing decreased expression 
ranged from -1.3 to -1.9 fold.   The genes changed at four hours are shown in 
table 4A.2 (Up-regulated) and table 4A.3 (Down-regulated), along with the fold 
change and the PFP (percentage false positive) for each gene.   
Table 4A.2 The five differentially expressed genes showing increased 
expression in caco2 after four hours of PTH treatment.  
PFP=percentage false positive. 
 
Gene 
Symbol Gene description 
Fold 
change PFP 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 +3.2 0 
MAFF v-maf musculoaponeurotic fibro-sarcoma oncogene homolog F (avian) +1.5 0.04 
AREG amphiregulin +1.5 0.01 
APOBEC3
B 
apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like 3B +1.5 0.02 
ARF6 ADP-ribosylation factor 6 +1.4 0. 04 
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Table 4A.3 The seventy seven differentially expressed genes with 
decreased expression in Caco2 after four hours of PTH treatment. 
 
Gene 
Symbol Gene description 
Fold 
change PFP 
STT3A STT3, subunit of the oligosaccharyl-transferase complex, homolog A  -1.9 0 
EIF2S3 eukaryotic translation initiation factor 2, subunit 3 gamma -1.9 0 
TMED2 transmembrane emp24 domain trafficking protein 2 -1.9 0 
PDCD4 programmed cell death 4  -1.8 0 
RTN3 reticulon 3 -1.8 0 
RDX radixin -1.7 0 
TXM1 thioredoxin-related transmembrane protein 1 -1.7 0 
RBBP4 retinoblastoma binding protein 4 -1.6 0.005 
SKP2 S-phase kinase-associated protein 2 (p45) -1.6 0.002 
PSPH phosphoserine phosphatase -1.6 0 
CANX calnexin -1.6 0.007 
SLC16A1 solute carrier family 16, member 1  -1.5 0.01 
MBNL2 muscleblind-like 2 (Drosophila) -1.5 0.003 
TOMM22 translocase of outer mitochondrial membrane 22 homolog (yeast) -1.5 0.02 
COPG coatomer protein complex, subunit gamma -1.5 0.01 
GSN gelsolin (amyloidosis, Finnish type) -1.5 0.01 
NUTF2 nuclear transport factor 2 -1.5 0.002 
RAB8A RAB8A, member RAS oncogene family -1.5 0.02 
LIN7C lin-7 homolog C (C. elegans) -1.5 0.02 
HSPA1B heat shock 70kDa protein 1B -1.5 0.01 
RHOB ras homolog gene family, member B -1.5 0.02 
NUP50 nucleoporin 50kDa -1.5 0.03 
ATF2 activating transcription factor 2 -1.5 0.03 
CALM1 calmodulin 1 (phosphorylase kinase, delta) -1. 5 0.03 
ACTB actin, beta -1.5 0.03 
SRPK1 SFRS protein kinase 1 -1.4 0.03 
TMOD3 tropomodulin 3 (ubiquitous) -1.4 0.02 
SELT selenoprotein T -1.4 0.04 
TTR transthyretin (prealbumin, amyloidosis type I) -1.4 0.02 
NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive -1.4 0.01 
CROP cisplatin resistance-associated overexpressed protein -1.4 0.03 
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OGT O-linked N-acetylglucosamine 
(GlcNAc) transferase  
-1.4 0.02 
EML4 echinoderm microtubule associated protein like 4 -1.4 0.02 
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 -1.4 0.03 
CD9 CD9 molecule -1.4 0.04 
ELL2 elongation factor, RNA polymerase II, 2 -1.4 0.04 
ARFIP1 ADP-ribosylation factor interacting protein 1  -1.4 0.05 
AGPS alkylglycerone phosphate synthase -1.4 0.05 
SCARB2 scavenger receptor class B, member 2 -1.4 0.05 
APLP2 amyloid beta (A4) precursor-like protein 2 -1.4 0.05 
KLF3 Kruppel-like factor 3 (basic) -1.4 0.05 
NLK nemo-like kinase -1.4 0.05 
DUSP5 dual specificity phosphatase 5 -1.4 0.05 
FBLN1 fibulin 1 -1.4 0.05 
UTP20 UTP20, small subunit (SSU) processome component, homolog -1.4 0.05 
RAB5B RAB5B, member RAS oncogene family -1.4 0.05 
JMJD1B jumonji domain containing 1B -1.4 0.06 
ICAM1 intercellular adhesion molecule 1  -1.4 0.03 
HSPA9B heat shock 70kDa protein 9B  -1.4 0.05 
B3GNT2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 -1.4 0.06 
CNN3 calponin 3, acidic -1.4 0.04 
PTPN11 protein tyrosine phosphatase, non-receptor type 11  -1.4 0.06 
GPC3 glypican 3 -1.4 0.05 
SPOP speckle-type POZ protein -1.4 0.05 
SERPINH1 serpin peptidase inhibitor, clade H member 1 -1.4 0.07 
HNRPU heterogeneous nuclear ribonucleoprotein U  -1.3 0.08 
PVR poliovirus receptor -1.3 0.08 
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha -1.3 0.08 
MOCS3 molybdenum cofactor synthesis 3 -1.3 0.04 
GPD2 glycerol-3-phosphate dehydrogenase 2  -1.3 0.06 
CTBP1 C-terminal binding protein 1 -1.3 0.08 
SRRM2 serine/arginine repetitive matrix 2 -1.3 0.05 
GSR glutathione reductase -1.3 0.07 
NCBP1 nuclear cap binding protein subunit 1, 80kDa -1.3 0.06 
GATM glycine amidinotransferase  -1.3 0.05 
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ARHGAP5 Rho GTPase activating protein 5 -1.3 0.06 
BTRC beta-transducin repeat containing -1.3 0.07 
STAT2 signal transducer and activator of transcription 2,  -1.3 0.09 
SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1 -1.3 0.04 
NDRG3 NDRG family member 3 -1.3 0.05 
PPAP2B phosphatidic acid phosphatase type 2B -1.3 0.07 
ANKRD11 ankyrin repeat domain 11 -1.3 0.06 
SFRS1 splicing factor, arginine/serine-rich 1  -1.3 0.08 
ROD1 ROD1 regulator of differentiation 1  -1.3 0.09 
CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 -1.3 0.03 
HOXA7 homeobox A7 -1.3 0.05 
SNRNP40 Small nuclear ribonuclear protein  -1.3 0.09 
 
4A.4.1.2 Twenty four hours 
After twenty four hours treatment with PTH sixty three genes were 
differentially expressed.  Increased expression was observed for two genes 
and sixty one genes showed decreased expression.  The two up regulated 
genes showed increased expression of +1.4 and +1.5 fold.  The genes 
showing decreased expression had fold changes ranging from -1.3 to -5.2 
fold.  The genes changed at twenty four hours are shown in table 4A.4 (Up-
regulated) and table 4A.4 (Down-regulated), along with the fold change and 
the PFP (percentage false positive) for each gene. 
Table 4A.4 The two differentially expressed genes showing increased 
expression after twenty four hours of PTH treatment 
 
Gene 
Symbol Gene description 
Fold 
change PFP 
ACF apobec-1 complementation factor +1.5 0.09 
GLULD1 glutamate-ammonia ligase (glutamine synthetase) domain containing 1 +1.4 0.09 
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Table 4A.5 The sixty one genes showing significantly decreased 
expression after twenty four hours PTH treatment of Caco2 
 
Gene 
Symbol Gene description 
Fold 
change PFP 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 -5.2 0 
MMP1 matrix metallopeptidase 1  -1.8 0 
SLC26A2 solute carrier family 26 member 2 -1.8 0.002 
PRKCI protein kinase C, iota -1.7 0.005 
EREG epiregulin -1.7 0.004 
MYC v-myc myelocytomatosis viral oncogene homolog  -1.6 0.004 
RBM3 RNA binding motif protein 3 -1.6 0.004 
AREG amphiregulin -1.6 0.003 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide -1.6 0.007 
ID1 inhibitor of DNA binding 1,  -1.5 0.004 
NRIP1 nuclear receptor interacting protein 1 -1.5 0.01 
PAFAH1B1 
Platelet-activating factor 
acetylhydrolase, isoform Ib, alpha 
subunit  -1.5 0.006 
SLC25A32 solute carrier family 25, member 32  -1.5 0.01 
PHLDA1 pleckstrin homology-like domain, family A, member 1 -1.5 0.007 
DUSP6 dual specificity phosphatase 6 -1.4 0.02 
ZNF148 zinc finger protein 148 -1.4 0.03 
HSPA1B heat shock 70kDa protein 1B -1.4 0.02 
FUS fusion (involved in t(12;16) in malignant liposarcoma) -1.4 0.02 
HOXA7 homeobox A7 -1.4 0.03 
DYNC1LI2 dynein, cytoplasmic 1, light intermediate chain 2 -1.4 0.02 
LRRFIP1 leucine rich repeat (in FLII) interacting protein 1 -1.4 0.03 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1  -1.4 0.01 
ASNS asparagine synthetase -1.4 0.01 
NUP98 nucleoporin 98kDa -1.4 0.02 
SFRS7 splicing factor, arginine/serine-rich 7, 35kDa -1.4 0.02 
DKK1 dickkopf homolog 1  -1.4 0.02 
SFRS3 splicing factor, arginine/serine-rich 3 -1.4 0.02 
PDCD2 programmed cell death 2 -1.4 0.03 
SGK1 serum/glucocorticoid regulated kinase 1 -1.4 0.04 
GJA1 gap junction protein, alpha 1 (connexin 43) -1.4 0.01 
WNK1 WNK lysine deficient protein kinase 1  -1.4 0.02 
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PHLDA2 pleckstrin homology-like domain, family A, member 2 -1.4 0.06 
SLC2A1 solute carrier family 2 member 1 -1.4 0.05 
SS18 synovial sarcoma translocation, chromosome 18 -1.4 0.06 
RFC3 replication factor C (activator 1) 3, 38kDa -1.4 0.03 
ABCG2 ATP-binding cassette, sub-family G, member 2 -1.4 0.04 
PRNP prion protein  -1.4 0.05 
TAF15 
TAF15 RNA polymerase II, TATA box 
binding protein (TBP)-associated 
factor, 68kDa -1.3 0.04 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 -1.3 0.08 
NOX1 NADPH oxidase 1 -1.3 0.06 
DARS aspartyl-tRNA synthetase -1.3 0.04 
RALA v-ral simian leukemia viral oncogene homolog A (ras related) -1.3 0.06 
STT3A 
STT3, subunit of the 
oligosaccharyltransferase complex, 
homolog A (S. cerevisiae) -1.3 0.07 
SOX9 
SRY (sex determining region Y)-box 9 
(campomelic dysplasia, autosomal 
sex-reversal) -1.3 0.06 
UTS2 urotensin 2 -1.3 0.05 
NOL5A nucleolar protein 5A  -1.3 0.06 
SLC12A2 solute carrier family 12 member 2 -1.3 0.07 
GNL2 guanine nucleotide binding protein-like 2 (nucleolar) -1.3 0.08 
UBIAD1 UbiA prenyltransferase domain containing 1 -1.3 0.03 
YTHDF2 YTH domain family, member 2 -1.3 0.07 
TGIF TGFB-induced factor (TALE family homeobox) -1.3 0.07 
ANKRD11 ankyrin repeat domain 11 -1.3 0.09 
PSPH phosphoserine phosphatase -1.3 0.05 
EFNB2 ephrin-B2 -1.3 0.08 
CKAP4 cytoskeleton-associated protein 4 -1.3 0.08 
FZD7 frizzled homolog 7 (Drosophila) -1.3 0.06 
ARL4C ADP-ribosylation factor-like 4C -1.3 0.08 
MSH2 mutS homolog 2, colon cancer, nonpolyposis type  -1.3 0.09 
BRD2 bromodomain containing 2 -1.3 0.09 
BRD4 bromodomain containing 4 -1.3 0.09 
PPAP2B phosphatidic acid phosphatase type 2B -1.3 0.09 
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4A.4.1.3 Genes differentially expressed at both 4 and 24 hours 
There were eight genes differentially expressed at both four and twenty four 
hours.  For six of these genes (STT3A, HOXA7, HSPA1B, ANKRD11, 
PPAP2B and PSPH) expression was decreased at both four and twenty four 
hours. In contrast, for two genes (CYP1A1, AREG) expression was increased 
at four hours but decreased at twenty four hours. 
 
4A.4.2 Identification of differentially expressed genes known to be 
targets of PTH/PTHrP signalling  
Comparison of the differentially expressed genes with genes already identified 
as targets of PTH signalling was carried out to identify common themes of 
PTH signalling in different tissue types. 
4A.4.2.1 Genes differentially expressed at four hours 
Of the eighty two genes differentially expressed after four hours of treatment 
with PTH, thirty one have been identified as PTH/PTHrP modulated genes in 
different organ systems. These PTH regulated genes are listed in Table 4A.6 
along with the studies in which they were identified.  Twenty one genes were 
differentially expressed in the same direction in both studies.   Twenty genes 
(HOXA7, ROD1, SFRS1, GPD2, GSR, SERPINH1, FBLN1, DNAJB6, NUP50, 
SLC16A1, CANX, RBBP4, SKP2, PDCD4, TMED2, EIF2S3, HSPA9, DUSP5, 
BRD4, and CALM1) were down-regulated in both studies and AREG was up-
regulated.  Nine genes showed different responses to PTH in this study.  
Eight genes (PVR, SCARB2, RHOB, PSPH, APLP2, CD9, PPAP2B and 
HSPA1B) were down-regulated by PTH in this study and up-regulated in the 
other studies and CYP1A1 showed the converse.  One gene, CEBPA is a 
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transcription factor thats expression correlates with known PTH regulated 
genes. 
Table 4A.6 The genes changed in expression in Caco2 after four hours 
of treatment with PTH that have also been previously demonstrated to 
be targets of PTH in other studies. 
Each study is briefly described and the direction of change of expression for 
each gene is given.  One gene (AREG) was changed in more than one study. 
 
Brief description of Study 
Genes in which expression 
changed in response to 
PTH/PTHrP and the 
direction of change  
Expression profiling of Parathyroid 
hormone treated rat osteoblastic cell line 
UMR106-01 (Qin, Qiu et al. 2003) 
Increased: AREG 
PCR study of the influence of Parathyroid 
hormone on PTH treated hepatocytes in-
vitro (Michaud, Naud et al. 2006) 
Decreased: CYP1A1 
Gene expression profiling study of bone 
biopsies from patients with primary 
hyperparathyroidism comparing before and 
after parathyroidectomy (Reppe, Stilgren et 
al. 2006) 
Decreased: HOXA7, ROD1, 
SFRS1, GPD2, GSR, 
SERPINH1, FBLN1, 
DNAJB6,  NUP50, 
SLC16A1, CANX, RBBP4, 
SKP2, PDCD4, TMED2, 
EIF2S3 
Gene expression profiling study of bone 
from rats treated with parathyroid hormone 
(Li, Liu et al. 2007) 
Increased: PVR, SCARB2, 
RHOB, PSPH, AREG 
Gene expression profiling study of bone 
from rats treated with parathyroid hormone 
(Onyia, Helvering et al. 2005) 
Decreased: HSPA9 
 
Increased: APLP2, CD9 
Gene expression profiling study of MCF7 
breast cancer cell lines treated with siRNA 
to PTHrP (Dittmer, Vetter et al. 2006) 
Increased: PPAP2B, 
HSPA1B 
  
Down-regulated: DUSP5, 
AREG 
Genes altered in expression following in-
vitro treatment of chondrocytes with PTHrP 
(Hoogendam, Farih-Sips et al. 2007) 
Decreased: BRD4, CALM1 
Promoter analysis study identifying 
transcription factors associated with PTH 
regulated genes (Qiu, Qin et al. 2003) 
Correlated with PTH 
regulated genes: CEBPA 
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4A.4.2.2 Genes differentially expressed at twenty four hours 
Of the sixty three genes changed after twenty four hours, twenty five have 
been identified as PTH/PTHrP modulated genes in different studies and three 
of them (AREG, GJA1 and SFRS3) were identified in more than one study.  
These PTH regulated genes are listed in Table 4A.7 along with the studies in 
which they were identified.  Fifteen genes (CYP1A1, MSH2, ARL4C, FZD7, 
PSPH, NOL5A, RFC3, ASNS, SFRS3, LRRFIP1, PHLDA1, AREG, GJA1, 
DKK1 and ID1) out of the twenty five were differentially expressed in the same 
direction, all of them being down-regulated in both studies.  Neither of the two 
genes showing increased expression after twenty four hours has been 
demonstrated to be a target of PTH signalling.  The other ten genes that 
showed decreased expression in this study (SOX9, GJA1, PHLDA2, HOXA7, 
ATP1B1, CKAP4   SGK1, DUSP6, MYC, PPAP2B and EFNB2) were up-
regulated in the other studies.  Two genes AREG and GJA1 have been 
demonstrated to be both up and down regulated in response to PTH. 
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Table 4A.7 The twenty five genes changed in expression in Caco2 after 
twenty-four hours of treatment with PTH that have also been previously 
demonstrated to be targets of PTH/PTHrP signalling in other studies.  
Each study is briefly described and the direction of change of expression for 
each gene is given.  Three genes (AREG, GJA1 and SFRS3) were changed 
in more than one study. 
Brief description of Study 
Genes in which expression 
changed and the direction of 
change 
Expression profiling of Parathyroid hormone 
treated rat osteoblastic cell line UMR106-01 
(Qin, Qiu et al. 2003) 
Increased: AREG 
PCR study of the influence of Parathyroid 
hormone on PTH treated hepatocytes in-
vitro (Michaud, Naud et al. 2006) 
Decreased: CYP1A1 
Gene expression profiling study of bone 
biopsies from patients with primary 
hyperparathyroidism comparing before and 
after parathyroidectomy (Reppe, Stilgren et 
al. 2006) 
Decreased: MSH2, ARL4C, 
FZD7, SFRS3 
 
Increased: SOX9, GJA1, 
PHLDA2, HOXA7, ATP1B1 
Gene expression profiling study of bone 
from rats treated with parathyroid hormone 
(Li, Liu et al. 2007) 
Decreased: PSPH, NOL5A, 
RFC3,  
ASNS 
Increased: CKAP4   SGK1, 
DUSP6, MYC 
Gene expression profiling study of MCF7 
breast cancer cell lines treated with siRNA 
to PTHrP (Dittmer, Vetter et al. 2006) 
Up-regulated: PPAP2B,  
 
Down-regulated: SFRS3, 
LRRFIP1, PHLDA1, AREG 
Gene expression changes during 
endodermal differentiation induced by 
PTHrP treatment (van der Heyden, Veltmaat 
et al. 2000) 
Decreased: GJA1 
Influence of PTH on bone (Allan, Hausler et 
al. 2008) 
Increased: EFNB2 
Influence of parathyroid hormone treatment 
on the Wnt pathway components in bone 
(Kulkarni, Halladay et al. 2005) 
Decreased: DKK1 
Gene expression profiling of the rat 
osteosarcoma cell line UMR106-01 treated 
with PTH (Qin, Qiu et al. 2003) 
Decreased:ID1 
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4A.4.3 Differentially expressed genes known to be changed in colorectal 
tumorigenesis 
To investigate the hypothesis that PTH influences signalling pathways 
involved in colorectal tumorigenesis, a review of the literature was performed.  
This identified any previously reported changes in expression of these genes 
in colorectal neoplasia.   
 
4A.4.3.1 Genes showing increased expression after four hours of PTH 
treatment 
Increased expression in colorectal neoplasia 
Of the five genes showing increased expression after four hours, two of them 
(AREG and MAFF) have been demonstrated to show increased expression in 
colorectal neoplasia.    Increased expression of AREG has been 
demonstrated in colorectal cancer compared to normal colonic mucosa 
(Croner, Foertsch et al. 2005) and MAFF shows increasing expression with 
advancing stage of colorectal cancer (Friederichs, Rosenberg et al. 2005).   
 
4A.4.3.2 Genes showing decreased expression after four hours of PTH 
treatment 
Decreased expression in colorectal neoplasia 
Of the seventy seven genes showing decreased expression after four hours of 
PTH treatment, decreased expression of fifteen of them has been implicated 
in colorectal tumorigenesis.  Decreased expression in adenomatous polyps 
compared to normal mucosa has been demonstrated for six genes ICAM1, 
PPAP2B, FBLN1, RDX (Segditsas, Sieber et al. 2008), PDCD4 (SEUNGKOO 
LEE 2006), and DUSP5 (Nikola A. Bowden 2007).  Decreased expression in 
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colorectal cancer compared to normal mucosa was found in five genes, 
ARHGAP5 (Lin YM 2002), GPD2 (Bianchini, Levy et al. 2006), HSPA9 
(Bertucci, Salas et al. 2004), GSN (Gay, Estornes et al. 2008) and BTRC 
(Grade, Hormann et al. 2007). 
For two genes (OGT and CD9), decreased expression was found in 
advanced stage disease compared to early stage disease.  Decreased 
expression of OGT and CD9 is more common in cancers with nodal 
involvement (Hashida, Takabayashi et al. 2003; Grade, Hormann et al. 2007).   
Decreased expression of OGT (Fritzmann, Morkel et al. 2009) and CNN3 
(Bertucci, Salas et al. 2004) is found in tumours with distant metastases.  
Inactivating mutations of OGT are also commonly found in tumours with 
micro-satellite instability (Woerner, Gebert et al. 2001). 
 
Increased expression in colorectal neoplasia 
Of the seventy seven genes showing decreased expression after four hours of 
PTH treatment, increased expression of six of them has been implicated in 
colorectal tumorigenesis.  Increased expression in adenomatous polyps 
compared to normal mucosa was found in two genes, SFRS1 and HNRPU 
(Gaspar, Cardoso et al. 2008) and increased expression in colorectal cancer 
compared to normal mucosa was found in four genes, MOCS3 (Wiese, Auer 
et al. 2007), SERPINH1 (Croner, Foertsch et al. 2005) SKP2 and SRPK1 (N 
Ancona and S Liuni 2006). 
Overall after four hours treatment with PTH, twenty three of the differentially 
expressed genes have been shown to be altered in colorectal neoplasia.  Of 
 98 
these, seventeen are changed in the same direction and six in the opposite 
direction by PTH.  These are shown in tables 4A.8 and 4A.9 respectively. 
  
Table 4A.8 The seventeen genes changed after four hours of PTH 
treatment, which are also changed in a similar manner in colorectal 
neoplasia.  The studies identifying these changes are included 
 Gene symbol 
Increased in 
cancer 
MAFF (Friederichs, Rosenberg et al. 2005), AREG 
(Croner, Foertsch et al. 2005) 
Decreased in 
cancer 
ARHGAP5 (Lin YM 2002), BTRC (Grade, Hormann 
et al. 2007), GPD2 (Bianchini, Levy et al. 2006), 
GSN (Gay, Estornes et al. 2008) 
Decreased in 
polyps 
PPAP2B, FBLN1, ICAM1, RDX (Segditsas, Sieber 
et al. 2008), PVR (Gaspar, Cardoso et al. 2008), 
DUSP5 (Bowden, Croft et al. 2007), PDCD4 (Lee, 
Bang et al. 2006) 
Decreased in 
advanced 
tumours 
HSPA9, CNN3 (Bertucci, Salas et al. 2004), OGT 
(Fritzmann, Morkel et al. 2009), 
Poor prognostic 
marker CD9, (Hashida, Takabayashi et al. 2003) 
 
 
 
Table 4A.9 The six genes changed after four hours of PTH treatment, 
which are changed in the opposite direction to that seen in colorectal 
neoplasia.  The studies identifying these changes are shown 
 Gene symbol 
Increased in 
cancer SRPK1, SKP2 (N Ancona and S Liuni 2006) 
Increased in 
polyps 
SFRS1, HNRPU, (Gaspar, Cardoso et al. 2008), 
MOCS3 (Wiese, Auer et al. 2007), SERPINH1 
(Croner, Foertsch et al. 2005) 
 
4A.4.3.3 Genes with increased expression after twenty four hours of PTH 
treatment 
Neither of the two genes showing increased expression after twenty four 
hours has been demonstrated to show altered expression in colorectal 
neoplasia.   
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4A.4.3.4 Genes showing decreased expression after twenty four hours 
of PTH treatment 
Decreased expression in colorectal neoplasia 
Of the sixty three genes showing decreased expression after twenty four 
hours of PTH treatment, decreased expression of ten of them has been 
implicated in colorectal tumorigenesis.  Decreased expression in 
adenomatous polyps compared to normal mucosa has been demonstrated in 
six genes, PPAP2B, ABCG2, SGK, GJA1 (Segditsas, Sieber et al. 2008), 
PRNP (Nikola A. Bowden 2007) and PRKCI (Kim, Park et al. 2008).  
Decreased expression in colorectal cancer compared to normal mucosa has 
been demonstrated for four genes, DKK1 (Gonzalez-Sancho, Aguilera et al. 
2005), ABCB1 (Birkenkamp-Demtroder, Olesen et al. 2005), ATP1B1 (Chen, 
Zhang et al. 2006) and SLC26A2 (Cardoso, Boer et al. 2007). 
 
Increased expression in colorectal neoplasia 
Of the sixty three genes showing decreased expression after twenty four 
hours of PTH treatment, increased expression of ten of them has been 
implicated in colorectal neoplasia.  Increased expression in adenomatous 
polyps compared to normal mucosa has been demonstrated for seven genes, 
NUP98 (Salahshor, Goncalves et al. 2005), NOL5A, SLC12A2, RFC3, 
PHLDA1, SOX9 and MYC (Gaspar, Cardoso et al. 2008).  Increased 
expression in colorectal cancer compared to normal mucosa has been 
demonstrated for three genes, TGIF (Cardoso, Boer et al. 2007), AREG and 
MMP1 (Croner, Foertsch et al. 2005). 
 
 100 
Overall at twenty-four hours, twenty differentially expressed genes have been 
shown to be altered in colorectal neoplasia.  Of these ten are changed in the 
same direction and ten in the opposite direction by PTH in this study.  These 
are shown in tables 4A.10 and 4A.11. 
Table 4A.10 The ten genes changed after twenty-four hours of PTH 
treatment, which are also changed in a similar manner in colorectal 
neoplasia.  The studies identifying these changes are shown 
 Gene symbol 
Decreased in 
cancer 
DKK1(Gonzalez-Sancho, Aguilera et al. 2005), 
ABCB1(Birkenkamp-Demtroder, Olesen et al. 2005) 
ATP1B1(Chen, Zhang et al. 2006), SLC26A2 
(Cardoso, Boer et al. 2007) 
Decreased in 
polyps 
PPAP2B, ABCG2, GJA1, SGK1 (Segditsas, Sieber 
et al. 2008) PRNP (Bowden, Croft et al. 2007) 
PRKCI (Kim, Park et al. 2008) 
 
Table 4A.11 The ten genes changed after twenty-four hours of PTH 
treatment, which are changed in the opposite direction to that seen in 
colorectal neoplasia.  The findings of the studies identifying these changes 
are included 
 Gene symbol 
Increased in 
cancer 
TGIF, SOX9 (Cardoso, Boer et al. 2007), NUP98 
(Salahshor, Goncalves et al. 2005), AREG, MMP1 
(Croner, Foertsch et al. 2005) 
Increased in 
polyps 
NOL5A, SLC12A2, RFC3, PHLDA1 (Gaspar, 
Cardoso et al. 2008), MYC (Segditsas, Sieber et al. 
2008) 
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4A.5 Discussion 
 
In these experiments, parathyroid hormone treatment of the colorectal cell line 
Caco2 resulted in the differential expression of a number of genes, 
demonstrating that parathyroid hormone alters gene expression in colonic 
cells: a non-classical PTH target.  At both time points, the majority of genes 
showed decreased expression: this suggests that in the colon PTH acts as a 
transcriptional repressor.  This differs from other in-vitro micro-array studies of 
PTH action in bone that show similar number of increased and decreased 
genes (Qin, Qiu et al. 2003). 
4A.5.1Parathyroid hormone responsive genes  
In this study a number (56/145) of the differentially expressed genes are 
recognised PTH/PTHrP targets, identified in other tissues, predominantly 
bone.  Inclusion of genes modulated by PTHrP is based on the observation 
that both PTH and PTHrP activate the PTH receptor, PTHR1, with similar 
efficacy.  This finding indicates that the same signalling mechanisms activated 
by PTH in bone are likely to be active in the colon.  The classical signalling 
mechanism for PTH is via stimulation of adenlyl-cyclase, production of cAMP 
(cyclic adenosine monophosphate) and activation of protein kinase A (PKA) 
(Swarthout, D'Alonzo et al. 2002).  PTH stimulates the production of cAMP in 
the colonic cell line Lovo (Yu, Seitz et al. 1992), indicating that the cAMP/PKA 
pathway is activated by the PTH signalling pathway in the colon.  This is 
consistent with the findings of differential expression of some of the genes in 
this study known to be regulated by the PTH/cAMP/PKA pathway.  For 
example, the most highly up-regulated gene after four hours is Amphiregulin 
(AREG).  Amphiregulin has been demonstrated to be up-regulated by PTH in 
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rat osteoblasts in-vitro (Qin, Tamasi et al. 2005) and rat bone in-vivo (Li, Liu et 
al. 2007) and is regulated by the cAMP/PKA pathway(Qin and Partridge 
2005).  Similarly, down-regulation of Dikkopf1 (DKK1) in bone, in response to 
PTH is mediated by cAMP (Kulkarni, Halladay et al. 2005).  Decreased 
expression of GJA1 is also mediated similarly by PTHrP and production of 
cAMP (van der Heyden, Veltmaat et al. 2000). The downstream signalling 
mechanisms of PTH signalling in the colon have not been fully investigated.  It 
seems likely, based on the above observations, that the cAMP/PKA pathway 
is active in colonic cells.  Parathyroid hormone has also been shown to 
activate a number of other signalling pathways in the small intestine, 
including: phospholipase C (PLC) (Gentili, Boland et al. 2001), calcium influx 
(Picotto, Massheimer et al. 1997) and MAP kinases (Gentili, Morelli et al. 
2001).  The contribution of specific signalling pathways to these PTH 
mediated changes has not been investigated in this study. 
   Some of the differentially expressed genes are regulated in a different 
direction to that seen in other tissues.  Differential regulation of other genes by 
PTH from different tissues (van der Heyden, Veltmaat et al. 2000; Qin, Qiu et 
al. 2003; Dittmer, Vetter et al. 2006; Reppe, Stilgren et al. 2006; Li, Liu et al. 
2007), or within the same tissue but different contexts(Li, Liu et al. 2007), has 
been observed.  These findings suggest that the changes induced by PTH 
may be tissue or context specific.   Having observed overlap with known PTH 
regulated genes it is important to note that the majority of the genes 
differentially expressed in this study have not been previously shown to be 
PTH target genes.  These genes therefore represent novel PTH target genes 
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in the colon, which it is predicted would be differentially expressed in 
response to PTH in-vivo. 
4A5.2 Colorectal neoplasia associated genes 
Identification of a number of genes differentially expressed in response to 
PTH, that are similarly differentially expressed in neoplastic colon compared 
to normal colon, indicates that PTH may have a role in colorectal 
tumorigenesis.  After four hours, seventeen genes were changed in a 
direction consistent with a role in tumorigenesis and six genes were changed 
in the opposite direction.  At twenty four hours a differential effect was not 
apparent with a similar number of genes (ten) showing changes both 
consistent with or opposite to those seen in neoplastic colon.  One possible 
explanation for this is that the pro-neoplastic effects of PTH are seen early 
after treatment and as the effect of the single PTH treatment diminishes, 
these pro-neoplastic changes are less apparent.  Another explanation is that 
the predominant effect of PTH is not to just to change the expression of genes 
known to be altered in colorectal tumorigenesis.  This is apparent from the 
observation that the majority of the differentially expressed genes are not 
differentially expressed in colorectal neoplasia.  Identification of the function of 
the differentially expressed genes is therefore of interest. 
 Of the differentially expressed genes also altered in colorectal 
neoplasia, the most interesting is Amphiregulin (AREG), which was up-
regulated by PTH at four hours.  Amphiregulin is a member of the epidermal 
growth factor family and acts via the EGFR (epidermal growth factor 
receptor).  Amphiregulin is a well recognised PTH target gene in bone and is 
involved in the growth of osteoblasts (Qin, Tamasi et al. 2005).  In addition to 
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being a recognised PTH target, Amphiregulin is strongly implicated in 
colorectal neoplasia.    Amphiregulin expression is higher in tumours 
compared to normal mucosa (Croner, Foertsch et al. 2005) and high 
expression level also predicts the development of liver metastases (Yamada, 
Ichikawa et al. 2008).  As well as altered expression in neoplastic colon 
Amphiregulin also has growth promoting effects on colorectal cells in-vitro 
(Damstrup, Kuwada et al. 1999).  Thus, PTH induced up-regulation of 
Amphiregulin provides evidence for a growth promoting effect of PTH on 
colorectal cells.  However, increased expression of AREG at four hours was 
followed by decreased expression at twenty-four hours.  Whether this is a 
homeostatic response, a downstream result of PTH or due to the diminishing 
effect of PTH with time from the treatment, is not clear.  It again demonstrates 
that the effect of PTH is not simply to alter the expression of genes known to 
be altered in colorectal neoplasia. 
4A.5.3 Comparison with other studies 
This is the first study identifying global changes in gene expression in a 
colorectal cell line in response to PTH.  Only one other study has investigated 
the effect of PTH on gene expression in a colorectal cell line.  In that study, 
PTH treatment of the colorectal cell line Lovo resulted in increased expression 
of ornithine decarboxylase (ODC) mRNA and increased ODC activity after two 
hours (Yu, Seitz et al. 1992).  Differential expression of ODC was not 
observed in this study, probably due to investigation of different time points.  
This suggests that increased ODC expression is an early response to PTH 
treatment, which returns promptly to normal in the absence of persistent PTH 
stimulation.     
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 Studies investigating the effect of PTHrP in colorectal cell lines have 
been more commonly carried out.  Over expression of full length PTHrP in 
Lovo has been shown to increase the expression of integrins α6 and β4 
(Shen, Rychahou et al. 2007).  These changes were not seen in this study. 
This could be for many reasons, including the use of a different cell line, Lovo.  
But there is also evidence that PTHrP mediates its effects via an intracrine 
pathway (Bhatia, Saini et al. 2009) as well as by activation of PTHR1.  
4A.5.4 Caveats and limitations 
The approach used in this study of identifying early (4hour) and late (24 hour) 
transcriptional targets, was the same taken in studies of parathyroid hormone 
treatment of bone (Qin, Qiu et al. 2003) and in studying the effect of other 
agents on colorectal cell lines (Palmer, Sanchez-Carbayo et al. 2003).  The 
nature of these in-vitro studies, using administration of a single treatment of 
PTH with a limited half life, differs from the in-vivo situation where a steady 
state of PTH stimulation is likely to be found.  The half-life of naturally 
occurring PTH in-vivo is around 4 minutes (Irvin and Carneiro 2000).  Of more 
relevance to this study, is that the half life of recombinant PTH used as 
treatment for osteoporosis has a half life of one hour (Deal 2004).  The in-vitro 
half life of PTH used in this study is not known (Personal communication) but 
it is likely to be similar to these two values.  It is therefore recognised that the 
nature of the response to the treatment schedule employed here represents a 
change in PTH level, rather than that seen in response to a steady state 
difference in serum PTH.  The two time points employed can be seen to 
represent the immediate transcriptional effects of PTH treatment (4 hours) 
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and the downstream consequences of this treatment (24 hours) and possibly 
homeostatic consequences. 
 It could be argued that the ideal cell line for investigating events early 
in tumorigenesis, would be an adenoma cell line, but those studied in chapter 
one (RGC2 and AAC1) did not express PTHR1.  Though it has some features 
of normal colonic epithelium, Caco2 is derived from a malignant colorectal 
tumour and has gene expression profiles similar in part to normal colonic 
mucosa and in part to tumours (Saaf, Halbleib et al. 2007).  Of note is that the 
caco2 gene expression profile becomes more like normal colonic gene 
expression profile with prolonged time in culture (Saaf, Halbleib et al. 2007).  
It is therefore predicted that the response of caco2 to PTH shows some 
features of normal colon and some of a colorectal tumour. 
 At twenty-four hours, the array studies were only carried out in 
duplicate compared to at four hours when the studies were performed in 
triplicate which is considered standard procedure, this was for logistical 
reasons.  This was taken into account by using Rank product to identify 
differentially expressed genes, as this method is well suited when few 
replicates are used (Jeffery, Higgins et al. 2006). 
 The fold changes seen in the array study are relatively small, 
suggesting that the overall effect of PTH is small; this may not be the case 
and could be due to a number of reasons.  As discussed above caco2 has 
altered gene expression profiles consistent with its malignant origin and may 
already highly express PTH target genes, limiting the ability of PTH to further 
stimulate expression.  Expression of PTHrP by Caco2 acting at the same 
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PTHR1 receptor will also limit the ability of PTH to further stimulate changes 
in gene expression. 
4A.5.5 Alternative techniques and future studies 
In completing this study it became clear how things could have been improved 
on and what further studies should be carried out.  Repeated treatments with 
PTH over a longer period (eg. 72-96 hours) would be expected to result in 
differential expression of genes regulated by PTH in a manner found in-vivo 
which is exposed to a continuous level of PTH.  Alternative strategies that 
could be employed to identify PTH regulated genes include interfering RNA 
inhibition of PTHR1 expression, or transfection with a constitutively active 
PTHR1 (Calvi, Sims et al. 2001). 
4A5.6 Conclusion 
In this study it has been demonstrated that PTH influences gene expression in 
an in-vitro model of the colonic epithelium.  A novel group of PTH target 
genes in the colon has been identified.  Some of these have a role in 
colorectal tumorigenesis, the majority do not.  The functions of these genes 
are of interest in determining the effect of PTH on the colon.  
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Chapter 4B 
FUNCTIONAL ANNOTATION OF THE GENES DIFFERENTIALLY 
EXPRESSED IN RESPONSE TO PARATHYROID HORMONE AND 
VALIDATION USING SEMI-QUANTITATIVE REAL-TIME PCR 
4B.1: Aims 
  1. Functional analysis of differentially expressed genes. 
  2. Validation of selected findings of array studies using real time 
  PCR 
 
4B.2: Introduction 
In the previous part of this chapter, genes differentially expressed in response 
to PTH treatment of Caco2 were identified.  It was demonstrated that a 
number of these genes are similarly altered during colorectal neoplasia.  
However, the majority of genes differentially expressed in response to PTH 
have no recognised role in colorectal tumorigenesis. Determining the 
biological activity of these genes is therefore of interest in identifying the 
function of PTH in the colon.  Analysis of the list of differentially expressed 
genes produced by micro-array studies is an important task in understanding 
the biological process being studied.  A commonly utilised approach is to map 
the list of genes to biological annotation terms and then to identify the 
statistically enriched or overrepresented biological annotation terms.  This 
approach has been used in a number of studies.  These include identifying 
the enriched biological processes and molecular functions of the genes 
differentially expressed in response to PTH treatment of bone (Onyia, 
Helvering et al. 2005).  There are also a number of studies that have identified 
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the annotation terms enriched in the genes differentially expressed in 
colorectal cancer or adenoma compared to normal mucosa (Sabates-Bellver, 
Van der Flier et al. 2007; Chan, Griffith et al. 2008); as well as those in 
proliferating or differentiated colonic epithelium (Kosinski, Li et al. 2007).  As 
enrichment analysis of large gene lists is more of an exploratory process than 
a strictly statistical solution, comparison of the results with those from other 
studies of colorectal cancer and PTH results will enable an additional layer of 
analysis.  Identification of annotation terms or signalling pathways enriched in 
the genes differentially expressed in response to PTH will provide clues to the 
function of PTH in the colon. 
 Validation of the micro array data was carried out for selected genes 
using semi-quantitative real time PCR.  Eight (AREG, CYP1A1, STT3A, 
PDCD4, CTBP1, GSN, DKK1 and GJA1) of the genes identified in the array 
studies were investigated.  These genes were chosen for a number of 
reasons.  Some of them are known targets of PTH signalling: AREG (Qin, 
Tamasi et al. 2005), GJA1(van der Heyden, Veltmaat et al. 2000), 
DKK1(Kulkarni, Halladay et al. 2005), PDCD4(Reppe, Stilgren et al. 2006)  
and  CYP1A1 (Michaud, Naud et al. 2006).  Some are altered in colorectal 
tumorigenesis, GSN (Gay, Estornes et al. 2008): involved in wnt signalling 
CTBP1 (Cuilliere-Dartigues, El-Bchiri et al. 2006) or changed at both four and 
twenty four hours (AREG, CYP1A1, STT3A). 
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4B.3: Methods 
4B.3.1 Functional annotation of the genes differentially expressed in 
response to PTH 
Two lists of genes were created from those identified using Rank Product.  As 
there were only a small number of up-regulated genes, the up and down 
regulated genes were combined for each time point.  These two gene lists 
were uploaded to DAVID (Database for Annotation, Visualization and 
Integrated Discovery (http://david.abcc.ncifcrf.gov/)) (Dennis, Sherman et al. 
2003; Huang da, Sherman et al. 2009).  This online resource enables the 
analysis of lists of gene resulting from micro-array expression studies.  The 
purpose of this analysis was to identify the biological function and meaning 
from a list of genes.  DAVID maps the genes from the list to associated 
biological annotation terms and employs enrichment analysis to statistically 
identify the most overrepresented annotation terms. This is done by 
identifying which annotation terms are enriched in the list of genes compared 
to the background genes.  The significance of gene term enrichment is 
examined by the calculation of an EASE score; this is derived from the name 
of the original software used for DAVID, Expression Analysis Systematic 
Explorer.   The EASE score is a modified Fishers exact test giving a p-value.  
The default cut-off is 0.1, the smaller the score the more significant the 
enrichment.  Multiple testing is corrected for by the calculation of a false 
detection rate (FDR).  The FDR is known to be a conservative approach and a 
value of up to 0.5 maybe considered significant.  It is recommended that the 
enrichment scores are used as a scoring system suggesting roles, rather than 
decision making roles (Huang da, Sherman et al. 2009).  The enriched 
 111 
annotation terms were identified using two different utilities available on 
DAVID.  
1. Functional annotation chart 
This identifies enriched terms within the gene list and performs a 
“term centric singular enrichment analysis”. The default settings 
were employed, apart from using an EASE score of 0.05 (instead of 
0.1), to identify enriched annotation terms.  
 
2. Functional annotation clustering                                                     
This clusters functionally similar enriched terms into groups, 
performing a “term centric modular enrichment analysis”.  Default 
settings were employed, apart from stringency being increased to 
high.  Clusters of terms with enrichment scores of >1.3, which is 
equivalent to non-log scale value of 0.05, were identified.  Clusters 
with enrichment scores less than 1.3 were also identified as 
enriched, if they included individual terms with EASE scores <0.05. 
 
For each analysis the background was set as Affymetrix HG-Focus.  This 
process was carried out separately for the genes differentially expressed at 
four and twenty four hours.  Additionally, clusters of annotation terms that did 
not meet the above criteria, but were enriched to any degree at both time 
points were identified. 
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4B.3.2 Annotation methods 
DAVID allows the use of several annotation methods, in this study two were 
use; the gene ontology (GO) annotation (Ashburner, Ball et al. 2000)( 
http://www.geneontology.org/)) and Kegg pathways (Kanehisa, Goto et al. 
2009) http://www.genome.jp/kegg.  The GO ontology provides a systematic 
method for the description of gene products in three biological domains; 
cellular component (CC), biological process (BP) and molecular function (MF).  
A cellular component (CC) is as described the component of a cell but 
specifically a defined anatomical component of a cell such as the nucleus.  A 
biological process (BP) is a series of events carried out by various molecular 
functions.  Biological processes include broad terms such as signal 
transduction and more specific terms such as alpha-glucoside transport.  
Molecular functions (MF) describe activities that occur at the molecular level 
and these terms can be broad (catalytic activity) or narrow (adenylate cyclase 
activity). 
Kegg (Kyoto Encyclopaedia of Genes and Genomes) pathways are an 
online resource of pathway maps representing our knowledge on the 
molecular reaction and interactions in the areas of: metabolism, genetic 
information processing, environmental information processing, cellular 
processes and Human diseases. 
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4B.4: Results 
4B.4.1 Functional annotation of the genes differentially expressed in 
response to PTH treatment 
Functional annotation of the differentially expressed genes was performed 
using the online utility DAVID.  The two approaches used identified: 
1. Enriched single GO annotation terms and Kegg pathways  
2. Enriched clusters of functionally related GO annotation term 
4B4.2 Enriched single GO annotation terms and Kegg pathways 
Identification of enriched single GO terms was carried out separately for the 
genes differentially expressed at four and twenty-four hours. 
4B4.2.1 Enriched single GO annotation terms after four hours  
Enriched single annotation terms for each of the three biological domains of 
the GO annotation (BP, MF and CC), were identified in the genes differentially 
expressed at four hours.  Twenty one biological process terms, ten cellular 
component terms and five molecular function annotation terms were enriched 
in the genes differentially expressed at four hours.  These are shown in Table 
4B.1.  
4B4.2.2 Enriched Kegg pathways after four hours 
One Kegg pathway, the Wnt signalling pathway was enriched in the genes 
differentially expressed at four hours.  The four genes from the wnt signalling 
pathway (CTBP1, NFAT5, NLK and BTRC) are all down regulated in 
response to PTH. 
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Table 4B.1:  List of individual GO annotation terms from each of the 
three biological domains (BP, CC and MF) enriched in the genes 
differentially expressed after four hours of treatment with PTH.   The p-
value and FDR (false detection rate) are included for each term. 
 
Biological process (BP) P value FDR 
macromolecule localisation   1x10-4 0.002 
protein localisation 2x10-4 0.005 
establishment of protein localisation 5x10-4 0.009 
mRNA metabolic process   9x10-4 0.017 
RNA splicing 8x10-3 0.13 
cellular component organisation and biogenesis 1x10-2 0.19 
mRNA processing 1x10-2 0.26 
vesicle mediated transport 1x10-2 0.28 
RNA processing 3x10-2 0.38 
cytoskeleton organisation and biogenesis 3x10-2 0.39 
regulation of actin polymerization and/or depolymerization   3x10-2 0.40 
localisation 3x10-2 0.47 
regulation of actin filament length 4x10-2 0.50 
regulation of actin cytoskeleton organisation and biogenesis 4x10-2 0.50 
regulation of cellular component size 4x10-2 0.50 
cellular process 4x10-2 0.50 
actin cytoskeleton organisation and biogenesis 4x10-2 0.50 
regulation of mRNA processing 4x10-2 0.50 
regulation of cellular process 4x10-2 0.50 
regulation of organelle organisation and biogenesis 4x10-2 0.50 
regulation of cytoskeleton organisation and biogenesis 5x10-2 0.50 
Cellular component (CC)   
intracellular membrane bound organelle 1x10-4 0.002 
membrane bound organelle 1x10-4 0.002 
intracellular part 2x10-4 0.004 
organelle membrane 3x10-4 0.002 
intracellular organelle part 9x10-4 0.01 
organelle part 9x10-4 0.01 
cytoplasm 1x10-3 0.02 
nucleus 3x10-3 0.04 
endomebrane system 3x10-3 0.05 
cytoplasmic part 2x10-2 0.25 
Molecular function (MF)   
protein binding 4x10-3 0.007 
GTP binding 7x10-3 0.01 
guanyl ribonucleotide binding   9x10-3 0.01 
guanyl nucleotide binding   9x10-3 0.01 
GTPase activity 3x10-2 0.45 
 
 
 
 
 115 
4B4.2.3 Enriched single GO annotation terms after twenty-four hours 
Enriched single annotation terms for each of the three biological domains of 
the GO annotation (BP, MF and CC) were identified in the genes differentially 
expressed at twenty-four hours. Nine biological process terms, three cellular 
component terms and eleven molecular function annotation terms were 
enriched in the genes differentially expressed at twenty-four hours.  These are 
shown in table 14.  No Kegg pathways were enriched at 24 hours. 
Table 4B.2:  The individual GO annotation terms from each of the three 
biological domains (BP, CC and MF) enriched in the genes differentially 
expressed after twenty-four hours of treatment with PTH.   The p-value 
and FDR (false detection rate) are included for each term. 
Biological process (BP) P value FDR 
gamete generation 8x10-3 0.15 
negative regulation of transcription 2x10-2 0.30 
sexual reproduction 2x10-2 0.30 
negative regulation of nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process 
2x10-2 0.40 
amino acid biosynthetic process 3x10-2 0.45 
negative regulation of cellular process 3x10-2 0.45 
negative regulation of biological process 4x10-2 0.50 
reproductive structure development 5x10-2 0.50 
gonad development 5x10-2 0.50 
Cellular component (CC)   
nucleus 5x10-3 0.08 
intracellular membrane bound organelle 3x10-2 0.39 
membrane bound organelle 3x10-2 0.39 
Molecular function (MF)   
nucleotide binding 4x10-4 0.007 
purine nucleotide binding 1x10-2 0.20 
active transmembrane transporter activity 2x10-2 0.30 
purine ribonucleotide binding 2x10-2 0.31 
ribonucleotide binding 2x10-2 0.31 
xenobiotic transporter activity 2x10-2 0.31 
xenobiotic-transporting ATPase activity 2x10-2 0.31 
multidrug transporter activity 3x10-2 0.40 
nucleoside-triphosphatase activity 4x10-2 0.52 
adenyl nucleotide binding 4x10-2 0.50 
pyrophosphatase activity 5x10-2 0.50 
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4B4.3 Enriched clusters of functionally related GO annotation terms  
This was carried out separately for the genes differentially expressed at four 
and twenty-four hours.  Subsequently, comparison was made of the results 
from both time points to identify clusters of GO annotation terms enriched at 
both time points. 
 
4B.4.3.1 Clusters of functionally related GO annotation terms enriched at 
four hours 
Five clusters of functionally related GO terms were identified as being 
enriched in the genes differentially expressed at four hours.  Three of these 
clusters showed enrichment scores >1.3 and two showed enrichment scores 
<1.3 but had individual annotation terms with p-values <0.05.  The five 
enriched annotation clusters, listed as cluster 4A to 4E, are shown in Table 
4B.3.  
 
4B.4.3.2 Clusters of functionally related GO annotation terms enriched at 
twenty-four hours 
Six clusters of related GO terms were identified as being enriched in the list of 
genes differentially expressed at twenty four hours.  Three of these clusters 
had enrichment scores >1.3 and four showed enrichment scores <1.3, but 
had individual annotation terms with p-values <0.05.  The six enriched 
annotation clusters, listed as cluster 24A to 24F, are shown in Table 4B.4. 
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Table 4B.3:  The five annotation clusters (4A to 4E) enriched in the 
genes differentially expressed at four hours.  The enrichment score for 
each cluster and the GO terms found in each cluster are shown. The 
differentially expressed genes found in each cluster and their direction of 
change is shown. 
 GO terms (Biological domain) ES 
Genes changed 
(direction of change) 
4A 
Macromolecule localisation (BP) 
Protein localisation(BP) 
Establishment of protein 
localisation (BP) 
Protein transport (BP) 
3.5 
COPG, RHOB, 
RFIP1,TOMM22, RAB8A, 
TMED2, CANX, LIN7C, 
NUP50, PTPN11, NUTF2, 
RDX, RAB5B, NCBP1 (Down)  
and  ARF6 (Up) 
4B 
mRNA metabolic process (BP) 
mRNA processing  (BP) 
RNA processing (BP) 
2.4 
SNRNP40, SRRM2, HSPA1B, 
NCBP1, SRPK1, SPOP, 
ROD1, SFRS1 (Down) 
4C 
GTP binding (MF) 
Guanyl ribonucleotide binding 
(MF) 
Guanyl nucleotide binding (MF) 
GTPase activity  (MF) 
2.1 
CEBPA, RHOB, EIF2S3, 
RAB8A, ARHGAP5, RAB5B 
(Down) 
ARF6 (Up) 
 
4D 
Regulation of cellular process 
(BP) 
Regulation of biological process 
(BP) 
Biological regulation (BP) 
1.2 
JMJD1B, CEBPA, GSR,  ELL2, 
DNAJB6, STAT2, PPAP2B, 
RAB8A, ICAM1, HSPA1B, 
SKP2, LIN7C, CTBP1, NFAT5, 
PTPN11, RAB5B, UTP20, 
RDX, NCBP1, RHOB, ARFIP1, 
KLF3, NLK, CD9, NDRG3, 
GPC3, GSN, PDCD4, SRPK1, 
RBBP4, ATF2, HOXA7, SELT 
(Down)ARF6,  MAFF  (Up) 
4E 
Regulation of actin 
polymerization and/or 
depolymerization (BP) 
Regulation of actin filament 
length (BP) 
Regulation of actin cytoskeleton 
organization and biogenesis (BP) 
Regulation of cytoskeleton 
organization 
and biogenesis (BP) 
Cell Leading edge (CC) 
Cell projection (CC) 
Cellular component organization 
and biogenesis (BP) 
1.1 
 
RDX, CNN3, GSN, ACTB 
(Down) 
ARF6 (Up) 
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Table 4B.4: The six annotation clusters (24A to 24F) enriched at twenty-
four hours, along with the enrichment score for each cluster.  The GO 
terms found in each cluster, the differentially expressed genes found in each 
cluster and their direction of change is shown. 
 
 GO terms  (Biological domain) ES 
Genes changed  
(direction of change) 
24A 
Purine nucleotide binding (MF) 
Ribonucleotide binding (MF)  
Purine ribonucleotide binding (MF) 
Adenyl nucleotide binding (MF) 
ATP binding (MF) 
Adenyl ribonucleotide binding (MF) 
1.6 
SGK1, GNL2, WNK1, 
DYNC1LI2, ARL4C, RALA, 
DARS, ABCB1, NOX1, 
HSPA1B, PRKCI, RFC3, 
MAP4K4, MSH2, ABCG2 
(Down) 
24B 
Negative regulation of transcription 
(BP) 
Negative regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolic process (BP) 
Negative regulation of cellular 
metabolic process (BP) 
Negative regulation of metabolic 
process (BP) 
1.5 ZNF148, LRRFIP1, EREG, SOX9, ID1, NRIP1 (Down) 
24C 
Nucleoside-triphosphatase activity 
(MF) 
Pyrophosphatase activity (MF) 
Hydrolase activity, acting on acid 
anhydrides, in phosphorus-
containing anhydrides (MF) 
Hydrolase activity, acting on acid 
anhydrides (MF) 
1.4 
ARL4C, ATP1B1, RFC3, 
ABCB1, MSH2, GNL2, 
ABCG2 (Down) 
24D 
Gamete generation (BP) 
Sexual reproduction (BP) 
Reproduction (BP) 
1.1 
ZNF148, BRD2, EREG, 
SOX9, PAFAH1B1, NRIP1 
(Down) 
24E 
Negative regulation of cellular 
process(BP) 
Negative regulation of biological 
process (BP) 
Regulation of cellular process(BP) 
1.1 
ZNF148, GJA1, HSPA1B, 
PRNP, MSH2, WNK1, EREG, 
SOX9, ID1, NRIP1, DKK1, 
LRRFIP1, HOXA7, DUSP6, 
MYC (Down) 
24F 
Cell development (BP) 
Cellular developmental process 
(BP) 
Cell differentiation (BP) 
0.8 
HSPA1B, SGK1, GJA1, 
SOX9, PHLDA2, PRKCI, 
PRNP, EREG, PHLDA1, 
PDCD2, , EFNB2, 
PAFAH1B1 (Down) 
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4B.4.3.3 Clusters of functionally related GO annotation terms enriched at 
both four and twenty-four hours 
The annotation terms enriched in response to PTH treatment at both four and 
twenty four hours were identified.  Clusters of annotation terms that were 
enriched to any degree at both time points were identified, even if they did not 
meet the enrichment and significance criteria used for individual time points. 
This process identified five annotation clusters (V-Z).  Only one of these 
clusters (Z) was identified as enriched at a single time point, the other four 
clusters though enriched at both time points have lower enrichment scores. 
The five enriched annotation clusters, listed as clusters V-Z are shown in 
Table 4B.5. 
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Table 4B.5 The five annotation clusters (V-Z) enriched at both four and twenty-four hours. 
The enrichment score for each cluster at both time points is shown along with the GO terms included in each cluster.  The 
differentially expressed genes found in each cluster and their direction of change is shown. 
 GO terms  (Biological domain) 
Four hours Twenty four hours 
ES Genes changed  (direction of change) ES 
Genes changed  
(direction of change) 
V 
Apoptosis (BP) 
Programmed cell death (BP) 
Death (BP) 
Cell death (BP) 
0.5 CROP, PDCD4, HSPA1B, DNAJB6, RTN3, RHOB, ARF6 (Down) 0.8 
HSPA1B, GJA1, SGK1, PRNP, 
PHLDA1, 
PDCD2 (Down) 
 
W 
Protein modification process (BP) 
Biopolymer modification (BP) 
Post-translational protein modification (BP) 
0.3 
SKP2, CTBP1, SRPK1, BTRC, NLK, 
SPOP, OGT, STT3A, DUSP5 
(Down) 
0.1 SGK1, PRKCI, WNK1, STT3A, DUSP6 (Down) 
X 
Phosphate metabolic process (BP) 
Phosphorus metabolic process (BP) 
Phosphorylation (BP) 
Protein amino acid phosphorylation (BP) 
  0.1 CTBP1, SRPK1, NLK, DUSP5 (Down) 0.3 
SGK1, PRKCI, WNK1, EREG, DUSP6 
(Down) 
 
Y 
Amino acid and derivative metabolic process 
(BP) 
Amine metabolic process (BP) 
Nitrogen compound metabolic process (BP) 
Carboxylic acid metabolic process (BP) 
Organic acid metabolic process (BP) 
0.3 TTR, CTBP1, GATM, PSPH (Down) 0.4 
ASNS, DARS, PSPH (Down) 
 
Z 
Regulation of cellular process (BP) 
Regulation of biological process (BP) 
Biological regulation (BP) 
1.1 
ELL2, DNAJB6,  RAB8A, ICAM1, 
HSPA1B, SKP2, LIN7C, CTBP1, 
NFAT5, RAB5B, UTP20, RDX, 
RHOB, ARFIP1, KLF3, NLK, CD9, 
NDRG3, GPC3, GSN, PDCD4, 
SRPK1, RBBP4, ATF2, HOXA7, 
SELT (Down) ARF6,  MAFF  (Up) 
0.2 
ZNF148, GJA1, UTS2, PRNP, WNK1, 
EREG, ID1,NRIP1, HSPA1B, DKK1, 
LRRFIP1, HOXA7, DUSP6, MYC 
(Down) 
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4B4.4 Semi-quantitative real time PCR for selected micro-array targets 
To validate the micro-array studies, expression of eight (AREG, CYP1A1, 
STT3A, PDCD4, CTBP1, GSN, DKK1 and GJA1) of the differentially 
expressed genes was investigated by semi-quantitative real time PCR.   
Expression of each of the genes was compared to an untreated control and 
fold change calculated.  Relative expression was studied at the time points at 
which the gene was differentially expressed in the array study (4 and 24 
hours).  Additionally relative expression at other time points was investigated, 
based on the predicted time course of PTH activity.  A fold change of > +/- 1.5 
fold was considered to indicate differential expression. 
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4B4.4.1 Amphiregulin (AREG) 
Expression of Amphiregulin mRNA showed increased relative expression at 
one hour (+4.3 fold), two hours (+1.5 fold), four hours (+2.5 fold) and twenty 
four hours (+1.7 fold).  This is shown graphically in Figure 4B.1.  These results 
are consistent with the array study at four hours but are in contrast with the 
results at twenty fours hours, in which AREG showed decreased expression.  
 
Figure 4B.1: Fold change in expression of Amphiregulin at a series of 
time points following PTH treatment. 
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4B4.4.2 Cytochrome P450, family 1, subfamily A, polypeptide1 (CYP1A1) 
Expression of CYP1A1 mRNA showed increased relative expression at four 
hours (+22.3 fold) and twenty four hours (+1.7 fold).  At twelve hours relative 
expression was +1.2 fold.  These results are consistent with the array study at 
four hours but are in contrast with the results at twenty fours hours, in which 
CYP1A1 showed decreased expression.  The magnitude of the change at four 
hours is however larger than that seen in the array study (+22.3 vs. 
+3.2 fold).  
 
Figure 4B.2: Fold change in expression of CYP1A1 at a series of time 
points following PTH treatment. 
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4B4.4.3 STT3, subunit of the oligosaccharyl transferase complex, 
homolog A (STT3A) 
Expression of STT3A mRNA was increased at twelve hours (+1.5 fold).  At 
four hours relative expression was +1.3 fold and at twenty four hours was 
+1.4 fold.  This contrasts with the array studies which showed decreased 
expression at four and twenty four hours. 
  
Figure 4B.3: Fold change in expression of STT3A at a series of time 
points following PTH treatment. 
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4B4.4.4 Programmed cell death 4 (PDCD4) 
Expression of PDCD4 mRNA was decreased at four hours (-1.6 fold) and 
eight hours (-1.8 fold) and unchanged at twelve hours.  This is consistent with 
the findings in the array study. 
 
Figure 4B.4: Fold change in expression of PDCD4 at a series of time 
points following PTH treatment. 
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4B.4.4.5 C-terminal binding protein 1 (CTBP1) 
Expression of CTBP1 mRNA was decreased at four hours (-2.2 fold) and 
eight hours (-2.1 fold).  At twelve hours relative expression was -1.1 fold.  This 
result is consistent with the findings in the array study. 
 
Figure 4B.5: Fold changes in expression of CTBP1 at a series of time 
points following PTH treatment. 
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4B.4.4.6 Gelsolin (GSN) 
Expression of GSN mRNA was decreased at four hours (-2.5 fold).  At eight 
and twelve hours, expression was altered by -1.4 and +1.1 fold respectively.  
This is consistent with findings in the array study. 
 
Figure 4B.6: Fold change in expression of GSN at a series of time points 
following PTH treatment. 
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4B.4.4.7 Dickkopf homolog 1 (DKK1) 
Expression of DKK1 mRNA was decreased at eight (-3.4 fold), twelve (-1.5 
fold), sixteen (-2.9 fold) and twenty four (-2.4 fold) hours.   This is consistent 
with findings in the array study. 
 
Figure 4B.7: Fold change in expression of DKK1 at a series of time 
points following PTH treatment. 
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Gap junction associated 1 (GJA1) 
Expression of GJA1 mRNA was decreased at eight (-3.2 fold), twelve (-5.2 
fold), sixteen (-5.8 fold) and twenty four (-4.5 fold) hours. 
 
Figure 4B.8 Fold changes in expression of GJA1 at a series of time 
points following PTH treatment. 
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4B.4.4.9 Summary of real-time PCR results 
For five of the six genes differentially expressed at four hours and two out of 
the five genes differentially expressed at twenty-four hours, the findings of the 
real-time PCR and array studies were consistent, although the fold changes 
were larger in the PCR study.  One gene STT3A was not changed at either 
four or twenty-four hours in the PCR study in contrast to the array results.  For 
two genes AREG and CYP1A1, differentially expressed at twenty-four hours, 
the findings in the PCR studies were the opposite of those in the array study. 
A summary of the real time PCR results for all eight of the genes are shown in 
Table 4B.6. 
 
Table 4B.6: Summary of the real-time PCR results for all eight genes.  
This shows the fold change at each time point studied.  The results from the 
array studies are shown for comparison. H=hours, nc=no change 
 
Gene 
Change  in 
array 1H 2 H 4 H 8 H 12 H 16 H 24 H 4H 24H 
AREG +1.5 -1.6 +4.3 +1.5 +2.5 - - - +1.7 
CYP1A1 +3.2 -5.2 - - +22.3 - +1.2 - +1.7 
STT3A -1.9 -1.3 - - +1.3 - +1.5 - +1.4 
PDCD4 -1.8 nc - - -1.6 -1.8 1 - - 
CTBP1 -1.3 nc - - -2.2 -2.1 -1.1 - - 
GSN -1.5 nc   -2.5 -1.4 +1.1 - - 
DKK1 nc -1.4 - - - -3.4 -1.5 -2.9 -2.4 
GJA1 nc -1.4 - - - -3.2 -5.2 -5.8 -4.5 
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4B.5 Discussion 
4B.5.1 Function of PTH regulated genes 
In this study DAVID (Database for Annotation, Visualization and Integrated 
Discovery) was used to identify enriched biological function in the genes 
differentially expressed in response to PTH.  It is suggested that the results 
produced by DAVID  be seen as a scoring system with statistical terms (eg p-
values) indicating likely involvement of the enriched biological phenomenon, 
but that these results should be judged in terms of known or predicted biology 
(Huang da, Sherman et al. 2009).  The results of the functional annotation are 
therefore discussed in the context of the known functions of PTH and a 
predicted role in colorectal tumorigenesis.  The stringency of the selection 
criteria for both the DAVID tools used were increased from the default 
settings; the aim of this was to increase the identification of relevant functional 
annotation.  
 The enriched single annotation terms for each of the three GO 
annotation term domains (BP, MF and CC) are included (Tables 4B.1 and 
4B.2) as this is the most commonly presented format and allows for 
comparison with other studies.  However, for attempting to identify the 
function of PTH, the clusters of enriched functionally related annotation terms 
demonstrates PTH function with greater clarity. There are a number of 
enriched annotation clusters suggesting a role for PTH in colorectal neoplasia.  
Rho-GTPase signalling (Cluster 4C) regulates various processes in colorectal 
tumorigenesis and expression of components of these signalling pathways 
are commonly altered (Karlsson, Pedersen et al. 2009).  PTH down-regulates 
genes involved in cell differentiation (Cluster 24F).  This suggests a role in 
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preventing differentiation, which is of relevance to tumorigenesis and 
suggests a possible role for PTH in the normal colon.  Inhibition of 
differentiation is consistent with a known physiological function of signalling 
via PTHR1, which inhibits differentiation of keratinocytes (Foley, Longely et al. 
1998). 
 Perhaps the most interesting enriched cluster indicates that PTH is 
involved in remodelling of the actin cytoskeleton and cell migration (Cluster 
4E).  The altered genes in cluster 4E have been implicated to varying degrees 
in tumorigenesis.   Gelsolin and Radixin show decreased expression in 
neoplastic compared to normal colonic mucosa (Gay, Estornes et al. 2008; 
Segditsas, Sieber et al. 2008) and decreased expression of CNN3 is found in 
tumours with metastases (Bertucci, Salas et al. 2004).  Reduction of Gelsolin 
expression using siRNA induces epithelial-mesenchymal transition, increased 
motility and invasion (Tanaka, Shirkoohi et al. 2006).  Though changes in 
expression of ARF6 in colorectal neoplasia have not been demonstrated, it 
has been shown to promote epithelial cell motility through the downstream 
activation of phospholipase D and the Rac1 GTPase (Santy and Casanova 
2001) and regulates melanoma cell invasion (Tague, Muralidharan et al. 
2004).  Remodelling of the actin cytoskeleton is part of epithelial-
mesenchymal transition (EMT) which is a process by which tumour migration 
and invasion occurs (Thiery, Acloque et al. 2009).  PTH stimulates the 
migration of osteosarcoma cell lines in-vitro (Yang, Hoang et al. 2007; 
Berdiaki, Datsis et al. 2010).  Although PTH itself has not been implicated in 
EMT, activation of PTHR1 by PTHRrP has been shown to induce EMT in 
kidney (Ardura, Rayego-Mateos et al. 2010) and during embryonic 
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development (van der Heyden, Veltmaat et al. 2000).  This provides support 
for the evidence provided here that PTH may promote migration, invasion and 
EMT. 
 A cluster of genes involved in apoptosis and programmed cell death 
(Cluster V) was weakly enriched at both time points.  It is not clear whether 
this indicates a pro or anti-apoptotic effect of PTH.  All the differentially 
expressed genes in this cluster were down-regulated and include genes with 
both pro-apoptotic (PDCD2, PDCD4, RTN3, RHOB and PHLDA1) (Liu, 
Cerniglia et al. 2001; Neef, Kuske et al. 2002; Fan, Chan et al. 2004; Zhang, 
Ozaki et al. 2006; Lee, Lee et al. 2009) and anti-apoptotic activity (DNAJB6 
and SGK1) (Dehner, Hadjihannas et al. 2008).  Based on the majority of the 
genes being pro-apoptotic and down regulated this suggests that PTH acts to 
prevent apoptosis.  Indeed, in bone Parathyroid Hormone results in the 
altered expression of genes with anti-apoptotic activity (Onyia, Helvering et al. 
2005).  This is consistent with its predicted role in tumorigenesis but it is not 
clearly the case. There is evidence that PTH has pro-apoptotic activity and 
since this work was carried out, a study demonstrating PTH induced 
apoptosis in Caco2 has been published (Calvo, Gentili et al. 2008).  Of note, 
the authors of this study acknowledge that PTH can have both pro or anti-
apoptotic effects depending on the cellular context.  Their experiments were 
carried out with cells 70% confluent in comparison to the 7days post-confluent 
cells used in this study.  This may explain the differences between these two 
studies and would require further work to clarify the effect of PTH on 
apoptosis in the colon. 
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 The one enriched KEGG pathway, the Wnt signalling pathway, is of 
significant interest as it is commonly deregulated in colorectal tumorigenesis, 
with constitutive activation of β-catenin/TCF4 mediated signalling found in the 
majority of colorectal tumours (Kinzler and Vogelstein 1996).  It has also been 
shown in a number of studies that Parathyroid hormone acts by modulating 
the wnt signalling pathway in bone (Reppe, Stilgren et al. 2006; Li, Liu et al. 
2007).  Parathyroid hormone activates the wnt signalling pathway in bone by 
two methods: activation of β-catenin by direct interaction of PTHR1 with 
Dishevelled-1 (Romero, Sneddon et al. 2010) and increased β-catenin 
expression, with evidence of increased activity of a wnt responsive reporter 
gene (Kulkarni, Halladay et al. 2005).    Of the differentially expressed genes 
in the Wnt signalling pathway, Nemo like kinase phosphorylates TCF4, 
resulting in reduction of its DNA binding ability and decreased β-catenin/TCF4 
mediated transcription (Ishitani, Ninomiya-Tsuji et al. 1999).  Similarly CTBP1 
binds TCF4 reducing its transcriptional activity (Cuilliere-Dartigues, El-Bchiri 
et al. 2006).  Mutations in TCF4 are commonly found in micro-satellite 
unstable tumours and result in loss of CTBP1 binding sites, with 
consequential loss of CTBP1 mediated inhibition of TCF mediated 
transcription (Cuilliere-Dartigues, El-Bchiri et al. 2006).  BTRC binds β-catenin 
and targets it for destruction (Spiegelman, Slaga et al. 2000). Decreased 
expression of these three negative regulators of the canonical wnt signalling 
pathway, suggests that PTH activates the canonical wnt signalling pathway in 
colonic cells. 
 Downstream targets of wnt signalling have been well characterised and 
of the differentially expressed genes at four hours, six down-regulated genes 
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(GSN, RHOB, TMOD3, DUSP5, FBLN1 and PPAB2B) show decreased 
expression in response to wnt signalling (van de Wetering, Sancho et al. 
2002; Segditsas, Sieber et al. 2008).  This would suggest that at four hours 
the altered expression of the wnt signalling pathway components results in the 
activation of wnt signalling and altered expression of wnt target genes.  At 
twenty-four hours the situation is less clear, with down-regulation of three 
genes (SLC26A2, SGK1 and ABCG2) known to be down regulated in 
response to wnt signalling (Segditsas, Sieber et al. 2008).  However, there are 
five down-regulated genes (PHLDA1, SOX9, SLC12A2, TGIF and MYC) that 
are known to be up-regulated in response to wnt signalling (van de Wetering, 
Sancho et al. 2002; Segditsas, Sieber et al. 2008).   These wnt target genes 
include Myc which is recognised to be a key mediator of wnt signalling 
(Sansom, Meniel et al. 2007).  The results presented here suggest that 
activation of the wnt signalling pathway is an early response to PTH.  And in 
the absence of continued PTH stimulation, the effect on wnt signalling 
decreases with time.  Consistent with this is the observed increase in 
expression of the wnt signalling target ornithine-decarboxylase (ODC) (Van 
der Flier, Sabates-Bellver et al. 2007).  Expression of ODC in the colorectal 
cell line Lovo was up-regulated with a peak after two hours treatment with 
PTH(Yu, Seitz et al. 1992).   
 The majority of the enriched annotation clusters seen at both four and 
twenty-four hours are of a general nature.  Enrichment of these would suggest 
that PTH: signals via altering transcription (4B, 24B), has a regulatory role in 
some biological processes (4D, 24B, 24E and Z), is involved in protein 
localisation (4A) and a number of metabolic processes (24A, 24C, W, X and 
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Y).  These are general annotation terms with no overlap between these 
annotation terms and those found to be enriched in the genes differentially 
expressed in colorectal cancers (Chan, Griffith et al. 2008) or adenomas 
(Sabates-Bellver, Van der Flier et al. 2007).  Comparison with the annotation 
terms enriched in genes differentially expressed in response to PTH treatment 
of bone, identified a number of related annotation terms, including anti-
apoptosis, cell migration and catalytic activity (Onyia, Helvering et al. 2005).  
This suggests there is some overlap between the function of PTH in the bone 
and in the colon. 
 
4B.5.2 Real time PCR 
The changes seen in the array studies were predominantly replicated in the 
real time PCR studies and the fold changes seen were larger than the array 
changes, a common finding.  There were discrepant findings between array 
and real-time PCR studies for the expression of STT3A which was down 
regulated at both time points in the array but unchanged in the real time PCR 
study.  For CYP1A1 and AREG, the changes in the array and real time PCR 
at four hours were consistent, both showing increased expression; but at 
twenty-four hours the array study showed decreased and the real-time PCR 
showed increased expression.  There are a number of possible explanations; 
this includes the possibility that either of the two methods have given an 
incorrect result.  In the absence of other supporting data there is no hierarchy 
in the validity of array and real time results.  In this study there were only two 
replicates in the array study at twenty-four hours so it may be argued that 
these results are less valid.  However the most likely explanation only became 
 137 
apparent after post-hoc analysis of the array data.  This shows changes in 
expression of cytokeratin 8 (KRT8) which was used as the control gene in the 
PCR study.  Cytokeratin 8 was down regulated by PTH at twenty-four hour by 
-1.22 fold and unchanged at four hours, though it was not identified as 
differentially expressed using rank product.  These changes are probably 
large enough to explain the discrepancies for CYP1A1, AREG and STT3A at 
twenty four hours in the PCR study.  The use of KRT8 as a control gene was 
routine in the laboratory at that time (Caldwell, Jones et al. 2004).  It was not 
known to be regulated by PTH and as it was not in the differentially expressed 
genes it was used in this study. 
 Having observed this finding, it may be considered ideal to repeat the 
real time PCR studies with a different control gene.  However this was not 
logistically possible at the stage it became apparent.  The change in KRT8 
was only seen at twenty-four hours with no discrepancy between the micro-
array and real time PCR results at four hours.  Thus it can be argued that the 
micro-array results at four hours have been validated.  Though, this is not the 
case for the twenty four hour point.  It seems likely based on these 
observations that where there is a discrepancy that the array results are more 
likely to be valid than the real-time PCR results. 
  
4B.5.3 Future studies 
The enriched annotation terms in the genes differentially expressed in 
response to PTH, suggest functions of PTH also implicated in colorectal 
neoplasia.  Future studies investigating hypotheses generated by this study 
would include functional studies investigating migration and invasion of PTH 
treated colonic cells.  As deranged wnt signalling is a ubiquitous feature of 
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colonic neoplasia the effect of PTH on wnt regulated genes and functions, 
would be of interest in further determining the function of PTH in the colon.  
4B.5.4 Conclusion 
The functions of PTH regulated genes in the colon have been identified.  This 
has highlighted the wnt signalling pathway and regulation of the cytoskeleton 
and cell migration with relevance to colorectal neoplasia.  The observations 
that PTH stimulates differential expression of genes in-vitro leads to the 
question: does PTH influence colonic epithelial cells in-vivo and if there is any 
relationship to the findings found in-vitro? These are the questions addressed 
in the following chapters.  Firstly, the influence of serum PTH and secondly, 
the effect of dietary calcium supplementation on gene expression in the 
normal rectal mucosa were investigated. 
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Chapter 5 
INVESTIGATION OF THE INFLUENCE OF DIETARY CALCIUM 
SUPPLEMENTATION ON SERUM BIOCHEMISTRY IN SUBJECTS 
UNDERGOING A STUDY OF GENE EXPRESSION IN RECTAL MUCOSA 
 
5.1: Aims: 
1. Determine the baseline serum levels of PTH, 25OH-vitamin D and calcium 
in subjects undergoing a study to asses the effect of these factors on gene 
expression in normal rectal mucosa. 
2. Determine the changes in the levels of serum PTH, 25OH-vitamin D and 
calcium in these subjects in response to dietary calcium supplementation  
 
5.2: Introduction 
Having observed that PTH induces changes in gene expression in colonic 
cells in-vitro, the next step was to investigate whether PTH had an effect on 
gene expression in colonic mucosa in-vivo.  The results of these in-vivo 
studies are described in the proceeding chapters.    
 The aims of this chapter are firstly, to describe the study methodology 
and the subjects involved.  Secondly, to investigate the baseline biochemical 
data of the patients taking part, particularly serum levels of PTH, calcium and 
25-OH Vitamin D and to describe the effect of dietary calcium 
supplementation on these parameters.  The results of this chapter will be 
used in the next chapters investigating gene expression in the rectal mucosa 
of these subjects.  The importance of measuring these biochemical 
parameters is that serum levels of both 25OH-Vitamin D and PTH have been 
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associated with colorectal neoplasia, as discussed in chapter one.  Also both 
PTH (Chapter 4) and vitamin D (Palmer, Sanchez-Carbayo et al. 2003) have 
been shown to influence gene expression in colonic cells in-vitro.  If the serum 
levels of these factors are directly relevant to the disease process, it would 
seem likely that there would be a relationship between these biochemical 
parameters and gene expression in the rectal epithelium.  Similarly, it is 
predicted that there would be changes in both the relevant biochemical factor 
and gene expression associated with calcium supplementation. 
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5.3 Methods 
5.3.1 Study overview 
A descriptive biological study was carried out.  This investigated the influence 
of serum biochemical factors and supplemental dietary calcium on the colonic 
epithelium of patients susceptible to colorectal neoplasia.  The main objective 
was to identify the transcriptional changes in rectal mucosa in a population 
susceptible to neoplasia, associated with;  
1. Serum biochemical factors, particularly PTH; 
2. Dietary calcium supplementation. 
The aim was to recruit twenty subjects with a history of colorectal adenomas 
to a crossover trial, six weeks of dietary calcium supplementation and six 
weeks of no treatment.  Rectal biopsies were taken at the beginning and after 
each six week period.  Blood samples were taken to measure Vitamin D, PTH 
and calcium.  RNA was extracted from the biopsies and Micro-array 
expression analysis was carried out on the biopsy samples.  Ethical approval 
was obtained from the Local Research and Ethics Committee and the study 
was carried out in the Wellcome Trust Clinical Research Facility at University 
Hospital, Birmingham. 
5.3.2 Rationale 
The number of patients selected for the study (20) was pragmatic, based on 
feasibility and a number that is likely to produce biological variability in the 
assessed parameters (eg serum PTH and 25OH-Vitamin D).    The study was 
carried out on patients with a past history of adenomas, because they are 
known to be susceptible to colorectal cancer, they therefore have a 
„predisposed‟ colonic epithelium.  They also formed the study group in the 
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Randomised Controlled Trials of calcium supplementation.  The rectum is 
easily accessible to obtain biopsies and is representative of the colon as a 
whole (Terpstra, van Blankenstein et al. 1987). 
 The efficacy of calcium in adenoma prevention has been established 
and the daily dose used in this study (1.5g), is in between the doses used in 
the two randomised controlled adenoma prevention trials (1.2g and 2.0g) 
(Baron, Beach et al. 1999; Bonithon-Kopp, Kronborg et al. 2000).  The six 
week period of calcium supplementation was also pragmatic.  However, other 
studies of calcium supplementation have shown an effect on rectal mucosa 
after as little as one week (Lans, Jaszewski et al. 1991) and after up to four 
months supplementation(Holt, Wolper et al. 2001).   The crossover study 
design in which dietary calcium will be varied means each patient could 
potentially contribute three data points: entry (baseline), low and high calcium 
intake.  
5.3.3 Recruitment 
Volunteer subjects were recruited from patients with a history of colonic 
adenomas, who were under colonoscopic surveillance at University Hospital 
Birmingham.  They were invited to take part in the study by letter.  Subjects 
who showed an interest in taking part in the study were invited to a 
preliminary appointment.  This provided the investigator with the opportunity 
to ensure the patients met inclusion and exclusion criteria and enabled the 
patients to get more information before they made a decision to take part in 
the study.  The inclusion criteria were a past history of treated adenomatous 
polyps.   Exclusion criteria included: a history of malignancy, sarcoidosis, 
renal impairment, hypercalcaemia or bleeding disorders.  Pre-menopausal 
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women were excluded, as were those taking digoxin, non-steroidal anti-
inflammatory, anti-platelet or anti-coagulant drugs.  Patients taking any over 
the counter vitamin or mineral supplements were not excluded from the study 
providing they were willing to stop taking them for the duration of the study.  If 
the patient wished to proceed and met the inclusion/exclusion criteria, written 
consent was obtained. 
5.3.4 Study protocol 
The study lasted twelve weeks and following the initial recruitment visit the 
subjects attended on three occasions: at the beginning (visit A), after 6 weeks 
(visit B) and at the end of the study, 12 weeks (visit C).  On each visit the 
subjects underwent: 
 -Venous blood sampling for PTH, calcium and Vitamin D levels. 
 -Rigid sigmoidoscopy and biopsy of rectal mucosa. 
All of the visits were carried out in the morning to reduce variability due to 
diurnal variation in any of the biochemical parameters.  The dietary calcium 
supplementation consisted of a daily dose of three1.25g tablets of calcium 
carbonate per day, as Calcichew® (Shire).  Each tablet provided 500mg of 
calcium, giving a total daily dose of 1.5g of calcium.  The subjects were 
encouraged to take one tablet three times a day with meals, though this was 
not compulsory.  The correct number of tablets for the six week period was 
provided for each subject.  Compliance with the calcium supplementation was 
assessed by direct questioning and counting of returned pills. 
 This was a crossover study and the patients were assigned randomly 
by selection of pre-sealed envelopes to one of two groups. 
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-Group one had no intervention for the first six weeks and then crossed over 
to take calcium carbonate for the second six week period. 
-Group two took calcium for the first six weeks and crossed over to no 
intervention for the second six weeks. 
Figure 5.1 Flow diagram for the study 
 
Recruitment 
│ 
│ 
Preliminary visit 
│ 
│ 
Time Zero 
Group one       Visit A   Group two 
Blood sample 
Rectal biopsy  
│ 
│ 
│ 
         1.5g calcium                       No treatment 
          per day                
│ 
│ 
│ 
Six weeks 
        Visit B     
Blood sample 
Rectal biopsy 
│ 
│ 
│ 
 No treatment                 1.5g calcium 
                   Per day 
│ 
│ 
│ 
Twelve weeks 
Visit C 
Blood sample 
Rectal biopsy 
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5.3.5 Protocol for sigmoidoscopic biopsy of rectal epithelium 
Rigid sigmoidoscopy was carried out with the patient in the left lateral position.  
The posterior wall of the lower rectum was visualised and biopsies were taken 
from this region.  The biopsies were snap frozen in liquid nitrogen.  Up to four 
biopsies were taken depending on the presence of excess bleeding and 
patient tolerance. 
5.3.6 Collection of serum samples 
Blood samples were all taken in the morning to avoid differences due to 
diurnal variation.   Venous blood was taken in a routine manner from the ante-
cubital fossa.  Three samples of 5-10mls each were taken.   Samples were 
centrifuged and the serum separated within 4 hours and then protected from 
the light (Vitamin D samples).  All the samples were stored at -80°C.  
Biochemical analysis of all study samples from the eleven subjects who 
completed the study was undertaken as a batch at the end of the study. 
5.3.7 Analysis of serum samples 
Analysis of the serum samples was undertaken in the NHS biochemistry 
laboratory at The University Hospital of Coventry and Warwickshire.  Serum 
PTH was measured using the ElectroChemiLuminescence Immunoassay 
(ECLIA) (Roche).  Serum 25OH-Vitamin D was measured using the IDS 
enzyme immunoassay (Boldon, UK) and serum calcium was measured on a 
modular analyzer (Roche). 
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5.3.8 Statistics 
The mean serum levels of PTH, 25OH-Vitamin D and calcium were compared 
before and after calcium supplementation.  Both 25OH-Vitamin D and calcium 
are normally distributed at the at the population level unlike PTH which has a 
skewed distribution (Jorde, Saleh et al. 2005).  Therefore paired t-tests were 
carried out for calcium and 25OH-Vitamin D using the online utility: 
http://www.graphpad.com/quickcalcs/ttest2.cfm. 
As PTH is not normally distributed the serum levels of PTH were compared 
before and after calcium supplementation using the Mann-Whitney U test.  
This was calculated using the online utility: http://www.holah.karoo.net/Mann-
WhitneyU-test.xls 
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5.4 Results 
 
5.4.1 Subjects 
Only thirteen subjects were recruited to the study; this was despite over eighty 
letters of invitation being sent out.  Of the thirteen who started the study two 
subjects withdrew after the initial visit, one because of ill health and one for 
personal reasons.  The remaining eleven subjects completed the study.  Nine 
of the eleven were male and two female, the mean age was 65, range (61-
69).  Of the eleven subjects who completed the study, nine were randomised 
to group one and two to group two (both the subjects who withdrew had been 
randomised to group two).  Compliance with the calcium supplementation 
regime was 94.8% overall and was >90% for all the subjects.  This data is 
shown in table 5.1.  
Table 5.1 Subject demographics 
This table shows the age and sex of the volunteers, the study group to which 
they were randomised and their compliance with calcium supplements. 
 
Subject Age Sex Group Compliance (%) 
1 62 M 1 100 
2 66 M 1 100 
3 61 M 1 90 
4 64 M 2 Withdrew 
5 69 F 2 Withdrew 
6 66 M 1 95 
7 62 F 2 92 
8 68 F 1 97 
9 65 M 2 93 
10 69 M 1 96 
11 68 M 1 91 
12 66 M 1 91 
13 67 M 1 98 
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5.4.2 Biochemistry results 
The biochemical results for all three time points are shown in Table 5.2 (PTH), 
Table 5.3 (25OH-Vitamin D) and Table 5.4 (calcium). Note that subjects 4 and 
5 withdrew before completing the study. 
5.4.2.1 Baseline biochemical data 
The baseline biochemical data, prior to calcium supplementation for the 
eleven subjects who completed the study is presented below.  This is of 
interest as the samples were taken prior to intervention with calcium. 
 
5.4.2.1.1Serum PTH 
At baseline mean serum PTH was 3.5 pmol/L, median PTH was 3.3pmol/L 
(Range 2.6-5.2 pmol/L).   The normal range is 1.1-4.2 pmol/L and two 
subjects (6 and 8) had high PTH values outside the normal range, see Table 
5.2. 
Table 5.2 Serum PTH levels (pmol/L) for each of the three visits. 
This table show the PTH levels for the eleven subjects who completed the 
study.  Subjects 7 and 9 were in group two and took calcium supplements 
between visits B and C.  The remaining nine subjects who were in group one 
took the calcium supplements between visits A and B. 
 
Subject 
parathyroid hormone 
(pmol/L) 
Visit A Visit B Visit C 
1 3.1 3.1 2.8 
2 2.9 2.3 1.9 
3 3.7 2.7 4.2 
6 4.7 3.7 4.5 
7 3.0 3.1 2.5 
8 5.2 4.5 4.5 
9 2.5 3.6 3.1 
10 3.1 2.4 3.0 
11 3.3 2.9 4.2 
12 2.6 2.2 2.4 
13 3.6 2.6 2.8 
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5.4.2.1.2 Serum 25OH-Vitamin D 
At baseline, mean serum 25OH-Vitamin D was 34.7ug/L, with a standard 
deviation of 21 and a range of 14.1-88.5ug/L.  These results are shown in 
Table 5.3.  The normal range is 10-60ug/L and none of the subjects had a 
value below the lower limit.  One subject (9) had a value above the upper 
limit; this sample was collected in the summer and this result is likely to 
represent high exposure to UVB.   
Table 5.3 Serum 25OH-Vitamin D levels (ug/L) for each of the three 
visits. 
This table show serum 25OH-Vitamin D levels for the eleven subjects who 
completed the study.  Subjects 7 and 9 were in group two and took calcium 
supplements between visits B and C.  The remaining nine subjects who were 
in group one took the calcium supplements between visits A and B. 
 
Subject 25OH-Vitamin D (ug/L) Visit A Visit B Visit C 
1 38.6 33.5 27.2 
2 43.6 33.2 23.8 
3 41.1 38.0 35.1 
6 14.1 16.1 25.0 
7 26.1 26.2 42.9 
8 22.6 27.3 35.4 
9 45.3 88.5 73.2 
10 22.2 21.2 22.5 
11 22.5 39.9 28.5 
12 16.8 21.3 31.2 
13 45.9 42.2 37.4 
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5.4.2.1.3 Serum calcium 
At baseline mean serum calcium was 2.30mmol/L, with a standard deviation 
of 0.09 and a range of 2.18-2.53mmol/L.  These results are shown in Table 
5.4.  The normal range is 2.10-2.58mmol/L and all of the subjects had a value 
within this range.  This includes subjects 6 and 8 who had PTH values outside 
of the normal range.  This indicates that they had secondary rather than 
primary hyperparathyroidism. 
 Table 5.4 Serum calcium levels (mmol/L) for each of the three visits 
This table shows the serum calcium levels (mmol/L) for the eleven subjects 
who completed the study.  Subjects 7 and 9 were in group two and took 
calcium supplements between visits B and C.  The remaining nine subjects 
who were in group one took the calcium supplements between visits A and B. 
 
Subject Serum Calcium Visit A Visit B Visit C 
1 2.35 2.28 2.31 
2 2.3 2.35 2.41 
3 2.35 2.28 2.24 
6 2.27 2.33 2.36 
7 2.53 2.48 2.59 
8 2.32 2.29 2.33 
9 2.32 2.28 2.39 
10 2.22 2.22 2.23 
11 2.18 2.33 2.20 
12 2.32 2.32 2.30 
13 2.21 2.21 2.22 
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5.4.2.2 Change in biochemical parameters in response to calcium 
supplementation 
The changes in biochemical parameters in response to six weeks calcium 
supplementation are shown in Table 5.5.  For the nine subjects in group 1 the 
comparison is between visits B and A, for those in group 2 the comparison is 
between visits C and B. 
 
 
Table 5.5 Changes in biochemical parameters after six weeks calcium 
supplementation 
This table shows the changes in the level of serum PTH, 25OH-vitamin D and 
calcium after six weeks of dietary calcium supplementation. 
 
Subject Change in PTH 
Change in 
25OH-Vit D 
Change in 
calcium 
1 0 -5.1 -0.07 
2 -0.6 -10.4 +0.05 
3 -1.0 -3.1 -0.07 
6 -1.0 +2.0 +0.06 
7 -0.6 +16.7 +0.11 
8 -0.7 +4.7 -0.03 
9 -0.5 -15.3 +0.11 
10 -0.7 -1.0 0 
11 -0.4 +17.4 +0.15 
12 -0.4 +4.5 0 
13 -1.0 -3.7 0 
Mean 
change -0.63 +0.6 -0.03 
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5.4.2.2.1 Serum PTH 
After six weeks of calcium supplementation, serum PTH was decreased in ten 
and unchanged in one subject.  The range of the change in PTH was 0 to  
-1.0pmol/L.  At baseline the median PTH value was 3.3pmol/L (Range 2.6-5.2 
pmol/L) and after calcium supplementation was 2.7pmol/L (Range 2.2-4.5 
pmol/L).  A Mann-Whitney U-test was performed to compare the difference 
between serum PTH levels before and after calcium supplementation (Table 
5.6), this showed a highly significant difference at the 5% level (p<0.05). 
 
Table 5.6 Statistical comparison of mean serum PTH, before and after 
calcium supplementation  
 
Group Baseline Calcium 
Median 3.3 2.7 
Range 2.6-5.2 2.2-4.5 
N 11 11 
 
U = 27.5 
Significant at 5% level 
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5.4.2.2.2 Serum 25OH-Vitamin D 
After six weeks of calcium supplementation, serum 25OH-Vitamin D was 
decreased in six and increased in five subjects.  The range of this change was  
-15.3 to +17.4ug/L.  At baseline, mean 25OH-Vitamin D was 34.7ug/L and 
after six weeks calcium supplementation was 35.3, representing an increase 
in the mean of 0.6ug/L (95%CI=-7.4 to +6.2), equivalent to a 2% increase in 
25OH-Vitamin D.  A paired t-test was performed to compare the differences of 
the mean serum 25OH-Vitamin D before and after calcium supplementation 
(Table 5.7), this showed no significant difference (p=0.85). 
 
Table 5.7 Statistical comparison of mean serum 25OH-Vitamin D, before 
and after calcium supplementation SD=Standard Deviation, 
SEM=Standard Error of Mean 
 
Group Baseline Calcium 
Mean 34.7 35.3 
SD 21.0 15.5 
SEM 6.3 4.7 
N 11 11 
 
t = 0.2004 
Degrees of freedom = 10 
Two-tailed P value = 0.85 
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5.4.2.2.3 Serum calcium 
After six weeks of calcium supplementation, serum calcium was decreased in 
three, increased in five and unchanged in three subjects.  The range of the 
change in calcium was -0.07 to +0.15mmol/L.  At baseline mean serum 
calcium was 2.31mmol/L and after calcium supplementation was 2.33 mmol/L 
representing a mean decrease in serum calcium of -0.03mmol/L (95%CI -
0.078 to +0.021), which is equivalent to a 1% reduction in mean serum 
calcium level.  A paired t-test was performed to compare the differences of the 
mean serum calcium before and after calcium supplementation, this showed 
no significant difference (p=0.24). 
 
Table 5.8 Statistical comparison of mean serum Calcium, before and 
after calcium supplementation SD=Standard Deviation, SEM=Standard 
Error of Mean 
 
Group Baseline Calcium 
Mean 2.30 2.33 
SD 0.083 0.102 
SEM 0.025 0.030 
N 11 11 
 
t = 1.2630 
Degrees of freedom = 10 
Two-tailed P value = 0.24 
 
These results demonstrate that six weeks dietary calcium supplementation 
significantly reduced serum PTH but had no effect on serum 25OH-Vitamin D 
or calcium. 
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5.5: Discussion 
 
In this study the main finding was that dietary calcium supplementation for six 
weeks resulted in a significant reduction in serum PTH levels with no 
significant effect on serum 25OH Vitamin D or calcium.  That calcium 
supplementation suppresses PTH is not a novel observation.  Calcium 
supplementation results in a reduced serum level of PTH after a single dose 
(Thomas, Need et al. 2008), after six weeks supplementation (Saleh, Jorde et 
al. 2003) or following two years supplementation (Reid, Ames et al. 2008).  
The magnitude of the change in PTH level is also similar to that found in these 
studies.  The effect of calcium on the level of serum PTH was not measured in 
either of the adenoma prevention studies (Baron, Beach et al. 1999; Bonithon-
Kopp, Kronborg et al. 2000).  But based on the observations above it seems 
reasonable to expect that serum PTH was lower in the calcium treated group. 
  Calcium supplementation had no effect on the serum level of 25OH-
Vitamin D, which is consistent with the finding of the polyp prevention study.  
In that study, there was no difference in 25OH-Vitamin D level between the 
calcium and placebo group after three years of calcium supplementation 
(Grau, Baron et al. 2003).  It is therefore not a novel observation, that calcium 
suppresses PTH, with no effect on 25OH-Vitamin D.  However, its importance 
relates to the interpretation of the results of the rectal mucosal gene 
expression studies described in the following chapters. 
 One criticism of this study could be that serum 1,25OH-Vitamin D was 
not measured.  There are a number of reasons for this; the studies of vitamin 
D and colorectal cancer have shown an inverse association with 25OH-
Vitamin D but not 1,25OH-Vitamin D (Tangrea, Helzlsouer et al. 1997; 
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Feskanich, Ma et al. 2004).  Similarly, the relationship observed between 
serum levels of vitamin D and the efficacy of calcium in preventing adenomas, 
was related to higher serum levels of 25OH-Vitamin D, with no relationship to 
1,25OH-Vitamin D (Grau, Baron et al. 2003).  Further evidence that calcium 
does not act by increasing the level of serum 1,25OH-Vitamin D is found in 
the polyp prevention study.  In this study there was a significant reduction in 
the level of 1, 25OH-Vitamin D at the end of the study in the calcium treated 
group, with no effect in the placebo group (Grau, Baron et al. 2003). 
 The baseline biochemical results for PTH show some features of note.  
The serum PTH levels show a wide range of values and two out of the eleven 
subjects had values above the upper limit of normal.  They both had normal 
serum calcium levels indicating that they had secondary rather than primary 
hyperparathyroidism.  Secondary hyperparathyroidism is common, with 
around 6% of healthy subjects having a level outside the normal range (Saleh, 
Jorde et al. 2006).  In the general population parathyroid hormone is not 
normally distributed, but has a positively skewed distribution. Factors that 
contribute to the level of serum PTH include serum 25OH-Vitamin D level and 
dietary calcium intake (Saleh, Jorde et al. 2006), body mass index 
(Kamycheva, Sundsfjord et al. 2004), age (Jorde, Bonaa et al. 1999) and 
renal function (Stein, Flicker et al. 2001).  However none of the factors above 
satisfactorily explains the causes of raised serum PTH.  In most cases it is 
multi-factorial and incompletely explained by known risk factors (Saleh, Jorde 
et al. 2006). 
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Conclusion 
In this study the baseline biochemical data for the subjects in this study have 
been reported and the suppressive effect of six weeks dietary calcium 
supplementation on serum PTH has been demonstrated. 
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Chapter 6A 
INVESTIGATION INTO THE RELATIONSHIP BETWEEN SERUM 
BIOCHEMICAL PARAMETERS AND GENE EXPRESSION IN NORMAL 
RECTAL MUCOSA 
 
6A.1 Primary aims: 
 1. Determine the gene expression profile in the normal rectal mucosa 
 of individuals at baseline prior to any intervention 
 2. Investigate the relationship between biochemical parameters (PTH, 
 25OH- Vitamin D and calcium) and gene expression in normal rectal 
 mucosa. 
 3. Identify individual genes whose expression correlates with the serum 
 levels of 25OH-Vitamin D, PTH and calcium. 
6A.1.1 Secondary aims: 
 1. Carry out functional annotation of genes showing correlation with 
 biochemical parameters. 
 
6A.2 Introduction 
In chapter two it was demonstrated that colonic cells in-vitro are sensitive to 
PTH.  It is therefore hypothesised that normal colorectal mucosa is sensitive 
to variation in serum PTH levels.  With this in mind it is predicted that there 
will be inter-individual variation in gene expression in normal rectal mucosa 
and that the observed variation is at least in part due to inter-individual 
variation in serum parathyroid hormone levels.  In studies of patients with 
primary hyperparathyroidism before and after parathyroidectomy, the in-vivo 
transcriptional targets of PTH have been identified in a classical PTH target, 
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bone (Reppe, Stilgren et al. 2006)  and two non classical PTH targets, muscle 
and haematopoietic cells (Reppe, Stilgren et al. 2007).  These studies indicate 
that PTH alters gene expression in non classical PTH targets, supporting the 
hypothesis that PTH may influence gene expression in the colon.  Biopsies of 
normal rectal epithelium are easily obtainable and have been used here to 
investigate the influence of biochemical factors on gene expression.  Previous 
studies of normal rectal mucosa have been used to investigate the influence 
of various agents implicated in the prevention of colorectal neoplasia (Holt, 
Atillasoy et al. 1998) and features associated with the risk of colorectal 
neoplasia (Ponz de Leon, Roncucci et al. 1988);  but only one study has used 
micro-arrays to study gene expression in normal mucosa before and after 
intervention (Glebov, Rodriguez et al. 2006).  As it has been demonstrated 
that both Vitamin D (Palmer, Sanchez-Carbayo et al. 2003) and calcium 
(Chakrabarty, Radjendirane et al. 2003) alter gene expression in-vitro, the 
relationship of these biochemical factors to gene expression in rectal mucosa 
will also be studied. 
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6A.3: Methods 
6A.3.1 Subjects 
Six subjects were investigated in the studies carried out in this chapter.  The 
subjects used in this study were selected from those described in the previous 
chapter.  The criteria for selecting which subjects would be studied were: 
1. The availability of enough good quality (10ug) RNA.  See table 6A.1 
2. Serum levels of 25OH-Vitamin D and PTH at baseline, specifically half 
of the subjects had high (>29ug/L) 25-OH-Vitamin D levels and half 
had levels below this.   
3. In view of the studies described in the next chapter; subjects in which a 
decrease in PTH was seen in response to calcium supplementation. 
Table 6A.1 Concentration and purity of RNA extracted from the rectal 
mucosal biopsies used in the studies described in chapters 6 and 7.  
The sample numbers anonymously identify the volunteers, A and B refer to 
samples taken at base line and after calcium supplementation. 
 
Sample 
RNA  
concentration 
(ng/µl) 
RNA purity 
(260/280nm ratio) 
3A 1293 2.08 
3B 1343 2.1 
7A 1012 2.09 
7B 1149 2.0 
8A 1157 2.1 
8B 1591 2.09 
10A 1610 2.08 
10B 1614 2.09 
11A 1424 2.1 
11B 2102 2.09 
13A 1864 2.08 
13B 3271 2.02 
 
There were two females and four males in the six subjects selected.  Their 
baseline biochemical data and demographics are shown in Table 6A.2.  
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6A.3.2 Micro-array analysis of gene expression in normal rectal mucosa 
Gene expression profiling was performed on the baseline samples of normal 
rectal mucosa from the six subjects using the Affymetrix Human genome 
U133A 2.0 gene chip.  RMA (Irizarry, Bolstad et al. 2003) was used to 
calculate gene expression level. 
6A.3.3 Identification of genes correlated with biochemical parameters 
It was hypothesised that there was a linear relationship between serum PTH 
and gene expression, with gene expression dependent on the serum PTH 
level.  A similar approach was taken for calcium and 25OH-Vitamin D.  Using 
the data from the six baseline samples, Pearson‟s product-moment correlation 
coefficient r was calculated for each probe on the gene chip.  Serum PTH 
levels were log2 transformed to normalise the data, as normally distributed 
data is a requirement for the calculation of r.  The population distribution of 
PTH is important in this context and this has been studied, with the majority of 
studies indicating that PTH is positively skewed (Jorde, Saleh et al. 2005). 
The sample size for this study is too small to determine whether PTH is 
normally distributed, but inspection of distribution plots of PTH suggest a right 
skew and for both of these reasons the PTH values were log transformed, 
these values are shown in Table 6A.2.   The values for calcium and 25OH-
Vitamin D were not log transformed as at a population level these are 
normally distributed. 
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Table 6A.2 Demographics and baseline biochemical values for the six 
subjects studied in this chapter. 
 
Subject Age Sex PTH pmol/l 
PTH 
pmol/l 
(log2) 
25OH-
Vitamin D 
ug/L 
Calcium 
mmol/L 
3 61 M 3.7 1.89 41.1 2.35 
7 62 F 3.1 1.63 26.2 2.48 
8 68 F 5.2 2.38 22.6 2.32 
10 69 M 3.1 1.63 22.2 2.22 
11 68 M 3.3 1.72 22.5 2.18 
13 67 M 3.6 1.85 45.9 2.21 
 
 Initial analysis of the Pearson‟s correlation coefficient for all of the 
genes identified was carried out using MSExcel.  This identified a large 
number of genes for which expression correlated with PTH.  The majority of 
these genes were negatively correlated, with a smaller number showing 
positive correlation with PTH.  Visualisation of x,y regression plots for some of 
this data indicated that a number of the genes showing correlation with PTH 
were expressed at very low levels, with a single outlying value resulting in 
significant correlation.  Examination of the present/absent calls was carried 
out using Gene Chip Operating System (GCOS).  The results of this are 
shown in table 6A.3, this demonstrates a binomial distribution, with around 
2./3 of genes called as present in the majority of the samples and just under a 
1/3 called as absent in the majority with a smaller number called as present in 
an intermediate number.   
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Table 6A.3 Relationship between number of subjects and the proportion 
of genes called as present using GCOS 
The binomial distribution can be seen. 
 
Number of samples in 
which gene expression 
was called as present 
Number of 
genes 
0 4010 
1 440 
2 231 
3 274 
4 295 
5 889 
6 7201 
 
The low expressing genes showing correlation were not surprisingly called as 
absent.  As the correlation for these genes may be spurious, it was decided to 
limit further analysis of correlation to genes called as present in at least two 
out of the six samples.  This resulted in 8890 genes being studied, 
representing around 2/3 of the genes on the chip.  Following initial explorative 
data-analysis, SAM (Significance Analysis of Micro-arrays) was used to 
identify those genes significantly correlated with PTH. 
6A.3.4 Significance analysis of micro-arrays (SAM) 
To identify genes correlated with serum PTH and determine their statistical 
significance, the SAM approach (Tusher, Tibshirani et al. 2001) was used.  
The RMA data was used with Pearson‟s correlation with each of the 
biochemical parameter as the response variable, with six hundred 
permutations.   The output from SAM is the (d)-score which is the outcome of 
the gene specific t-test and the q-value which is the lowest false discovery 
rate (FDR) at which the gene is called significant.  In this study a q-value of 
<1% was considered significant. 
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6A.3.5 Regression plots 
Regression plots were constructed for genes of interest using MSExcel.  Log2 
transformed values for PTH and micro-array RMA data were plotted on the x 
and y axes respectively.  Log2 transformed array data was used as that is the 
format used by SAM 
6A.3.6 Functional annotation of PTH correlated genes using DAVID 
The list of correlated genes was uploaded to DAVID (Database for 
Annotation, Visualization and Integrated Discovery 
(http://david.abcc.ncifcrf.gov/) (Dennis, Sherman et al. 2003; Huang da, 
Sherman et al. 2009).  The background to and the methods employed by 
DAVID were described in section 4B.3.1.  The enriched annotation terms 
were identified using two different utilities available on DAVID and for each 
analysis the background was set as Affymetrix HG U133A 2.0.   
1. Functional annotation chart 
This identifies enriched terms within the gene list and performs a 
“term centric singular enrichment analysis”. The default settings 
were deployed apart from using an EASE score of 0.01 (instead of 
0.1) to identify enriched annotation terms.  
 
2. Functional annotation clustering                                                     
This clusters functionally similar enriched terms into groups, 
performing a “term centric modular enrichment analysis”.  Default 
settings were employed apart from stringency being increased to 
high.  Clusters of terms with enrichment scores of >2, which is 
equivalent to non-log scale value of 0.01, were identified.  
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6A.4 Results 
6A.4.1 Correlation of gene expression level with serum biochemical 
parameters 
The expression of genes in the normal rectal mucosa from the six baseline 
samples was determined using the Affymetrix HG U133A 2.0 array.  The SAM 
(significance analysis of micro-arrays) utility was used to identify statistically 
significant genes, for which expression correlates with the measured serum 
biochemical parameter; Parathyroid hormone (PTH), 25OH-Vitamin D and 
calcium.  
6A.4.1.1 Parathyroid hormone (PTH) 
Using a q-value of 1%, the expression of 2693 genes was negatively 
correlated with serum PTH levels.  That is, at higher levels of PTH, expression 
of these genes was lower and at lower levels of PTH, expression of these 
genes was higher.  There were no statistically significant genes for which 
expression correlated positively with PTH identified by this method.  Initial 
analysis of all of the genes present on the chip identified some positively 
correlated genes.  Limiting the analysis to the “expressed” genes (>2/6 
present call) for the reasons discussed in the methods, meant some of these 
were removed and the others were not subsequently identified as statistically 
significant and are not further analysed here. 
6A.4.1.2 25OH-Vitamin D 
There were no genes for which expression correlated with serum levels of 
25OH-vitamin D, with a q value<10%. 
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6A.4.1.3 Calcium 
There was only one gene in which expression correlated with the serum levels 
of calcium with a q-value of less than 10%.  This single gene was VIP 
(vasoactive intestinal peptide), which had a d-score of -6.4 and a q value of 0.  
Of note the analyses for calcium and 25OH-vitamin D were carried out on all 
the genes and the “present” genes with no difference in result and no genes 
were correlated with a q-value up to 10%. 
This analysis demonstrates that there are a large number of genes for which 
expression level correlates with serum PTH level.  This contrasts with the 
situation for calcium and 25OH-Vitamin D.  As correlation does not equal 
causation further studies will be needed for it to be argued that serum PTH is 
a significant determinant of gene expression in the rectal mucosa.  However, 
in analysing the set of genes showing negative correlation with PTH it is 
presumed that the relationship is functional and that the expression of these 
genes is in part regulated by PTH.   Therefore identifying the function of this 
set of genes may provide evidence for the biological actions of PTH in the 
normal rectal mucosa.   
6A.4.2 Functional annotation of the genes which showed correlation with 
serum PTH 
The online utility DAVID was used to identify the GO biological annotation 
terms enriched in the set of PTH correlated genes.  As described in the 
methods, two features of DAVID were used.  First, enriched single GO 
annotation terms were identified.  Secondly, from within these enriched single 
annotations terms, enriched clusters of functionally related GO annotation 
terms were identified. 
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6A.4.2.1 Enriched single GO annotation terms in the PTH correlated 
genes 
Enriched single annotation terms for each of the three biological domains of 
the GO annotation (BP, MF and CC), were identified.  There are sixty-four 
biological process terms, forty two cellular component and twenty-four 
molecular function annotation terms enriched in the PTH correlated genes.  
These are shown in Tables 6A.4, 6A.5 and 6A.6.  
Table 6A.4 The 63 GO biological process annotation terms enriched in 
the 2693 genes negatively correlated with PTH 
The p-value and false detection rate (FDR) for each term is shown. 
 
Biological process (BP) P value FDR % 
intracellular transport 6E-12 3E-08 
protein transport 1E-11 4E-08 
establishment of protein localization 2E-11 4E-08 
protein catabolic process 1E-10 2E-07 
protein localization 5E-10 5E-07 
macromolecule catabolic process 1E-09 9E-07 
cellular protein catabolic process 1E-09 9E-07 
proteolysis involved in cellular protein catabolic 
process 1E-09 9E-07 
vesicle-mediated transport 2E-09 1E-06 
modification-dependent protein catabolic process 5E-09 2E-06 
modification-dependent macromolecule catabolic 
process 5E-09 2E-06 
cellular macromolecule catabolic process 1E-08 5E-06 
cellular macromolecule localization 1E-08 5E-06 
cellular protein localization 3E-08 1E-05 
intracellular protein transport 4E-08 1E-05 
small GTPase mediated signal transduction 1E-07 5E-05 
ubiquitin-dependent protein catabolic process 1E-07 5E-05 
regulation of apoptosis 6E-07 2E-04 
regulation of cell death 6E-07 2E-04 
regulation of programmed cell death 8E-07 2E-04 
negative regulation of apoptosis 8E-07 2E-04 
negative regulation of programmed cell death 1E-06 4E-04 
negative regulation of cell death 2E-06 4E-04 
cell death 3E-06 8E-04 
death 5E-06 1E-03 
macromolecular complex assembly 5E-06 1E-03 
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apoptosis 7E-06 1E-03 
Golgi vesicle transport 8E-06 1E-03 
programmed cell death 1E-05 2E-03 
anti-apoptosis 1E-05 2E-03 
intracellular signaling cascade 1E-05 2E-03 
enzyme linked receptor protein signaling pathway 1E-05 2E-03 
induction of apoptosis 2E-05 3E-03 
induction of programmed cell death 2E-05 3E-03 
macromolecular complex subunit organization 3E-05 3E-03 
membrane organization 3E-05 4E-03 
protein complex biogenesis 3E-05 4E-03 
protein complex assembly 3E-05 4E-03 
protein targeting 4E-05 5E-03 
transmembrane receptor protein tyrosine kinase 
signaling pathway 5E-05 6E-03 
nitrogen compound biosynthetic process 6E-05 7E-03 
regulation of cell proliferation 9E-05 1E-02 
G1/S transition of mitotic cell cycle 1E-04 1E-02 
negative regulation of macromolecule metabolic 
process 1E-04 2E-02 
positive regulation of protein kinase cascade 2E-04 2E-02 
dephosphorylation 3E-04 3E-02 
positive regulation of I-kappaB kinase/NF-kappaB 
cascade 3E-04 3E-02 
positive regulation of signal transduction 3E-04 3E-02 
chromatin remodeling 4E-04 4E-02 
regulation of I-kappaB kinase/NF-kappaB cascade 4E-04 4E-02 
positive regulation of cell death 4E-04 4E-02 
cofactor biosynthetic process 4E-04 4E-02 
protein amino acid dephosphorylation 4E-04 4E-02 
phosphorus metabolic process 4E-04 4E-02 
phosphate metabolic process 4E-04 4E-02 
positive regulation of programmed cell death 5E-04 4E-02 
induction of apoptosis by extracellular signals 5E-04 5E-02 
negative regulation of gene expression 6E-04 5E-02 
positive regulation of apoptosis 6E-04 5E-02 
ER to Golgi vesicle-mediated transport 6E-04 5E-02 
protein import 6E-04 5E-02 
endosome transport 6E-04 5E-02 
steroid hormone receptor signaling pathway 7E-04 5E-02 
cellular macromolecular complex assembly 8E-04 6E-02 
cellular response to insulin stimulus 9E-04 7E-02 
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Table 6A.5 The 42 GO cellular component annotation terms enriched in 
the 2693 genes negatively correlated with PTH. 
 The p-value and false detection rate (FDR) for each term is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cellular component (CC) P value FDR % 
Golgi apparatus 3E-15 2E-12 
endoplasmic reticulum 2E-13 8E-11 
endomembrane system 6E-13 2E-10 
nuclear lumen 2E-10 4E-08 
membrane-enclosed lumen 5E-10 7E-08 
organelle membrane 8E-10 1E-07 
organelle lumen 9E-10 1E-07 
intracellular organelle lumen 1E-09 1E-07 
nucleoplasm 1E-08 8E-07 
Golgi apparatus part 9E-08 6E-06 
endosome 1E-07 8E-06 
cytosol 1E-07 1E-05 
cell fraction 2E-07 1E-05 
vacuole 4E-07 2E-05 
endoplasmic reticulum membrane 2E-06 6E-05 
nuclear envelope-endoplasmic reticulum 
network 1E-06 7E-05 
nucleoplasm part 2E-06 7E-05 
vesicle 5E-06 1E-04 
insoluble fraction 1E-05 5E-04 
membrane fraction 2E-05 5E-04 
cytoplasmic vesicle 4E-05 1E-03 
Golgi membrane 7E-05 2E-03 
nucleolus 7E-05 2E-03 
lytic vacuole 7E-05 2E-03 
lysosome 7E-05 2E-03 
membrane-bounded vesicle 9E-05 2E-03 
nuclear envelope 1E-04 2E-03 
trans-Golgi network 1E-04 3E-03 
endoplasmic reticulum part 2E-04 6E-03 
cytoplasmic membrane-bounded vesicle 2E-04 6E-03 
focal adhesion 3E-04 6E-03 
vacuolar membrane 3E-04 7E-03 
cell-substrate junction 3E-04 7E-03 
adherens junction 4E-04 9E-03 
apical part of cell 4E-04 9E-03 
apical plasma membrane 5E-04 1E-02 
histone acetyltransferase complex 6E-04 1E-02 
cell-substrate adherens junction 6E-04 1E-02 
anchoring junction 6E-04 1E-02 
perinuclear region of cytoplasm 7E-04 1E-02 
vacuolar part 9E-04 1E-02 
protein serine/threonine phosphatase 
complex 1E-03 1E-02 
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Table 6A.6 The 24 GO molecular functions annotation terms enriched in 
the 2693 genes negatively correlated with PTH.  
The p-value and false detection rate (FDR) for each term is shown. 
 
Molecular Function (MF) P value FDR % 
enzyme binding 2E-07 2-04 
phosphoprotein phosphatase activity 1E-05 9E-03 
GTPase activity 1E-05 7E-03 
ubiquitin protein ligase binding 1E-05 6E-03 
protein serine/threonine phosphatase activity 3E-05 1E-02 
phosphatase activity 4E-05 1E-02 
transcription factor binding 4E-05 9E-03 
ligase activity, forming carbon-nitrogen bonds 4E-05 8E-03 
GTP binding 6E-05 1E-02 
SMAD binding 8E-05 1E-02 
protein C-terminus binding 9E-05 1E-02 
acid-amino acid ligase activity 1E-04 2E-02 
protein dimerization activity 1E-04 2E-02 
guanyl ribonucleotide binding 1E-04 2E-02 
guanyl nucleotide binding 1E-04 2E-02 
transcription coactivator activity 2E-04 3E-02 
transcription cofactor activity 2E-04 3E-02 
transcription activator activity 3E-04 3E-02 
purine ribonucleotide binding 3E-04 3E-02 
ribonucleotide binding 4E-04 3E-02 
small conjugating protein ligase activity 4E-04 3E-02 
purine nucleotide binding 4E-04 4E-02 
signal sequence binding 4E-04 4E-02 
transcription repressor activity 7E-04 5E-02 
 
6A.4.2.2 Enriched clusters of functionally related GO annotation terms 
Fifteen enriched clusters of functionally related annotation terms were 
identified using the criteria described in the methods.  These fifteen enriched 
clusters are shown in Table 6A.7.  The findings of particular note include: four 
clusters (5, 6, 7 and 14) of enriched annotation terms related to apoptosis and 
cell death.  These include terms indicating the induction of apoptosis and both 
the positive and negative regulation of apoptosis, as well as the process itself.  
There are two clusters of enriched annotation terms (1 and 4) relating to the 
localisation of macromolecules and proteins; and another (10), indicating the 
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formation of these protein and macromolecule complexes.  A cluster of 
annotation terms relating to focal adhesion and adherens junctions (15), was 
enriched.  Apoptosis, localisation and cell-cell adhesion are features of 
differentiated crypt top cells (Kosinski, Li et al. 2007) suggesting that PTH 
may be a negative regulator of these biological activities and cellular 
components.  Consistent with this is the finding that two single annotation 
terms “apical part of cell” and “apical plasma membrane” are also enriched 
(See Table 6A.5). 
The biological significance of the other enriched clusters is less clear as they 
have a general role, though both cluster 9 and 11 may indicate the secretory 
function of mature enterocytes.  There is also some overlap between the 
annotation terms enriched in the genes negatively correlated with PTH in this 
study and those up-regulated by PTH in-vitro, as discussed below.     
Table 6A.7 The fifteen clusters of annotation terms enriched in the 2693 
genes negatively correlated with PTH. 
The enrichment score (ES) for each is cluster is shown. 
Cluster GO terms  (Biological domain) ES 
1 
protein transport (BP) 
establishment of protein localization (BP) 
protein localization (BP) 
9.8 
2 
nuclear lumen (CC) 
membrane-enclosed lumen (CC) 
organelle lumen(CC)  
intracellular organelle lumen (CC) 
8.2 
3 
protein catabolic process (BP) 
macromolecule catabolic process (BP) 
cellular protein catabolic process (BP) 
proteolysis involved in cellular protein catabolic process 
(BP) 
modification-dependent macromolecule catabolic 
process(BP) 
modification-dependent protein catabolic process (BP) 
cellular macromolecule catabolic process (BP) 
7.7 
4 
cellular macromolecule localization (BP) 
cellular protein localization (BP) 
intracellular protein transport (BP) 
6.4 
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5 
regulation of apoptosis (BP) 
regulation of cell death (BP) 
regulation of programmed cell death (BP) 
6.2 
6 
negative regulation of apoptosis (BP) 
negative regulation of programmed cell death(BP)  
negative regulation of cell death (BP) 
5.8 
7 
cell death (BP) 
death (BP) 
apoptosis (BP) 
programmed cell death (BP) 
5.2 
8 
endoplasmic reticulum membrane (CC) 
nuclear envelope-endoplasmic reticulum network (CC) 
endoplasmic reticulum part (CC) 
5.1 
9 
vacuole (CC) 
lysosome (CC) 
lytic vacuole(CC)  
4.9 
10 
macromolecular complex assembly (BP) 
macromolecular complex subunit organization (BP) 
protein complex biogenesis (BP) 
protein complex assembly (BP)  
4.0 
11 
vesicle (CC) 
cytoplasmic vesicle (CC) 
membrane-bounded vesicle (CC) 
cytoplasmic membrane-bounded vesicle (CC) 
3.9 
12 
phosphoprotein phosphatase activity (MF) 
dephosphorylation (BP) 
protein amino acid dephosphorylation (BP) 
3.8 
13 
GTP binding (MF) 
guanyl nucleotide binding (MF) 
guanyl ribonucleotide binding (MF) 
3.2 
14 
induction of apoptosis (BP) 
induction of programmed cell death (BP) 
positive regulation of cell death (BP) 
positive regulation of programmed cell death(BP)  
positive regulation of apoptosis (BP) 
2.6 
15 
focal adhesion (CC) 
cell-substrate junction (CC)  
adherens junction (CC) 
cell-substrate adherens junction (CC) 
2.2 
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6A.4.2.3 Comparison with functional annotation of genes differentially 
expressed in response to PTH in-vitro 
Comparison with the functional annotation identified in the PTH regulated 
genes in-vitro identified a number of features in common (Compare Tables 
4B.4, 4B.5 and 4B.6 with table 6A.7).  These are clusters 13 and 4C, which 
includes GTP binding and GTPase activity; clusters 1 and 4A, which include 
protein localisation and establishment of protein localisation and clusters 5 
and V, which include apoptosis and cell death.   
 
6A.4.3 Relationship of genes correlated with PTH to genes differentially 
expressed in response to PTH in-vitro 
Having identified a group of genes negatively correlated with PTH in-vivo, it 
was hypothesised that there would be similarity with those genes differentially 
expressed in response to PTH in-vitro.  Out of the one hundred and twenty-
four genes differentially expressed in response to PTH in-vitro (at either four 
or twenty-four hours), forty eight were also negatively correlated with serum 
PTH.  These forty-eight genes are shown in Table 6A.8. 
 Regression plots for some of the genes that are negatively correlated 
and down regulated by PTH in-vitro are shown in Figure 6A.1.  These plots 
graphically demonstrate the relationship between serum PTH and gene 
expression level. 
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Figure 6A.1 Regression plots comparing gene expression and serum 
PTH 
These genes are examples of genes that are negatively correlated with PTH 
in-vivo and also down-regulated by PTH in-vitro. X=PTH, Y=Expression level, 
both are log2 transformed values.  
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Table 6A.8 The 48 genes that negatively correlate with serum PTH and 
were down-regulated by PTH in-vitro.  
The SAM output is shown along with the Pearson‟s correlation coefficient r.  
q=False detection rate and d value is the degree of difference from the 
expected variance. 
 
Gene 
SAM data Pearson‟s 
correlation 
coefficient (r) d q 
DUSP5 -3.8 0 -0.97 
RHOB -3.5 0 -0.98 
DUSP6 -2.8 0 -0.97 
SPOP -2.5 0.1 -0.94 
SCARB2 -2.5 0.1 -0.90 
RBM3 -2.4 0.1 -0.95 
KDM3B -2.4 0.1 -0.91 
FZD7 -2.2 0.3 -0.88 
SLC16A1 -2.2 0.3 -0.74 
ABCG2 -2.1 0.3 -0.83 
AREG -2.0 0.3 -0.88 
PHLDA2 -2.0 0.3 -0.92 
RALA -2.0 0.3 -0.80 
APLP2 -2.0 0.3 -0.93 
ABCB1 -1.9 0.3 -0.80 
PHLDA1 -1.9 0.3 -0.86 
SGK1 -1.9 0.3 -0.78 
PDCD2 -1.9 0.3 -0.93 
RTN3 -1.8 0.3 -0.90 
ROD1 -1.8 0.3 -0.84 
PAFAH1B1 -1.7 0.3 -0.85 
YTHDF2 -1.7 0.3 -0.88 
CEACAM5 -1.7 0.3 -0.94 
GSR -1.7 0.5 -0.85 
NLK -1.7 0.5 -0.87 
CTBP1 -1.6 0.5 -0.87 
TMOD3 -1.6 0.5 -0.80 
NUP98 -1.6 0.5 -0.89 
GATM -1.6 0.5 -0.87 
SLC25A32 -1.5 0.5 -0.86 
EFNB2 -1.5 0.6 -0.89 
ATP1B1 -1.5 0.6 -0.86 
RFC3 -1.5 0.6 -0.83 
GJA1 -1.4 0.6 -0.76 
LRRFIP1 -1.4 0.6 -0.74 
FBLN1 -1.4 0.6 -0.78 
RBBP4 -1.4 0.6 -0.87 
MAP4K4 -1.3 0.6 -0.86 
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ACTB -1.3 0.9 -0.79 
CALM1 -1.3 0.9 -0.83 
EREG -1.3 0.9 -0.59 
BRD2 -1.3 0.9 -0.89 
ARHGAP5 -1.3 0.9 -0.80 
PTPN11 -1.3 0.9 -0.82 
RAB8A -1.3 0.9 -0.97 
SS18 -1.3 0.9 -0.85 
ARL4C -1.2 0.9 -0.77 
BRD4 -1.2 0.9 -0.87 
 
 
 
 
6A.4.4 Relationship of genes correlated with PTH to position in the 
colonic crypt 
It was noted that there were a number of genetic markers expressed in 
differentiated colonic cells in the genes negatively correlated with PTH 
including; CDKN1A, GPA33, PRSS3, CEACAM1, BMP2 and EZR. 
This suggests the possibility that PTH negatively regulates differentiation of 
colonic cells. The statistical significance was not assessed in this analsyses, 
but will be investigated in the next chapter. 
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6A.5 Discussion 
 
In this study it was identified that some of the inter-individual variation in gene 
expression correlated with serum PTH level, with the expression of a large 
number of genes showing negative correlation with serum PTH levels.  In 
contrast, no correlation was found between gene expression and serum 
25OH-Vitamin D levels and only a single gene showed significant correlation 
with serum calcium.  These findings would suggest that serum PTH level may 
be a significant determinant of gene expression in normal rectal mucosa, 
particularly in view of the large number of genes showing negative correlation 
with PTH.  It is acknowledged that correlation does not equal causation and 
this will be addressed in further studies in this thesis.  There are however, 
some interesting data provided in this chapter to suggest that the relationship 
between PTH and gene expression may be functional.  Firstly, both the in-
vitro and in-vivo studies of PTH are consistent; in both studies PTH down-
regulated gene expression.  The in-vivo study identified only genes showing 
negative correlation and in the in-vitro study the majority (>90%) of genes 
were down-regulated in response to PTH.   
Secondly, there were a large number of genes showing correlation with PTH 
and these were enriched with interesting functional annotation terms.  The 
use of SAM enabled the identification of genes which were statistically 
significantly correlated with serum PTH.  This produced a large list of genes, 
which can be difficult to analyse, but all of these genes met the stringent 1% 
FDR cut off and it was felt appropriate to analyse all of these genes.  In 
analysing such a list it is desirable to identify the biological processes 
enriched within the whole group rather than carry out singular functional 
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analysis of each gene in the list.  DAVID is well suited to this, being able to 
carry out functional annotation of up to 3000 genes.  A large number of 
functional annotation terms were highly statistically enriched in the group of 
genes negatively correlated with PTH.  This large number of enriched 
annotation terms is more significant than would be expected were this a 
random set of genes. The annotation terms enriched in the genes negatively 
correlated with PTH include features consistent with mature colonic cells.  
Particularly, the regulation and process of apoptosis; and structural features 
such as adherens junctions and the apical parts of cell membranes were 
enriched.  This suggests that PTH negatively regulates genes found in 
differentiated colonic crypt cells.   
6A.5.1 Caveats and limitations 
The decision to investigate only those genes identified as present in >2/6 
samples seems reasonable, though the cut-off may be arbitrary.  Not all 
genes are expressed at the mRNA level in every tissue with a number of 
tissue specific (including colonic) transcripts (Axelsen, Lotem et al. 2007). 
In investigating the relationship between biochemical parameters and gene 
expression in the rectal mucosa, this study has a number of strengths.  The 
individuals studied had a past history of adenomatous polyps and therefore 
had a pre-disposed rectal epithelium but had no current neoplasia.  The 
patients had not received any intervention prior to this study and biopsies and 
serum samples were taken simultaneously, thus any direct influence of 
biochemical factors would be apparent.  The main weakness is the small 
number of samples and the skewed distribution of the PTH values.  The main 
negative finding was the absence of any relationship between serum 25OH-
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Vitamin D and gene expression.  It may be suggested that this is because of 
the small number of samples.  However, it has been argued in this thesis that 
the relationship between the serum level of 25OH-Vitamin D and colorectal 
neoplasia seen in other studies is secondary, representing the relationship 
between PTH and colorectal neoplasia.  Therefore the lack of correlation 
between gene expression and 25OH-Vitamin D, in contrast with the strong 
correlation with PTH is consistent with the hypothesis underlying this thesis. 
There may be an unrecognised alternative explanation for the observed 
difference between individuals unrelated but coincident with serum PTH levels 
and in aiming to improve the study a larger number of samples may have 
provided further clarity on this point.  
6A.5.2 Conclusion 
This study identified a large number of genes for which expression showed 
significant negative correlation with serum levels of PTH.  These negatively 
correlated genes have interesting associated biology.  There is the suggestion 
of a relationship between the genes correlated with PTH and those regulated 
by PTH in-vitro and genetic markers of colonic differentiation.  Further 
evidence showing a relationship between recognised biological processes 
and the genes identified in this study would add support to the notion that 
these correlations are real.  In the second part of this chapter, such a 
comparison will be made using gene set enrichment analysis (GSEA). 
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Chapter 6B 
GENE SET ENRICHMENT ANALYSIS OF GENES CORRELATED WITH 
SERUM PTH IN NORMAL RECTAL MUCOSA 
 
6B.1 Aim 
 
 1. Identify gene sets which are enriched in the genes whose 
 expression correlates with PTH, using gene set enrichment analysis 
 (GSEA). 
6B.2 Introduction 
  
In chapter 6A it was demonstrated that the expression of a large number of 
genes was negatively correlated with serum PTH level.  This suggests that 
the variation between individuals in gene expression in the rectal mucosa is 
due at least in part to variation in serum PTH level.  Functional annotation of 
these genes indicated a number of interesting biological features of the 
correlated genes.  It is hypothesised that the genes correlated with PTH in-
vivo would include the genes identified as PTH targets in Chapter 4A.  To 
address this hypothesis further, an alternative approach was used that 
identified the sets of genes enriched in the genes correlated with PTH.  This 
Gene Set Enrichment Analysis (GSEA) approach (Subramanian, Tamayo et 
al. 2005) additionally allows the study of other sets of genes that are 
hypothesised to be regulated by PTH in the colon.  These include genes 
altered in colorectal adenomas and cancer compared to normal mucosa, 
markers of colonic proliferation and differentiation.  It is also hypothesised that 
there will be overlap with the sets of genes regulated by PTH in other tissues 
including bone (Reppe, Stilgren et al. 2006),  muscle and haematopoietic cells 
(Reppe, Stilgren et al. 2007).  This approach may add further to the 
understanding of the biology of the genes for which expression correlates with 
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serum PTH and therefore the consequences of PTH signalling on the 
colorectal epithelium.  
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6B.3 Methods 
 
 
6B.3.1 Analysis of micro-array data 
A gene set approach was used to study the same samples analysed in 
chapter 6A. 
6B.3.2 Gene set enrichment analysis (GSEA) 
Gene set enrichment analysis is a computational method used to identify 
biological activity from the results of micro-array studies (Subramanian, 
Tamayo et al. 2005).  In this method, the relationship between pre-defined 
gene sets and the biological classes under investigation are compared.  
Rather than identify a list of up or down differentially expressed genes, as was 
done in Chapter Four, the whole dataset is interrogated to identify any 
enriched gene sets.  This is done by applying a ranking metric (eg fold 
change) to the micro-array data based on its class or correlation to 
phenotype.  In addition to allowing a class comparison, eg comparing before 
and after a treatment, the GSEA programme allows the calculation of 
Pearson‟s correlation coefficient r and genes are ranked by their correlation to 
phenotype.  In this study the correlation to serum PTH (log2) was used as the 
ranking metric and the genes were ranked by their correlation to serum PTH 
levels. 
 The rank position of genes from each pre-defined gene set within the 
ranked data is determined and an enrichment score is calculated by walking 
down the ranked list and increasing a rank-sum statistic when a gene is in the 
gene set and decreasing it when it is not.  The enrichment score calculates 
the difference between the observed rankings and that which would be 
expected from a random distribution, this is normalised to the gene set size to 
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give a normalised enrichment score (NES).  The NES is the principal 
statistical outcome used for determining the outcome of GSEA.  The 
significance of the results is determined by reiterative permutation using either 
random phenotype permutations or gene set permutations and the calculation 
of a false detection rate (FDR).  The real results that outperform the iterative 
permutations are considered significant.  The method is more fully described 
in (Subramanian, Tamayo et al. 2005). 
 The advantages of GSEA over single gene techniques are its ability to 
identify biological meaning where the changes in individual genes are small 
(Mootha, Lindgren et al. 2003).  Using GSEA, all genes in the dataset are 
analysed, not just those above a certain threshold.  The use of pathways and 
gene sets allows more clear definition of biological processes than single 
genes and is more reproducible.  The GSEA enrichment programme is 
available as a Java executable desktop application (Subramanian, Kuehn et 
al. 2007) and was used in this analysis. 
 The biological information derived from GSEA is highly dependent on 
the gene sets employed and their relationship to the biological processes 
being studied.  A database of gene sets, (MSIGdB), has been established for 
use with GSEA and is available at http://www.broadinstitute.org/gsea/msigdb/.  
For this study the C2 curated gene sets (version 2.5) were used, this consists 
of a total of 1892 gene sets.  The C2 gene sets consist of two types of gene 
sets; canonical pathways (CP) derived from online pathway databases (eg 
KEGG) and chemical and genetic perturbations (CGP) derived from 
publications in Pubmed.  Additionally, GSEA allows the use of user generated 
gene sets, either constructed or experimentally determined by them.  This 
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enables the user to investigate the relationship between specific biology 
relevant to the study and investigate specific hypotheses. 
6B.3.2.1 User defined gene sets 
Seventeen user defined gene sets were employed in the analysis.  Twelve 
colorectal specific gene sets and five PTH related gene sets were developed 
to investigate specific biological questions.  These are discussed below and 
shown in Table 6B.1.  Three gene sets were created from the experimental 
data in chapter two; caco2_pth4 and caco2_24h consist of the genes down-
regulated in response to PTH at four and twenty four hours respectively; and 
caco_2pthall contains all the genes down-regulated at both time points.  
There were too few genes to create a list of genes up-regulated in response 
to PTH.  The other additional gene sets were derived from published studies.  
There were four gene sets related to changes found in colorectal neoplasia, 
adenoma_up and adenoma_down consist of genes changed in adenomas 
compared to normal mucosa (Segditsas, Sieber et al. 2008); and crc_down 
and crc_up consist of genes changed in colorectal cancer compared to 
normal mucosa (Cardoso, Boer et al. 2007).  Genes differentially expressed at 
the top and bottom of the colonic crypt, crypt_base and crypt_top have been 
identified using SAM analysis (Kosinski, Li et al. 2007).   The genes showing a 
fold change >2 following transfection of a colorectal cell line with a dominant 
negative TCF4, dn_tcf4_up and dn_tcf_dn, representing the effects of 
abrogation of wnt signalling. (van de Wetering, Sancho et al. 2002).  
Colorectal cancer cells positive for CD133 have the features of cancer 
initiating stem cells  and differentially express a number of genes 
cd133_stemcells (Ieta, Tanaka et al. 2008).  The parathyroid hormone 
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related gene sets were from two studies of patients with primary 
hyperparathyroidism and gene expression was compared in three different 
tissues before and after parathyroidectomy.  pth_bone_dn and pth_bone_up 
are from studies of bone, pth_haem_dn and pth_haem_up from studies of 
haematopoietic cells and pth_muscle_up from studies of muscle (Reppe, 
Stilgren et al. 2006; Reppe, Stilgren et al. 2007).  There were too few genes 
down-regulated in muscle to provide a gene set and the pth_bone_dn gene 
set was limited to the top 500 down-regulated genes. 
 
6B.3.2.2 Parameters used for GSEA 
In this study GSEA was run with the following parameters.  The expression 
datasets used were the RMA data from the six baseline samples.   The genes 
were ranked by their correlation with serum PTH, log2 transformed PTH 
values were used for the reasons discussed in section 6A.3.3.  The C2 
curated set of genes from the MSigDB was used.  This consists of a total of 
1892 gene sets.  Additionally, the seventeen user defined gene sets 
described above were used.  The gene sets were filtered to exclude sets with 
>500 or <25 genes, this left a total of 1048 gene sets within this size range.  
The ranking metric used was Pearson.  Gene set permutation was used and 
the number of permutations set at 1000, as recommended.  A FDR of<0.05 
was considered significant; however, usually the most highly ranked gene 
sets are the ones of most interest, even if those lower down the ranking have 
a FDR of <0.05. 
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Table 6B.1The user defined gene sets used in the gene set enrichment 
analysis. The gene set name, the number of genes in the set, the biology 
represented and the source of the gene set are shown. 
Gene set name 
Number 
of 
genes 
Description of biology 
caco2_pth4 77 Genes down-regulated in response to PTH after 4 hours treatment of Caco2 
caco2_pth24 61 Genes down-regulated in response to PTH after 24 hours treatment of Caco2 
caco2_pthall 134 Genes down-regulated in response to PTH treatment of Caco2 at both 4 and 24 hours 
crypt_base 290 
Genes identified as differentially expressed at 
the crypt base using SAM (Kosinski, Li et al. 
2007) 
crypt_top 406 
Genes identified as differentially expressed at 
the crypt top using SAM (Kosinski, Li et al. 
2007) 
dn_tcf4_up 287 
Genes up-regulated by dominant-negative  TCF 
with  fold change >2 in both replicates(van de 
Wetering, Sancho et al. 2002) 
dn_tcf_dn 101 
Genes down-regulated by dominant-negative  
TCF with  fold change >2 in both replicates(van 
de Wetering, Sancho et al. 2002) 
adenoma_up 194 Genes up-regulated in adenomas compared to normal mucosa (Segditsas, Sieber et al. 2008) 
adenoma_down 474 Genes up-regulated in adenomas compared to normal mucosa (Segditsas, Sieber et al. 2008) 
crc_down 60 
Genes down-regulated in colorectal cancer 
compared to normal mucosa (Cardoso, Boer et 
al. 2007) 
crc_up 68 
Genes up-regulated in colorectal cancer 
compared to normal mucosa (Cardoso, Boer et 
al. 2007) 
cd133_stemcells 39 
A genetic markers of colonic stem cells 
identified by presence of CD133 (Ieta, Tanaka 
et al. 2008) 
pth_bone_dn 488 Genes down-regulated by PTH in bone (Reppe, Stilgren et al. 2006) 
pth_bone_up 500 Genes up-regulated by PTH in bone (Reppe, Stilgren et al. 2006) 
pth_haem_dn 123 
Genes down-regulated by PTH in 
haematopoietic cells (Reppe, Stilgren et al. 
2007) 
pth_haem_up 38 Genes up-regulated by PTH in haematopoietic cells (Reppe, Stilgren et al. 2007) 
pth_muscle_up 168 Genes up-regulated by PTH in haematopoietic cells (Reppe, Stilgren et al. 2007) 
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6B.4Results 
6B.4.1 Gene set enrichment analysis 
Gene set enrichment analysis was performed to identify gene sets enriched in 
the genes strongly correlated with PTH.  The primary outcomes are the 
normalised enrichment score (NES) and the false detection rate (FDR).  Gene 
sets with FDR of <0.05 were identified as significant. 
6B.4.2 Enriched gene sets 
There were 1049 gene sets meeting the size criteria.  There were one 
hundred and four gene sets enriched in the negatively correlated phenotype 
and twenty-one enriched in the positively correlated phenotype with a FDR 
<0.05. 
6B.4.2.1Gene sets enriched in negatively correlated with PTH phenotype 
Gene sets enriched in the negatively correlated phenotype can be considered 
as though they were negatively correlated with PTH.  The gene sets with the 
highest enrichment scores are most likely to represent the biology of the 
negatively correlated with PTH phenotype.  The top twenty-five enriched gene 
sets are listed in Table 6B.2.  These top twenty-five enriched gene sets can 
be divided into a number of groups, including three gene sets derived from 
studies of the colon.   These three gene sets should be considered the most 
relevant findings as they are derived from the tissue on which this study was 
carried out.  The most highly enriched gene set is crypt_top which contains 
genes up-regulated at the top of normal colonic crypts compared to the base 
of the crypt (Kosinski, Li et al. 2007).  It has a significantly higher enrichment 
score than all of the gene sets with a score of 3.75, with the next highest 
score being 2.45.  The crypt_top gene set contains genes involved in cell 
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adhesion, cell maturation, apoptosis and inhibition of cell proliferation, 
including antagonists of myc.  These genes also encode proteins involved in 
the function of mature intestinal cells (Kosinski, Li et al. 2007).  A gene set 
crc_down representing the genes most commonly down-regulated in 
colorectal cancer (Cardoso, Boer et al. 2007) was also prominently enriched.  
The other two enriched colonic gene sets are derived from in-vitro studies.  
Interestingly, the gene set containing all the genes down-regulated by PTH in 
caco2, caco2_pthall in chapter two was significantly enriched in the 
negatively correlated genes.  Enrichment plots for these three gene sets are 
shown in Figure 6B.1.   
 The finding that these three gene sets (crypt_top, caco2_pthall, 
crc_down) are significantly enriched provides information on the function of 
the genes correlated with serum PTH in the colorectal epithelium.  These 
findings suggest that PTH down-regulates the expression of genes found in 
differentiated colonic cells and genes commonly found to be down-regulated 
in colorectal cancer.  There is also overlap between the genes regulated by 
PTH in-vitro and those correlated with PTH in-vivo.  These three are the only 
gene sets in the top twenty-five enriched sets derived from studies of the 
colon and therefore are the most pertinent to the biological function of the 
PTH correlated genes.  The additional information derived from the other 
gene sets is therefore only likely to be complementary. 
 The remaining twenty-two enriched gene sets are displayed in Table 
6B.3.  There are two canonical pathway (CP) and twenty chemical and 
genetic perturbations (CGP) gene sets.  A number of the gene sets are from 
the same source and have overlapping gene sets.  The biological relevance of 
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these gene sets is not as clear as for those derived from the colon.  They 
however are likely to involve similar overlapping biological processes.   
Table6B.2 The top twenty-five ranked gene sets in the negatively 
correlated with PTH phenotype.   
They are ranked by NES.   NES= normalised enrichment score. P-
value=nominal p-value, not corrected for multiple testing.  FDR=false 
detection rate. 
Gene set NES 
p-
value 
 
FDR  
CRYPT_TOP -3.75 0 0 
AGUIRRE_PANCREAS_CHR12 -2.40 0 8.1E-04 
HEARTFAILURE_ATRIA_DN -2.45 0 0.001 
FALT_BCLL_DN -2.45 0 0.001 
RNA_TRANSCRIPTION_REACTOME -2.40 0 0.001 
HSC_INTERMEDIATEPROGENITORS_ 
SHARED -2.39 0 0.001 
CRC_DOWN -2.38 0 0.002 
FLECHNER_KIDNEY_TRANSPLANT_REJ
ECTION_DN -2.36 0 0.002 
UVC_HIGH_ALL_DN -2.35 0 0.001 
FALT_BCLL_IG_MUTATED_VS_WT_DN -2.35 0 0.002 
HSC_LATEPROGENITORS_ADULT -2.29 0 0.003 
HCC_SURVIVAL_GOOD_VS_POOR_DN -2.28 0 0.003 
ROME_INSULIN_2F_UP -2.27 0 0.003 
BRCA1_OVEREXP_UP -2.27 0 0.003 
CACO2_PTHALL -2.26 0 0.003 
HSC_LATEPROGENITORS_SHARED -2.25 0 0.003 
HSC_INTERMEDIATEPROGENITORS_ 
ADULT -2.24 0 0.003 
HSC_LATEPROGENITORS_FETAL -2.22 0 0.003 
GOLDRATH_HP -2.23 0 0.003 
CAMPTOTHECIN_PROBCELL_DN -2.21 0 0.004 
FLECHNER_KIDNEY_TRANSPLANT_ 
WELL_UP -2.21 0 0.004 
NOUZOVA_CPG_H4_UP -2.19 0 0.004 
IDX_TSA_UP_CLUSTER5 -2.17 0 0.004 
HSC_INTERMEDIATEPROGENITORS_ 
FETAL -2.17 0 0.005 
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Figure 6B.1 Enrichment plots for three colorectal gene sets that were 
enriched in the genes negatively correlated with PTH.  The top portion of 
the plot shows the running ES for the gene set as the analysis walks down the 
ranked list. The score at the peak of the plot (the score furthest from 0.0) is 
the ES for the gene set.  The middle portion indicates where each of the 
genes in the set occurs in the ranked list. The bottom portion of the plot shows 
the value of the ranking metric (pearson correlation factor r +1 to -1). The 
gene sets shown here are a) crypt_top, b) crc_down c) caco2_pthall. 
a) 
b)  
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c) 
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Table6B.3 The twenty two gene sets that were enriched in the negatively correlated with PTH phenotype. The four gene 
sets derived from colonic tissue are not listed (see text).  These gene sets are all from the MSigDb C2 collection; gene sets from 
the same source publication are listed together.  The tissue and related disease state are described and where relevant the source 
publication.  CP=canonical pathway, CGP=chemical and genetic perturbation. 
 
Gene Set 
 
Collection 
 
Tissue origin 
 
Involved biology 
and source publication 
HSC_INTERMEDIATEPROGENITORS_SHARED 
HSC_INTERMEDIATEPROGENITORS_ADULT 
HSC_INTERMEDIATEPROGENITORS_FETAL 
HSC_INTERMEDIATEPROGENITORS_SHARED 
HSC_LATEPROGENITORS_ADULT 
HSC_LATEPROGENITORS_FETAL 
CGP 
Murine 
haematopoietic stem 
cells (HSC) 
Identification of gene expression 
profiles of various stages of HSC 
development (Ivanova, Dimos et al. 
2002) 
FLECHNER_KIDNEY_TRANSPLANT_WELL_UP 
FLECHNER_KIDNEY_TRANSPLANT_REJECTION_DN CGP 
Human kidney 
transplant 
Genes differentially expressed 
between well functioning and rejected 
kidneys (Flechner, Kurian et al. 2004) 
FALT_BCLL_DN 
FALT_BCLL_IG_MUTATED_VS_WT_DN CGP 
Human  B-cell 
lymphoma 
Genes down-regulated in BCLL and 
in BCLL with a mutation in IGVH 
(Falt, Merup et al. 2005) 
AGUIRRE_PANCREAS_CHR12 CGP Human pancreatic adenocarcinoma 
Genes from chromosome 12 
amplified in pancreatic 
cancer(Aguirre, Brennan et al. 2004) 
HEARTFAILURE_ATRIA_DN CGP Explanted failing human hearts 
Genes down-regulated in failing 
human atria (Kaab, Barth et al. 2004) 
RNA_TRANSCRIPTION_REACTOME CP Human Genes involved in transcription 
UVC_HIGH_ALL_DN CGP Human fibroblasts 
Gene expression changes due to 
exposure UVC radiation, increased 
expression of cell cycle arrest and 
apoptosis associated genes was the 
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main finding(Gentile, Latonen et al. 
2003). 
HCC_SURVIVAL_GOOD_VS_POOR_DN CP Human hepato-cellular carcinoma 
Genes highly expressed in 
hepatocellular carcinoma with good 
survival 
ROME_INSULIN_2F_UP CGP Human skeletal muscle 
Genes up-regulated after 2 hours in 
response to insulin (Rome, Clement 
et al. 2003) 
BRCA1_OVEREXP_UP CGP 
BRCA1 negative 
human breast 
cancer cell line 
Genes up-regulated in response to 
expression of BRCA1 (Welcsh, Lee 
et al. 2002) 
GOLDRATH_HP CGP CD8+ T-cells 
Genes down-regulated in proliferating 
T-cells in response to 
lymphopenia(Goldrath, Luckey et al. 
2004) 
CAMPTOTHECIN_PROBCELL_DN CGP Human Pro-B cells 
Genes down-regulated in response to 
the chemotherapy agent 
camptothecin (Brachat, Pierrat et al. 
2002) 
NOUZOVA_CPG_H4_UP CGP Leukaemia cell line NB4 
Genes expressed in response to 
treatment with retinoic acid. 
(Nouzova, Holtan et al. 2004) 
IDX_TSA_UP_CLUSTER5 CGP Human fibroblasts 
Genes up-regulated in fibroblasts 
stimulated to differentiate into 
adipocytes (Burton, Nagarajan et al. 
2004) 
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6B.4.2.2 Gene sets enriched in positively correlated with PTH phenotype 
The twenty one gene sets enriched in the positively correlated with phenotype 
are show in Table6B.4.  This is considerably fewer gene sets than was found 
enriched in the negatively correlated with PTH phenotype.  Of these gene sets 
none are derived from colonic tissue, though two of them (pth_bone_up and 
pth_muscle_up) are the transcriptional targets of PTH in bone and muscle.  
Enrichment plots for pth_bone_up and pth_muscle_up are shown in Figure 
6B.2.  The remaining eighteen enriched gene sets are shown in Table 6B.4 
with a description of their biology.  
Table 6B.4 The twenty one gene sets enriched in the positively 
correlated with serum PTH phenotype, with a FDR of <0.05.  
NES= normalised enrichment score. FDR=false detection rate. 
Gene set NES 
p-
value 
 
FDR 
HSA04080_NEUROACTIVE_LIGAND_RE
CEPTOR_INTERACTION +2.62 0 0 
GPCRDB_CLASS_A_RHODOPSIN_LIKE +2.42 0 2.7E-04 
REFRACTORY_GASTRIC_UP +2.34 0 0.002 
PTH_MUSCLE_UP +2.28 0 0.002 
HSA04940_TYPE_I_DIABETES_MELLITU
S +2.23 0 0.004 
HUMAN_TISSUE_LIVER +2.24 0 0.004 
GPCRS_CLASS_A_RHODOPSIN_LIKE +2.16 0 0.006 
MYOD_BRG1_UP +2.08 0 0.008 
MONOAMINE_GPCRS +2.09 0.002 0.008 
PEPTIDE_GPCRS +2.11 0 0.008 
MOREAUX_TACI_HI_VS_LOW_UP +2.1 0 0.008 
HSA04020_CALCIUM_SIGNALING_PATH
WAY +2.11 0 0.009 
STRIATED_MUSCLE_CONTRACTION +2.06 0 0.009 
MOREAUX_TACI_HI_IN_BMPC +2.01 0 0.01 
KANG_TERT_DN +1.99 0 0.01 
TESTIS_EXPRESSED_GENES +1.99 0 0.02 
IGF_VS_PDGF_UP +1.92 0 0.02 
PTH_BONE_UP +1.91 0 0.02 
SHIPP_DLBCL_CURED_UP +1.86 0.002 0.05 
BCNU_GLIOMA_MGMT_48HRS_DN +1.82 0 0.05 
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Figure 6B.2 Enrichment plots for the two PTH related gene sets that 
were enriched in the genes positively correlated with PTH.  The top 
portion of the plot shows the running ES for the gene set as the analysis 
walks down the ranked list. The score at the peak of the plot (the score 
furthest from 0) is the ES for the gene set.  The middle portion indicates 
where each of the genes in the set occurs in the ranked list. The bottom 
portion of the plot shows the value of the ranking metric (pearson correlation 
factor r +1 to -1). a) pth_muscle _up b) pth_bone_down 
 
a) 
 
b) 
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Table6B.5 Nineteen gene sets that were enriched in the positively correlated with PTH phenotype not discussed in the text 
These gene sets are all from the MSigDb C2 collection; gene sets from the same source publication are listed together.  The tissue 
and related disease state are described and where relevant the source publication.  CP=canonical pathway, CGP=chemical and 
genetic perturbation. 
Gene Set 
 Collection 
Tissue origin 
 
Involved biology 
and source publication 
HSA04080_NEUROACTIVE_LIGAND_RECEPTOR
_INTERACTION 
GPCRDB_CLASS_A_RHODOPSIN_LIKE 
GPCRS_CLASS_A_RHODOPSIN_LIKE 
MONOAMINE_GPCRS 
PEPTIDE_GPCRS 
CP Human G-protein coupled receptors 
MOREAUX_TACI_HI_VS_LOW_UP 
MOREAUX_TACI_HI_IN_BMPC CGP 
Human multiple 
myeloma cells 
(MMC) 
Gene expression profiles comparing 
MMC‟s with low expression of TACI 
(Moreaux, Cremer et al. 2005) 
REFRACTORY_GASTRIC_UP CGP Human gastric cancer 
Genes enriched in gastric cancers 
resistant to treatment with 5FU(Kim, Choi 
et al. 2004) 
HSA04940_TYPE_I_DIABETES_MELLITUS CP Human Genes involved in type I diabetes mellitus 
HUMAN_TISSUE_LIVER CGP Human and murine liver 
The transcriptome of mammalian liver 
(Su, Cooke et al. 2002) 
MYOD_BRG1_UP CGP Human fibroblasts 
Genes up-regulated in fibroblasts in 
response to expression of Myo-D (de la 
Serna, Ohkawa et al. 2005) 
HSA04020_CALCIUM_SIGNALING_PATHWAY CP Human Genes involved in calcium signaling pathway 
STRIATED_MUSCLE_CONTRACTION CP Human muscle Genes involved in striated muscle contraction 
KANG_TERT_DN CGP Human stroma Genes down-regulated in response to 
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expression of the catalytic subunit of 
telomerase in adipose derived stromal 
cells (Kang, Putnam et al. 2004) 
TESTIS_EXPRESSED_GENES CP Human testis Testis related genes curated from the GNF normal tissue compendium 
IGF_VS_PDGF_UP CGP Human myoblasts 
Genes differentially expressed between 
IGF versus PDGF treated myoblasts 
(Kuninger, Kuzmickas et al. 2004) 
SHIPP_DLBCL_CURED_UP CGP Human B-cell lymphoma 
Genes highly expressed in B-cell 
lymphoma that was cured rather than 
refractory (Shipp, Ross et al. 2002) 
BCNU_GLIOMA_MGMT_48HRS_DN CGP 
Human glioma 
cell line 
expressing 
MGMT 
Genes down-regulated following 
treatment with alkylating chemotherapy 
agent BCNU (Bandres, Andion et al. 
2005) 
 198 
6B.4.3 Outcome for the user defined gene sets  
The twelve user defined gene sets selected specifically for use in this study 
are of particular interest due to their tissue and disease process specific 
nature, so their outcomes are described here.  Of theses twelve gene sets, 
three of them (crypt_top, crc_down and caco2_pthall) were enriched in the 
top twenty-five PTH negatively correlated gene sets, as described above.  A 
further two gene sets (caco2_pth24 and caco2_pth4) were enriched in the 
negatively correlated with PTH phenotype with a FDR of <0.05.  This is 
unsurprising as these two gene sets together make up the caco2_pthall gene 
set.  The relevance of these findings has been discussed above.  Another 
gene set of interest (dn_tcf_up) showed a low level enrichment in the 
negatively correlated with PTH phenotype, with a FDR of 0.15.  This gene set 
consists of the genes up-regulated in response to expression of a dominant-
negative TCF4 in the Lovo colorectal cancer cell line and represents the 
genes negatively regulated by the wnt signalling pathway.  There is overlap 
between the genes found in the crypt_top  and dn_tcf_up sets (Kosinski, Li 
et al. 2007).  Two gene sets dn_tcf_dn and cd133_stemcells were enriched 
in the positively correlated with PTH phenotype, both showed low level 
enrichment with a FDR of >0.05. 
 The other four gene sets (adenoma_up, adenoma_down,  crc_up 
and crypt_base ) showed very low level enrichment with high FDR, 
suggesting that there is no relationship between these gene sets and either 
negative or positive correlation with PTH phenotype 
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6B.5 Discussion 
 
The findings of this gene set enrichment analysis provide information on the 
biological function of the genes for which expression correlated with serum 
PTH.  This second analytical approach was taken to provide consistent 
evidence in view of the difficulties of interpreting micro-array studies.   Both 
the single gene and gene set approach are considered valid in trying to 
identify biological meaning from micro-array studies (Allison, Cui et al. 2006).  
The use of GSEA may also identify relevant biological processes where the 
relationship is weaker and takes account of all the genes in the dataset; in 
contrast to the single gene approach, which only analyses those identified as 
significant.  This was not particularly relevant for the negatively correlated 
genes in this study, as there were a large number of highly significantly genes 
identified, but may be of interest for the positively correlated genes.  More 
useful in this study, was that GSEA also allows the investigation of specific 
hypotheses by the use of user generated gene sets.   
 Both of the approaches used provide evidence of a functional role for 
the PTH correlated genes, with overlap of the findings from the two methods.  
This is despite small differences in the methods used to identify genes 
correlated with PTH.  In particular SAM uses log2 transformed micro-array 
data and GSEA uses natural data, but the RMA data was used for both.  For 
GSEA, all of the dataset was used; in contrast in the single gene SAM 
approach only those genes identified as present in >2/6 samples were used.  
Both analytical approaches were consistent in demonstrating that the majority 
of the interesting biological features were present in the genes negatively 
correlated with PTH, with relatively few gene sets enriched in the genes 
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positively correlated with PTH.  This again suggests that PTH acts as a 
transcriptional repressor. 
 
6B.5.1 Colorectal related gene sets 
Of the two methods of analysis, GSEA perhaps provided the clearest 
description of the biology associated with the genes correlated with PTH.   In 
the GSEA, the set of genes differentially expressed at the top of the colonic 
crypt (crypt_top) was highly significantly enriched in the genes negatively 
correlated with PTH. The enriched functional annotation terms found in the 
genes identified by the SAM analysis were also consistent with this finding as 
they contain a number of biological features of differentiated crypt top cells; 
particularly apoptosis and structural features such as adherens junction and 
the apical of cell membranes.  The genes in crypt_top are found in 
differentiated post-mitotic cells at the top of the colonic crypt.  This suggests 
that PTH down-regulates the genes found in differentiated colonic cells and 
therefore inhibits differentiation.  Differentiation of colonic epithelial cells 
occurs as a consequence of decreased Wnt pathway signalling with evidence 
for this from both in-vitro (Mariadason, Bordonaro et al. 2001) and in-vivo 
studies (Sansom, Reed et al. 2004). There is also overlap between the genes 
found in differentiated colonic cells and those negatively regulated by wnt 
signalling (Kosinski, Li et al. 2007).  These findings suggest that PTH may 
stimulate the wnt signalling pathway to alter gene expression in rectal 
mucosa.  Parathyroid hormone has been shown to stimulate the wnt signalling 
pathway (Kulkarni, Halladay et al. 2005).  Recently it has been shown that the 
PTH receptor, PTHR1 interacts with the wnt effector molecule dishevelled and 
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that PTH activates β-catenin, resulting in nuclear localisation independent of a 
wnt signal (Romero, Sneddon et al. 2010).  Consistent with this, the gene set 
representing genes negatively regulated by Wnt signalling (dn_tcf4_up) is 
also weakly enriched (NES -1.47) in the negatively correlated with PTH 
phenotype.  Less clearly relevant, is that the gene set representing genes 
positively regulated by wnt signalling (dn_tcf_dn) is found in the positively 
correlated with PTH phenotype, but its enrichment is very weak and non-
significant.  The observation that they are enriched in opposite directions 
along with the findings for the crypt_top gene set suggests that PTH 
modulates the Wnt signalling pathway in the rectal mucosa; this effect would 
appear to be predominantly to influence the expression of genes negatively 
regulated by wnt signalling.   
 A role in colorectal tumorigenesis is suggested by the observation that 
the crc_down gene set was enriched in the negatively correlated with PTH 
phenotype.  This suggests that PTH negatively regulates the expression of 
genes commonly down regulated in colorectal cancer.  The converse was not 
true, with no effect on genes commonly up-regulated in colorectal cancer.  It is 
perhaps surprising that there was no relationship with genes altered in 
adenomas.  Gene expression changes in adenomas represent the early 
events in the development of colorectal neoplasia and may therefore be 
expected to be those seen in normal mucosa.  The reason for this is not clear, 
but may relate to the gene sets studied.  The crc_down gene set was derived 
from a meta-analysis of other studies, with only genes consistently changed in 
three or more studies were included.  It also contained relatively few genes 
compared to those found in the adenoma_up and adenoma_down gene 
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sets which were derived from only one study.  A role for PTH in the 
development of colorectal neoplasia would suggest an effect on colonic stem 
cells as these have been shown to be the cells of origin of colorectal cancer 
(Barker, Ridgway et al. 2009).  Parathyroid hormone is known to regulate the 
haematopoietic stem cell niche (Calvi, Adams et al. 2003) and has been 
shown to mobilise bone-marrow stem cells (Ballen, Shpall et al. 2007). 
Parathyroid hormone is not known to regulate colonic stem cells, though wnt 
signalling is (Korinek, Barker et al. 1998), which suggests that PTH could 
influence stem cells via modulation of Wnt signalling.  The cd133_stemcells 
gene set is a set of genes found in colonic stem cells (Ieta, Tanaka et al. 
2008) and is weakly enriched in the positively correlated with PTH phenotype.  
That it is only weakly enriched may indicate the absence of an effect or may 
be due to the fact that stem cells form only a small part of the crypt with only 
minor variance in stem cell related gene expression between individuals.  To 
determine whether PTH influences colonic stem cells would require other 
studies. 
 
6B.5.2 Parathyroid hormone regulated gene sets 
The observation that the set of genes down-regulated by PTH in-vitro 
(caco2_pth_all) is also enriched in the genes negatively correlated with 
serum PTH is consistent with the proposed hypothesis.  Overlap between the 
same biological processes in independent micro-array experiments is unusual 
(Fortunel, Otu et al. 2003).  Particularly as; though caco2 is used as a model 
of the normal mucosa, it remains a malignant cell line with the features of 
such.  The experiments on Caco2 also employed a different micro-array with 
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fewer genes represented, thus limiting the potential observable overlap.  It is 
also interesting that there is overlap between the gene sets of PTH stimulated 
genes from bone (pth_bone_up) and muscle (pth_muscle_up) in the genes 
positively correlated with PTH.  More intriguing, is the observation that a 
number of the gene sets enriched in the negatively correlated with PTH 
phenotype shown in Table 6B.2 represent biological processes in which PTH 
is implicated.   For instance, it is known that PTH increases the proliferation 
rate and size of the haematopoietic stem cell pool (Whitfield 2005).  PTH also 
inhibits adipocyte differentiation (Rickard, Wang et al. 2006). High serum 
levels of PTH are a predictor of graft failure after renal transplantation 
(Roodnat, van Gurp et al. 2006) and are high in patients with heart failure 
(Alsafwah, Laguardia et al. 2008).  Whether the relationship between these 
findings is related to serum PTH is not clear.  However similar transcriptional 
targets of PTH in different tissues could explain these observations as PTH 
acts in multiple tissue types by stimulating the same receptor PTHR1.  This 
activates the same signalling pathways with some recognised generic 
downstream targets (Qiu, Qin et al. 2003).  So, although there may be tissue 
specific features, overlapping transcriptional targets between tissues can be 
expected.  This provides further support for the notion that the genes 
correlated with PTH represent real PTH targets and supports the proposed 
hypothesis that PTH acts directly on the colorectal epithelium to alter gene 
expression.  
 The information derived from the user defined gene sets, particularly 
those derived from studies of the colon, provides greater understanding of the 
biological processes of the enriched genes.   The biological relevance of the 
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other gene sets is less clear.  However, they are likely to represent similar 
overlapping biological processes as found in the colon (eg apoptosis). 
. 
6B.5.3 Conclusion 
This study identified a large number of gene sets which were enriched in the 
genes significantly negatively correlated with serum levels of PTH.  These 
negatively correlated gene sets have interesting biology, consisting of; genes 
found in differentiated crypt top cells which are negatively regulated by wnt 
signalling, genes down-regulated in colorectal cancer and genes down-
regulated by PTH in-vitro.  Acknowledging the limitations of the data, it seems 
possible to infer that this relationship is functional and that serum PTH level 
determines gene expression in normal rectal mucosa. 
 However, it is important to acknowledge that correlation alone does not 
equal causation.  It is predicted that modulating serum PTH would result in 
changes in the same genes, gene sets and biological functions as are 
correlated with PTH.  Therefore the next step is to identify the genes 
differentially expressed in response to modulating serum PTH by dietary 
calcium supplementation. 
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Chapter 7A 
IDENTIFICATION OF GENES DIFFERENTIALLY EXPRESSED IN NORMAL 
RECTAL MUCOSA IN RESPONSE TO MODULATING SERUM PTH BY 
DIETARY CALCIUM SUPPLEMENTATION 
 
7A.1 Primary aim 
1) Identify genes differentially expressed in the rectal mucosa of 
individuals taking dietary calcium supplementation using oligo-
nucleotide micro-arrays. 
7A.1.1 Secondary aims 
1) Functional annotation of the genes differentially expressed in 
response to calcium supplementation 
2) Determine the relationship between the differentially expressed 
genes and: 
 a) Genes altered in colorectal neoplasia. 
 b) Genes expressed in differentiated cells from the top of the  
 colonic crypt 
 c) Genes expressed in proliferating cells from the base of   
 the colonic crypt 
 d) Genes differentially expressed in response to PTH stimulation  
 of Caco2  
7A.2 Introduction 
In previous chapters it has been demonstrated that parathyroid hormone 
influences gene expression in the colonic epithelium both in-vitro and in-vivo.  
In Chapter Five, dietary calcium supplementation was shown to significantly 
suppress serum PTH levels.   Dietary calcium supplementation has been 
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shown to reduce the incidence of colorectal neoplasia in randomised 
controlled trials (Weingarten, Zalmanovici et al. 2008) but its mechanism of 
action is unknown.  The hypothesis behind this study is that the effect of 
calcium on normal rectal epithelium is mediated by suppression of PTH.  The 
aim of the experiments described in this chapter is to identify genes 
differentially expressed before and after six weeks of calcium supplementation 
using oligo-nucleotide micro-arrays.  A similar study was carried out to 
determine the effect of the COX-2 inhibitor Celecoxib on gene expression in 
the colorectal epithelium, with significant changes in gene expression found 
(Glebov, Rodriguez et al. 2006).   
 It is hypothesised that calcium will result in changes in gene expression 
similar to those seen in response to PTH in chapter four; and that these 
changes will be consistent with its known anti-neoplastic action.   
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7A.3 Methods 
7A.3.1 Subjects 
The same six subjects were studied in this chapter as in chapter six and their 
demographics are shown in Table 6A.1.  The study protocol was described in 
section 5.3. 
7A.3.2 Micro-array analysis of gene expression in normal rectal mucosa 
Gene expression profiling was performed on the baseline and calcium treated 
normal rectal mucosa samples from the six subjects studied in the previous 
chapter, using the Affymetrix Human genome U133A 2.0 gene chip. 
Genes that were differentially expressed following dietary calcium 
supplementation were identified.  These genes were then analysed by a 
descriptive analysis, performing functional annotation and comparing them to 
known biological processes. 
7A.3.3 Identification of differentially expressed genes 
To identify differentially expressed genes two approaches were taken. 
7A.3.3.1 GCOS>3 
For this approach, the GCOS (Gene chip operating software, Affymetrix ®) 
was used; the method is described in section 2.6.2.  A gene was recognised 
as differentially expressed if it was similarly changed in three or more of the 
six subjects. 
7A.3.3.1 Rank product (RP) 
The rank products method was described in section 2.6.1.  In this study it was 
used with a FDR of 10% and matched pair wise comparisons.  This approach 
provides a measure of statistical significance for the differentially expressed 
genes, unlike GCOS>3. 
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7A.3.4 Functional annotation of differentially expressed genes using 
DAVID 
The background to this approach and the methods employed by DAVID were 
described in section 4B.3.1.  The enriched annotation terms were identified 
using two different utilities available on DAVID. 
7A.3.4.1 Functional annotation chart 
This identifies enriched terms within the gene list and performs a “term centric 
singular enrichment analysis”. The default settings were deployed apart from 
using an EASE score of 0.05 (instead of 0.1) to identify enriched annotation 
terms.  
7A.3.4.2 Functional annotation clustering                                                      
This clusters functionally similar enriched terms into groups, performing a 
“term centric modular enrichment analysis”.  Default settings were employed 
apart from stringency being increased to high.  Clusters of terms with 
enrichment scores of >1.3, which is equivalent to non-log scale value of 0.05, 
were identified.  For each analysis the background was set as Affymetrix 
HGU-133A 2.0.   
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7A.4 Results 
7A.4.1 Identification of genes differentially expressed in response to 
calcium supplementation 
To identify genes that were differentially expressed in response to calcium, 
comparison was made between the rectal mucosa samples taken at baseline 
and those taken after six weeks of calcium supplementation.  The results of 
the two methods used (GCOS>3 and RP) are described separately and then 
the genes identified as differentially expressed by both methods are reported. 
7A.4.1.1 Differentially expressed genes identified by GCOS>3 
Two hundred and thirty three (233) genes were changed in half or more (3-
6/6) of the subjects.  There were a greater number of genes that were up-
regulated in response to calcium supplementation, with 156 genes increased 
and 77 genes having decreased expression. The 156 genes in which 
expression was increased are shown in Appendix 1 and the 77 genes 
showing decreased expression are shown in Appendix 2.  Out of the 13,480 
genes on the chip, 3479 showed a change in expression in at least one pair 
wise comparison.  For the remaining 10,001 genes no change in expression 
was seen in any of the six pair wise comparisons.  For the majority of the 
3479 changed genes, this change occurred in only one of the six subjects with 
2262 (65%) genes showing altered expression in only one subject.  The 
number of genes showing significant changes in expression in 2/6 subjects is 
635, in 3/6 is 199, in 4/6 is 26, in 5/6 is 5 and in 6/6 is 2.  Overall, and at each 
level of change more genes were up-regulated than down regulated, as is 
shown in Table 7A.1. 
 
 210 
Table 7A.1 The frequency with which genes were identified as changed 
using GCOS. 
A threshold of being changed in 3 or more subjects was used to identify a 
gene as being differentially expressed.  There are 156 genes with increased 
expression and seventy seven genes with decreased expression in >3 
subjects.  
Number of subjects 
showing change in 
gene expression 
Number of genes 
with increased 
expression 
Number of genes 
with decreased 
expression 
6 2 0 
5 5 0 
4 19 7 
3 130 70 
2 373 262 
1 1285 977 
 
7A.4.1.2 Differentially expressed genes identified by Rank Product (RP) 
Using the rank product method there were seventy six genes differentially 
expressed in response to calcium supplementation.  As with the GCOS >3 
method there were more genes up-regulated in response to calcium, with 68 
genes up-regulated and 8 genes down regulated.  The up-regulated genes 
are shown in Appendix 3 and the down-regulated genes in Appendix 4. 
7A.4.1.3 Genes found to be differentially expressed by both methods 
One hundred and seventy nine genes were identified as differentially up-
regulated in response to calcium by either GCOS>3 or RP, of these forty-five 
genes were identified as differentially up-regulate by both methods.  
Therefore, there were one hundred and ten genes identified as up-regulated 
by GCOS>3 only and twenty three genes identified as up-regulated by RP 
only.  There were six genes that were identified as differentially down-
regulated by both methods.  Therefore, there were seventy one genes 
identified as down-regulated by GCOS>3 only and two genes identified as 
down-regulated by RP only. 
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7A.4.1.4 Fold change 
The magnitude of the fold change in expression level for each of the 
differentially expressed genes is shown in Appendices 1-4.  It is of note that 
for some genes there are differences between the GCOS and RP values due 
to the different pre-processing methods used (GCOS vs RMA).  There is 
however no major differences in the values. 
GCOS>3 
The majority of differentially expressed genes showed an increase in 
expression of less than +1.5 fold, with only fifteen genes increased greater 
than this.  The maximum increase in expression is +2.1 fold.  Only two genes 
were decreased in expression > -1.5 fold and the maximum decrease in 
expression is -1.6 fold. 
Rank product 
Similar results were seen using rank-product with twenty five genes showing 
an increase in expression > +1.5 and only one gene showing a decrease in 
expression > -1.5 fold.   The maximum increase in expression is +2.1 fold and 
the maximum decrease is -1.7 fold. 
7A.4.2 Determination of the biological correlates of the genes 
differentially expressed in response to calcium 
The biological function of the genes differentially expressed in response to 
calcium supplementation genes was assessed in five ways; 
1.  Investigation of the relationship between the differentially expressed genes 
and markers of specific cell types found in normal colonic mucosa. 
2.  Functional annotation of the differentially expressed genes using DAVID 
and the gene ontology (GO). 
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3.  Investigation of whether any of the differentially expressed genes are also 
differentially expressed in colon neoplasia. 
4.  Investigation of the changes in expression in response to calcium of the 
genes differentially expressed in caco2 response to PTH in-vitro. 
 
7A.4.3 The effect of calcium supplementation on the expression of 
genetic markers of specific cell types 
The colonic epithelium is made up of three cell types; colonocytes (absorptive 
cells), entero-endocrine cells and mucus secreting goblet cells (Crosnier, 
Stamataki et al. 2006).  These three cell types are derived from multi-potent 
stem cells situated at the crypt base.  The epithelium is supported by stroma 
with peri-cryptal myofibroblasts forming part of the stem cell niche (Humphries 
and Wright 2008). There are a number of genetic markers specific to each of 
these cell types.  The effect of calcium on the expression of marker genes for 
each of these cell types was studied.    
7A.4.3.1 Colonocytes (Absorptive cells) 
It was observed that a number of the genes up-regulated in response to 
calcium were markers of differentiated colonocytes, including; CEACAM1, 
HPGD, ABCG2, EZR, MXD1, TMPRSS2 and BCL10.  Comparison was made 
between the genes differentially expressed in response to calcium with those 
differentially expressed in differentiated cells at the top of the colonic crypt 
(Kosinski, Li et al. 2007).   Of the genes identified as up-regulated by calcium 
using GCOS>3; 68/156 (44%) are differentially expressed in differentiated 
crypt top cells.  The number for the RP analysis was 38/68 (55%).  This 
suggests that calcium results in the increased expression of genes found in 
differentiated crypt cells.  
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7A.4.3.2 Entero-endocrine cells 
Calcium resulted in the down-regulation (GCOS>3) of a number of markers of 
intestinal enteroendocrine cells.   These down regulated genes are Peptide 
YY (PYY), Glucagon (GCG), Somatostatin (SST), Chromogranin A (CHGA), 
Chromogranin B (CHGA), Tryptophan hydroxylase (TPH1), Secretogranin 5 
(SCG5) and insulinoma-associated 1 (INSM1) (Bezencon, Furholz et al. 
2008). 
7A.4.3.3 Goblet Cells 
There was no clear direction of effect of calcium on goblet cell markers.  
Calcium supplementation resulted in the down regulation of two well defined 
markers of goblet cells Mucin 2 (MUC2) and trefoil factor 3 (TFF3) but also 
up-regulation of other goblet cell genes; glucosaminyl (N-acetyl) transferase 3 
(GCNT3), mucin 13 (MUC13) and mucin 4 (MUC4). 
7A.4.3.4 Stem cells 
A number of markers for normal colonic and colonic cancer stem cells have 
been described (LGR5, ITGB1, CD133) (Todaro, Francipane et al. 2010).  
None of these were identified as differentially expressed in response to 
calcium.  
7A.4.3.5 Stromal cells 
Four of the calcium up-regulated genes (GREM1, TAGLN, MYL9 and CNN1) 
were identified in the cluster of genes expressed in the stroma at the crypt 
base (Kosinski, Li et al. 2007).  A number of other genes up-regulated in 
response to calcium are also expressed predominantly in stroma rather than 
epithelium.  These include FHL1, MYH11, COL1A2, COL6A3 (Smith, Culhane 
et al. 2009), ACTG2, COL5A1, MGP, PLN, SPARC, PLEKHC1, IGFBP5, 
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MFAP5, CAV1 (Li, Madison et al. 2007), DES and CALD1 (Powell, 
Adegboyega et al. 2005).  Only one gene Gremlin 2 (GREM2) expressed in 
the stroma was found to be decreased in response to calcium. 
 Overall these data suggest that calcium increases the expression of 
genes found in differentiated colonocytes and the peri-crypt stroma and 
decreases the expression of genes found in enteroendocrine cells with no 
clear effect on goblet cells. 
 
7A.4.4 Functional annotation of differentially expressed genes 
DAVID was use to identify the GO biological annotation terms enriched in the 
genes differentially expressed in response to calcium.  The list of genes used 
in this analysis consisted of all the genes identified as differentially expressed 
by either GCOS>3 or RP.  There were one hundred and seventy-nine up-
regulated and eighty down-regulated genes.  Firstly enriched single GO 
annotation terms were identified.  Secondly from within these enriched single 
annotation terms enriched clusters of functionally related GO annotation terms 
were identified to clarify the biology associated with the differentially 
expressed genes. 
 
7A.4.4.1 Enriched GO annotation terms in the genes up-regulated by 
calcium 
Enriched single annotation terms for each of the three biological domains of 
the GO annotation (BP, MF and CC) were identified.  There are one hundred 
and seventeen biological process terms, thirty four cellular component and 
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twelve molecular function annotation terms enriched in the 179 genes up-
regulated by calcium.  These are shown in Appendices 5, 6 and 7. 
7A.4.4.2 Enriched clusters of functionally related GO annotation 
terms in the genes up-regulated by calcium 
Twenty one enriched clusters of functionally related annotation terms were 
identified.  These twenty one enriched annotation clusters are shown in Table 
7A.2 with their enrichment scores.  The clusters of enriched annotation terms 
are described first, as these grouped terms provide the clearest description of 
the biology of genes up-regulated by calcium. Any additional interesting 
enriched single annotation terms are then described. 
 This analysis of the enriched clusters indicates that the genes 
differentially up-regulated in response to calcium have a role in a number of 
processes.  These include the control of cell migration and locomotion 
(clusters 1, 5 and 20), regulation of kinase and phosphate mediated signalling 
(clusters 2, 7, 10 and 13), immune processes (clusters 11, 17 and 18), 
apoptosis (clusters 19 and 21), cell-matrix adhesion (cluster 22) and functions 
of specialised colonic cells (cluster 9).  The relevance of some of these 
enriched annotation clusters to the colon is unclear as some of them relate to 
the development of specialised tissue other than intestine (clusters 3, 14 and 
15). 
 In the single enriched annotation terms there are a number of terms 
that are features of differentiated colonic cells (eg „epithelial cell 
differentiation‟, „regulation of cell proliferation‟, „apoptosis‟, „cell adhesion‟, 
„adherens junction‟, „apical plasma membrane‟ and „anion transmembrane 
transporter activity‟) and stromal  cells  („proteinaceous extra-cellular matrix‟, 
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„anchoring junction‟, „contractile fiber‟ „regulation of smooth muscle cell 
proliferation‟ and „extra-cellular matrix organization‟).  This finding is 
consistent with the observation above of increased expression of genes found 
in differentiated crypt top cells and the peri-crypt stroma. 
Table 7A.2 The twenty one clusters of annotation terms enriched in the 
179 genes differentially up regulated in response to calcium.  The 
enrichment score (ES) is shown and for each for each annotation cluster the 
genes which contributed to the enrichment of the annotation cluster are listed. 
 
Cluster GO terms  (Biological domain) ES 
1 
regulation of cell migration (BP) 
regulation of locomotion (BP) 
regulation of cell motion (BP) 
3.5 
2 
negative regulation of protein kinase activity (BP) 
negative regulation of kinase activity (BP) 
negative regulation of transferase activity (BP) 
negative regulation of catalytic activity (BP) 
3.2 
3 
epidermal cell differentiation (BP) 
epidermis development (BP) 
ectoderm development (BP) 
3.2 
4 
sterol biosynthetic process (BP) 
cholesterol biosynthetic process (BP) 
sterol metabolic process (BP) 
steroid biosynthetic process (BP) 
2.9 
5 
negative regulation of cell migration (BP) 
negative regulation of locomotion (BP) 
negative regulation of cell motion (BP) 
2.0 
6 
negative regulation of transcription factor activity (BP) 
negative regulation of DNA binding (BP) 
negative regulation of binding (BP) 
regulation of transcription factor activity (BP) 
regulation of binding (BP) 
regulation of DNA binding (BP) 
2.0 
7 
regulation of MAP kinase activity (BP) 
regulation of phosphorylation (BP) 
regulation of phosphorus metabolic process (BP) 
regulation of phosphate metabolic process (BP) 
regulation of protein kinase activity (BP) 
regulation of kinase activity (BP) 
regulation of transferase activity (BP) 
1.9 
8 
response to glucose stimulus (BP) 
response to monosaccharide stimulus (BP) 
response to hexose stimulus (BP) 
response to carbohydrate stimulus (BP) 
1.6 
9 chloride ion binding (MF) 1.3 
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anion binding (MF) 
chloride channel activity (MF) 
anion channel activity (MF) 
10 
negative regulation of cytokine-mediated signaling 
pathway (BP) 
regulation of cytokine-mediated signaling pathway 
(BP) 
regulation of peptidyl-tyrosine phosphorylation (BP) 
1.5 
11 
regulation of leukocyte activation (BP) 
regulation of cell activation (BP) 
regulation of lymphocyte activation (BP) 
1.5 
12 
response to nutrient (BP) 
response to extracellular stimulus (BP) 
response to nutrient levels (BP) 
1.5 
13 
positive regulation of phosphorylation (BP) 
positive regulation of phosphorus metabolic process 
(BP) 
positive regulation of phosphate metabolic process 
(BP) 
positive regulation of signal transduction (BP) 
positive regulation of multicellular organismal process 
(BP) 
positive regulation of cell communication (BP) 
1.4 
14 
blood vessel development (BP) 
vasculature development (BP) 
blood vessel morphogenesis (BP) 
 
15 
ossification (BP) 
bone development (BP) 
skeletal system development (BP) 
1.4 
16 
endoplasmic reticulum membrane (CC) 
nuclear envelope-endoplasmic reticulum network (CC) 
endoplasmic reticulum part (CC) 
1.3 
17 
regulation of leukocyte chemotaxis (BP) 
regulation of leukocyte migration (BP) 
regulation of chemotaxis (BP) 
regulation of behaviour (BP) 
1.3 
18 
toll-like receptor signaling pathway (BP) 
pattern recognition receptor signaling pathway (BP) 
positive regulation of innate immune response (BP) 
innate immune response-activating signal transduction 
(BP) 
activation of innate immune response (BP) 
immune response-activating signal transduction (BP) 
immune response-regulating signal transduction (BP) 
regulation of innate immune response (BP) 
activation of immune response (BP) 
positive regulation of immune effector process (BP)  
regulation of immune effector process (BP) 
1.3 
19 anti-apoptosis (BP) negative regulation of apoptosis (BP) 1.3 
 218 
negative regulation of programmed cell death (BP) 
negative regulation of cell death (BP) 
20 
positive regulation of cell migration (BP) 
positive regulation of cell motion (BP) 
positive regulation of locomotion (BP) 
1.3 
21 
apoptosis (BP) 
programmed cell death (BP) 
cell death (BP) 
death (BP) 
1.3 
22 
focal adhesion (CC) 
cell-substrate adherens junction (CC) 
cell-substrate junction (CC) 
1.3 
 
7A.4.4.3 Enriched GO annotation terms in the genes down-regulated 
by calcium 
Enriched single annotation terms for each of the three biological domains of 
the GO annotation (BP, MF and CC) were identified.  There are eight 
biological process terms, five cellular component and nine molecular function 
annotation terms enriched in the 80 genes down-regulated by calcium.  These 
are shown in appendices 8, 9 and 10.   
7A.4.4.4 Enriched clusters of functionally related GO annotation 
terms in the genes down-regulated by calcium 
Three enriched clusters of functionally related annotation terms were 
identified as enriched in the genes down-regulated by calcium.  These three 
enriched annotation clusters are shown in Table 7A.3 with the enrichment 
scores and the differentially expressed genes contributing to the enrichment. 
This analysis suggests that the down-regulated genes are involved in the 
processes of antigen processing, cytokine activity and metal ion binding. 
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Table 7A.3 The three clusters of annotation terms enriched in the 80 
genes differentially down-regulated in response to calcium.  The 
enrichment score (ES) is shown and for each for each annotation cluster the 
genes which contributed to the enrichment of the annotation cluster are listed. 
 
Cluster GO terms  (Biological domain) ES 
1 
MHC class II receptor activity (MF) 
MHC class II protein complex (CC) 
antigen processing and presentation of peptide 
or polysaccharide antigen via MHC class II 
(BP) 
MHC protein complex (CC) 
antigen processing and presentation (BP) 
2.3 
2 
chemokine activity (MF) 
chemokine receptor binding (MF) 
cytokine activity (MF) 
taxis (BP) 
chemotaxis (BP) 
locomotory behavior (BP) 
1.9 
3 
integral to plasma membrane (CC) 
intrinsic to plasma membrane (CC) 
plasma membrane part (CC) 
1.8 
 
 
7A.4.5 Relationship of differentially expressed genes to colorectal 
neoplasia 
The relationship between the genes differentially expressed in response to 
calcium and colorectal neoplasia was investigated by reviewing the literature.  
The genes differentially expressed in colorectal neoplasia and also 
differentially expressed in response to calcium (both GCOS>3 and RP) and 
the relevant studies are shown in Tables 7A.4 and 7A.5. 
7A.4.5.1 GCOS>3 Up-regulated genes  
Of the 156 genes showing increased expression in response to calcium 
supplementation, forty eight have been reported to have decreased 
expression in colorectal neoplasia, twenty genes have shown increased 
expression and for eighty eight no changes in expression have been reported.   
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7A.4.5.2 GCOS>3 Down-regulated genes  
Of the 79 genes showing decreased expression in response to calcium 
supplementation, twelve have been reported to have increased expression 
and twenty-two to have decreased expression in colorectal neoplasia. 
7A.4.5.3 Rank-product Up-regulated genes  
Of the sixty-eight genes up-regulated in response to calcium, twenty six have 
been reported to have decreased expression in colorectal neoplasia, ten have 
increased expression and for thirty two no changes in expression have been 
reported. 
7A.4.5.4 Rank-product Down-regulated genes  
Of the eight genes down-regulated in response to calcium, five are reported to 
be down-regulated and one to have increased expression in colorectal 
neoplasia.   
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Table 7A.4  The genes differentially up-regulated by calcium which have also been shown to be differentially expressed in 
colorectal neoplasia. RED=GCOS>3 only, BLUE=RP only, BLACK=GCOS>3 and RP.   
Study type 
Genes up-regulated in response to Calcium which are also changed in colorectal neoplasia 
Up-regulated in colorectal neoplasia Down-regulated in colorectal neoplasia 
Micro-array; Normal 
mucosa vs Cancer 
KIAA0101 (Notterman, Alon et al. 2001) 
MAFF(Friederichs, Rosenberg et al. 2005) 
AREG (Croner, Foertsch et al. 2005) 
COL1A2, SPARC, S100P, MMP12  
(Cardoso, Boer et al. 2007) COL1A1, HSPD1 
(T. Komori and Monden 2004) RRM2 (Grade, 
Hormann et al. 2007) 
HPGD, CEACAM1, FHL1, CEACAM7, KLF4, MYL9, MYH11, CNN1, SLC26A3  
(Cardoso, Boer et al. 2007), CLCA4 (Grade, Hormann et al. 2007) 
TMPRSS2, PDE9A, SLC4A4, DSC2, MUC4 (N Ancona and S Liuni 2006) 
MUC13, IFI27 (Lin YM 2002), TXNIP (T. Komori and Monden 2004) 
GUCA2B, TAGLN, PLN, THBS1  (Birkenkamp-Demtroder, Olesen et al. 2005) 
PAFAH1B1, TNS1, CXADR, MGC14376, PTPRC (Hlubek, Brabletz et al. 2007) 
BMP2 (Wiese, Auer et al. 2007), CALD1, DES (Bertucci, Salas et al. 2004) 
SFN (Kitahara, Furukawa et al. 2001), IL6ST (Nosho, Yamamoto et al. 2005) 
CRIP1 (Martinez, Bhattacharya et al. 2005), GPD2 (Bianchini, Levy et al. 2006) 
Micro-array; Advanced 
vs early cancer 
IGFBP5 (Koehler, Bataille et al. 2004) 
TM4SF1(Kleivi, Lind et al. 2007) 
CFTR (Groene, Mansmann et al. 2006) 
DDX3X (Fritzmann, Morkel et al. 2009) 
Micro-array; Normal 
mucosa vs adenoma 
OLFM4 (SEUNGKOO LEE 2006) 
DUOX2,  (Kita, Hikichi et al. 2006) 
DHRS9, TRIM15, FLNA, PALLD, EFNA1, COL6A2  (Nikola A. Bowden 2007) 
CD177 (Kita, Hikichi et al. 2006) 
CLIC5, GREM1, CXCL9, MFAP5, SGK1, ZBTB16 (Segditsas, Sieber et al. 2008) 
MXD1 (Sabates-Bellver, Van der Flier et al. 2007) 
PCR; Normal mucosa 
vs cancer 
FHL2 (Wang, Yang et al. 2007) 
SLC6A14 (Gupta, Miyauchi et al. 2005) 
KLF6 (Reeves, Narla et al. 2004), SPRED2 (Lü, Xu et al. 2008) 
ABCG2 (Gupta, Martin et al. 2006), MGP (Fan, Sheu et al. 2001) 
PCR; Normal mucosa 
vs adenoma CYP3A5 (Bergheim, Bode et al. 2005) - 
Protein expression; 
Normal mucosa vs  
cancer 
MCL1 (Krajewska, Moss et al. 1996) 
CAV1 (Bender, Reymond et al. 2000) 
FAS (Zhu, Liu et al. 2005) 
RARRES3 (Shyu, Jiang et al. 2003) 
- 
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Table 7A.5.  The genes differentially down-regulated by calcium which have also been shown to be differentially 
expressed in colorectal neoplasia. RED=GCOS>3 only, BLUE=RP only, BLACK=GCOS>3 and RP. Of the 80 genes identified as 
down regulated by calcium using either GCOS>3 or RP, 13 are up regulated in colorectal neoplasia and 24 are down regulated. 
Study type 
Genes down-regulated in response to Calcium which are also changed in colorectal neoplasia 
Up-regulated in colorectal neoplasia Down-regulated in colorectal neoplasia 
Micro-array; 
Normal mucosa 
vs Cancer 
IGL@ (Friederichs, Rosenberg et al. 2005) 
MT1H, MT2A (Giacomini, Leung et al. 2005) 
PTTG1 (Hlubek, Brabletz et al. 2007) 
CCNA2 (N Ancona and S Liuni 2006) 
PIGR (Chen, Zhang et al. 2006) 
IGHG1 (Grade, Hormann et al. 2007) 
MT1G, PCK1 (Birkenkamp-Demtroder, Olesen et al. 2005), PYY, 
CKB, FXYD3, SST, GCG, CHGA, SL26A2, MUC2 (Cardoso, Boer et 
al. 2007) 
DNASE1L3, INSL5, HAPLN1 (Croner, Foertsch et al. 2005) 
IGHA1 (Koehler, Bataille et al. 2004) 
Micro-array; 
Advanced vs 
early cancer 
TFF3, BAMBI (Fritzmann, Morkel et al. 2009) - 
Micro-array; 
Normal mucosa 
vs adenoma 
HLA-DPA1, IL1R2 (Salahshor, Goncalves et al. 2005) 
HBB, (Salahshor, Goncalves et al. 2005) 
MT1F, IGLJ3, HLA-DQA1 (SEUNGKOO LEE 2006) 
INSM1, MT1M, ABCA8 (Kita, Hikichi et al. 2006) 
MS4A1, CXCL13 (Segditsas, Sieber et al. 2008) 
 
PCR; Normal 
mucosa vs 
cancer 
IL8 (Rubie, Frick et al. 2007) GALNT12 (Guo, Chen et al. 2004) 
Protein 
expression; 
Normal mucosa 
vs  cancer 
NDRG1(Koshiji, Kumamoto et al. 2007) - 
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7A.4.6 Relationship between genes differentially expressed in response 
to calcium supplementation and genes regulated by PTH  
To address the hypothesis that calcium acts by modulating PTH levels the 
overlap between the genes differentially expressed in response to calcium 
and those regulated by PTH in-vitro was studied.  Firstly the effect of calcium 
supplementation on serum PTH levels in the six subjects was studied. 
7A.4.6.1 Influence of calcium supplementation on Serum PTH 
It was demonstrated in chapter three that calcium supplementation for six 
weeks resulted in a statistically significant suppression of PTH in the eleven 
subjects studied.  This analysis was repeated for the six subjects studied 
here.  In each subject PTH decreased following calcium supplementation, 
baseline and post calcium supplementation serum PTH results are shown in 
Tables 5.2 and 5.5.  There was mean decrease in PTH of 0.73pmol/L (95%CI 
0.49 to 0.98).  A Mann-Whitney U test was performed to compare the 
difference between serum PTH levels before and after calcium 
supplementation, this showed a difference significant at the 5% level: 
pmol Before calcium 
After 
calcium 
Median PTH 
(pmol/L) 3.45 2.65 
Range 3.1-5.2 2.4-4.5 
N 6 6 
U= 5 
  
7A.4.6.2 Effect of calcium supplementation on the genes changed in 
response to PTH in-vitro 
The effect of calcium supplementation on the genes differentially expressed in 
response to PTH in-vitro was studied.  The majority of genes differentially 
expressed in response to PTH were down-regulated and the 133 down-
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regulated genes from the two time points (4 and 24 hours) were studied 
together.  For each of these 133 genes the outcomes in response to calcium 
in-vivo were analysed.  The following features were identified for each gene; 
fold-change, number of subjects in which change in expression occurred 
using GCOS and those identified as differentially expressed by GCOS>3 and 
RP.  These features are shown in table 7A.6. 
7A.4.6.2.1 Fold change 
The majority of PTH regulated genes were up-regulated in response to 
calcium with only nineteen genes showing a decrease in expression.  The 
fold-change for these nineteen genes was small with none showing a fold 
change greater than -1.2 fold.  The fold change for the up-regulated genes 
was also small but there were 31 genes in which expression changed greater 
than +1.2 fold.  The fold changes in response to calcium supplementation are 
shown in Table 7A.6. 
7A.4.6.2.2 Number of subjects changed (GCOS) 
The majority of PTH regulated genes showed an increase in expression in 
more subjects than decreased expression.  Eight genes were increased in 3/6 
subjects, twenty three were increased in 2/6 subjects and 35 were increased 
in 1/6 subject.  In contrast one gene was decreased in 3/6 subjects and two 
genes were decreased in 1/6 subjects and the remaining fifty five genes were 
unchanged in any of the subjects. 
7A.4.6.2.3 Differentially expressed genes 
Using GCOS>3 there were eight PTH regulated genes that were differentially 
expressed in response to calcium (AREG, PAFAH1B1, DUSP6, GPD2, LIN7C, 
ID1, ABCG2 and SFRS3).  Using RP there were six PTH regulated genes that 
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were differentially expressed in response to calcium (EREG, AREG, SGK1, 
PAFAH1B1, GPD2 and ABCG2).  There was one down-regulated gene identified 
by GCOS>3.  These genes are identified in Table 7A.6.  
Table 7A.6  The effect of calcium on the 133 genes differentially 
expressed in response to PTH treatment of Caco2 cell line.  
The genes are ranked by fold-change.  Up and Dn refer to the number of 
subjects (out of 6) a gene was identified as up or down regulated using 
GCOS.  The eight genes differentially expressed in response to calcium using 
GCOS>3 are noted with a * and those by RP are identified with a #.  FC=fold 
change 
Symbol Description Up Dn  FC  
EREG # Epiregulin 2 1 +1.59 
AREG* # Amphiregulin  3 1 +1.54 
PSPH phosphoserine phosphatase 1 0 +1.47 
SGK1 # serum/glucocorticoid regulated kinase 2 2 +1.46 
TMOD3 tropomodulin 3 (ubiquitous) 1 0 +1.4 
PAFAH1B1*# 
Platelet-activating factor 
acetylhydrolase, isoform Ib, alpha 
subunit 45kDa 
3 0 +1.35 
MMP1 matrix metallopeptidase 1 (interstitial collagenase) 2 0 +1.34 
ROD1 ROD1 regulator of differentiation 1 (S. pombe) 1 0 +1.34 
DUSP6* dual specificity phosphatase 6 3 0 +1.33 
GPD2* # glycerol-3-phosphate dehydrogenase 2  3 0 +1.33 
RHOB ras homolog gene family, member B 2 0 +1.32 
MBNL2 muscleblind-like 2 (Drosophila) 1 0 +1.31 
LIN7C* lin-7 homolog C (C. elegans) 3 0 +1.28 
SS18 synovial sarcoma translocation, chromosome 18 2 0 +1.28 
PHLDA2 pleckstrin homology-like domain, family A, member 2 2 0 +1.27 
PTPN11 protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) 1 0 +1.27 
GJA1 gap junction protein, alpha 1, 43kDa (connexin 43) 1 1 +1.24 
NUP50 nucleoporin 50kDa 0 0 +1.24 
ID1* inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 3 1 +1.23 
SRPK1 SFRS protein kinase 1 1 0 +1.23 
AGPS alkylglycerone phosphate synthase 1 0 +1.22 
ARFIP1 ADP-ribosylation factor interacting protein 1  1 0 +1.22 
CANX calnexin 2 0 +1.22 
EML4 echinoderm microtubule associated protein like 4 1 0 +1.22 
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RFC3 replication factor C (activator 1) 3, 38kDa 1 0 +1.22 
DUSP5 dual specificity phosphatase 5 1 1 +1.21 
PHLDA1 pleckstrin homology-like domain, family A, member 1 1 0 +1.21 
SCARB2 scavenger receptor class B, member 2 2 0 +1.21 
ABCG2* # ATP-binding cassette, sub-family G (WHITE), member 2 3 2 +1.2 
EFNB2 ephrin-B2 2 0 +1.2 
NCBP1 nuclear cap binding protein subunit 1 1 0 +1.2 
HSPA1B heat shock 70kDa protein 1B 2 0 +1.18 
PRKCI protein kinase C, iota 2 1 +1.18 
SFRS3* splicing factor, arginine/serine-rich 3 3 0 +1.18 
TXNDC1 thioredoxin domain containing 1 2 0 +1.18 
ACTB actin, beta 1 0 +1.17 
CALM1 calmodulin 1 (phosphorylase kinase, delta) 1 0 +1.17 
NLK nemo-like kinase 0 0 +1.17 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 2 0 +1.16 
BRD2 bromodomain containing 2 0 0 +1.16 
RALA v-ral simian leukemia viral oncogene homolog A (ras related) 2 0 +1.16 
SFRS1 splicing factor, arginine/serine-rich 1 1 0 +1.16 
CNN3 calponin 3, acidic 1 0 +1.15 
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 1 0 +1.15 
HSPA9 heat shock 70kDa protein 9 1 0 +1.15 
LRRFIP1 leucine rich repeat (in FLII) interacting protein 1 2 1 +1.15 
RDX radixin 0 0 +1.15 
SLC25A32 solute carrier family 25, member 32 0 0 +1.15 
BRD4 bromodomain containing 4 0 0 +1.14 
EIF2S3 eukaryotic translation initiation factor 2, subunit 3 gamma 2 1 +1.14 
NOX1 NADPH oxidase 1 1 0 +1.14 
NUP98 nucleoporin 98kDa 1 0 +1.14 
CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 2 0 +1.13 
OGT O-linked N-acetylglucosamine (GlcNAc) transferase  2 1 +1.13 
KLF3 Kruppel-like factor 3 (basic 1 0 +1.12 
NDRG3 NDRG family member 3 0 0 +1.12 
SFRS7 splicing factor, arginine/serine-rich 7, 35kDa 0 0 +1.12 
SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 0 0 +1.12 
ATF2 activating transcription factor 2 1 0 +1.11 
GSN gelsolin (amyloidosis, Finnish type) 2 1 +1.11 
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SELT selenoprotein T 0 0 +1.11 
SKP2 S-phase kinase-associated protein 2 (p45) 1 0 +1.11 
TMED2 transmembrane emp24 domain trafficking protein 2 1 0 +1.11 
ARL4C ADP-ribosylation factor-like 4C 1 0 +1.1 
DYNC1LI2 dynein, cytoplasmic 1, light intermediate chain 2 1 0 1.1 
NOL5A nucleolar protein 5A (56kDa with KKE/D repeat) 1 0 +1.1 
PDCD2 programmed cell death 2 0 0 +1.1 
SLC12A2 
solute carrier family 12 
(sodium/potassium /chloride 
transporters), member 2 
2 1 +1.1 
WNK1 WNK lysine deficient protein kinase 1 0 0 +1.1 
MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 0 0 +1.09 
ARHGAP5 Rho GTPase activating protein 5 0 0 +1.08 
BTRC beta-transducin repeat containing 0 0 +1.08 
JMJD1B jumonji domain containing 1B 0 0 +1.08 
PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) 2 0 +1.08 
RAB8A RAB8A, member RAS oncogene family 1 0 +1.08 
YTHDF2 YTH domain family, member 2 0 0 +1.08 
B3GNT2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 0 0 +1.07 
FBLN1 fibulin 1 2 0 +1.07 
PRNP prion protein (p27-30)  0 0 +1.07 
STAT2 signal transducer and activator of transcription 2 0 0 +1.07 
TOMM22 translocase of outer mitochondrial membrane 22 homolog (yeast) 0 0 +1.07 
FZD7 frizzled homolog 7 (Drosophila) 0 0 +1.06 
RBBP4 retinoblastoma binding protein 4 0 0 +1.06 
UBIAD1 UbiA prenyltransferase domain containing 1 0 0 +1.06 
APLP2 amyloid beta (A4) precursor-like protein 2 1 0 +1.05 
CD9 CD9 molecule 1 0 +1.05 
DARS aspartyl-tRNA synthetase 0 0 +1.05 
GNL2 guanine nucleotide binding protein-like 2 (nucleolar) 0 0 +1.05 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 0 0 +1.05 
ZNF148 zinc finger protein 148 1 0 +1.05 
CROP cisplatin resistance-associated overexpressed protein 2 1 +1.04 
GSR glutathione reductase 0 0 +1.04 
PVR poliovirus receptor 0 0 +1.04 
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RAB5B RAB5B, member RAS oncogene family 0 0 +1.04 
FUS fusion (involved in t(12;16) in malignant liposarcoma) 0 0 +1.03 
HOXA7 homeobox A7 0 0 +1.03 
RBM3 RNA binding motif (RNP1, RRM) protein 3 0 0 +1.03 
ASNS asparagine synthetase 1 0 +1.02 
CTBP1 C-terminal binding protein 1 0 0 +1.02 
SERPINH1 serpin peptidase inhibitor, clade H (heat shock protein 47), member 1 0 0 +1.02 
SOX9 SRY (sex determining region Y)-box 9  1 0 +1.02 
SPOP speckle-type POZ protein 0 0 +1.02 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 1 1 +1.01 
NRIP1 nuclear receptor interacting protein 1 1 1 +1.01 
NUTF2 nuclear transport factor 2 1 0 +1.01 
CKAP4 cytoskeleton-associated protein 4 1 1 1 
COPG coatomer protein complex, subunit gamma 0 0 1 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 0 0 1 
ELL2 elongation factor, RNA polymerase II, 2 0 0 1 
SRRM2 serine/arginine repetitive matrix 2 0 0 1 
TGIF1 TGFB-induced factor (TALE family homeobox) 0 0 1 
UTS2 urotensin 2 0 0 1 
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 1 0 -1.01 
DKK1 dickkopf homolog 1 (Xenopus laevis) 0 0 -1.01 
MOCS3 molybdenum cofactor synthesis 3 0 0 -1.01 
RTN3 reticulon 3 0 0 -1.01 
SNRNP40 WD repeat domain 57 (U5 snRNP specific) 0 0 -1.02 
STT3A 
STT3, subunit of the 
oligosaccharyltransferase complex, 
homolog A  
0 0 -1.02 
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 1 0 -1.03 
NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive 0 0 -1.04 
SLC16A1 solute carrier family 16, member 1 (monocarboxylic acid transporter 1) 1 1 -1.04 
ICAM1 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor 0 0 -1.05 
UTP20 
UTP20, small subunit (SSU) 
processome component, homolog 
(yeast) 
0 0 -1.05 
PPAP2B phosphatidic acid phosphatase type 2B 0 1 -1.06 
GATM glycine amidinotransferase (L- 0 1 -1.1 
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arginine:glycine amidinotransferase) 
ANKRD11 ankyrin repeat domain 11 0 0 -1.12 
SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1 0 0 -1.12 
GPC3 glypican 3 0 0 -1.14 
TTR transthyretin (prealbumin, amyloidosis type I) 0 0 -1.14 
TAF15 
TAF15 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
68kDa 
0 0 -1.15 
SLC26A2 solute carrier family 26 (sulfate transporter), member 2 1 3 -1.16 
HNRPU 
heterogeneous nuclear 
ribonucleoprotein U (scaffold 
attachment factor A) 
- - - 
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7A.5 Discussion 
 
This study has demonstrated that dietary calcium supplementation results in 
the differential expression of a number of genes in the rectal mucosa of the 
individuals studied.   Firstly the findings will be discussed in general terms.  
Two approaches were used to identify the genes differentially expressed in 
response to calcium.  Both of them (GCOS>3 and RP) employed a matched 
pair approach, allowing identification of genes that are differentially expressed 
in each individual following treatment with calcium.  This is particularly true for 
the GCOS>3 approach, which only compares each individuals „before‟ and 
„after‟ sample.  The rank-product (RP) analysis was performed alongside this 
because it provides a measure of statistical significance which the GCOS>3 
method does not.  Because of it matched pair wise comparison the GCOS>3 
approach is intuitively attractive.  The selection of altered in >3/6 samples is 
an arbitrary, though reasonable, cut-off.  Notably, there was significant 
overlap between the genes identified by the two different methods, suggesting 
these changes are valid. 
 Another general observation is that more genes showed increased 
expression in response to calcium than decreased expression.  This suggests 
either calcium induced gene expression or relief of transcriptional repression.  
Also, the magnitude of the fold change was relatively small with a maximum 
fold change of just over two.  Even among the genes identified as up-
regulated by calcium only 15/156 (GCOS>3) and 25/68 (RP) showed a fold 
change of >1.5 fold and only one gene down-regulated by calcium was 
decreased by a fold change of >1.5.  It is perhaps not surprising that the fold 
changes seen are small in contrast to studies comparing normal and diseased 
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tissues as the normal mucosa has various homeostatic mechanisms 
controlling crypt kinetics.  The fold changes seen are also similar to those 
seen in the only other micro-array study investigating the effect of a chemo-
preventive agent on gene expression in rectal mucosa (Glebov, Rodriguez et 
al. 2006).  In this study investigating the effect of Celecoxib, a two fold change 
in gene expression was again the maximum effect size seen. 
 
7A.5.1 Action of calcium on the colonic epithelium  
In analysing the results of these array studies the aim was to determine the 
biological processes that are represented by the genes differentially 
expressed in response to calcium.  The results suggest that calcium 
supplementation increases the numbers of differentiated cells within the crypt.  
This is based on the observation of a number of genes found in differentiated 
cells.  These include genes negatively regulated by wnt signalling including 
MXD1, EZR, PDE9A, ISG20, CEACAM1, TRIM31 and HPGD (van de 
Wetering, Sancho et al. 2002), suggesting calcium negatively regulates Wnt 
signalling.  This is consistent with a pro-differentiation effect of calcium, as 
differentiation is a consequence of decreased Wnt pathway signalling 
(Mariadason, Bordonaro et al. 2001).  The annotation terms enriched in the 
differentially expressed genes also demonstrated biological features of 
differentiated colonic cells particularly apoptosis, anion binding and anion 
channel activity, as well as control of migration and differentiation. 
 Other evidence that the effect of calcium is mediated by modulation of 
the Wnt signalling pathway is provided by the observation that calcium 
supplementation resulted in the down-regulation of a number of genetic 
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markers of entero-endocrine cells.  Deletion of TCF4 in mice results in the 
absence of entero-endocrine cells, whilst mature enterocytes and goblet cells 
remain (Korinek, Barker et al. 1998). This suggests that the effect of calcium 
in reducing markers of entero-endocrine cells may be mediated by a 
suppressive effect on wnt signalling.  Modulation of wnt signalling by calcium 
in combination with vitamin D has been demonstrated in a study of gene 
expression in colonic mucosa of mice. Calcium and vitamin D decreased 
expression of the wnt effectors beta-catenin and TCF (Yang, Kurihara et al. 
2008). 
 Other signalling pathways that may be influenced by calcium include 
the hedgehog signalling pathway, this is suggested by the finding that calcium 
supplementation results in the increased expression of a number of genes 
found in the peri-crypt stroma, particularly myofibroblasts.  An increase in the 
number of myofibroblasts is a consequence of activation of the hedgehog 
signalling pathway (van Dop, Uhmann et al. 2009).  The hedgehog signalling 
pathway is also activated by down regulation of the wnt signalling pathway 
(van den Brink, Bleuming et al. 2004).  Therefore, as well as down-regulating 
wnt signalling, calcium may also act partly by modulating hedgehog signalling.  
Though, there are no known targets of hedgehog signalling to compare with. 
 
7A.5.2 Comparison with previous studies of calcium 
Other studies have investigated whether calcium results in increased 
apoptosis in colorectal epithelium; some of these have shown no effect on 
apoptosis (Holt, Wolper et al. 2001; Holt, Bresalier et al. 2006), while others 
have suggested that calcium may enhance apoptosis (Miller, Keku et al. 2005; 
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Fedirko, Bostick et al. 2009).  Annotation terms representing apoptosis were 
enriched in the differentially expressed genes, suggesting calcium does 
increase apoptosis.  
   
7A.5.3 Relationship between genes differentially expressed in response 
to calcium and those differentially expressed in colorectal neoplasia 
Calcium does alter the expression of genes involved in colorectal 
tumorigenesis.  However, it is clear that the effect of calcium is not just to alter 
the expression of genes known to be differentially expressed in colorectal 
neoplasia in the opposite direction.  Calcium up-regulates genes commonly 
up and down regulated in colorectal neoplasia, with similar results for the 
genes down-regulated by calcium. 
  
7A.5.4 Effect of calcium on normal mucosal markers of the risk of 
neoplasia 
Reduced apoptosis has been shown to predict current (Anti, Armuzzi et al. 
2001) and future neoplasia (Keku, Amin et al. 2008).  In this study, calcium 
resulted in the increased expression of genes involved in apoptosis, 
suggesting, as have others, (Miller, Keku et al. 2005; Fedirko, Bostick et al. 
2009) that calcium induces apoptosis.  These observations indicate that 
calcium supplementation influences normal mucosa in a manner predicted to 
reduce the incidence of neoplasia.  This is consistent with its observed 
chemo-preventive action.  It also underlines the importance of understanding 
the mechanism of action of calcium. 
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7A.5.5 Mechanism of action of calcium 
 The hypothesis of this thesis is that that raised PTH acts on the normal colon 
increasing the risk of neoplasia and that calcium acts by reducing serum PTH.  
There are a number of results in this chapter that support the hypothesis that 
calcium influences gene expression in the rectal mucosa by modulating PTH 
level.  Firstly, the influence of calcium on gene expression was predominantly 
to increase the expression of certain genes and the effect of PTH both in-vitro 
and in-vivo was predominantly to decrease the expression of certain genes.  
This raises the possibility that PTH signalling results in transcriptional 
repression and that calcium, by reducing PTH relieves that repression. There 
are more genes for which expression correlates with PTH in-vivo, than are 
changed by calcium.  However, it is not surprising that all of the genes 
correlated with PTH were not up-regulated by calcium as the degree of 
correlation does not indicate the slope of the regression line; or how much 
expression will change in response to a change in PTH. 
 There is support in the data, for the hypothesis that calcium acts by 
modulating PTH.   Most of the genes down-regulated by PTH in-vitro are up-
regulated by calcium in-vivo, if only with a small fold change.  However there 
were only eight gene (GCOS>3), identified as differentially expressed by both 
PTH in-vitro and calcium in-vivo.  The effect of calcium on the genes 
regulated by PTH in-vitro will be studied further using GSEA in the second 
part of this chapter.   
7A.5.6 Strengths and limitations 
This study has a number of strengths; it is a study of human subjects with a 
past history of colorectal adenomas and has employed a standardised 
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protocol for determining the effect of calcium on gene expression in the rectal 
mucosa.  In identifying genes differentially expressed in response to calcium 
both the GCOS>3 and RP method employed a pair wise approach so that 
each subject acts as their own control, thus enabling identification of only 
those genes changed in response to calcium.  The weaknesses of this study 
include the absence of an untreated control group.  This was planned for in 
the study design but was not possible for logistical reasons.  In a similar study 
investigating the effect of Celecoxib on gene expression in rectal mucosa, 
there was an untreated control groups. In the treated group one hundred and 
seventy three genes were identified as altered in expression and only fourteen 
in the placebo group.  It would seem reasonable therefore that the majority of 
the changes seen in response to calcium are real. 
  
7A.5.6 Conclusion 
This study provides further evidence that dietary calcium supplementation has 
an effect on the rectal mucosa, with demonstrable changes in gene 
expression.  These changes suggest that calcium induces differentiation and 
apoptosis, contributing evidence to support an anti-neoplastic action of 
calcium.  These results also suggest overlap between the genes changed by 
calcium and PTH.  In the second part of this chapter gene set enrichment 
analysis will be used to further address this question. 
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Chapter 7B 
GENE SET ENRICHMENT ANALYSIS TO INVESTIGATE THE EFFECT OF 
DIETARY CALCIUM SUPPLEMENTATION ON GENE EXPRESSION IN 
NORMAL RECTAL MUCOSA 
 
7B.1 Aim 
 1. Identify gene sets enriched in the genes differentially expressed in 
 the rectal mucosa of individuals taking dietary calcium supplementation 
 using oligo-nucleotide micro-arrays. 
  
7B.2 Introduction 
 
In the first part of this chapter it was demonstrated that calcium 
supplementation resulted in the differential expression of a number of genes. 
Descriptive analysis and functional annotation of these genes indicated a 
number of interesting biological features of these genes.  It is hypothesised 
that calcium supplementation results in the differential expression of genes 
representing different biological processes.  Particularly that calcium alters the 
genes identified as regulated by PTH in the studies described in chapters 4 
and 6.  To address this hypothesis further, the gene set enrichment analysis 
(GSEA) approach (Subramanian, Tamayo et al. 2005) will be used.  As was 
carried out in chapter 6B; investigation of the expression of user defined gene 
sets will be carried out. 
 GSEA was performed as there were relatively few differentially 
expressed genes identified with small fold changes. The advantages of GSEA 
over single gene techniques lie in its ability to identify biological meaning 
where the fold changes for individual genes are small (Mootha, Lindgren et al. 
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2003).  It also analyses all genes in the dataset not just those above a certain 
threshold.  The use of gene sets allows more clear definition of biological 
processes than single genes and is more reproducible. 
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7B.3 Methods 
 
7B.31 Gene set enrichment analysis (GSEA) 
The gene set enrichment analysis methodology was described in section 
6B.3.2. In this study, GSEA was run with the parameters described below.  
The RMA data from the six controls and the six treated samples were the 
expression datasets, a class comparison was made comparing control and 
treated samples.  The C2 curated set of genes from the MSigDB (V2.5) was 
used; this consists of a total of 1892 gene sets.  The gene sets were filtered to 
exclude sets with >500 or <25 genes, this left a total of 1048 gene sets within 
this size range. The default setting for ranking metric, signal to noise ratio was 
used. Signal to noise ratio is the difference of the mean expression between 
treated and control samples scaled by the standard deviation. Gene set 
permutation was used and the number of permutations, set at 1000 as 
recommended.  A FDR of<0.05 was considered significant; however, the most 
highly ranked gene sets are usually the ones of most interest, even if those 
lower down the ranking have a FDR of <0.05. 
 In addition to the C2 gene sets, twenty user defined gene sets were 
used.  Seventeen of these were used in the Chapter 6B and have been 
described in section 6B.3.2.1 and Table 6B.1.  In addition three other gene 
sets were used.  The relationship between the effect of Celecoxib (A NSAID 
with chemo-preventive activity) and calcium was compared by studying the 
gene sets celecoxib_dn and celecoxib_up.  These sets contain the genes 
differentially expressed in normal colonic mucosa in response to celecoxib 
treatment (Glebov, Rodriguez et al. 2006).  The influence of calcium on the 
genes negatively correlated with PTH in vivo was studied by the inclusion of a 
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gene set consisting of the top five hundred genes; pth_neg, found to be 
negatively correlated with PTH in chapter three. 
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7B.4Results 
7B.4.1 Enriched gene sets 
Of the 1049 gene sets studied, 204 were enriched in the calcium treated 
phenotype, which are the gene sets up-regulated in response to calcium.   
And there were 11 enriched in the control phenotype with a FDR <0.05, 
representing the gene sets down-regulated in response to calcium. 
7B.4.1.1Gene sets enriched in calcium treated phenotype 
The 204 gene sets enriched in the treated phenotype represent those up-
regulated in response to calcium.  The top ranked gene sets with the highest 
enrichment scores represent the biology associated with the calcium treated 
phenotype.  The top twenty-five enriched gene sets are shown in Table 7B.1.  
These top twenty-five enriched gene sets can be divided into a number of 
groups.  These groups are either derived from the same or similar studies or 
containing genes with overlapping function.  The most relevant of which are 
those from studies of the colon.  
 The most highly enriched gene set is crypt_top, this contains genes 
differentially expressed at the top of normal colonic crypts compared to the 
base of the crypt (Kosinski, Li et al. 2007).  The crypt_top gene set contains 
markers of differentiation with genes involved in; cell adhesion, cell 
maturation, apotosis and inhibition of cell proliferation.  This set of genes also 
showed significant overlap with the genes induced by a dominant negative 
TCF4 (Kosinski, Li et al. 2007).  It is consistent with this that the gene set 
dn_tcf4_up is also significantly enriched in the genes up-regulated by 
calcium. 
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 The second most enriched gene set is caco2_pthall, this consists of 
all the genes up-regulated by PTH in caco2 at both time points.  The two gene 
sets from twenty-four caco2_pth24 and four hours caco2_pth4 were also 
separately, strongly enriched.  The genes in these sets and their function 
were described in chapter 2; they represent down-regulated transcriptional 
targets of PTH in colonic epithelial cells in-vitro.  The third colonic related 
gene set that was enriched pth_neg, consists of the top 500 genes that 
showed negative correlation with PTH.  The finding that these three clusters 
of colorectal specific gene sets are enriched in response to calcium provides 
evidence on the mechanism of action of calcium. Enrichment plots for these 
six gene sets are shown in Figure 7B.1. 
The three clusters of colon derived gene sets are the most pertinent to 
understanding the biological action of calcium on colon.  The additional 
information derived from the other gene sets may be complementary, but is 
most likely to represent overlapping biological processes occurring in other 
tissues.  All of the top twenty five gene sets are shown, in related clusters, in 
Appendix 12 along with a brief description of their biology.   
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Table 7B.1 The top 25 gene sets enriched in the treated by calcium 
phenotype.  The gene sets are ranked by normalised enrichment score 
(NES).  Size, is the number of genes in the genes set.  Significance of the 
enrichment results are represented by p-value and false detection rates 
(FDR). 
 
Gene set NES 
p-
value 
 
FDR 
CRYPT_TOP +3.2 0 0 
CACO2_PTHALL +3.1 0 0 
REOVIRUS_HEK293_UP +3.0 0 0 
PTH-NEG +2.9 0 0 
ET743_SARCOMA_24HRS_DN +2.8 0 0 
CHEN_HOXA5_TARGETS_UP +2.8 0 0 
CACO2_PTH24 +2.8 0 0 
ET743_SARCOMA_48HRS_DN +2.7 0 0 
IFNA_HCMV_6HRS_UP +2.7 0 0 
ET743_SARCOMA_DN +2.6 0 0 
CACO2_PTH4 +2.6 0 0 
ET743_SARCOMA_72HRS_DN +2.5 0 0 
UVB_NHEK3_C1 +2.4 0 0 
CANCER_UNDIFFERENTIATED_META_
UP +2.4 0 0 
UVC_HIGH_ALL_DN +2.4 0 0 
UVB_NHEK3_ALL +2.4 0 0 
STEMCELL_COMMON_UP +2.4 0 0 
UVB_NHEK3_C0 +2.4 0 0 
FSH_OVARY_MCV152_DN +2.3 0 0 
BRCA_PROGNOSIS_NEG +2.3 0 0 
DSRNA_UP +2.3 0 0 
DER_IFNB_UP +2.3 0 0 
CMV_HCMV_TIMECOURSE_ALL_UP +2.2 0 0 
DN_TCF4_UP +2.3 0 0 
FLECHNER_KIDNEY_TRANSPLANT_WE
LL_UP +2.2 0 8x10
-5 
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Figure 7B.1(a)-(e).  Enrichment plots for the six colorectal gene sets that 
were enriched in the genes up-regulated by calcium.  The top portion of 
the plot shows the running ES for the gene set as the analysis walks down the 
ranked list. The score at the peak of the plot (the score furthest from 0.0) is 
the ES for the gene set.  The middle portion shows a line for where each of 
the genes in the set occurs in the ranked set. The bottom portion of the plot 
shows the value of the ranking metric (signal to noise ratio) as you move 
down the list of ranked genes. The gene sets shown here are a) Crypt-top, b) 
DN_TCF4, c) caco2_pthall, d) caco2_pth24 e) caco2_pth4, f) PTH_NEG 
a b
 
c d
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7B.4.1.2Gene sets enriched in control phenotype 
There are eleven gene sets enriched in the control phenotype with a 
FDR<0.05.  These represent the gene sets down-regulated in response to 
calcium and they are shown in Tables 7B.2.  Within these eleven gene set 
there is one cluster of highly similar genes, the remaining gene sets are 
unrelated.  They are shown in Appendix 13, with a brief discussion of their 
biology.  None of these enriched gene sets are derived from colonic tissue.  
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Table 7B.2  The top 11 gene sets enriched in the control phenotype with 
an FDR<0.05.  The gene sets are ranked by normalised enrichment score 
(NES).  Significance of the enrichment results are represented by p-value and 
false detection rates (FDR). 
 
Gene set NES 
p-
value 
 
FDR 
REFRACTORY_GASTRIC_UP -2.2 0 0 
PEPTIDE_GPCRS -2.1 0 0.003 
HSA04080_NEUROACTIVE_LIGAND_RECE
PTOR_INTERACTION -2.1 0 0.002 
FETAL_LIVER_VS_ADULT_LIVER_GNF2 -1.9 0 0.015 
GPCRDB_CLASS_A_RHODOPSIN_LIKE -1.9 0 0.03 
IGF_VS_PDGF_UP -1.9 0 0.03 
MOREAUX_TACI_HI_VS_LOW_UP -1.8 0 0.04 
STEMCELL_COMMON_DN -1.8 0 0.04 
GPCRS_CLASS_A_RHODOPSIN_LIKE -1.8 0 0.04 
HSA03010_RIBOSOME -1.8 0 0.04 
NUCLEAR_RECEPTORS -1.8 0.003 0.05 
 
 
 
7B.4.2 Outcomes for user defined gene sets 
The twenty user defined gene sets were employed in this study to address 
specific hypotheses.  The outcomes will be presented separately here and are 
shown in Table 7B.3.   Six of these gene sets were in the top twenty-five gene 
sets that were enriched in the treated with calcium phenotype and were 
described above.  The two sets of genes representing genes up and down 
regulated in colorectal cancer (crc_up and crc_down) were both enriched in 
the treatment phenotype, these results were statistically significant but these 
gene sets were found a long way down the list of enriched gene sets, with 
more than one hundred gene sets showing higher levels of enrichment 
suggesting the effect is comparatively weak.  The results for the sets of genes 
up and down regulated in adenomas (adenoma_up and adenoma_ down 
are contrary to what might have been predicted, with the adenoma_up gene 
set enriched in the treated with calcium phenotype and the adenoma_down 
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gene set none-significantly enriched in the down regulated by calcium 
phenotype.  Again, for both these sets there were a large number of other 
gene sets more strongly enriched, suggesting that the effect is small. 
 The crypt_base set of genes is not regulated in the opposite direction 
to the crypt_top gene set, also being weakly enriched in the treated 
phenotype.  This may be because a number of the genes up-regulated by 
calcium are found in the crypt stroma at the crypt base.  Similarly the 
dn_tcf_dn gene set was non-significantly weakly enriched in the treated 
phenotype.  Comparison of the genes differentially expressed in response to 
calcium, with those differentially expressed in the rectal mucosa in response 
to Celecoxib (a cyclo-oxygenase 2 inhibitor) showed no similarity.  In fact, the 
two gene sets were weakly enriched in the opposite way to that expected, 
with celecoxib_up weakly enriched in the control phenotype and 
celecoxib_dn in the treatment phenotype.  Of the user defined gene sets 
none were significantly enriched in the control phenotype.  Two of the sets 
representing PTH targets in bone and muscle (pth_bone_up and 
pth_muscle_up) were weakly enriched as was cd133_stemcells.  The three 
other PTH related gene sets (pth_bone_dn, pth_haem_dn, pth_haem_up) 
showed no significant enrichment in either phenotype. 
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Table 7B.3  Outcome for the user defined gene sets in the gene set 
enrichment analysis.  They are ranked by normalised enrichment score 
(NES), with those enriched in the up-regulated by calcium phenotype at the 
top. 
 
Gene set NES 
p- 
value 
 
FDR  
CRYPT_TOP +3.2 0 0 
CACO2_PTHALL +3.1 0 0 
PTH_NEG +2.9 0 0 
CACO2_PTH24 +2.8 0 0 
CACO2_PTH4 +2.6 0 0 
DN_TCF4_UP +2.3 0 0 
CELECOXIB_DN +2.0 0 0.001 
CRC_UP +1.8 0 0.005 
ADENOMA_UP +1.6 0 0.03 
CRYPT_BASE +1.6 0 0.03 
DN_TCF_DN +1.0 0.36 0.47 
CRC_DOWN +1.6 0.009 0.03 
CELECOXIB_UP -1.1 0.3 0.70 
ADENOMA_DOWN -1.2 0.06 0.55 
CD133_STEMCELLS -1.4 0.05 0.27 
PTH_BONE_UP -1.5 0 0.21 
PTH_MUSCLE_UP -1.6 0 0.12 
 
 
7B.4.3 Comparison of the genes sets correlated with PTH and changed 
in response to calcium supplementation 
To further address the hypothesis that calcium acts on the colonic epithelium 
by modulating serum PTH, comparison was made between the gene sets 
changed in response to calcium and those correlated with PTH. It has already 
been shown that the pth_neg set of genes containing the 500 genes most 
strongly negatively correlated with PTH in-vivo is strongly enriched in the 
genes up-regulated by calcium.  It was predicted that there would be overlap 
between the other gene sets enriched in the treated with calcium phenotype 
and the negatively correlated with PTH phenotype.  Conversely it was 
predicted that there would be overlap between the gene sets enriched in the 
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control phenotype and the positively correlated with PTH phenotype. 
Comparison was made between all of the gene sets enriched with an 
FDR<0.05 in the negatively correlated with PTH (104) and treated by calcium 
phenotypes (204).  This showed fifty-nine gene sets which were enriched in 
both phenotypes; these are shown in Appendix 13.  Perhaps more importantly 
overlap between the top twenty-five gene sets revealed that there were four 
gene sets in common, these are; crypt_top, caco2_pthall, UVC_HIGH_ALL 
_DN and FLECHNER_KIDNEY_ TRANSPLANT_WELL_UP.  The gene set 
crypt_top was the most highly enriched gene set in both the negatively 
correlated with PTH phenotype and the up-regulated by calcium phenotype. 
 Comparison was made between the gene sets enriched with an 
FDR<0.05 in the positively correlated with PTH (20) and control (untreated 
with calcium) phenotypes (11).  There were seven overlapping gene sets; 
these are shown in Appendix 14.  There were no gene sets that overlapped in 
the opposite unpredicted fashion. 
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7B.5 Discussion 
This analysis has demonstrated that dietary calcium supplementation results 
in the differential expression of a number of sets of genes in the rectal 
mucosa of the individuals studied.  The identification of these gene sets 
provides evidence on the effect of calcium on the normal rectal mucosa and 
support for its anti-neoplastic effect.  A general observation is the finding that 
there are a large number of genes enriched in the treated by calcium 
phenotype and relatively few in the control phenotype.  This finding is 
consistent with the single gene analysis, which identified more genes up-
regulated by calcium than down.  The large number of enriched gene sets 
could be seen to make further analysis difficult.  However, as a method using 
ranking, the important gene sets are those found at the top of the list of 
enriched sets.  There is also a lot of overlap in the biological processes 
represented by the gene sets, hence the high number of enriched gene sets. 
7B.5.1 Action of calcium on the colonic epithelium  
The aim in analysing this study was to determine the biological processes that 
are altered in response to calcium by analysing gene sets representing known 
biological processes.  The most obvious finding was the crypt_top gene set 
being the most highly enriched.  This observation suggests that calcium 
results in the increased expression of genes commonly found in differentiated 
post-mitotic cells at the top of the colonic crypt.  This is consistent with the 
findings of the single gene analysis.  In this, the annotation terms enriched in 
the differentially up-regulated genes represented a number of biological 
features of differentiated crypt cells (See Appendix 5, 6 and 7).  Differentiation 
of colonic epithelial cells occurs as a consequence of decreased Wnt pathway 
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signalling, with evidence for this from both in-vitro (Mariadason, Bordonaro et 
al. 2001) and in-vivo studies (Sansom, Reed et al. 2004).  There is also 
significant overlap between the genes found in differentiated colonic cells and 
those negatively regulated by wnt signalling (Kosinski, Li et al. 2007).  This 
suggests that calcium induces differentiation by negatively regulating the wnt 
signalling pathway.  Consistent with this is the observation that the set of 
genes negatively regulated by wnt signalling in vitro dn_tcf4_up (van de 
Wetering, Sancho et al. 2002) is also enriched in the genes up-regulated by 
calcium. Other evidence that the effect of calcium is mediated by modulation 
of the Wnt signalling pathway was provided by the single gene analysis.  In 
this, it was observed that calcium supplementation resulted in the down-
regulation of a number of genetic markers of entero-endocrine cells.  One 
consequence of the deletion of TCF4 in mice is the absence of entero-
endocrine cells, whilst mature enterocytes and goblet cells remain (Korinek, 
Barker et al. 1998). This suggests that Wnt signalling controls the 
development of entero-endocrine cells.  The effect of calcium in reducing 
markers of entero-endocrine cells is therefore consistent with a suppressive 
effect on wnt signalling.  Modulation of wnt signalling by calcium in 
combination with vitamin D has been demonstrated in a micro-array study of 
gene expression in colonic mucosa of mice (Yang, Kurihara et al. 2008).  In 
this study mice fed a „Western diet‟ showed changes similar to those found in 
APC mutant mice.  These changes were reversed by calcium and vitamin D.  
Calcium and vitamin D most notably decreased expression of the wnt 
effectors beta-catenin and TCF (Yang, Kurihara et al. 2008). 
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 The converse was not seen with calcium having no significant effect on 
the expression of proliferation associated genes found at the crypt base or 
those positively regulated by wnt signalling.  These results suggest that 
calcium supplementation increases the numbers of differentiated cells within 
the crypt. 
7B.5.2 Comparison with previous studies of calcium 
The induction of genes expressed in differentiated cells by calcium adds to 
the growing evidence that calcium acts to induce differentiation in the colonic 
crypt.  A study of ninety two patients demonstrated that calcium increased the 
expression of p21 (CDKN1A), a cyclin-dependent kinase inhibitor only 
expressed in fully differentiated cells but had no effect on the expression of 
the proliferation marker MIB-1 (Fedirko, Bostick et al. 2009).  Although p21 
was not recognised as changed by calcium using either GCOS or RP, it was 
up-regulated in 2/6 samples using GCOS with a fold change of +1.15.  A 
number of studies have examined the effect of calcium on proliferating cells 
on the colonic crypt.  The common finding in these studies is a reduction in 
the number of proliferating cells in the upper parts of the crypt, with a 
redistribution of the proliferation zone to the lower portion of the crypt (Nobre-
Leitao, Chaves et al. 1995; Holt, Atillasoy et al. 1998; Holt, Wolper et al. 
2001).  In the only randomised double blind placebo controlled trial, with 170 
patients, no change in overall proliferative index was seen.  However,  again 
there was a decrease in the number of proliferating cells in the upper portion 
of the crypt, resulting in what the authors describe as a normalisation of the 
distribution of proliferating cells (Bostick, Fosdick et al. 1995). This study has 
used a different method to those above to investigate the effect of calcium on 
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colorectal epithelium.  In demonstrating an increase in the expression of 
genes found in differentiated colonic cells the results are consistent with the 
findings above, showing that calcium results in the earlier differentiation of 
cells as they migrate up the crypt. 
7B.5.1.3 Relationship between gene sets differentially expressed in 
response to calcium and colorectal neoplasia 
There was no clear relationship between calcium supplementation and the 
gene sets representing the changes found in colorectal neoplasia.  The genes 
both up and down regulated in colorectal cancer (crc_up and crc_down) 
were weakly enriched in the calcium treated phenotype.  The adenoma gene 
sets (adenoma_up and adenoma_down) were also weakly enriched and in 
the directions opposite of that predicted.  This suggests that the effect of 
calcium is not just to result in the expression of genes in a direction opposite 
to that seen in colorectal neoplasia.  This is not surprising, as the 
transcriptional changes found in colorectal neoplasia represent the 
consequences of multiple genetic changes. Further explanation for this is that 
some of the genes found in the differentiated crypt top are also increased in 
neoplastic compared to normal colon.  Amphiregulin (AREG) is frequently up-
regulated in colorectal cancer but is also expressed in differentiated cells at 
the crypt top (Saeki, Stromberg et al. 1992; Kosinski, Li et al. 2007) and was 
up-regulated by calcium.  Another set of genes commonly down regulated in 
colorectal neoplasia are genes found in entero-endocrine cells, these were 
also down regulated in response to calcium.   Thus the effect of calcium is not 
just to alter the expression of genes altered in colorectal neoplasia. 
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7B.5.1.4 Effect of calcium on normal mucosal markers of the risk of 
neoplasia 
There are features of normal epithelium that have been recognised to indicate 
an increased risk of colorectal neoplasia.  These are of relevance to the action 
of calcium.  Firstly, the presence of proliferating cells in the upper part of the 
colonic crypt has been demonstrated to predict the risk of current (Ponz de 
Leon, Roncucci et al. 1988; Risio, Lipkin et al. 1991) or future neoplasia 
(Scalmati, Roncucci et al. 1990; Anti, Marra et al. 1993).  In this study, 
calcium results in increased expression of markers of differentiation, 
consistent with a reduction in proliferating cells in the upper portion of the 
crypt; as has been demonstrated by different methods by others (Bostick, 
Fosdick et al. 1995; Holt, Atillasoy et al. 1998; Holt, Wolper et al. 2001).   
 The second feature of normal mucosa that has been shown to predict 
current (Anti, Armuzzi et al. 2001) and future neoplasia (Keku, Amin et al. 
2008) is reduced apoptosis.  Apoptosis is a feature of differentiated cells and 
the crypt_top gene set contains genes involved in apoptosis.  Apoptosis is 
also a biological feature of some of the other gene sets enriched in the 
calcium treated phenotype; REOVIRUS_HEK293_UP and 
UVC_HIGH_ALL_DN (DeBiasi, Clarke et al. 2003; Gentile, Latonen et al. 
2003).  As was discussed in the previous part of this chapter, the differentially 
expressed genes were also enriched with apoptosis related annotation terms.  
Calcium has also been shown in other studies to result in increased apoptosis 
(Miller, Keku et al. 2005; Fedirko, Bostick et al. 2009). These observations 
indicate that calcium supplementation influences normal mucosa in a manner 
predicted to reduce the incidence of neoplasia.  This is consistent with its 
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observed chemo-preventive action.  It also underlines the importance of 
understanding the mechanism of action of calcium. 
7B.5.5 Mechanism of action of calcium 
The preceding discussion describes the consequences of calcium 
supplementation on the rectal epithelium.  These are consistent with calcium 
having an anti-neoplastic effect.  An understanding of the mechanism of 
action of calcium is more pertinent for developing the use of calcium as a 
chemo-preventive agent.  In particular the recognition of individuals who are 
likely to benefit from calcium and are at risk of colorectal neoplasia would 
provide a rationale for its use in a chemo-preventive strategy.  The hypothesis 
of this thesis is that that raised PTH acts on the normal colon increasing the 
risk of neoplasia and that calcium acts by reducing serum PTH.  There are a 
number of results in this chapter that support the hypothesis that calcium 
influences gene expression in the rectal mucosa by modulating PTH level.  
Firstly, the influence of calcium on gene expression was predominantly to 
increase the expression of certain genes and the effect of PTH both in-vitro 
and in-vivo was predominantly to decrease the expression of certain genes.  
This raises the possibility that PTH signalling results in transcriptional 
repression and that calcium, by reducing PTH relieves that repression.  This 
appears to be the case as the gene sets highly enriched in the calcium treated 
phenotype include the gene sets negatively correlated with serum PTH in-vivo 
(pth_neg) and down-regulated by PTH in-vitro (caco2_pth_all).  Comparison 
with the GSEA results in chapter 6B show that crypt_top is also the most 
highly enriched gene set in the negatively correlated with PTH phenotype.  
 Perhaps the most striking finding in support of this hypothesis was that 
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the set of genes down-regulated by PTH in-vitro (caco2_pth_all) were 
statistically significantly enriched in the genes up-regulated by calcium.  This 
is striking because it is unusual to find overlapping results from micro-array 
experiments studying the same biological process (Subramanian, Tamayo et 
al. 2005). This is particularly when comparing in-vitro and in-vivo studies using 
different array chips, with two seemingly different interventions.  This finding 
was suggested in the single gene analysis, but was dependent on the finding 
of only a small number of overlapping genes.  This demonstrates the power of 
GSEA to identify the underlying biological processes where fold changes are 
relatively small. 
 As was discussed above the pro-differentiation effect of calcium 
appears to be mediated by abrogation of wnt signalling.  Parathyroid hormone 
is known to stimulate the wnt signalling pathway in bone (Kulkarni, Halladay et 
al. 2005) and PTH activation of PTHR1 induces it to interact with the wnt 
effecter molecule dishevelled resulting in nuclear localisation and activation of 
beta-catenin independent of wnt (Romero, Sneddon et al. 2010).  In the in-
vitro studies of Caco2, PTH treatment down-regulated wnt signalling pathway 
genes suggesting that the wnt signalling pathway was stimulated.  Similarly in 
chapter three the genes negatively correlated with PTH (pth_neg) are those 
found in differentiated colonic cells which are negatively regulated by wnt 
signalling (Mariadason, Bordonaro et al. 2001). This suggests that PTH up 
regulates the wnt signalling pathway resulting in down regulation of 
differentiation related genes. 
There is considerable overlap between the gene sets enriched in the calcium 
treated phenotype and correlated with PTH phenotype.  This provides support 
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for the validity of the results presented in chapter six, indicating that inter-
individual variation in gene expression is mediated in part by variation in 
serum PTH levels.  It is of course relevant that for each of the six individuals 
studied here calcium supplementation resulted in a significant reduction in 
serum PTH level.  This selection ensured that the hypothesised mechanism of 
action of calcium could be studied and further studies would need to address 
whether calcium had any effect on gene expression in the absence of a 
change in PTH level. 
 An important negative finding is that there was no relationship with the 
gene sets (celecoxib_up and celecoxib_down).  This indicates that calcium 
acts by a different mechanism to the COX-2 inhibitor, Celecoxib.  The gene 
sets enriched in the control phenotype provide limited biological information, 
having no clear unifying biological theme.  However, there is also overlap 
between these gene sets and those positively correlated with PTH.  Similarly 
the two PTH related gene sets (pth_muscle_up and pth_bone_up ), are 
weakly enriched in the control phenotype, as well as the positively correlated 
with PTH phenotype.   It is also noteworthy that the cd133_stemcells gene 
set is weakly enriched in the control phenotype as well as the positively 
correlated with PTH phenotype.  This raises the possibility that calcium acting 
via PTH influences colonic stem cells.   An influence of calcium, acting via 
PTH, on colonic stem cells would be consistent with its anti-neoplastic effect, 
as well as the known functions of PTH.  However, this is only hinted at by the 
data here and further studies would be needed to clarify this.  Further studies 
using different approaches should be undertaken to confirm the changes in 
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expression of the genes identified in this study.  Other approaches could 
include real-time PCR or immuno-histochemistry. 
 
7B.5.6 Conclusion 
This study demonstrates that dietary calcium supplementation results in the 
increased expression of genes found in differentiated crypt top cells.  This 
suggests that calcium acts by down-regulation of wnt signalling with 
consequent induction of differentiation.  These calcium induced changes in 
the normal crypt are consistent with a reduced risk of colorectal cancer and 
contribute further evidence to support an anti-neoplastic action of calcium. 
 The most important aspect of these results is the overlap between 
genes regulated by calcium and those regulated by PTH in-vitro and in-vivo.  
This provides evidence that calcium acts by suppressing serum PTH levels 
and that it is serum PTH that acts on the rectal epithelium inhibiting the 
differentiation of colonic cells by stimulating Wnt signalling.  It also provides 
evidence to support the hypothesis that increased serum PTH is a risk factor 
for the development of colorectal neoplasia as evidenced by its effect on the 
normal colorectal mucosa. 
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Chapter 8 
CONCLUDING REMARKS 
8.1 Calcium acts on the normal colorectal mucosa 
The aim of this study was to investigate the effect of calcium on normal rectal 
epithelium.  The main finding was that calcium supplementation results in the 
increased expression of genes found in differentiated colorectal cells.  This 
suggests that calcium induces differentiation, which occurs as a result of 
suppression of Wnt signalling.  This finding is consistent with previously 
observed effects of calcium, detected by different methods.  It is also indicates 
that calcium has an anti-neoplastic effect on normal colorectal epithelium. 
 
8.2 Relationship between the effects of dietary calcium and PTH on 
gene expression 
A hypothesis was put forward in this thesis: it proposed that PTH acted 
directly on colorectal epithelium and that the effects of calcium would have 
opposing effects by modulating serum PTH.  Within the confines of this small 
study, there is evidence to support this hypothesis.  The main support comes 
from the observed overlap between the genes differentially expressed in 
response to calcium and those regulated by PTH in-vitro and in-vivo. 
 Micro-array studies are generally not used to address specific 
hypotheses but are often used in a more exploratory role.  However, the use 
of GSEA allowed specific hypotheses to be addressed and, I believe, 
provided significant support for the hypothesis.  The results of these studies 
clearly require further investigation to explore the observations made.   The 
clinical study has provided more samples, which will allow alternative 
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approaches to investigate further the influence of PTH and calcium on the 
rectal mucosa. 
The evidence linking raised serum PTH to an increased risk of colorectal 
cancer and the results from this study may have implications for the use of 
calcium in preventing colorectal neoplasia in routine clinical practice.   
 There are also other implications of a raised serum PTH being a risk 
factor for the development of colorectal cancer.  The influence of an endocrine 
factor on tumorigenesis is novel; colorectal neoplasia classically results from 
events within the cell rather than external hormonal influence. 
Hyperparathyroidsim is common in the general public, particularly in winter, at 
high latitudes, it is also potentially reversible.  Finally as was discussed in the 
introduction to this thesis; calcium and vitamin D act together on colorectal 
neoplasia.  These observations have implications for the proposed direct 
mechanism of action of Vitamin D. 
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Appendices 
Appendix 1 
 
The one hundred and fifty six genes identified as differentially up regulated by 
calcium using the GCOS>3 approach.  The genes are listed by the number of 
subjects in which an increase was seen and then by fold change. I= Number 
of subject showing increased expression.  FC=fold change 
 
Gene 
symbol Gene title I FC 
TMPRSS2 transmembrane protease, serine 2 6 1.52 
EZR ezrin (villin 2) 6 1.31 
CLCA4 chloride channel, calcium activated, family member 4 5 1.73 
PDE9A phosphodiesterase 9A 5 1.49 
DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 5 1.34 
IER3 immediate early response 3 5 1.32 
LDLR low density lipoprotein receptor 5 1.28 
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) 4 1.71 
ACTG2 actin, gamma 2, smooth muscle, enteric 4 1.64 
FHL1 four and a half LIM domains 1 4 1.63 
ISG20 interferon stimulated exonuclease gene 20kDa 4 1.57 
CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 4 1.56 
RHOF ras homolog gene family, member F (in filopodia) 4 1.45 
DHRS9 dehydrogenase/reductase (SDR family) member 9 4 1.45 
TRIM31 tripartite motif-containing 31 4 1.43 
HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 4 1.39 
PLA2G2A phospholipase A2, group IIA (platelets, synovial fluid) 4 1.37 
ARL14 ADP-ribosylation factor-like 14 4 1.34 
CYP51A1 cytochrome P450, family 51, subfamily A, polypeptide 1 4 1.32 
IDI1 isopentenyl-diphosphate delta isomerase 1 4 1.25 
GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 4 1.25 
TWF1 twinfilin, actin-binding protein, homolog 1 (Drosophila) 4 1.24 
LAMA3 laminin, alpha 3 4 1.23 
CFTR 
cystic fibrosis transmembrane conductance 
regulator (ATP-binding cassette sub-family C, 
member 7) 
4 1.19 
RNF19B ring finger protein 19B 4 1.19 
FOS v-fos FBJ murine osteosarcoma viral 4 -1.08 
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oncogene homolog 
SLC6A14 solute carrier family 6 (amino acid transporter), member 14 3 2.13 
HBEGF heparin-binding EGF-like growth factor 3 1.89 
FKBP5 FK506 binding protein 5 3 1.82 
SPINK4 serine peptidase inhibitor, Kazal type 4 3 1.8 
TM4SF1 transmembrane 4 L six family member 1 3 1.77 
DUOX2 dual oxidase 2 3 1.63 
AREG amphiregulin 3 1.56 
RARRES3 retinoic acid receptor responder3 3 1.53 
IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) 3 1.45 
PLN phospholamban 3 1.45 
COL1A2 collagen, type I, alpha 2 3 1.45 
GNA13 guanine nucleotide binding protein (G protein), alpha 13 3 1.43 
MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) 3 1.41 
CNN1 calponin 1, basic, smooth muscle 3 1.4 
GPD2 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 3 1.39 
S100P S100 calcium binding protein P 3 1.39 
DUSP6 dual specificity phosphatase 6 3 1.36 
OASL 2'-5'-oligoadenylate synthetase-like 3 1.34 
PDLIM5 PDZ and LIM domain 5 3 1.34 
GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 3 1.34 
KCNK1 potassium channel, subfamily K, member 1 3 1.33 
F2RL1 coagulation factor II (thrombin) receptor-like 1 3 1.33 
CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 3 1.33 
TXNIP thioredoxin interacting protein 3 1.32 
IGFBP5 insulin-like growth factor binding protein 5 3 1.31 
DPT dermatopontin 3 1.3 
SFN stratifin 3 1.3 
OLFM4 olfactomedin 4 3 1.3 
HRASLS2 HRAS-like suppressor 2 3 1.29 
SEPT2 septin 2 3 1.29 
CALD1 caldesmon 1 3 1.29 
SC4MOL sterol-C4-methyl oxidase-like 3 1.29 
DSC2 desmocollin 2 3 1.28 
INPP1 inositol polyphosphate-1-phosphatase 3 1.28 
MMP12 matrix metallopeptidase 12 3 1.28 
FHL2 four and a half LIM domains 2 3 1.27 
ETNK1 ethanolamine kinase 1 3 1.27 
S100A14 S100 calcium binding protein A14 3 1.27 
TRIM15 tripartite motif-containing 15 3 1.27 
ELOVL6 ELOVL family member 6, elongation of long chain fatty acids 3 1.27 
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KLF6 Kruppel-like factor 6 3 1.27 
TRIB1 tribbles homolog 1 (Drosophila) 3 1.27 
MGP matrix Gla protein 3 1.27 
SNRK SNF related kinase 3 1.26 
COL6A3 collagen, type VI, alpha 3 3 1.26 
COL1A1 collagen, type I, alpha 1 3 1.26 
SLC26A3 Solute carrier family 26, member 3 3 1.25 
SFRS3 splicing factor, arginine/serine-rich 3 3 1.25 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 3 1.25 
ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 3 1.25 
PTP4A1 protein tyrosine phosphatase type IVA, member 1 3 1.24 
CEBPG CCAAT/enhancer binding protein (C/EBP), gamma 3 1.24 
LMNA lamin A/C 3 1.24 
PAFAH1B1 platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit 45kDa 3 1.24 
DES desmin 3 1.24 
AA156240 CDNA clone IMAGE:6025865 3 1.24 
MAPK6 mitogen-activated protein kinase 6 3 1.23 
GLS glutaminase 3 1.22 
YWHAZ tyrosine 3-monooxygenase 3 1.22 
GLUL glutamate-ammonia ligase (glutamine synthetase) 3 1.22 
HSPD1 heat shock 60kDa protein 1 (chaperonin) 3 1.22 
DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 3 1.22 
ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 3 1.22 
MYL9 myosin, light chain 9, regulatory 3 1.22 
CD59 CD59 molecule, complement regulatory protein 3 1.21 
FEM1C fem-1 homolog c (C. elegans) 3 1.21 
AMD1 adenosylmethionine decarboxylase 1 3 1.21 
TNC tenascin C (hexabrachion) 3 1.21 
MAR6 membrane-associated ring finger (C3HC4) 6 3 1.21 
MUC4 mucin 4, cell surface associated 3 1.2 
RRM2 ribonucleotide reductase M2 polypeptide 3 1.2 
BMP2 bone morphogenetic protein 2 3 1.2 
CD97 CD97 molecule 3 1.2 
ANXA1 annexin A1 3 1.2 
TAGLN transgelin 3 1.2 
RFK riboflavin kinase 3 1.2 
KLF4 Kruppel-like factor 4 (gut) 3 1.19 
RRAGC Ras-related GTP binding C 3 1.19 
SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 3 1.19 
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MYH11 myosin, heavy chain 11, smooth muscle 3 1.19 
MGC14376 hypothetical protein MGC14376 3 1.19 
CLIC5 chloride intracellular channel 5 3 1.19 
CEACAM7 carcinoembryonic antigen-related cell adhesion molecule 7 3 1.18 
MUC13 mucin 13, cell surface associated 3 1.18 
TNFRSF21 tumor necrosis factor receptor superfamily, member 21 3 1.18 
IFI27 interferon, alpha-inducible protein 27 3 1.18 
TMEM70 transmembrane protein 70 3 1.17 
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 3 1.17 
PLEKHC1 pleckstrin homology domain containing, family C (with FERM domain) member 1 3 1.17 
GUCA2B guanylate cyclase activator 2B (uroguanylin) 3 1.17 
SPRED2 sprouty-related, EVH1 domain containing 2 3 1.16 
IFNGR1 interferon gamma receptor 1 3 1.16 
HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 3 1.16 
FDFT1 farnesyl-diphosphate farnesyltransferase 1 3 1.15 
PALLD palladin, cytoskeletal associated protein 3 1.15 
SCD stearoyl-CoA desaturase (delta-9-desaturase) 3 1.15 
CAV1 caveolin 1, caveolae protein, 22kDa 3 1.15 
CRIP1 cysteine-rich protein 1 (intestinal) 3 1.14 
TNS1 tensin 1 3 1.14 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 3 1.14 
CRK v-crk sarcoma virus CT10 oncogene homolog (avian) 3 1.13 
ANKRD12 ankyrin repeat domain 12 3 1.12 
UBE2A ubiquitin-conjugating enzyme E2A (RAD6 homolog) 3 1.11 
SLC30A1 solute carrier family 30 (zinc transporter), member 1 3 1.11 
TAGLN2 transgelin 2 3 1.11 
SPINK5 serine peptidase inhibitor, Kazal type 5 3 1.11 
MAP1LC3B microtubule-associated protein 1 light chain 3 beta 3 1.1 
hCG_17762
59 hypothetical protein FLJ23556 3 1.1 
FAS Fas (TNF receptor superfamily, member 6) 3 1.09 
SLC44A4 solute carrier family 44, member 4 3 1.09 
KIAA0101 KIAA0101 3 1.09 
FLNA filamin A, alpha (actin binding protein 280) 3 1.09 
BCL10 B-cell CLL/lymphoma 10 3 1.08 
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 3 1.08 
RBM25 RNA binding motif protein 25 3 1.07 
RBM5 RNA binding motif protein 5 3 1.07 
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STX3 syntaxin 3 3 1.07 
ACSL1 acyl-CoA synthetase long-chain family member 1 3 1.06 
CXADR coxsackie virus and adenovirus receptor 3 1.06 
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 3 1.06 
APPL2 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 3 1.05 
CD177 CD177 molecule 3 1.05 
PTPRC protein tyrosine phosphatase, receptor type, C 3 1.05 
COL6A2 collagen, type VI, alpha 2 3 1.04 
COL15A1 collagen, type XV, alpha 1 3 1.02 
LIN7C lin-7 homolog C (C. elegans) 3 1.01 
SLC1A1 solute carrier family 1 member 1 3 1.01 
RDH11 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 3 1 
ZKSCAN1 zinc finger with KRAB and SCAN domains 1 3 -1.07 
EFNA1 ephrin-A1 3 -1.08 
 
 
 
Appendix2 
The seventy seven genes identified as differentially down regulated by 
calcium using the GCOS>3 approach.  The genes are listed by the number of 
subjects in which a decrease was seen and then by fold change. D= Number 
of subject showing decreased expression.  FC= Fold change 
 
Gene symbol Gene title D FC 
HBB hemoglobin, beta 4 -1.35 
CXCL14 chemokine (C-X-C motif) ligand 14 4 -1.22 
HBA2 hemoglobin, alpha 2 4 -1.22 
IGLV2-14 immunoglobulin lambda variable 2-14 4 -1.21 
HBA1 hemoglobin, alpha 1 4 -1.2 
SORL1 sortilin-related receptor, L(DLR class) A repeats-containing 4 -1.14 
IGL@ Immunoglobulin lambda locus 4 -1.05 
RIMBP2 RIMS binding protein 2 3 -1.62 
SLC22A4 solute carrier family 22 (organic cation transporter), member 4 3 -1.53 
CHGB chromogranin B (secretogranin 1) 3 -1.48 
TNFRSF17 tumor necrosis factor receptor superfamily, member 17 3 -1.44 
IGHA1 Immunoglobulin heavy constant alpha 1 3 -1.41 
IGKC Immunoglobulin kappa constant 3 -1.41 
STAP1 signal transducing adaptor family member 1 3 -1.39 
MSTP9 macrophage stimulating, pseudogene 9 3 -1.39 
SST somatostatin 3 -1.35 
PILRB paired immunoglobin-like type 2 receptor beta 3 -1.35 
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AMPD1 adenosine monophosphate deaminase 1 (isoform M) 3 -1.34 
C10orf116 chromosome 10 open reading frame 116 3 -1.33 
ALOX5 arachidonate 5-lipoxygenase 3 -1.33 
SLC6A8 solute carrier family 6 (neurotransmitter transporter, creatine), member 8 3 -1.32 
HAPLN1 hyaluronan and proteoglycan link protein 1 3 -1.31 
MT1M metallothionein 1M 3 -1.3 
IGLJ3 immunoglobulin lambda joining 3 3 -1.29 
IGKV1D-13 immunoglobulin kappa variable 1D-13 3 -1.26 
RNASE6 ribonuclease, RNase A family, k6 3 -1.24 
ADAMDEC1 ADAM-like, decysin 1 3 -1.24 
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 3 -1.23 
TYROBP TYRO protein tyrosine kinase binding protein 3 -1.23 
PYY peptide YY 3 -1.23 
TRPM6 transient receptor potential cation channel, subfamily M, member 6 3 -1.23 
NDRG1 N-myc downstream regulated gene 1 3 -1.22 
GCG glucagon 3 -1.21 
CHGA chromogranin A (parathyroid secretory protein 1) 3 -1.21 
GOLGA8B golgi autoantigen, golgin subfamily a, 8B 3 -1.21 
AMACR alpha-methylacyl-CoA racemase 3 -1.2 
TPH1 tryptophan hydroxylase 1 (tryptophan 5-monooxygenase) 3 -1.2 
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 3 -1.2 
CKB creatine kinase, brain 3 -1.19 
LIPA lipase A, lysosomal acid, cholesterol esterase  3 -1.18 
IGSF6 immunoglobulin superfamily, member 6 3 -1.18 
INSM1 insulinoma-associated 1 3 -1.17 
GALNT12 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 12 (GalNAc-
T12) 
3 -1.17 
DNASE1L3 deoxyribonuclease I-like 3 3 -1.17 
SLC26A2 solute carrier family 26 (sulfate transporter), member 2 3 -1.17 
RHOBTB3 Rho-related BTB domain containing 3 3 -1.17 
FXYD3 FXYD domain containing ion transport regulator 3 3 -1.17 
IL1R2 interleukin 1 receptor, type II 3 -1.16 
MT1H metallothionein 1H  3 -1.15 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1  3 -1.15 
SCG5 secretogranin V (7B2 protein) 3 -1.14 
GREM2 gremlin 2, cysteine knot superfamily, 3 -1.14 
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homolog (Xenopus laevis) 
HLA-DRB1 major histocompatibility complex, class II, DR beta 1  3 -1.13 
IL8 Interleukin 8 3 -1.13 
CCL21 chemokine (C-C motif) ligand 21 3 -1.13 
MT1F metallothionein 1F 3 -1.12 
MT1G metallothionein 1G 3 -1.11 
TGOLN2 trans-golgi network protein 2 3 -1.11 
TFF3 trefoil factor 3 (intestinal) 3 -1.11 
TTRAP TRAF and TNF receptor associated protein 3 -1.1 
BAMBI BMP and activin membrane-bound inhibitor homolog  3 -1.09 
PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 3 -1.09 
PTTG1 pituitary tumor-transforming 1 3 -1.09 
INSL5 insulin-like 5 3 -1.09 
MT2A metallothionein 2A 3 -1.08 
SLC3A1 solute carrier family 3, member 1 3 -1.08 
FTH1 ferritin, heavy polypeptide 1  3 -1.07 
WASL Wiskott-Aldrich syndrome-like 3 -1.03 
IGKC immunoglobulin kappa constant  3 -1.03 
PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) 3 -1.02 
PIGR polymeric immunoglobulin receptor 3 -1.02 
CCNA2 cyclin A2 3 -1.01 
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 3 -1 
IGHG1 immunoglobulin heavy constant gamma 1 (G1m marker)  3 1.01 
MUC2 mucin 2, oligomeric mucus/gel-forming 3 1.01 
WWTR1 WW domain containing transcription regulator 1 3 1.05 
LOC339047 hypothetical protein LOC339047 3 1.07 
RSAD2 radical S-adenosyl methionine domain containing 2 3 1.56 
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Appendix 3 
The sixty eight genes identified as differentially up regulated in response to 
calcium using Rank Product.The genes are ranked by percentage false 
positive (PFP) and then fold change.  PFP is equivalent to the false detection 
rate (FDR). FC= Fold change 
 
Gene 
Symbol Description FC PFP 
TM4SF1 transmembrane 4 L six family member 1 +2.12 0 
CLCA4 chloride channel regulator 4 +1.81 0 
CCL20 chemokine (C-C motif) ligand 20 +1.78 0 
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) +1.66 0 
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog +1.43 0 
TRIM31 tripartite motif-containing 31 +1.88 0.001 
GNA13 guanine nucleotide binding protein (G protein), alpha 13 +1.54 0.002 
EREG epiregulin +1.50 0.003 
LARP4 La ribonucleoprotein domain family, member 4 +1.62 0.003 
TMPRSS
2 transmembrane protease, serine 2 +1.59 0.003 
SPINK4 serine peptidase inhibitor, Kazal type 4 +1.53 0.003 
MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) +1.72 0.009 
HBEGF heparin-binding EGF-like growth factor +1.62 0.009 
DPT dermatopontin +1.44 0.01 
CXCL9 chemokine (C-X-C motif) ligand 9 +1.55 0.012 
ELOVL6 ELOVL family member 6, elongation of long chain fatty acids  +1.71 0.013 
OLFM4 olfactomedin 4 +1.73 0.013 
EZR ezrin +1.49 0.014 
DUOX2 dual oxidase 2 +1.87 0.017 
IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) +1.44 0.02 
MXD1 MAX dimerization protein 1 +1.52 0.024 
DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked +1.40 0.024 
NCOA2 nuclear receptor coactivator 2 +1.43 0.025 
CALD1 caldesmon 1 +1.41 0.026 
SLC6A14 solute carrier family 6 (amino acid transporter), member 14 +1.58 0.028 
NEAT1 nuclear paraspeckle assembly transcript 1 +1.29 0.029 
PLN phospholamban +1.43 0.032 
ATF3 activating transcription factor 3 +1.59 0.033 
HIPK3 homeodomain interacting protein kinase 3 +1.39 0.034 
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CMAH cytidine monophosphate-N-acetylneuraminic acid hydroxylase  +1.36 0.035 
ACTG2 actin, gamma 2, smooth muscle, enteric +1.38 0.04 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 +1.41 0.042 
MFAP5 microfibrillar associated protein 5 +1.44 0.043 
FHL1 four and a half LIM domains 1 +1.35 0.045 
SCYL2 SCY1-like 2 (S. cerevisiae) +1.43 0.045 
CLIC5 chloride intracellular channel 5 +1.47 0.047 
ETNK1 ethanolamine kinase 1 +1.49 0.05 
EPHA2 EPH receptor A2 +1.44 0.051 
DHRS9 dehydrogenase/reductase (SDR family) member 9 +1.54 0.054 
CEACAM
1 
carcinoembryonic antigen-related cell 
adhesion molecule 1 (biliary 
glycoprotein) 
+1.56 0.058 
CFTR 
cystic fibrosis transmembrane 
conductance regulator (ATP-binding 
cassette sub-family C, member 7) 
+1.34 0.059 
LDLR low density lipoprotein receptor +1.34 0.06 
KPNA4 karyopherin alpha 4 (importin alpha 3) +1.50 0.06 
PAFAH1
B1 
platelet-activating factor 
acetylhydrolase, isoform Ib, alpha 
subunit 45kDa 
+1.44 0.06 
AREG amphiregulin +1.41 0.06 
FKBP5 FK506 binding protein 5 +1.22 0.06 
KIF2A kinesin heavy chain member 2A +1.55 0.061 
TWF1 twinfilin, actin-binding protein, homolog 1 (Drosophila) +1.41 0.061 
TXNIP thioredoxin interacting protein +1.23 0.062 
IER3 immediate early response 3 +1.35 0.062 
SGK1 serum/glucocorticoid regulated kinase 1 +1.51 0.064 
GREM1 gremlin 1, cysteine knot superfamily +1.31 0.066 
ARL14 ADP-ribosylation factor-like 14 +1.52 0.068 
IGFBP5 insulin-like growth factor binding protein 5 +1.31 0.073 
SCAMP1 secretory carrier membrane protein 1 +1.42 0.074 
MMP12 matrix metallopeptidase 12 (macrophage elastase) +1.15 0.082 
GPD2 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) +1.32 0.083 
PDE9A phosphodiesterase 9A +1.39 0.084 
KNTC1 kinetochore associated 1 +1.35 0.087 
THBS1 thrombospondin 1 +1.29 0.087 
COL1A2 collagen, type I, alpha 2 +1.37 0.087 
ZBTB16 zinc finger and BTB domain containing 16 +1.13 0.088 
SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 +1.37 0.088 
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SYNM synemin, intermediate filament protein +1.48 0.088 
ZNF165 zinc finger protein 165 +1.42 0.089 
CLIC4 chloride intracellular channel 4 +1.43 0.089 
GUCA2B guanylate cyclase activator 2B (uroguanylin) +1.39 0.094 
MGP matrix Gla protein +1.09 0.097 
 
 
 
Appendix 4 
Shows the eight genes identified as differentially down regulated in response 
to calcium using Rank Product. The genes are ranked by percentage false 
positive (PFP) and then fold change. 
Gene 
Symbol Description  FC PFP 
SST somatostatin -1.75 0.003 
HBA1 hemoglobin, alpha 1  -1.24 0.005 
MT1M metallothionein 1M -1.35 0.005 
MS4A1 membrane-spanning 4-domains, subfamily A, member 1 -1.01 0.048 
IGHG1 Immunoglobulin lambda heavy chain -1.34 0.052 
RNASE6 ribonuclease, RNase A family, k6 -1.18 0.056 
CXCL13 chemokine (C-X-C motif) ligand 13 -1.14 0.066 
HBB hemoglobin, beta -1.31 0.095 
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Appendix 5 
The 117 GO biological process annotation terms enriched in the 179 genes 
differentially up-regulated by calcium.  The p-value and false detection rate 
(FDR) for each term is shown.  The notation E indicates to the power of 10 
(x10). 
 
Biological process (BP) P value FDR 
epidermal cell differentiation 6.7E-05 1.1E-01 
negative regulation of protein kinase activity 1.3E-04 1.0E-01 
muscle organ development 1.5E-04 7.7E-02 
sterol biosynthetic process 1.5E-04 6.2E-02 
negative regulation of kinase activity 1.7E-04 5.5E-02 
regulation of cell migration 1.7E-04 4.6E-02 
negative regulation of transferase activity 2.5E-04 5.8E-02 
regulation of locomotion 4.0E-04 8.1E-02 
regulation of cell motion 4.6E-04 8.2E-02 
epithelium development 4.8E-04 7.7E-02 
cholesterol biosynthetic process 5.2E-04 7.6E-02 
response to organic substance 5.3E-04 7.1E-02 
regulation of cell proliferation 6.7E-04 8.2E-02 
regulation of MAP kinase activity 7.0E-04 7.9E-02 
negative regulation of MAP kinase activity 1.2E-03 1.3E-01 
response to mechanical stimulus 1.3E-03 1.2E-01 
epithelial cell differentiation 1.3E-03 1.2E-01 
epidermis development 1.7E-03 1.5E-01 
negative regulation of cell proliferation 1.8E-03 1.4E-01 
isoprenoid metabolic process 2.4E-03 1.8E-01 
isoprenoid biosynthetic process 2.4E-03 1.8E-01 
ectoderm development 3.1E-03 2.1E-01 
keratinocyte differentiation 3.2E-03 2.1E-01 
response to progesterone stimulus 3.3E-03 2.1E-01 
sterol metabolic process 3.7E-03 2.2E-01 
negative regulation of transcription factor activity 3.8E-03 2.2E-01 
enzyme linked receptor protein signaling pathway 3.9E-03 2.2E-01 
positive regulation of defense response 4.1E-03 2.1E-01 
regulation of smooth muscle cell proliferation 5.3E-03 2.6E-01 
positive regulation of response to stimulus 5.7E-03 2.7E-01 
negative regulation of DNA binding 5.7E-03 2.6E-01 
negative regulation of cytokine-mediated signaling pathway 6.2E-03 2.7E-01 
negative regulation of molecular function 6.6E-03 2.8E-01 
steroid biosynthetic process 8.0E-03 3.3E-01 
negative regulation of cell migration 8.7E-03 3.4E-01 
negative regulation of binding 9.3E-03 3.5E-01 
steroid metabolic process 9.4E-03 3.5E-01 
positive regulation of phosphorylation 9.8E-03 3.5E-01 
regulation of phosphorylation 1.0E-02 3.6E-01 
negative regulation of locomotion 1.1E-02 3.6E-01 
positive regulation of phosphorus metabolic process 1.1E-02 3.7E-01 
positive regulation of phosphate metabolic process 1.1E-02 3.7E-01 
regulation of leukocyte chemotaxis 1.2E-02 3.7E-01 
cholesterol metabolic process 1.2E-02 3.7E-01 
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negative regulation of cell motion 1.2E-02 3.6E-01 
regulation of transcription factor activity 1.3E-02 3.8E-01 
response to wounding 1.3E-02 3.8E-01 
regulation of smooth muscle cell migration 1.4E-02 3.9E-01 
regulation of phosphate metabolic process 1.4E-02 3.9E-01 
regulation of phosphorus metabolic process 1.4E-02 3.9E-01 
extracellular matrix organization 1.5E-02 4.1E-01 
toll-like receptor signaling pathway 1.6E-02 4.2E-01 
response to protein stimulus 1.7E-02 4.2E-01 
response to nutrient 1.8E-02 4.3E-01 
negative regulation of smooth muscle cell proliferation 1.9E-02 4.5E-01 
regulation of binding 1.9E-02 4.5E-01 
regulation of protein kinase activity 2.1E-02 4.7E-01 
response to steroid hormone stimulus 2.1E-02 4.6E-01 
regulation of cytokine-mediated signaling pathway 2.2E-02 4.7E-01 
inactivation of MAPK activity 2.2E-02 4.7E-01 
maintenance of protein location in cell 2.2E-02 4.7E-01 
response to glucose stimulus 2.2E-02 4.7E-01 
osteoblast differentiation 2.2E-02 4.7E-01 
ossification 2.2E-02 4.6E-01 
regulation of leukocyte activation 2.3E-02 4.7E-01 
extracellular structure organization 2.3E-02 4.8E-01 
negative regulation of immune system process 2.3E-02 4.7E-01 
lipid biosynthetic process 2.4E-02 4.7E-01 
pattern recognition receptor signaling pathway 2.4E-02 4.7E-01 
response to hexose stimulus 2.5E-02 4.7E-01 
response to monosaccharide stimulus 2.5E-02 4.7E-01 
regulation of DNA binding 2.5E-02 4.7E-01 
blood vessel development 2.5E-02 4.7E-01 
regulation of kinase activity 2.5E-02 4.7E-01 
anti-apoptosis 2.6E-02 4.7E-01 
striated muscle tissue development 2.7E-02 4.8E-01 
protein kinase cascade 2.7E-02 4.8E-01 
cytoskeleton organization 2.7E-02 4.7E-01 
bone development 2.8E-02 4.7E-01 
positive regulation of innate immune response 2.8E-02 4.7E-01 
apoptosis 2.8E-02 4.7E-01 
cell motion 2.8E-02 4.7E-01 
vasculature development 2.9E-02 4.7E-01 
actin cytoskeleton organization 2.9E-02 4.7E-01 
regulation of cell activation 2.9E-02 4.7E-01 
maintenance of protein location 3.0E-02 4.7E-01 
innate immune response-activating signal transduction 3.0E-02 4.7E-01 
activation of innate immune response 3.0E-02 4.7E-01 
negative regulation of signal transduction 3.0E-02 4.7E-01 
regulation of transferase activity 3.1E-02 4.7E-01 
tissue morphogenesis 3.1E-02 4.7E-01 
programmed cell death 3.2E-02 4.7E-01 
muscle tissue development 3.3E-02 4.8E-01 
maintenance of location in cell 3.3E-02 4.8E-01 
epidermis morphogenesis 3.4E-02 4.8E-01 
response to extracellular stimulus 3.4E-02 4.8E-01 
positive regulation of cytokine production 3.4E-02 4.8E-01 
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biological adhesion 3.5E-02 4.8E-01 
cell adhesion 3.5E-02 4.8E-01 
immune response-activating signal transduction 3.5E-02 4.8E-01 
MAPKKK cascade 3.6E-02 4.8E-01 
leukocyte mediated immunity 3.6E-02 4.7E-01 
terpenoid metabolic process 3.7E-02 4.8E-01 
regulation of leukocyte migration 3.7E-02 4.8E-01 
response to drug 3.8E-02 4.8E-01 
anion transport 3.8E-02 4.9E-01 
negative regulation of catalytic activity 3.9E-02 4.9E-01 
immune response-regulating signal transduction 3.9E-02 4.9E-01 
immune effector process 4.1E-02 5.0E-01 
actin filament-based process 4.1E-02 5.0E-01 
regulation of innate immune response 4.3E-02 5.1E-01 
response to calcium ion 4.3E-02 5.1E-01 
positive regulation of cell migration 4.5E-02 5.2E-01 
positive regulation of macrophage activation 4.5E-02 5.2E-01 
positive regulation of DNA metabolic process 4.7E-02 5.4E-01 
regulation of lymphocyte activation 5.0E-02 5.5E-01 
positive regulation of immune response 5.0E-02 5.5E-01 
response to carbohydrate stimulus 5.0E-02 5.5E-01 
 
 
Appendix 6 
The 34 GO cellular component annotation terms enriched in the 179 genes 
differentially up-regulated by calcium.  The p-value and false detection rate 
(FDR) for each term is shown. 
 
Cellular component (CC) P value FDR 
extracellular region part 4.9E-05 1.4E-02 
plasma membrane 1.5E-04 2.1E-02 
extracellular region 1.7E-04 1.6E-02 
extracellular matrix 4.3E-04 3.0E-02 
proteinaceous extracellular matrix 6.6E-04 3.7E-02 
vesicle 7.6E-04 3.6E-02 
extracellular matrix part 8.7E-04 3.5E-02 
actin cytoskeleton 4.7E-03 1.5E-01 
extracellular space 5.5E-03 1.6E-01 
contractile fiber part 5.9E-03 1.5E-01 
cytoplasmic vesicle 6.2E-03 1.5E-01 
contractile fiber 8.1E-03 1.7E-01 
insoluble fraction 8.6E-03 1.7E-01 
anchoring junction 9.1E-03 1.7E-01 
cell cortex 1.2E-02 2.0E-01 
cell fraction 1.3E-02 2.0E-01 
anchored to membrane 1.4E-02 2.0E-01 
collagen 1.4E-02 1.9E-01 
plasma membrane part 1.6E-02 2.2E-01 
organelle membrane 1.6E-02 2.1E-01 
adherens junction 1.8E-02 2.2E-01 
membrane-bounded vesicle 2.4E-02 2.6E-01 
 273 
endoplasmic reticulum membrane 2.8E-02 2.9E-01 
collagen type I 3.1E-02 3.1E-01 
apical plasma membrane 3.5E-02 3.3E-01 
cytoplasmic membrane-bounded vesicle 3.7E-02 3.4E-01 
nuclear envelope-endoplasmic reticulum network 3.7E-02 3.3E-01 
secretory granule 4.0E-02 3.4E-01 
endomembrane system 4.0E-02 3.3E-01 
membrane fraction 4.1E-02 3.3E-01 
endosomal part 4.2E-02 3.2E-01 
endosome membrane 4.2E-02 3.2E-01 
cytoskeleton 4.3E-02 3.2E-01 
cell surface 4.9E-02 3.5E-01 
 
 
Appendix 7 
The 12 GO molecular function annotation terms enriched in the 179 genes 
differentially up-regulated by calcium.  The p-value and false detection rate 
(FDR) for each term is shown. 
 
 
 
Appendix 8 
The eight GO biological process annotation terms enriched in the 80 genes 
differentially down-regulated by calcium.  The p-value and false detection rate 
(FDR) for each term is shown. The notation E indicates to the power of 10 
(x10). 
Biological process (BP) P value FDR 
immune response 3.1E-08 1.5E-05 
antigen processing and presentation of peptide or 
polysaccharide antigen via MHC class II 2.6E-03 4.8E-01 
defense response 6.9E-03 6.8E-01 
digestion 9.0E-03 6.7E-01 
cell surface receptor linked signal transduction 2.1E-02 8.8E-01 
antigen processing and presentation 3.3E-02 9.4E-01 
chemotaxis 3.8E-02 9.4E-01 
taxis 3.8E-02 9.4E-01 
 
 
Molecular function (MF) P value FDR % 
extracellular matrix structural constituent 1.0E-03 3.7E-01 
identical protein binding 5.3E-03 6.9E-01 
anion transmembrane transporter activity 9.2E-03 7.5E-01 
structural molecule activity 1.3E-02 7.7E-01 
chloride ion binding 1.4E-02 7.1E-01 
actin binding 2.2E-02 8.1E-01 
anion binding 2.5E-02 8.0E-01 
protein dimerization activity 3.4E-02 8.5E-01 
enzyme inhibitor activity 3.8E-02 8.5E-01 
kinase binding 3.8E-02 8.2E-01 
double-stranded DNA binding 4.7E-02 8.6E-01 
chloride channel activity 4.9E-02 8.4E-01 
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Appendix 9 
The six GO cellular component annotation terms enriched in the 80 genes 
differentially up-regulated by calcium.  The p-value and false detection rate 
(FDR) for each term is shown. 
Cellular component (CC) P value FDR 
extracellular region 3.2E-05 3.8E-03 
MHC class II protein complex 1.4E-03 8.4E-02 
integral to plasma membrane 6.8E-03 2.4E-01 
MHC protein complex 1.3E-02 2.7E-01 
extracellular region part 2.2E-02 3.6E-01 
 
 
 
Appendix 10 
The nine GO molecular function annotation terms enriched in the 80 genes 
differentially up-regulated by calcium.  The p-value and false detection rate 
(FDR) for each term is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular function (MF) P value FDR % 
cadmium ion binding 5.8E-06 1.1E-03 
antigen binding 9.1E-04 8.4E-02 
chemokine activity 1.1E-03 7.0E-02 
MHC class II receptor activity 1.2E-03 5.6E-02 
chemokine receptor binding 1.4E-03 5.1E-02 
hormone activity 1.4E-03 4.5E-02 
iron ion binding 3.0E-03 7.9E-02 
copper ion binding 3.9E-03 8.9E-02 
cytokine activity 1.2E-02 2.3E-01 
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Appendix 11 
The top twenty five enriched gene sets in the treated with calcium phenotype.  The gene sets are grouped into clusters with similar 
biology or from the same study.  A brief description of the biology is given along with references for the source publication The gene 
sets are from the C2 gene sets found on the MSIGDb website, CGP=chemical and genetic perturbations.   
Gene Set Collection Tissue origin Involved biology and source publication 
CRYPT_TOP User defined Human colon Genes found in differentiated crypt top cells (Kosinski, Li et al. 2007) 
DN_TCF4_UP User defined Human colon 
Genes negatively regulated by wnt signalling (van de Wetering, Sancho et 
al. 2002) 
CACO2_PTHALL 
CACO2_PTH24 
CACO2_PTH4 
User 
defined Human colon 
Genes down regulated in the Caco2 cell line in response to PTH treatment 
(Chapter 2). 
PTH_NEG User defined Human colon 
Genes for which expression was negatively correlated with serum PTH 
levels (Chapter 4). 
ET743_SARCOMA_24HRS_DN 
ET743_SARCOMA_48HRS_DN 
ET743_SARCOMA_DN 
ET743_SARCOMA_72HRS_DN 
CGP Sarcoma cell line 
Genes down-regulated in soft-tissue sarcoma cell lines in-vitro at different 
time points following treatment with  novel chemotherapy agent (ET743) 
(Martinez, Sanchez-Beato et al. 2005) 
UVB_NHEK3_C1 
 UVB_NHEK3_ALL 
UVB_NHEK3_C0 
CGP 
Primary 
human 
keratinocytes 
Genes regulated by UVB exposure of primary human keratinocytes 
(Gentile, Latonen et al. 2003) 
UVC_HIGH_ALL_DN  
UVC_XPCS_ALL_DN CGP 
Human 
fibroblasts 
Gene expression changes due to exposure to UVC radiation. Increased 
expression of cell cycle arrest and apoptosis associated genes was the 
main finding(Gentile, Latonen et al. 2003). 
IFNA_HCMV_6HRS_UP 
CMV_HCMV_TIMECOURSE_AL
L_UP 
CGP Human fibroblasts The transcriptional response of fibroblasts to exposure to CMV  
REOVIRUS_HEK293_UP CGP HEK293 The transcriptional response to exposure to reovirus of human embryonic kidney cells 
DSRNA_UP CGP Neuronal cell Transcriptional response of neuronal cell line to the viral component 
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line double-stranded RNA 
DER_IFNB_UP CGP Fibrosarcoma cell line Genes up-regulated in fibrosarcoma cells in response to interferon 
CHEN_HOXA5_TARGETS_UP CGP Breast cancer cell line 
Genes up-regulated in response to HOXA5 induction in a breast cancer cell 
line 
FSH_OVARY_MCV152_DN CGP Ovarian cell line MCV152 
Genes down-regulated in response to FSH stimulation of the ovarian cell 
line MCV152  
FLECHNER_KIDNEY_TRANSPL
ANT_WELL_UP CGP 
Human 
kidney 
transplant 
Genes differentially expressed between well functioning and rejected 
kidneys (Flechner, Kurian et al. 2004) 
CANCER_UNDIFFERENTIATED 
_META _UP CGP 
Various 
human 
cancers  
Represents a meta-signature of genes enriched in various poorly 
differentiated cancers, but not derived from colorectal cancer. (Rhodes, Yu 
et al. 2004) 
BRCA_PROGNOSIS_NEG CGP Human breast cancers 
Genes enriched in poor prognosis breast cancers from patients with 
BRCA1 mutations. 
STEMCELL_ COMMON_UP CGP Murine stem cells 
Genes commonly enriched in embryonic, neural and haematopoietic stem 
cells compared to differentiated tissue. 
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Appendix 12 
The top twenty five enriched gene sets in the treated with calcium phenotype.  The gene sets are grouped into clusters with similar 
biology or from the same study.  A brief description of the biology is given along with references for the source publication. All the 
gene sets are from the C2 gene sets found on the MSIGDb website, CGP=chemical and genetic perturbations.   
Gene Set Collection Tissue origin Involved biology and source publication 
HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_IN
TERACTION 
GPCRDB_CLASS_A_RHODOPSIN_LIKE 
GPCRS_CLASS_A_RHODOPSIN_LIKE 
PEPTIDE_GPCRS 
CP Human G-protein coupled receptors 
REFRACTORY_GASTRIC_UP CGP Human gastric cancer 
Genes enriched in gastric cancers 
resistant to treatment with 5FU(Kim, Choi 
et al. 2004) 
FETAL_LIVER_VS_ADULT_LIVER_ GNF2 CP   
IGF_VS_PDGF_UP CGP Human myoblasts 
Genes differentially expressed between 
IGF versus PDGF treated myoblasts 
(Kuninger, Kuzmickas et al. 2004) 
MOREAUX_TACI_HI_VS_LOW_UP CGP 
Human 
multiple 
myeloma cells 
(MMC) 
Gene expression profiles comparing 
MMC‟s with low expression of TACI 
(Moreaux, Cremer et al. 2005) 
STEMCELL_COMMON_DN CGP Murine stem cells 
Genes commonly down-regulated in 
embryonic, neural and haematopoietic 
stem cells compared to differentiated 
tissue. 
HSA03010_RIBOSOME CP Generic Kegg 
NUCLEAR_RECEPTORS CP Generic Kegg 
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Appendix13 
 The 59 gene sets enriched in both the negatively correlated with PTH phenotype (chapter 6B) and treated by calcium phenotype in 
the GSEA analyses with a FDR of<0.05. The gene sets of particular interest are highlighted.  
Gene sets negatively correlated with PTH and up-regulated by calcium 
CRYPT_TOP, HEARTFAILURE_ATRIA_DN, RNA_TRANSCRIPTION_REACTOME, CRC_DOWN, UVC_HIGH_ALL_DN, 
HSC_LATEPROGENITORS_ADULT, HCC_SURVIVAL_GOOD_VS_POOR_DN, ROME_INSULIN_2F_UP, BRCA1_OVEREXP_UP,CACO2_PTHALL, 
HSC_LATEPROGENITORS_SHARED, HSC_LATEPROGENITORS_FETAL, GOLDRATH_HP, FLECHNER_KIDNEY_TRANSPLANT_WELL_UP, 
CACO2_PTH24, STEMCELL_COMMON_UP, SERUM_FIBROBLAST_CORE_UP, ET743_SARCOMA_48HRS_DN, WANG_MLL_CBP_VS_GMP_DN, 
UVB_NHEK3_C0, UVB_NHEK3_ALL, UVC_HIGH_D7_DN, UVC_HIGH_D3_DN, KUROKAWA_5FU_IFN_SENSITIVE_VS_RESISTANT_DN, 
CMV_HCMV_TIMECOURSE_16HRS_UP, SMITH_HTERT_UP, ET743_SARCOMA_DN, 
HSA05131_PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EPEC, REOVIRUS_HEK293_UP, ET743_SARCOMA_24HRS_DN, 
HSA05130_PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EHEC, UVB_NHEK3_C1, CHANG_SERUM_RESPONSE_UP, UVB_NHEK2_DN, 
FSH_OVARY_MCV152_DN, HYPOXIA_RCC_NOVHL_UP, HSC_MATURE_ADULT, HDACI_COLON_SUL16HRS_UP, RCC_NL_UP, 
IGLESIAS_E2FMINUS_UP, ET743_SARCOMA_72HRS_DN, JECHLINGER_EMT_DN, HDACI_COLON_CURSUL_UP, UVB_SCC_UP, 
GENOTOXINS_ALL_24HRS_REG, HDACI_COLON_SUL48HRS_UP, BAF57_BT549_DN, CMV_HCMV_TIMECOURSE_18HRS_UP, 
HSC_MATURE_SHARED, PASSERINI_EM, CHEN_HOXA5_TARGETS_UP, EMT_DN, PENG_RAPAMYCIN_DN, LEE_E2F1_UP, HDACI_COLON_SUL_UP, 
ELONGINA_KO_DN, CACO2_PTH4, UVB_NHEK1_DN, MRNA_PROCESSING 
 
 
Appendix 14 
 This table lists all the gene sets enriched in both the positively correlated with PTH phenotype (chapter 4) and control phenotype in 
the GSEA analyses with a FDR of<0.05. 
Gene sets positively correlated with PTH and down-regulated by calcium 
REFRACTORY_GASTRIC_UP, PEPTIDE_GPCRS, HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION, 
GPCRDB_CLASS_A_RHODOPSIN_LIKE, IGF_VS_PDGF_UP, MOREAUX_TACI_HI_VS_LOW_UP, GPCRS_CLASS_A_RHODOPSIN_LIKE, 
 
 
 
 
 
 279 
BIBLIOGRAPHY 
 
Abbas, S., J. Linseisen, et al. (2008). "Serum 25-hydroxyvitamin D and risk of post-
menopausal breast cancer--results of a large case-control study." 
Carcinogenesis 29(1): 93-9. 
Adami, S., O. Viapiana, et al. (2008). "Relationship between serum parathyroid 
hormone, vitamin D sufficiency, age, and calcium intake." Bone 42(2): 267-
70. 
Aguirre, A. J., C. Brennan, et al. (2004). "High-resolution characterization of the 
pancreatic adenocarcinoma genome." Proc Natl Acad Sci U S A 101(24): 
9067-72. 
Allan, E. H., K. D. Hausler, et al. (2008). "EphrinB2 regulation by PTH and PTHrP 
revealed by molecular profiling in differentiating osteoblasts." J Bone Miner 
Res 23(8): 1170-81. 
Allison, D. B., X. Cui, et al. (2006). "Microarray data analysis: from disarray to 
consolidation and consensus." Nat Rev Genet 7(1): 55-65. 
Alsafwah, S., S. P. Laguardia, et al. (2008). "Hypovitaminosis D in African 
Americans residing in Memphis, Tennessee with and without heart failure." 
Am J Med Sci 335(4): 292-7. 
Anti, M., A. Armuzzi, et al. (2001). "Severe imbalance of cell proliferation and 
apoptosis in the left colon and in the rectosigmoid tract in subjects with a 
history of large adenomas." Gut 48(2): 238-46. 
Anti, M., G. Marra, et al. (1993). "Rectal epithelial cell proliferation patterns as 
predictors of adenomatous colorectal polyp recurrence." Gut 34(4): 525-30. 
Apperly, F. (1941). "The relation of solar radiation to cancer mortality in North 
America." cancer Res 1: 191-195. 
Appleton, G. V., P. W. Davies, et al. (1987). "Inhibition of intestinal carcinogenesis 
by dietary supplementation with calcium." Br J Surg 74(6): 523-5. 
Ardura, J. A., S. Rayego-Mateos, et al. (2010). "Parathyroid hormone-related protein 
promotes epithelial-mesenchymal transition." J Am Soc Nephrol 21(2): 237-
48. 
Asano, T. and R. S. McLeod (2002). "Dietary fibre for the prevention of colorectal 
adenomas and carcinomas." Cochrane Database Syst Rev(2): CD003430. 
Ashburner, M., C. A. Ball, et al. (2000). "Gene ontology: tool for the unification of 
biology. The Gene Ontology Consortium." Nat Genet 25(1): 25-9. 
Atkin, W. S., C. F. Cook, et al. (2002). "Single flexible sigmoidoscopy screening to 
prevent colorectal cancer: baseline findings of a UK multicentre randomised 
trial." Lancet 359(9314): 1291-300. 
Atkin, W. S., R. Edwards, et al. (2010). "Once-only flexible sigmoidoscopy screening 
in prevention of colorectal cancer: a multicentre randomised controlled trial." 
Lancet 375(9726): 1624-33. 
Atkin, W. S. and B. P. Saunders (2002). "Surveillance guidelines after removal of 
colorectal adenomatous polyps." Gut 51 Suppl 5: V6-9. 
Axelsen, J. B., J. Lotem, et al. (2007). "Genes overexpressed in different human solid 
cancers exhibit different tissue-specific expression profiles." Proc Natl Acad 
Sci U S A 104(32): 13122-7. 
Ballen, K. K., E. J. Shpall, et al. (2007). "Phase I trial of parathyroid hormone to 
facilitate stem cell mobilization." Biol Blood Marrow Transplant 13(7): 838-
43. 
 280 
Bandres, E., E. Andion, et al. (2005). "Gene expression profile induced by BCNU in 
human glioma cell lines with differential MGMT expression." J Neurooncol 
73(3): 189-98. 
Barker, N., R. A. Ridgway, et al. (2009). "Crypt stem cells as the cells-of-origin of 
intestinal cancer." Nature 457(7229): 608-11. 
Baron, J. A., M. Beach, et al. (1999). "Calcium supplements for the prevention of 
colorectal adenomas. Calcium Polyp Prevention Study Group." N Engl J Med 
340(2): 101-7. 
Baron, J. A., R. S. Sandler, et al. (2006). "A randomized trial of rofecoxib for the 
chemoprevention of colorectal adenomas." Gastroenterology 131(6): 1674-82. 
Bender, F. C., M. A. Reymond, et al. (2000). "Caveolin-1 levels are down-regulated 
in human colon tumors, and ectopic expression of caveolin-1 in colon 
carcinoma cell lines reduces cell tumorigenicity." Cancer Res 60(20): 5870-8. 
Berdiaki, A., G. A. Datsis, et al. (2010). "Parathyroid hormone (PTH) peptides 
through the regulation of hyaluronan metabolism affect osteosarcoma cell 
migration." IUBMB Life 62(5): 377-86. 
Bergheim, I., C. Bode, et al. (2005). "Decreased expression of cytochrome P450 
protein in non-malignant colonic tissue of patients with colonic adenoma." 
BMC Gastroenterol 5: 34. 
Bertucci, F., S. Salas, et al. (2004). "Gene expression profiling of colon cancer by 
DNA microarrays and correlation with histoclinical parameters." Oncogene 
23(7): 1377-1391. 
Bertucci, F., S. Salas, et al. (2004). "Gene expression profiling of colon cancer by 
DNA microarrays and correlation with histoclinical parameters." Oncogene 
23(7): 1377-91. 
Bezencon, C., A. Furholz, et al. (2008). "Murine intestinal cells expressing Trpm5 are 
mostly brush cells and express markers of neuronal and inflammatory cells." J 
Comp Neurol 509(5): 514-25. 
Bhatia, V., M. K. Saini, et al. (2009). "Nuclear PTHrP targeting regulates PTHrP 
secretion and enhances LoVo cell growth and survival." Regul Pept 158(1-3): 
149-55. 
Bianchini, M., E. Levy, et al. (2006). "Comparative study of gene expression by 
cDNA microarray in human colorectal cancer tissues and normal mucosa." Int 
J Oncol 29(1): 83-94. 
Birkenkamp-Demtroder, K., S. H. Olesen, et al. (2005). "Differential gene expression 
in colon cancer of the caecum versus the sigmoid and rectosigmoid." Gut 
54(3): 374-384. 
Bonithon-Kopp, C., O. Kronborg, et al. (2000). "Calcium and fibre supplementation 
in prevention of colorectal adenoma recurrence: a randomised intervention 
trial. European Cancer Prevention Organisation Study Group." Lancet 
356(9238): 1300-6. 
Bos, J. L. (1989). "ras oncogenes in human cancer: a review." Cancer Res 49(17): 
4682-9. 
Bostick, R. M., L. Fosdick, et al. (1995). "Calcium and colorectal epithelial cell 
proliferation in sporadic adenoma patients: a randomized, double-blinded, 
placebo-controlled clinical trial." J Natl Cancer Inst 87(17): 1307-15. 
Bowden, N. A., A. Croft, et al. (2007). "Gene expression profiling in familial 
adenomatous polyposis adenomas and desmoid disease." Hered Cancer Clin 
Pract 5(2): 79-96. 
 281 
Brachat, A., B. Pierrat, et al. (2002). "A microarray-based, integrated approach to 
identify novel regulators of cancer drug response and apoptosis." Oncogene 
21(54): 8361-71. 
Braun, M. M., K. J. Helzlsouer, et al. (1995). "Colon cancer and serum vitamin D 
metabolite levels 10-17 years prior to diagnosis." Am J Epidemiol 142(6): 
608-11. 
Breitling, R., P. Armengaud, et al. (2004). "Rank products: a simple, yet powerful, 
new method to detect differentially regulated genes in replicated microarray 
experiments." FEBS Lett 573(1-3): 83-92. 
Bresalier, R. S., R. S. Sandler, et al. (2005). "Cardiovascular events associated with 
rofecoxib in a colorectal adenoma chemoprevention trial." N Engl J Med 
352(11): 1092-102. 
Bryden, A. A., J. A. Hoyland, et al. (2002). "Parathyroid hormone related peptide and 
receptor expression in paired primary prostate cancer and bone metastases." Br 
J Cancer 86(3): 322-5. 
Bulow, S. (1989). "Familial adenomatous polyposis." Ann Med 21(4): 299-307. 
Burton, G. R., R. Nagarajan, et al. (2004). "Microarray analysis of differentiation-
specific gene expression during 3T3-L1 adipogenesis." Gene 329: 167-85. 
Caldwell, G. M., C. Jones, et al. (2004). "The Wnt antagonist sFRP1 in colorectal 
tumorigenesis." Cancer Res 64(3): 883-8. 
Calvi, L. M., G. B. Adams, et al. (2003). "Osteoblastic cells regulate the 
haematopoietic stem cell niche." Nature 425(6960): 841-6. 
Calvi, L. M., N. A. Sims, et al. (2001). "Activated parathyroid hormone/parathyroid 
hormone-related protein receptor in osteoblastic cells differentially affects 
cortical and trabecular bone." J Clin Invest 107(3): 277-86. 
Calvo, N. G., C. R. Gentili, et al. (2008). "The early phase of programmed cell death 
in Caco-2 intestinal cells exposed to PTH." J Cell Biochem 105(4): 989-97. 
Cardoso, J., J. Boer, et al. (2007). "Expression and genomic profiling of colorectal 
cancer." Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1775(1): 
103-137. 
Caron de Fromentel, C. and T. Soussi (1992). "TP53 tumor suppressor gene: a model 
for investigating human mutagenesis." Genes Chromosomes Cancer 4(1): 1-
15. 
Carron, J. A., W. D. Fraser, et al. (1997). "PTHrP and the PTH/PTHrP receptor are 
co-expressed in human breast and colon tumours." Br J Cancer 76(8): 1095-8. 
Center, M. M., A. Jemal, et al. (2009). "Worldwide variations in colorectal cancer." 
CA Cancer J Clin 59(6): 366-78. 
Chakrabarty, S., V. Radjendirane, et al. (2003). "Extracellular calcium and calcium 
sensing receptor function in human colon carcinomas: promotion of E-
cadherin expression and suppression of beta-catenin/TCF activation." Cancer 
Res 63(1): 67-71. 
Chan, A. T., S. Ogino, et al. (2007). "Aspirin and the risk of colorectal cancer in 
relation to the expression of COX-2." N Engl J Med 356(21): 2131-42. 
Chan, S. K., O. L. Griffith, et al. (2008). "Meta-analysis of colorectal cancer gene 
expression profiling studies identifies consistently reported candidate 
biomarkers." Cancer Epidemiol Biomarkers Prev 17(3): 543-52. 
Charalampopoulos, A., A. Charalabopoulos, et al. (2010). "Parathormone and 
1,25(OH)(2)D (3) but not 25(OH)D (3) serum levels, in an inverse correlation, 
reveal an association with advanced stages of colorectal cancer." Clin Exp 
Med 10(1): 69-72. 
 282 
Chen, Y., Y. Z. Zhang, et al. (2006). "Identification of differently expressed genes in 
human colorectal adenocarcinoma." World J Gastroenterol 12(7): 1025-32. 
Cho, E., S. A. Smith-Warner, et al. (2004). "Dairy foods, calcium, and colorectal 
cancer: a pooled analysis of 10 cohort studies." J Natl Cancer Inst 96(13): 
1015-22. 
Citarda, F., G. Tomaselli, et al. (2001). "Efficacy in standard clinical practice of 
colonoscopic polypectomy in reducing colorectal cancer incidence." Gut 
48(6): 812-5. 
Clark, J. C., Y. Collan, et al. (1985). "Prevalence of polyps in an autopsy series from 
areas with varying incidence of large-bowel cancer." Int J Cancer 36(2): 179-
86. 
Clemens, T. L., S. Cormier, et al. (2001). "Parathyroid hormone-related protein and its 
receptors: nuclear functions and roles in the renal and cardiovascular systems, 
the placental trophoblasts and the pancreatic islets." Br J Pharmacol 134(6): 
1113-36. 
Cole, B. F., J. A. Baron, et al. (2007). "Folic acid for the prevention of colorectal 
adenomas: a randomized clinical trial." JAMA 297(21): 2351-9. 
Cole, B. F., R. F. Logan, et al. (2009). "Aspirin for the chemoprevention of colorectal 
adenomas: meta-analysis of the randomized trials." J Natl Cancer Inst 101(4): 
256-66. 
Croner, R. S., T. Foertsch, et al. (2005). "Common denominator genes that distinguish 
colorectal carcinoma from normal mucosa." Int J Colorectal Dis 20(4): 353-
62. 
Crosnier, C., D. Stamataki, et al. (2006). "Organizing cell renewal in the intestine: 
stem cells, signals and combinatorial control." Nat Rev Genet 7(5): 349-59. 
Cuilliere-Dartigues, P., J. El-Bchiri, et al. (2006). "TCF-4 isoforms absent in TCF-4 
mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and 
repress TCF-4-mediated transcription." Oncogene 25(32): 4441-8. 
Cunningham, D., W. Atkin, et al. (2010). "Colorectal cancer." Lancet 375(9719): 
1030-47. 
Cuzick, J., F. Otto, et al. (2009). "Aspirin and non-steroidal anti-inflammatory drugs 
for cancer prevention: an international consensus statement." Lancet Oncol 
10(5): 501-7. 
Damstrup, L., S. K. Kuwada, et al. (1999). "Amphiregulin acts as an autocrine growth 
factor in two human polarizing colon cancer lines that exhibit domain selective 
EGF receptor mitogenesis." Br J Cancer 80(7): 1012-9. 
Davies, R. J., R. Miller, et al. (2005). "Colorectal cancer screening: prospects for 
molecular stool analysis." Nat Rev Cancer 5(3): 199-209. 
de la Serna, I. L., Y. Ohkawa, et al. (2005). "MyoD targets chromatin remodeling 
complexes to the myogenin locus prior to forming a stable DNA-bound 
complex." Mol Cell Biol 25(10): 3997-4009. 
Deal, C. (2004). "The use of intermittent human parathyroid hormone as a treatment 
for osteoporosis." Curr Rheumatol Rep 6(1): 49-58. 
DeBiasi, R. L., P. Clarke, et al. (2003). "Reovirus-induced alteration in expression of 
apoptosis and DNA repair genes with potential roles in viral pathogenesis." J 
Virol 77(16): 8934-47. 
Dehner, M., M. Hadjihannas, et al. (2008). "Wnt signaling inhibits Forkhead box 
O3a-induced transcription and apoptosis through up-regulation of serum- and 
glucocorticoid-inducible kinase 1." J Biol Chem 283(28): 19201-10. 
 283 
Dennis, G., Jr., B. T. Sherman, et al. (2003). "DAVID: Database for Annotation, 
Visualization, and Integrated Discovery." Genome Biol 4(5): P3. 
Dittmer, A., M. Vetter, et al. (2006). "Parathyroid hormone-related protein regulates 
tumor-relevant genes in breast cancer cells." J Biol Chem 281(21): 14563-72. 
Doll, R. and R. Peto (1981). "The causes of cancer: quantitative estimates of 
avoidable risks of cancer in the United States today." J Natl Cancer Inst 66(6): 
1191-308. 
Dove-Edwin, I., P. Sasieni, et al. (2005). "Prevention of colorectal cancer by 
colonoscopic surveillance in individuals with a family history of colorectal 
cancer: 16 year, prospective, follow-up study." BMJ 331(7524): 1047. 
Downey, S. E., J. Hoyland, et al. (1997). "Expression of the receptor for parathyroid 
hormone-related protein in normal and malignant breast tissue." J Pathol 
183(2): 212-7. 
Dukes, C. (1932). "The classifi cation of cancer of the rectum." J Pathol Bacteriol(35): 
323-332. 
Dunlop, M. G. (2002). "Guidance on gastrointestinal surveillance for hereditary non-
polyposis colorectal cancer, familial adenomatous polypolis, juvenile 
polyposis, and Peutz-Jeghers syndrome." Gut 51 Suppl 5: V21-7. 
Dunlop, M. G. (2002). "Guidance on large bowel surveillance for people with two 
first degree relatives with colorectal cancer or one first degree relative 
diagnosed with colorectal cancer under 45 years." Gut 51 Suppl 5: V17-20. 
Dunlop, M. G., S. M. Farrington, et al. (1997). "Cancer risk associated with germline 
DNA mismatch repair gene mutations." Hum Mol Genet 6(1): 105-10. 
Eaden, J. A., K. R. Abrams, et al. (2001). "The risk of colorectal cancer in ulcerative 
colitis: a meta-analysis." Gut 48(4): 526-35. 
Eberhart, C. E., R. J. Coffey, et al. (1994). "Up-regulation of cyclooxygenase 2 gene 
expression in human colorectal adenomas and adenocarcinomas." 
Gastroenterology 107(4): 1183-8. 
Edwards, B. K., H. L. Howe, et al. (2002). "Annual report to the nation on the status 
of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer 
burden." Cancer 94(10): 2766-92. 
Evliyaoglu, C., R. Carroll, et al. (2000). "Parathyroid hormone-related protein and its 
receptor in human glial tumors." Acta Neurochir (Wien) 142(8): 871-8. 
Falt, S., M. Merup, et al. (2005). "Distinctive gene expression pattern in VH3-21 
utilizing B-cell chronic lymphocytic leukemia." Blood 106(2): 681-9. 
Fan, C., D. Sheu, et al. (2001). "Down-regulation of matrix Gla protein messenger 
RNA in human colorectal adenocarcinomas." Cancer Lett 165(1): 63-9. 
Fan, C. W., C. C. Chan, et al. (2004). "Expression patterns of cell cycle and apoptosis-
related genes in a multidrug-resistant human colon carcinoma cell line." Scand 
J Gastroenterol 39(5): 464-9. 
Fearon, E. R. and B. Vogelstein (1990). "A genetic model for colorectal 
tumorigenesis." Cell 61(5): 759-67. 
Fedirko, V., R. M. Bostick, et al. (2009). "Effects of vitamin D and calcium 
supplementation on markers of apoptosis in normal colon mucosa: a 
randomized, double-blind, placebo-controlled clinical trial." Cancer Prev Res 
(Phila) 2(3): 213-23. 
Fedirko, V., R. M. Bostick, et al. (2009). "Effects of vitamin d and calcium on 
proliferation and differentiation in normal colon mucosa: a randomized 
clinical trial." Cancer Epidemiol Biomarkers Prev 18(11): 2933-41. 
 284 
Fedirko, V., E. Riboli, et al. (2010). "Pre-diagnostic circulating parathyroid hormone 
concentration and colorectal cancer in the European Prospective Investigation 
into Cancer and Nutrition (EPIC) cohort." Eur J Cancer supplements 8(5): 16. 
Ferguson, J. E., 2nd, R. M. Seaner, et al. (1998). "Expression and specific 
immunolocalization of the human parathyroid hormone/parathyroid hormone-
related protein receptor in the uteroplacental unit." Am J Obstet Gynecol 
179(2): 321-9. 
Feskanich, D., J. Ma, et al. (2004). "Plasma vitamin D metabolites and risk of 
colorectal cancer in women." Cancer Epidemiol Biomarkers Prev 13(9): 1502-
8. 
Fevr, T., S. Robine, et al. (2007). "Wnt/beta-catenin is essential for intestinal 
homeostasis and maintenance of intestinal stem cells." Mol Cell Biol 27(21): 
7551-9. 
Fierabracci, P., A. Pinchera, et al. (2001). "Increased prevalence of primary 
hyperparathyroidism in treated breast cancer." J Endocrinol Invest 24(5): 315-
20. 
Flechner, S. M., S. M. Kurian, et al. (2004). "Kidney transplant rejection and tissue 
injury by gene profiling of biopsies and peripheral blood lymphocytes." Am J 
Transplant 4(9): 1475-89. 
Flossmann, E. and P. M. Rothwell (2007). "Effect of aspirin on long-term risk of 
colorectal cancer: consistent evidence from randomised and observational 
studies." Lancet 369(9573): 1603-13. 
Foley, J., B. J. Longely, et al. (1998). "PTHrP regulates epidermal differentiation in 
adult mice." J Invest Dermatol 111(6): 1122-8. 
Fortunel, N. O., H. H. Otu, et al. (2003). "Comment on " 'Stemness': transcriptional 
profiling of embryonic and adult stem cells" and "a stem cell molecular 
signature"." Science 302(5644): 393; author reply 393. 
Friederichs, J., R. Rosenberg, et al. (2005). "Gene expression profiles of different 
clinical stages of colorectal carcinoma: toward a molecular genetic 
understanding of tumor progression." Int J Colorectal Dis 20(5): 391-402. 
Fritzmann, J., M. Morkel, et al. (2009). "A colorectal cancer expression profile that 
includes transforming growth factor beta inhibitor BAMBI predicts metastatic 
potential." Gastroenterology 137(1): 165-75. 
Garland, C. F., G. W. Comstock, et al. (1989). "Serum 25-hydroxyvitamin D and 
colon cancer: eight-year prospective study." Lancet 2(8673): 1176-8. 
Garland, C. F. and F. C. Garland (1980). "Do sunlight and vitamin D reduce the 
likelihood of colon cancer?" Int J Epidemiol 9(3): 227-31. 
Gaspar, C., J. Cardoso, et al. (2008). "Cross-species comparison of human and mouse 
intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli 
(APC)-driven tumorigenesis." Am J Pathol 172(5): 1363-80. 
Gay, F., Y. Estornes, et al. (2008). "In colon carcinogenesis, the cytoskeletal protein 
gelsolin is down-regulated during the transition from adenoma to carcinoma." 
Hum Pathol 39(10): 1420-30. 
Gensure, R. C., T. J. Gardella, et al. (2005). "Parathyroid hormone and parathyroid 
hormone-related peptide, and their receptors." Biochem Biophys Res Commun 
328(3): 666-78. 
Gentile, M., L. Latonen, et al. (2003). "Cell cycle arrest and apoptosis provoked by 
UV radiation-induced DNA damage are transcriptionally highly divergent 
responses." Nucleic Acids Res 31(16): 4779-90. 
 285 
Gentili, C., R. Boland, et al. (2001). "PTH stimulates PLCbeta and PLCgamma 
isoenzymes in rat enterocytes: influence of ageing." Cell Signal 13(2): 131-8. 
Gentili, C., S. Morelli, et al. (2001). "Parathyroid hormone activation of map kinase in 
rat duodenal cells is mediated by 3',5'-cyclic AMP and Ca(2+)." Biochim 
Biophys Acta 1540(3): 201-12. 
Giacomini, C. P., S. Y. Leung, et al. (2005). "A gene expression signature of genetic 
instability in colon cancer." Cancer Res 65(20): 9200-5. 
Glebov, O. K., L. M. Rodriguez, et al. (2006). "Celecoxib treatment alters the gene 
expression profile of normal colonic mucosa." Cancer Epidemiol Biomarkers 
Prev 15(7): 1382-91. 
Goldrath, A. W., C. J. Luckey, et al. (2004). "The molecular program induced in T 
cells undergoing homeostatic proliferation." Proc Natl Acad Sci U S A 
101(48): 16885-90. 
Gonzalez-Sancho, J. M., O. Aguilera, et al. (2005). "The Wnt antagonist DICKKOPF-
1 gene is a downstream target of beta-catenin/TCF and is downregulated in 
human colon cancer." Oncogene 24(6): 1098-103. 
Gorham, E. D., C. F. Garland, et al. (2007). "Optimal vitamin D status for colorectal 
cancer prevention: a quantitative meta analysis." Am J Prev Med 32(3): 210-6. 
Grade, M., P. Hormann, et al. (2007). "Gene expression profiling reveals a massive, 
aneuploidy-dependent transcriptional deregulation and distinct differences 
between lymph node-negative and lymph node-positive colon carcinomas." 
Cancer Res 67(1): 41-56. 
Grant, W. B. (2002). "An estimate of premature cancer mortality in the U.S. due to 
inadequate doses of solar ultraviolet-B radiation." Cancer 94(6): 1867-75. 
Grant, W. B. (2009). "How strong is the evidence that solar ultraviolet B and vitamin 
D reduce the risk of cancer?: An examination using Hill's criteria for 
causality." Dermatoendocrinol 1(1): 17-24. 
Grant, W. B. (2010). "Relation between prediagnostic serum 25-hydroxyvitamin D 
level and incidence of breast, colorectal, and other cancers." J Photochem 
Photobiol B 101(2): 130-6. 
Grau, M. V., J. A. Baron, et al. (2003). "Vitamin D, calcium supplementation, and 
colorectal adenomas: results of a randomized trial." J Natl Cancer Inst 95(23): 
1765-71. 
Grau, M. V., J. A. Baron, et al. (2007). "Prolonged effect of calcium supplementation 
on risk of colorectal adenomas in a randomized trial." J Natl Cancer Inst 99(2): 
129-36. 
Gregoire, R. C., H. S. Stern, et al. (1989). "Effect of calcium supplementation on 
mucosal cell proliferation in high risk patients for colon cancer." Gut 30(3): 
376-82. 
Gregorieff, A., D. Pinto, et al. (2005). "Expression pattern of Wnt signaling 
components in the adult intestine." Gastroenterology 129(2): 626-38. 
Groene, J., U. Mansmann, et al. (2006). "Transcriptional census of 36 microdissected 
colorectal cancers yields a gene signature to distinguish UICC II and III." Int J 
Cancer 119(8): 1829-36. 
Guo, J. M., H. L. Chen, et al. (2004). "Expression of UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase-12 in gastric and colonic cancer cell lines and 
in human colorectal cancer." Oncology 67(3-4): 271-6. 
Gupta, N., P. M. Martin, et al. (2006). "Down-regulation of BCRP/ABCG2 in 
colorectal and cervical cancer." Biochemical and Biophysical Research 
Communications 343(2): 571-577. 
 286 
Gupta, N., S. Miyauchi, et al. (2005). "Upregulation of the amino acid transporter 
ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans." Biochim 
Biophys Acta 1741(1-2): 215-23. 
Habener, J. F., M. Rosenblatt, et al. (1984). "Parathyroid hormone: biochemical 
aspects of biosynthesis, secretion, action, and metabolism." Physiol Rev 64(3): 
985-1053. 
Hardcastle, J. D., J. O. Chamberlain, et al. (1996). "Randomised controlled trial of 
faecal-occult-blood screening for colorectal cancer." Lancet 348(9040): 1472-
7. 
Hashida, H., A. Takabayashi, et al. (2003). "Clinical significance of transmembrane 4 
superfamily in colon cancer." Br J Cancer 89(1): 158-67. 
He, T. C., A. B. Sparks, et al. (1998). "Identification of c-MYC as a target of the APC 
pathway." Science 281(5382): 1509-12. 
Heaney, R. P. (2004). "Functional indices of vitamin D status and ramifications of 
vitamin D deficiency." Am J Clin Nutr 80(6 Suppl): 1706S-9S. 
Heaney, R. P., M. S. Dowell, et al. (2003). "Calcium absorption varies within the 
reference range for serum 25-hydroxyvitamin D." J Am Coll Nutr 22(2): 142-
6. 
Hill, A. B. (1965). "The Environment and Disease: Association or Causation?" Proc R 
Soc Med 58: 295-300. 
Hlubek, F., T. Brabletz, et al. (2007). "Heterogeneous expression of Wnt/beta-catenin 
target genes within colorectal cancer." Int J Cancer 121(9): 1941-8. 
Hoey, R. P., C. Sanderson, et al. (2003). "The parathyroid hormone-related protein 
receptor is expressed in breast cancer bone metastases and promotes autocrine 
proliferation in breast carcinoma cells." Br J Cancer 88(4): 567-73. 
Holt, P. R., E. O. Atillasoy, et al. (1998). "Modulation of abnormal colonic epithelial 
cell proliferation and differentiation by low-fat dairy foods: a randomized 
controlled trial." JAMA 280(12): 1074-9. 
Holt, P. R., R. S. Bresalier, et al. (2006). "Calcium plus vitamin D alters preneoplastic 
features of colorectal adenomas and rectal mucosa." Cancer 106(2): 287-96. 
Holt, P. R., C. Wolper, et al. (2001). "Comparison of calcium supplementation or low-
fat dairy foods on epithelial cell proliferation and differentiation." Nutr Cancer 
41(1-2): 150-5. 
Hoogendam, J., H. Farih-Sips, et al. (2007). "Novel late response genes of PTHrP in 
chondrocytes." Horm Res 67(4): 159-70. 
Huang da, W., B. T. Sherman, et al. (2009). "Systematic and integrative analysis of 
large gene lists using DAVID bioinformatics resources." Nat Protoc 4(1): 44-
57. 
Humphries, A. and N. A. Wright (2008). "Colonic crypt organization and 
tumorigenesis." Nat Rev Cancer 8(6): 415-24. 
Ieta, K., F. Tanaka, et al. (2008). "Biological and genetic characteristics of tumor-
initiating cells in colon cancer." Ann Surg Oncol 15(2): 638-48. 
Irizarry, R. A., B. M. Bolstad, et al. (2003). "Summaries of Affymetrix GeneChip 
probe level data." Nucleic Acids Res 31(4): e15. 
Irvin, G. L., 3rd and D. M. Carneiro (2000). "Management changes in primary 
hyperparathyroidism." JAMA 284(8): 934-6. 
Iseki, K., A. Osawa, et al. (1993). "Evidence for increased cancer deaths in chronic 
dialysis patients." Am J Kidney Dis 22(2): 308-13. 
 287 
Ishitani, T., J. Ninomiya-Tsuji, et al. (1999). "The TAK1-NLK-MAPK-related 
pathway antagonizes signalling between beta-catenin and transcription factor 
TCF." Nature 399(6738): 798-802. 
Ivanova, N. B., J. T. Dimos, et al. (2002). "A stem cell molecular signature." Science 
298(5593): 601-4. 
Jacobs, E. T., D. S. Alberts, et al. (2007). "Serum 25(OH)D levels, dietary intake of 
vitamin D, and colorectal adenoma recurrence." J Steroid Biochem Mol Biol 
103(3-5): 752-6. 
Jarvinen, H. J., M. Aarnio, et al. (2000). "Controlled 15-year trial on screening for 
colorectal cancer in families with hereditary nonpolyposis colorectal cancer." 
Gastroenterology 118(5): 829-34. 
Jeffery, I. B., D. G. Higgins, et al. (2006). "Comparison and evaluation of methods for 
generating differentially expressed gene lists from microarray data." BMC 
Bioinformatics 7: 359. 
Jorde, R., K. H. Bonaa, et al. (1999). "Population based study on serum ionised 
calcium, serum parathyroid hormone, and blood pressure. The Tromso study." 
Eur J Endocrinol 141(4): 350-7. 
Jorde, R., F. Saleh, et al. (2005). "Serum parathyroid hormone (PTH) levels in 
smokers and non-smokers. The fifth Tromso study." Eur J Endocrinol 152(1): 
39-45. 
Juppner, H., A. B. Abou-Samra, et al. (1991). "A G protein-linked receptor for 
parathyroid hormone and parathyroid hormone-related peptide." Science 
254(5034): 1024-6. 
Kaab, S., A. S. Barth, et al. (2004). "Global gene expression in human myocardium-
oligonucleotide microarray analysis of regional diversity and transcriptional 
regulation in heart failure." J Mol Med 82(5): 308-16. 
Kamycheva, E., J. Sundsfjord, et al. (2004). "Serum parathyroid hormone level is 
associated with body mass index. The 5th Tromso study." Eur J Endocrinol 
151(2): 167-72. 
Kanehisa, M., S. Goto, et al. (2009). "KEGG for representation and analysis of 
molecular networks involving diseases and drugs." Nucleic Acids Res. 
Kang, S. K., L. Putnam, et al. (2004). "Expression of telomerase extends the lifespan 
and enhances osteogenic differentiation of adipose tissue-derived stromal 
cells." Stem Cells 22(7): 1356-72. 
Karaplis, A. C. and D. Goltzman (2000). "PTH and PTHrP effects on the skeleton." 
Rev Endocr Metab Disord 1(4): 331-41. 
Karlsson, R., E. D. Pedersen, et al. (2009). "Rho GTPase function in tumorigenesis." 
Biochim Biophys Acta 1796(2): 91-8. 
Karsa, L. V., T. A. Lignini, et al. (2010). "The dimensions of the CRC problem." Best 
Pract Res Clin Gastroenterol 24(4): 381-96. 
Keku, T. O., A. Amin, et al. (2008). "Apoptosis in normal rectal mucosa, baseline 
adenoma characteristics, and risk of future adenomas." Cancer Epidemiol 
Biomarkers Prev 17(2): 306-10. 
Kim, H. K., I. J. Choi, et al. (2004). "DNA microarray analysis of the correlation 
between gene expression patterns and acquired resistance to 5-FU/cisplatin in 
gastric cancer." Biochem Biophys Res Commun 316(3): 781-9. 
Kim, K., U. Park, et al. (2008). "Gene profiling of colonic serrated adenomas by using 
oligonucleotide microarray." Int J Colorectal Dis 23(6): 569-80. 
Kimlin, M. G. (2004). "The climatology of Vitamin D producing ultraviolet radiation 
over the United States." J Steroid Biochem Mol Biol 89-90(1-5): 479-83. 
 288 
Kinzler, K. W. and B. Vogelstein (1996). "Lessons from hereditary colorectal cancer." 
Cell 87(2): 159-70. 
Kita, H., Y. Hikichi, et al. (2006). "Differential gene expression between flat adenoma 
and normal mucosa in the colon in a microarray analysis." J Gastroenterol 
41(11): 1053-63. 
Kitahara, O., Y. Furukawa, et al. (2001). "Alterations of Gene Expression during 
Colorectal Carcinogenesis Revealed by cDNA Microarrays after Laser-
Capture Microdissection of Tumor Tissues and Normal Epithelia." Cancer Res 
61(9): 3544-3549. 
Kleivi, K., G. E. Lind, et al. (2007). "Gene expression profiles of primary colorectal 
carcinomas, liver metastases, and carcinomatoses." Mol Cancer 6: 2. 
Koehler, A., F. Bataille, et al. (2004). "Gene expression profiling of colorectal cancer 
and metastases divides tumours according to their clinicopathological stage." J 
Pathol 204(1): 65-74. 
Korinek, V., N. Barker, et al. (1998). "Depletion of epithelial stem-cell compartments 
in the small intestine of mice lacking Tcf-4." Nat Genet 19(4): 379-83. 
Korinek, V., N. Barker, et al. (1997). "Constitutive transcriptional activation by a 
beta-catenin-Tcf complex in APC-/- colon carcinoma." Science 275(5307): 
1784-7. 
Koshiji, M., K. Kumamoto, et al. (2007). "Correlation of N-myc downstream-
regulated gene 1 expression with clinical outcomes of colorectal cancer 
patients of different race/ethnicity." World J Gastroenterol 13(20): 2803-10. 
Kosinski, C., V. S. Li, et al. (2007). "Gene expression patterns of human colon tops 
and basal crypts and BMP antagonists as intestinal stem cell niche factors." 
Proc Natl Acad Sci U S A 104(39): 15418-23. 
Kosinski, C., D. E. Stange, et al. (2010). "Indian hedgehog regulates intestinal stem 
cell fate through epithelial-mesenchymal interactions during development." 
Gastroenterology 139(3): 893-903. 
Krajewska, M., S. F. Moss, et al. (1996). "Elevated Expression of Bcl-X and Reduced 
Bak in Primary Colorectal Adenocarcinomas." Cancer Res 56(10): 2422-2427. 
Kronborg, O., C. Fenger, et al. (1996). "Randomised study of screening for colorectal 
cancer with faecal-occult-blood test." Lancet 348(9040): 1467-71. 
Kulkarni, N. H., D. L. Halladay, et al. (2005). "Effects of parathyroid hormone on 
Wnt signaling pathway in bone." J Cell Biochem 95(6): 1178-90. 
Kuninger, D., R. Kuzmickas, et al. (2004). "Gene discovery by microarray: 
identification of novel genes induced during growth factor-mediated muscle 
cell survival and differentiation." Genomics 84(5): 876-89. 
Lane, D. P. (1992). "Cancer. p53, guardian of the genome." Nature 358(6381): 15-6. 
Lans, J. I., R. Jaszewski, et al. (1991). "Supplemental calcium suppresses colonic 
mucosal ornithine decarboxylase activity in elderly patients with adenomatous 
polyps." Cancer Res 51(13): 3416-9. 
Lanske, B., P. Divieti, et al. (1998). "The parathyroid hormone (PTH)/PTH-related 
peptide receptor mediates actions of both ligands in murine bone." 
Endocrinology 139(12): 5194-204. 
Lanske, B., A. C. Karaplis, et al. (1996). "PTH/PTHrP receptor in early development 
and Indian hedgehog-regulated bone growth." Science 273(5275): 663-6. 
Lappe, J. M., D. Travers-Gustafson, et al. (2007). "Vitamin D and calcium 
supplementation reduces cancer risk: results of a randomized trial." Am J Clin 
Nutr 85(6): 1586-91. 
 289 
Lee, J. T., T. J. Lee, et al. (2009). "Over-expression of Reticulon 3 (RTN3) enhances 
TRAIL-mediated apoptosis via up-regulation of death receptor 5 (DR5) and 
down-regulation of c-FLIP." Cancer Lett 279(2): 185-92. 
Lee, S., S. Bang, et al. (2006). "Differential expression in normal-adenoma-carcinoma 
sequence suggests complex molecular carcinogenesis in colon." Oncol Rep 
16(4): 747-54. 
Lepourcelet, M., L. Tou, et al. (2005). "Insights into developmental mechanisms and 
cancers in the mammalian intestine derived from serial analysis of gene 
expression and study of the hepatoma-derived growth factor (HDGF)." 
Development 132(2): 415-27. 
Leslie, A., F. A. Carey, et al. (2002). "The colorectal adenoma-carcinoma sequence." 
Br J Surg 89(7): 845-60. 
Levine, A. J., J. M. Harper, et al. (2001). "Serum 25-hydroxyvitamin D, dietary 
calcium intake, and distal colorectal adenoma risk." Nutr Cancer 39(1): 35-41. 
Levine, J. S. and D. J. Ahnen (2006). "Clinical practice. Adenomatous polyps of the 
colon." N Engl J Med 355(24): 2551-7. 
Li, H., P. K. Seitz, et al. (1995). "Widespread expression of the parathyroid hormone-
related peptide and PTH/PTHrP receptor genes in intestinal epithelial cells." 
Lab Invest 73(6): 864-70. 
Li, X., H. Liu, et al. (2007). "Determination of dual effects of parathyroid hormone on 
skeletal gene expression in vivo by microarray and network analysis." J Biol 
Chem 282(45): 33086-97. 
Li, X., B. B. Madison, et al. (2007). "Deconvoluting the intestine: molecular evidence 
for a major role of the mesenchyme in the modulation of signaling cross talk." 
Physiol Genomics 29(3): 290-301. 
Lin, J., S. M. Zhang, et al. (2004). "Body mass index and risk of colorectal cancer in 
women (United States)." Cancer Causes Control 15(6): 581-9. 
Lin YM, F. Y., Tsunoda T, Yue CT, Yang KC, Nakamura Y. (2002). "Molecular 
diagnosis of colorectal tumors by expression profiles of 50 genes expressed 
differentially in adenomas and carcinomas." Oncogene 21(26): 4120-4128. 
Linforth, R., N. Anderson, et al. (2002). "Coexpression of parathyroid hormone 
related protein and its receptor in early breast cancer predicts poor patient 
survival." Clin Cancer Res 8(10): 3172-7. 
Lips, P. (2001). "Vitamin D deficiency and secondary hyperparathyroidism in the 
elderly: consequences for bone loss and fractures and therapeutic 
implications." Endocr Rev 22(4): 477-501. 
Liu, A., G. J. Cerniglia, et al. (2001). "RhoB is required to mediate apoptosis in 
neoplastically transformed cells after DNA damage." Proc Natl Acad Sci U S 
A 98(11): 6192-7. 
Lockhart-Mummery, J. P. and C. Dukes (1928). "The precancerous changes in the 
rectum and colon." Surg Gynecol Obstet 46(5): 591-596. 
Loeve, F., R. Boer, et al. (2004). "National Polyp Study data: evidence for regression 
of adenomas." Int J Cancer 111(4): 633-9. 
Logan, R. F., M. J. Grainge, et al. (2008). "Aspirin and folic acid for the prevention of 
recurrent colorectal adenomas." Gastroenterology 134(1): 29-38. 
Lotfi, A. M., R. J. Spencer, et al. (1986). "Colorectal polyps and the risk of 
subsequent carcinoma." Mayo Clin Proc 61(5): 337-43. 
Lü, B., J. Xu, et al. (2008). "TaqMan low density array is roughly right for gene 
expression quantification in colorectal cancer." Clinica Chimica Acta 389(1-
2): 146-151. 
 290 
Lupp, A., C. Klenk, et al. (2010). "Immunohistochemical identification of the PTHR1 
parathyroid hormone receptor in normal and neoplastic human tissues." Eur J 
Endocrinol 162(5): 979-86. 
Lupton, J. R., G. Steinbach, et al. (1996). "Calcium supplementation modifies the 
relative amounts of bile acids in bile and affects key aspects of human colon 
physiology." J Nutr 126(5): 1421-8. 
Macdonald, H. M., A. Mavroeidi, et al. "Sunlight and dietary contributions to the 
seasonal vitamin D status of cohorts of healthy postmenopausal women living 
at northerly latitudes: a major cause for concern?" Osteoporos Int. 
Malabanan, A., I. E. Veronikis, et al. (1998). "Redefining vitamin D insufficiency." 
Lancet 351(9105): 805-6. 
Mandel, J. S., T. R. Church, et al. (2000). "The effect of fecal occult-blood screening 
on the incidence of colorectal cancer." N Engl J Med 343(22): 1603-7. 
Mandel, J. S., T. R. Church, et al. (1999). "Colorectal cancer mortality: effectiveness 
of biennial screening for fecal occult blood." J Natl Cancer Inst 91(5): 434-7. 
Mariadason, J. M., M. Bordonaro, et al. (2001). "Down-regulation of beta-catenin 
TCF signaling is linked to colonic epithelial cell differentiation." Cancer Res 
61(8): 3465-71. 
Martinez, C., S. Bhattacharya, et al. (2005). "Expression profiling of murine intestinal 
adenomas reveals early deregulation of multiple matrix metalloproteinase 
(Mmp) genes." J Pathol 206(1): 100-10. 
Martinez, M. E., J. R. Marshall, et al. (2008). "Diet and cancer prevention: the roles of 
observation and experimentation." Nat Rev Cancer. 
Martinez, N., M. Sanchez-Beato, et al. (2005). "Transcriptional signature of 
Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted 
from chemo-naive patients." Mol Cancer Ther 4(5): 814-23. 
Massfelder, T., H. Lang, et al. (2004). "Parathyroid hormone-related protein is an 
essential growth factor for human clear cell renal carcinoma and a target for 
the von Hippel-Lindau tumor suppressor gene." Cancer Res 64(1): 180-8. 
Matusiak, D., G. Murillo, et al. (2005). "Expression of vitamin D receptor and 25-
hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human 
colon." Cancer Epidemiol Biomarkers Prev 14(10): 2370-6. 
McArdle, C. S. and D. J. Hole (2002). "Outcome following surgery for colorectal 
cancer." Br Med Bull 64: 119-25. 
McCashland, T. M., R. Brand, et al. (2001). "Gender differences in colorectal polyps 
and tumors." Am J Gastroenterol 96(3): 882-6. 
Michaud, J., J. Naud, et al. (2006). "Role of parathyroid hormone in the 
downregulation of liver cytochrome P450 in chronic renal failure." J Am Soc 
Nephrol 17(11): 3041-8. 
Michels, K. B., F. Xue, et al. (2004). "Hyperparathyroidism and subsequent incidence 
of breast cancer." Int J Cancer 110(3): 449-51. 
Miller, E. A., T. O. Keku, et al. (2005). "Calcium, vitamin D, and apoptosis in the 
rectal epithelium." Cancer Epidemiol Biomarkers Prev 14(2): 525-8. 
Miller, E. A., T. O. Keku, et al. (2007). "Calcium, dietary, and lifestyle factors in the 
prevention of colorectal adenomas." Cancer 109(3): 510-7. 
Mithal, A., D. A. Wahl, et al. (2009). "Global vitamin D status and determinants of 
hypovitaminosis D." Osteoporos Int 20(11): 1807-20. 
Mootha, V. K., C. M. Lindgren, et al. (2003). "PGC-1alpha-responsive genes involved 
in oxidative phosphorylation are coordinately downregulated in human 
diabetes." Nat Genet 34(3): 267-73. 
 291 
Moreaux, J., F. W. Cremer, et al. (2005). "The level of TACI gene expression in 
myeloma cells is associated with a signature of microenvironment dependence 
versus a plasmablastic signature." Blood 106(3): 1021-30. 
Morin, P. J., A. B. Sparks, et al. (1997). "Activation of beta-catenin-Tcf signaling in 
colon cancer by mutations in beta-catenin or APC." Science 275(5307): 1787-
90. 
Murray, R. M., V. Grill, et al. (2001). "Hypocalcemic and normocalcemic 
hyperparathyroidism in patients with advanced prostatic cancer." J Clin 
Endocrinol Metab 86(9): 4133-8. 
Muto, T., H. J. Bussey, et al. (1975). "The evolution of cancer of the colon and 
rectum." Cancer 36(6): 2251-70. 
N Ancona, R. M., A Piepoli, A D'Addabbo, R Cotugno, M Savino, and M. C. S Liuni, 
G Pesole and F Perri (2006). "On the statistical assessment of classifiers using 
DNA microarray 
data." BMC Bioinformatics 7: 387. 
Need, A. G., P. D. O'Loughlin, et al. (2004). "The effects of age and other variables 
on serum parathyroid hormone in postmenopausal women attending an 
osteoporosis center." J Clin Endocrinol Metab 89(4): 1646-9. 
Neef, R., M. A. Kuske, et al. (2002). "Identification of the human PHLDA1/TDAG51 
gene: down-regulation in metastatic melanoma contributes to apoptosis 
resistance and growth deregulation." Cancer Res 62(20): 5920-9. 
Neugut, A. I., C. M. Johnsen, et al. (1985). "Recurrence rates for colorectal polyps." 
Cancer 55(7): 1586-9. 
Newmark, H. L., K. Yang, et al. (2009). "Western-style diet-induced colonic tumors 
and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical 
model for human sporadic colon cancer." Carcinogenesis 30(1): 88-92. 
Nikola A. Bowden, A. C., Rodney J. Scott (2007). "Gene Expression Profiling in 
Familial Adenomatous Polyposis Adenomas and Desmoid Disease." 
Hereditary Cancer in Clinical Practice 5(2): 79-96. 
Nilsson, I. L., J. Zedenius, et al. (2007). "The association between primary 
hyperparathyroidism and malignancy: nationwide cohort analysis on cancer 
incidence after parathyroidectomy." Endocr Relat Cancer 14(1): 135-40. 
Nishihara, M., M. Ito, et al. (1999). "Clinicopathological implications of parathyroid 
hormone-related protein in human colorectal tumours." J Pathol 187(2): 217-
22. 
Niv, Y., A. D. Sperber, et al. (1999). "In colorectal carcinoma patients, serum vitamin 
D levels vary according to stage of the carcinoma." Cancer 86(3): 391-7. 
Nobre-Leitao, C., P. Chaves, et al. (1995). "Calcium regulation of colonic crypt cell 
kinetics: evidence for a direct effect in mice." Gastroenterology 109(2): 498-
504. 
Nosho, K., H. Yamamoto, et al. (2005). "Gene expression profiling of colorectal 
adenomas and early invasive carcinomas by cDNA array analysis." Br J 
Cancer 92(7): 1193-200. 
Notterman, D. A., U. Alon, et al. (2001). "Transcriptional gene expression profiles of 
colorectal adenoma, adenocarcinoma, and normal tissue examined by 
oligonucleotide arrays." Cancer Res 61(7): 3124-30. 
Nouzova, M., N. Holtan, et al. (2004). "Epigenomic changes during leukemia cell 
differentiation: analysis of histone acetylation and cytosine methylation using 
CpG island microarrays." J Pharmacol Exp Ther 311(3): 968-81. 
 292 
Onyia, J. E., L. M. Helvering, et al. (2005). "Molecular profile of catabolic versus 
anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an 
analysis by DNA microarray." J Cell Biochem 95(2): 403-18. 
Palmer, H. G., M. Sanchez-Carbayo, et al. (2003). "Genetic signatures of 
differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon 
cancer cells." Cancer Res 63(22): 7799-806. 
Palmer, M., H. O. Adami, et al. (1988). "Increased risk of malignant diseases after 
surgery for primary hyperparathyroidism. A nationwide cohort study." Am J 
Epidemiol 127(5): 1031-40. 
Palmieri, C., T. MacGregor, et al. (2006). "Serum 25-hydroxyvitamin D levels in 
early and advanced breast cancer." J Clin Pathol 59(12): 1334-6. 
Pasco, J. A., M. J. Henry, et al. (2004). "Seasonal periodicity of serum vitamin D and 
parathyroid hormone, bone resorption, and fractures: the Geelong 
Osteoporosis Study." J Bone Miner Res 19(5): 752-8. 
Pence, B. C. and F. Buddingh (1988). "Inhibition of dietary fat-promoted colon 
carcinogenesis in rats by supplemental calcium or vitamin D3." 
Carcinogenesis 9(1): 187-90. 
Peters, U., R. B. Hayes, et al. (2004). "Circulating vitamin D metabolites, 
polymorphism in vitamin D receptor, and colorectal adenoma risk." Cancer 
Epidemiol Biomarkers Prev 13(4): 546-52. 
Peters, U., K. A. McGlynn, et al. (2001). "Vitamin D, calcium, and vitamin D receptor 
polymorphism in colorectal adenomas." Cancer Epidemiol Biomarkers Prev 
10(12): 1267-74. 
Picotto, G., V. Massheimer, et al. (1997). "Parathyroid hormone stimulates calcium 
influx and the cAMP messenger system in rat enterocytes." Am J Physiol 
273(4 Pt 1): C1349-53. 
Platz, E. A., S. E. Hankinson, et al. (2000). "Plasma 1,25-dihydroxy- and 25-
hydroxyvitamin D and adenomatous polyps of the distal colorectum." Cancer 
Epidemiol Biomarkers Prev 9(10): 1059-65. 
Ponz de Leon, M., M. Marino, et al. (2004). "Trend of incidence, subsite distribution 
and staging of colorectal neoplasms in the 15-year experience of a specialised 
cancer registry." Ann Oncol 15(6): 940-6. 
Ponz de Leon, M., L. Roncucci, et al. (1988). "Pattern of epithelial cell proliferation 
in colorectal mucosa of normal subjects and of patients with adenomatous 
polyps or cancer of the large bowel." Cancer Res 48(14): 4121-6. 
Powell, D. W., P. A. Adegboyega, et al. (2005). "Epithelial cells and their neighbors I. 
Role of intestinal myofibroblasts in development, repair, and cancer." Am J 
Physiol Gastrointest Liver Physiol 289(1): G2-7. 
Powell, S. M., N. Zilz, et al. (1992). "APC mutations occur early during colorectal 
tumorigenesis." Nature 359(6392): 235-7. 
Qin, L. and N. C. Partridge (2005). "Stimulation of amphiregulin expression in 
osteoblastic cells by parathyroid hormone requires the protein kinase A and 
cAMP response element-binding protein signaling pathway." J Cell Biochem 
96(3): 632-40. 
Qin, L., P. Qiu, et al. (2003). "Gene expression profiles and transcription factors 
involved in parathyroid hormone signaling in osteoblasts revealed by 
microarray and bioinformatics." J Biol Chem 278(22): 19723-31. 
Qin, L., J. Tamasi, et al. (2005). "Amphiregulin is a novel growth factor involved in 
normal bone development and in the cellular response to parathyroid hormone 
stimulation." J Biol Chem 280(5): 3974-81. 
 293 
Qiu, P., L. Qin, et al. (2003). "Comparative promoter analysis and its application in 
analysis of PTH-regulated gene expression." J Mol Biol 326(5): 1327-36. 
Rajakumar, K. (2003). "Vitamin D, cod-liver oil, sunlight, and rickets: a historical 
perspective." Pediatrics 112(2): e132-5. 
Reeves, H. L., G. Narla, et al. (2004). "Kruppel-like factor 6 (KLF6) is a tumor-
suppressor gene frequently inactivated in colorectal cancer." Gastroenterology 
126(4): 1090-1103. 
Reid, I. R., R. Ames, et al. (2008). "Randomized controlled trial of calcium 
supplementation in healthy, nonosteoporotic, older men." Arch Intern Med 
168(20): 2276-82. 
Reppe, S., L. Stilgren, et al. (2007). "Abnormal muscle and hematopoietic gene 
expression may be important for clinical morbidity in primary 
hyperparathyroidism." Am J Physiol Endocrinol Metab 292(5): E1465-73. 
Reppe, S., L. Stilgren, et al. (2006). "Gene expression profiles give insight into the 
molecular pathology of bone in primary hyperparathyroidism." Bone 39(1): 
189-98. 
Rhodes, D. R., J. Yu, et al. (2004). "Large-scale meta-analysis of cancer microarray 
data identifies common transcriptional profiles of neoplastic transformation 
and progression." Proc Natl Acad Sci U S A 101(25): 9309-14. 
Rickard, D. J., F. L. Wang, et al. (2006). "Intermittent treatment with parathyroid 
hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 
receptor inhibits adipocyte differentiation in human bone marrow stromal 
cells." Bone 39(6): 1361-72. 
Risio, M., M. Lipkin, et al. (1991). "Correlations between rectal mucosa cell 
proliferation and the clinical and pathological features of nonfamilial neoplasia 
of the large intestine." Cancer Res 51(7): 1917-21. 
Rome, S., K. Clement, et al. (2003). "Microarray profiling of human skeletal muscle 
reveals that insulin regulates approximately 800 genes during a 
hyperinsulinemic clamp." J Biol Chem 278(20): 18063-8. 
Romero, G., W. B. Sneddon, et al. (2010). "Parathyroid hormone receptor directly 
interacts with dishevelled to regulate beta-Catenin signaling and 
osteoclastogenesis." J Biol Chem 285(19): 14756-63. 
Roodnat, J. I., E. A. van Gurp, et al. (2006). "High pretransplant parathyroid hormone 
levels increase the risk for graft failure after renal transplantation." 
Transplantation 82(3): 362-7. 
Rozen, P., Z. Fireman, et al. (1989). "Oral calcium suppresses increased rectal 
epithelial proliferation of persons at risk of colorectal cancer." Gut 30(5): 650-
5. 
Rubie, C., V. O. Frick, et al. (2007). "Correlation of IL-8 with induction, progression 
and metastatic potential of colorectal cancer." World J Gastroenterol 13(37): 
4996-5002. 
Saaf, A. M., J. M. Halbleib, et al. (2007). "Parallels between global transcriptional 
programs of polarizing Caco-2 intestinal epithelial cells in vitro and gene 
expression programs in normal colon and colon cancer." Mol Biol Cell 18(11): 
4245-60. 
Sabates-Bellver, J., L. G. Van der Flier, et al. (2007). "Transcriptome profile of 
human colorectal adenomas." Mol Cancer Res 5(12): 1263-75. 
Saeki, T., K. Stromberg, et al. (1992). "Differential immunohistochemical detection of 
amphiregulin and cripto in human normal colon and colorectal tumors." 
Cancer Res 52(12): 3467-73. 
 294 
Salahshor, S., J. Goncalves, et al. (2005). "Differential gene expression profile reveals 
deregulation of pregnancy specific beta1 glycoprotein 9 early during colorectal 
carcinogenesis." BMC Cancer 5: 66. 
Saleh, F., R. Jorde, et al. (2003). "Effect of calcium supplementation on blood 
pressure in patients with secondary hyperparathyroidism." J Endocrinol Invest 
26(1): 35-41. 
Saleh, F., R. Jorde, et al. (2006). "Causes of secondary hyperparathyroidism in a 
healthy population: the Tromso study." J Bone Miner Metab 24(1): 58-64. 
Samanic, C., W. H. Chow, et al. (2006). "Relation of body mass index to cancer risk 
in 362,552 Swedish men." Cancer Causes Control 17(7): 901-9. 
Sampson, J. R., S. Dolwani, et al. (2003). "Autosomal recessive colorectal 
adenomatous polyposis due to inherited mutations of MYH." Lancet 
362(9377): 39-41. 
Sansom, O. J., V. S. Meniel, et al. (2007). "Myc deletion rescues Apc deficiency in 
the small intestine." Nature 446(7136): 676-9. 
Sansom, O. J., K. R. Reed, et al. (2004). "Loss of Apc in vivo immediately perturbs 
Wnt signaling, differentiation, and migration." Genes Dev 18(12): 1385-90. 
Santy, L. C. and J. E. Casanova (2001). "Activation of ARF6 by ARNO stimulates 
epithelial cell migration through downstream activation of both Rac1 and 
phospholipase D." J Cell Biol 154(3): 599-610. 
Satoh, S., Y. Daigo, et al. (2000). "AXIN1 mutations in hepatocellular carcinomas, 
and growth suppression in cancer cells by virus-mediated transfer of AXIN1." 
Nat Genet 24(3): 245-50. 
Scalmati, A., L. Roncucci, et al. (1990). "Epithelial cell kinetics in the remaining 
colorectal mucosa after surgery for cancer of the large bowel." Cancer Res 
50(24): 7937-41. 
Schwartz, G. G. (2008). "Prostate cancer, serum parathyroid hormone, and the 
progression of skeletal metastases." Cancer Epidemiol Biomarkers Prev 17(3): 
478-83. 
Schwartz, G. G. and W. J. Blot (2006). "Vitamin D status and cancer incidence and 
mortality: something new under the sun." J Natl Cancer Inst 98(7): 428-30. 
Scott, N. A., J. Jeacock, et al. (1995). "Risk factors in patients presenting as an 
emergency with colorectal cancer." Br J Surg 82(3): 321-3. 
Segditsas, S., O. Sieber, et al. (2008). "Putative direct and indirect Wnt targets 
identified through consistent gene expression changes in APC-mutant 
intestinal adenomas from humans and mice." Hum Mol Genet 17(24): 3864-
75. 
SEUNGKOO LEE, S. B., KYUYOUNG SONG and INCHUL LEE (2006). 
"Differential expression in normal-adenoma-carcinoma 
sequence suggests complex molecular carcinogenesis in colon." ONCOLOGY 
REPORTS 16: 747-754. 
Shen, X., R. V. Mula, et al. (2007). "Increased cell survival, migration, invasion, and 
Akt expression in PTHrP-overexpressing LoVo colon cancer cell lines." Regul 
Pept 141(1-3): 61-72. 
Shen, X., P. G. Rychahou, et al. (2007). "PTHrP increases xenograft growth and 
promotes integrin alpha6beta4 expression and Akt activation in colon cancer." 
Cancer Lett 258(2): 241-52. 
Shipp, M. A., K. N. Ross, et al. (2002). "Diffuse large B-cell lymphoma outcome 
prediction by gene-expression profiling and supervised machine learning." Nat 
Med 8(1): 68-74. 
 295 
Shyu, R. Y., S. Y. Jiang, et al. (2003). "RARRES3 expression positively correlated to 
tumour differentiation in tissues of colorectal adenocarcinoma." Br J Cancer 
89(1): 146-51. 
Sitrin, M. D., A. G. Halline, et al. (1991). "Dietary calcium and vitamin D modulate 
1,2-dimethylhydrazine-induced colonic carcinogenesis in the rat." Cancer Res 
51(20): 5608-13. 
Sjoblom, T., S. Jones, et al. (2006). "The consensus coding sequences of human breast 
and colorectal cancers." Science 314(5797): 268-74. 
Skinner, H. G. and G. G. Schwartz (2009). "The relation of serum parathyroid 
hormone and serum calcium to serum levels of prostate-specific antigen: a 
population-based study." Cancer Epidemiol Biomarkers Prev 18(11): 2869-73. 
Smith, M. J., A. C. Culhane, et al. (2009). "Analysis of differential gene expression in 
colorectal cancer and stroma using fluorescence-activated cell sorting 
purification." Br J Cancer 100(9): 1452-64. 
Sobin, L., .  and C. Wittikind (2010). "TNM classifi cation of malignant tumours." 7th 
edn. London: Wiley and Sons. 
Spiegelman, V. S., T. J. Slaga, et al. (2000). "Wnt/beta-catenin signaling induces the 
expression and activity of betaTrCP ubiquitin ligase receptor." Mol Cell 5(5): 
877-82. 
Steele, R. J. (2004). "Results of the first round of a demonstration pilot of screening 
for colorectal cancer in the United Kingdom." BMJ 329(7458): 133. 
Stein, M. S., L. Flicker, et al. (2001). "Relationships with serum parathyroid hormone 
in old institutionalized subjects." Clin Endocrinol (Oxf) 54(5): 583-92. 
Stryker, S. J., B. G. Wolff, et al. (1987). "Natural history of untreated colonic polyps." 
Gastroenterology 93(5): 1009-13. 
Su, A. I., M. P. Cooke, et al. (2002). "Large-scale analysis of the human and mouse 
transcriptomes." Proc Natl Acad Sci U S A 99(7): 4465-70. 
Subramanian, A., H. Kuehn, et al. (2007). "GSEA-P: a desktop application for Gene 
Set Enrichment Analysis." Bioinformatics 23(23): 3251-3. 
Subramanian, A., P. Tamayo, et al. (2005). "Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression profiles." 
Proc Natl Acad Sci U S A 102(43): 15545-50. 
Suva, L. J., G. A. Winslow, et al. (1987). "A parathyroid hormone-related protein 
implicated in malignant hypercalcemia: cloning and expression." Science 
237(4817): 893-6. 
Swarthout, J. T., R. C. D'Alonzo, et al. (2002). "Parathyroid hormone-dependent 
signaling pathways regulating genes in bone cells." Gene 282(1-2): 1-17. 
T. Komori, I. T., H. Higuchi, M. Yamasaki, M. Ikeda, H. Yamamoto, M. Ohue, S. 
Nakamori, M. Sekimoto, K. Matsubara and a. M. Monden (2004). 
"Identification of Differentially Expressed Genes Involved in 
Colorectal Carcinogenesis Using a cDNA Microarray." J.Exp. Clin. Cancer Res 23(3): 
521-7. 
Tague, S. E., V. Muralidharan, et al. (2004). "ADP-ribosylation factor 6 regulates 
tumor cell invasion through the activation of the MEK/ERK signaling 
pathway." Proc Natl Acad Sci U S A 101(26): 9671-6. 
Tanaka, H., R. Shirkoohi, et al. (2006). "siRNA gelsolin knockdown induces 
epithelial-mesenchymal transition with a cadherin switch in human mammary 
epithelial cells." Int J Cancer 118(7): 1680-91. 
 296 
Tangrea, J., K. Helzlsouer, et al. (1997). "Serum levels of vitamin D metabolites and 
the subsequent risk of colon and rectal cancer in Finnish men." Cancer Causes 
Control 8(4): 615-25. 
Tenenbaum, A., E. Grossman, et al. (2001). "Long-term diuretic therapy in patients 
with coronary disease: increased colon cancer-related mortality over a 5-year 
follow-up." J Hum Hypertens 15(6): 373-9. 
Terpstra, O. T., M. van Blankenstein, et al. (1987). "Abnormal pattern of cell 
proliferation in the entire colonic mucosa of patients with colon adenoma or 
cancer." Gastroenterology 92(3): 704-8. 
Thiery, J. P., H. Acloque, et al. (2009). "Epithelial-mesenchymal transitions in 
development and disease." Cell 139(5): 871-90. 
Thomas, S. D., A. G. Need, et al. (2008). "Suppression of parathyroid hormone and 
bone resorption by calcium carbonate and calcium citrate in postmenopausal 
women." Calcif Tissue Int 83(2): 81-4. 
Tobimatsu, T., H. Kaji, et al. (2006). "Parathyroid hormone increases beta-catenin 
levels through Smad3 in mouse osteoblastic cells." Endocrinology 147(5): 
2583-90. 
Todaro, M., M. G. Francipane, et al. (2010). "Colon cancer stem cells: promise of 
targeted therapy." Gastroenterology 138(6): 2151-62. 
Turnbull, R. B., Jr., K. Kyle, et al. (1967). "Cancer of the colon: the influence of the 
no-touch isolation technic on survival rates." Ann Surg 166(3): 420-7. 
Tusher, V. G., R. Tibshirani, et al. (2001). "Significance analysis of microarrays 
applied to the ionizing radiation response." Proc Natl Acad Sci U S A 98(9): 
5116-21. 
Umar, A., J. C. Boyer, et al. (1994). "Defective mismatch repair in extracts of 
colorectal and endometrial cancer cell lines exhibiting microsatellite 
instability." J Biol Chem 269(20): 14367-70. 
Urena, P., X. F. Kong, et al. (1993). "Parathyroid hormone (PTH)/PTH-related 
peptide receptor messenger ribonucleic acids are widely distributed in rat 
tissues." Endocrinology 133(2): 617-23. 
van de Wetering, M., E. Sancho, et al. (2002). "The beta-catenin/TCF-4 complex 
imposes a crypt progenitor phenotype on colorectal cancer cells." Cell 111(2): 
241-50. 
van den Brink, G. R., S. A. Bleuming, et al. (2004). "Indian Hedgehog is an 
antagonist of Wnt signaling in colonic epithelial cell differentiation." Nat 
Genet 36(3): 277-82. 
Van der Flier, L. G., J. Sabates-Bellver, et al. (2007). "The Intestinal Wnt/TCF 
Signature." Gastroenterology 132(2): 628-32. 
van der Heyden, M. A., J. M. Veltmaat, et al. (2000). "Dynamic connexin43 
expression and gap junctional communication during endoderm differentiation 
of F9 embryonal carcinoma cells." Eur J Cell Biol 79(4): 272-82. 
van Dop, W. A., A. Uhmann, et al. (2009). "Depletion of the colonic epithelial 
precursor cell compartment upon conditional activation of the hedgehog 
pathway." Gastroenterology 136(7): 2195-2203 e1-7. 
Vasen, H. F., B. G. Taal, et al. (1995). "Hereditary nonpolyposis colorectal cancer: 
results of long-term surveillance in 50 families." Eur J Cancer 31A(7-8): 1145-
8. 
Vogelstein, B., E. R. Fearon, et al. (1988). "Genetic alterations during colorectal-
tumor development." N Engl J Med 319(9): 525-32. 
 297 
Wactawski-Wende, J., J. M. Kotchen, et al. (2006). "Calcium plus vitamin D 
supplementation and the risk of colorectal cancer." N Engl J Med 354(7): 684-
96. 
Wallace, K., J. A. Baron, et al. (2004). "Effect of calcium supplementation on the risk 
of large bowel polyps." J Natl Cancer Inst 96(12): 921-5. 
Wallis, Y. L., D. G. Morton, et al. (1999). "Molecular analysis of the APC gene in 
205 families: extended genotype-phenotype correlations in FAP and evidence 
for the role of APC amino acid changes in colorectal cancer predisposition." J 
Med Genet 36(1): 14-20. 
Wang, J., Y. Yang, et al. (2007). "Suppression of FHL2 expression induces cell 
differentiation and inhibits gastric and colon carcinogenesis." 
Gastroenterology 132(3): 1066-76. 
Wargovich, M. J., G. Isbell, et al. (1992). "Calcium supplementation decreases rectal 
epithelial cell proliferation in subjects with sporadic adenoma." 
Gastroenterology 103(1): 92-7. 
Wass, J. A. H. and S. M. Shalett (2002). Oxford textbook of endocrinology  
Wei, M. Y., C. F. Garland, et al. (2008). "Vitamin D and prevention of colorectal 
adenoma: a meta-analysis." Cancer Epidemiol Biomarkers Prev 17(11): 2958-
69. 
Weingarten, M. A., A. Zalmanovici, et al. (2008). "Dietary calcium supplementation 
for preventing colorectal cancer and adenomatous polyps." Cochrane Database 
Syst Rev(1): CD003548. 
Welcsh, P. L., M. K. Lee, et al. (2002). "BRCA1 transcriptionally regulates genes 
involved in breast tumorigenesis." Proc Natl Acad Sci U S A 99(11): 7560-5. 
Whitfield, J. F. (2005). "Parathyroid hormone (PTH) and hematopoiesis: new support 
for some old observations." J Cell Biochem 96(2): 278-84. 
Wiese, A. H., J. Auer, et al. (2007). "Identification of gene signatures for invasive 
colorectal tumor cells." Cancer Detect Prev 31(4): 282-95. 
Winawer, S. J., A. G. Zauber, et al. (2006). "Guidelines for colonoscopy surveillance 
after polypectomy: a consensus update by the US Multi-Society Task Force on 
Colorectal Cancer and the American Cancer Society." Gastroenterology 
130(6): 1872-85. 
Winawer, S. J., A. G. Zauber, et al. (1993). "Prevention of colorectal cancer by 
colonoscopic polypectomy. The National Polyp Study Workgroup." N Engl J 
Med 329(27): 1977-81. 
Woerner, S. M., J. Gebert, et al. (2001). "Systematic identification of genes with 
coding microsatellites mutated in DNA mismatch repair-deficient cancer 
cells." Int J Cancer 93(1): 12-9. 
Wu, K., W. C. Willett, et al. (2002). "Calcium intake and risk of colon cancer in 
women and men." J Natl Cancer Inst 94(6): 437-46. 
Yamada, M., Y. Ichikawa, et al. (2008). "Amphiregulin is a promising prognostic 
marker for liver metastases of colorectal cancer." Clin Cancer Res 14(8): 
2351-6. 
Yan, D., M. Wiesmann, et al. (2001). "Elevated expression of axin2 and hnkd mRNA 
provides evidence that Wnt/beta -catenin signaling is activated in human colon 
tumors." Proc Natl Acad Sci U S A 98(26): 14973-8. 
Yang, K., N. Kurihara, et al. (2008). "Dietary induction of colonic tumors in a mouse 
model of sporadic colon cancer." Cancer Res 68(19): 7803-10. 
 298 
Yang, R., B. H. Hoang, et al. (2007). "Over-expression of parathyroid hormone Type 
1 receptor confers an aggressive phenotype in osteosarcoma." Int J Cancer 
121(5): 943-54. 
Yu, D., P. K. Seitz, et al. (1992). "Effects of parathyroid hormone-related peptide on 
adenosine 3',5'-monophosphate and ornithine decarboxylase in a human 
colonic cell line." Endocrinology 130(4): 1993-2000. 
Zhang, H., I. Ozaki, et al. (2006). "Involvement of programmed cell death 4 in 
transforming growth factor-beta1-induced apoptosis in human hepatocellular 
carcinoma." Oncogene 25(45): 6101-12. 
Zheng, W., K. E. Anderson, et al. (1998). "A prospective cohort study of intake of 
calcium, vitamin D, and other micronutrients in relation to incidence of rectal 
cancer among postmenopausal women." Cancer Epidemiol Biomarkers Prev 
7(3): 221-5. 
Zhu, Q., J. Y. Liu, et al. (2005). "Mechanism of counterattack of colorectal cancer cell 
by Fas/Fas ligand system." World J Gastroenterol 11(39): 6125-9. 
 
 
